<SEC-DOCUMENT>0001390478-20-000037.txt : 20201113
<SEC-HEADER>0001390478-20-000037.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201113161717
ACCESSION NUMBER:		0001390478-20-000037
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		201311709

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gale-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457,d:bab9091ab18243cd80fc8b0fdb9ba8dc--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:gale="http://www.galenabiopharma.com/20200930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gale-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl80LTEtMS0xLTA_642ddf2a-ddff-4ac7-be0c-80a962b5339b">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl81LTEtMS0xLTA_4b37cf7e-bb2a-40b4-b0d2-5ff3dea821e6">December 31</ix:nonNumeric><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl85LTEtMS0xLTA_743aad66-747f-481d-a9ef-4993b97a9980">2020</ix:nonNumeric><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl8xMC0xLTEtMS0w_e18f8f2c-af2c-4365-b11d-f29ba5d106ee">Q3</ix:nonNumeric><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl8xMS0xLTEtMS0w_53dc4268-0cc8-43af-b32d-76b3768dc92f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i28c703bfbd66411799afac37b66ff593_D20200109-20200109" format="ixt-sec:duryear" name="gale:ClassofWarrantorRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180My9mcmFnOmM4NGQ2NzA3ZTJjYjQ1YjZiN2E5MzljN2EzYzJjZjk5L3RleHRyZWdpb246Yzg0ZDY3MDdlMmNiNDViNmI3YTkzOWM3YTNjMmNmOTlfMTEw_6b4c3a93-098a-44f9-a8cc-e889960cdcf5">5.5</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie6b0a09ffc074f6a9ca8dbb88f9820a5_D20191107-20191107" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180OS9mcmFnOjFjOTZiYThkN2U3ODRmYmViNzJhMGFmZTkxYzZhZWYyL3RhYmxlOjE0Mzg5YWJmNTA3YjQ3NGRhYTVkZTI3MTc1NGU2NGUzL3RhYmxlcmFuZ2U6MTQzODlhYmY1MDdiNDc0ZGFhNWRlMjcxNzU0ZTY0ZTNfMS0xLTEtMS0w_29fd6e08-f0a9-45ae-b475-d47a81450c0c">0.02</ix:nonFraction><ix:nonNumeric contextRef="i784b47aa030d491fb2d324b3fc9ef92a_D20200101-20200930" name="gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4MQ_25e0b964-a33f-48bd-9fac-2954e0ad7f70">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i28c703bfbd66411799afac37b66ff593_D20200109-20200109" format="ixt-sec:duryear" name="gale:ClassofWarrantorRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182NC9mcmFnOjNiNmM3ZTcxMjYwNjQ3ZTY4ZjEzYTE5NDRkYmYzZjIyL3RleHRyZWdpb246M2I2YzdlNzEyNjA2NDdlNjhmMTNhMTk0NGRiZjNmMjJfMTEy_6b4c3a93-098a-44f9-a8cc-e889960cdcf5">5.5</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gale-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1113bd5f1bec43d2af7664330b6cbdeb_I20201113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526ba136e5e243d480e699d976eac2a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic022585050ae4612867b99cbfb4d849b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a23f1f812448a1b0e6a3596e39276e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5157db189dde4c2695638890e78b8126_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e0e8582c5944e28e652902589c2bc8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8e37103bd64af1b9cc06f485522288_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1497135158547e98a1d099f75b92b6c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017b702a13f64d4b98692ac37c6a1053_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia609730176c14fdab04d34b43a971355_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1db2db5213477e963d08ffc4069d65_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17705d1efab94dde907052dd981f02a0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i645c600a848a471a83b9b22bb3e706b1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448e315df994429faf64be5d9e92cab2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic676874210a241b0962cf4ef4c61a42c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef9e512b2a5468ebe07f8b90a06af96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b1bd6d180f405fa9db296c77b6ed97_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if021b546b0cf4d20ba09dbffea09d212_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4efe31e6a2740e2a47f900a8411a6ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic656a9beca124dbd893b34aa5140bd0a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98a9c1849c14b238f015a559fd03855_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50a7116a1f45c48a4530ec81fdf221_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d096b69f27a4dc9b506bd230ab72aa2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd470f4d5da4812aa588bd34055fd56_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8251699c639640ee881bf02c2e33e139_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333c91c266364b2eae464c53a8817f07_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789a0f37c09142ab985c13adff90f7a2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e733b367c614849b02a9fd90805dcb2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7750e980bf85451d98229836daffbd55_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3865ec252344ced80fdda5644983129_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12900c59fe2a4ff096fd101b525adf14_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b2f91724d24900ac8e54e3b467f7f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f75e0d3fed4888b7432f8ab49025d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b97499a01c4bbd86d34124af212071_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8205cb47ed594c60af87958ca345c78a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad85cecbb6d478c84dd680e20b243d9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:PIPEInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe21654d5bd481094895b468bb60e02_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:PIPEInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354bd279ed2542818d5f6d96946a39b1_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea994a777cf84044889ade0f0cfca5c7_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gale:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gale:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-09</xbrli:startDate><xbrli:endDate>2020-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c703bfbd66411799afac37b66ff593_D20200109-20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-09</xbrli:startDate><xbrli:endDate>2020-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d45ff94435e4d21ba5468a5bebac6bf_I20191107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f256c92ebda4e238a9aee699650ec0f_I20191108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib323751cda864ddea7a8246c632828fc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d28b5ddb4f4e639e1959c1669e686e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236474c05e0144e19db3cd5297f11f83_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7605f1eb40c54e9c842276a939abedd4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336f4731de7d4c87aac9eb314ce2c08f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a636ae8cbfc46d18fa54ecab7fe2024_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie6b0a09ffc074f6a9ca8dbb88f9820a5_D20191107-20191107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-07</xbrli:startDate><xbrli:endDate>2019-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31133d38f51742738c72afb224c21907_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f4af32287b4eebbb3e4bb756720009_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312df3f093ec493b8184ebf1b42c5b63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4007eb8b70cc49a894e1bdf6a68b797d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a08e3cbcb5346b484952fa5670010dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484453f41b684c819bd4de89fe5e44d7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b789d256a64b4c94443e234118e471_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15be4f3595049579ffb1c76ee6bffb9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3529684d284f57abc0008fc0964ea3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">gale:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ed1616c836452e8084ab91d06bef5c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">gale:MeasurementInputCostOfDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784b47aa030d491fb2d324b3fc9ef92a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8564c243eb44d16943c0ae16d68c94c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8fdb34b2cc44a58467c8e3974f9096_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b0db59425c4a98acfb161fe0504728_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65906fccb4494d56a3acf5118e25adbf_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringJuly312020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483df898bc3046c6803892473d43f9dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringJuly312020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:DistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35672082f7945928e2de21782c5ccf4_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if77a8a8ce50a4065b099f3a4946f25d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a06969186f544b098f9823b6f201beb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd662d374f5e4b9b9f63ff15501e6a9b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2003e91715cd42cd807932a074fadd24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id011ae33db9a49bfa4332611238d7399_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f67ec1048a462997aa215f62c15d3a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4dd7532088040d9b73af1f7afd90860_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ccbdec896542ac98d4fd115dff1bcf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ef75fb2fbe4b15858d159ac382757d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d32eceb309447d9a734885748db45e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fb77bdd14a4391afb857bad525ac58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92d800c33d7429d83e6b450093d5217_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8dbce17eee4277b5a56ab7ba7dee3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f18bc2fcbb74091bfc8098930a1503d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9131a32521e475eab282e97afd922ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953ec750bdd64786866ccfc3f7f8baa2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c5ca7b25c443cab31a8bdd3b02bad6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c6c834d79b43b2b4810fe704177d48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde95ad8907947079b64dbecdb9a5118_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b14755124449839e31591a62b76734_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03011f148cb4758a40c754e531e9467_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc95b8a4af8c45868a82d2bdc59aba55_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454630a01309432fa2cd4d7cff6dfe26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057e07bc9bcb479399b79efcba85a739_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56a535a800d461ab07716bd1239fb0f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcee970816de4898aab068f1436dc88c_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie359a0832f7942bdbf02a2c59e430ed4_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Warrants2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21ba327b68645e39db322f2b5490a05_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Warrants2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c4d8cbc2a54d81bb75603f21e71592_I20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e452b96408744e7b8df56fd8bb09e82_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2016b111d5d5438a9afb8026836b746a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-10</xbrli:startDate><xbrli:endDate>2019-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0346c87fde44172b58c4033836ca055_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0326b4a15fb4f79b56050d8f382451e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e7017a8cdc4a0282dd6943f37e6465_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7978d211d17840e58f2b8d3d7d3796a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa5608939c04c9f8ee26f0aac67c972_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37be4be95af44ceaaaa2b49b0947ba57_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c151f4f312b4f67ae012e478ef3df7e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcce4f272d22498990237677ea1747bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26e5d011619471ead5000df2785d4af_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670c721655b24536abbe20f1d9e66a1e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i046188f82f2c42d1b09d3e35bf7d8bf5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97541f70c99c4d0d99f8987a97e11b2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg1_6eea6bad-ab29-484b-a625-7e10272792f9">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6OTU4ZmVlMjEyNTQzNGY4MDhkMGMwNzY5ZmFkYjJmNGQvdGFibGVyYW5nZTo5NThmZWUyMTI1NDM0ZjgwOGQwYzA3NjlmYWRiMmY0ZF8wLTAtMS0xLTA_78c11148-ec7a-49a9-95b5-5087bedfdc8e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8xOTI_ee79290e-7bda-40e6-a410-38bce413abfb">September 30, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YWUzMDNkMDU3Y2FjNGYwMWFjN2UwMjU2MDkxYzEzNzYvdGFibGVyYW5nZTphZTMwM2QwNTdjYWM0ZjAxYWM3ZTAyNTYwOTFjMTM3Nl8wLTAtMS0xLTA_00ca64f4-2e40-417c-9c4c-b1acbe5a7dfb">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDkx_08844eba-74ae-41ea-beea-db51b8a2941a"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDkx_8d7de0b5-372e-4e6e-b870-3b44252bc560">001-33958</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><img src="gale-20200930_g1.jpg" alt="gale-20200930_g1.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDky_a1ba84a0-d110-4725-a01a-899dd02d76f4"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDky_bf0a4329-b785-4a6f-a189-ed083074b414">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:47.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.510%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YmExYTMxNjBmZWUwNDMzYzllMDZkMTQ4ZDIwYzBkMjUvdGFibGVyYW5nZTpiYTFhMzE2MGZlZTA0MzNjOWUwNmQxNDhkMjBjMGQyNV8wLTAtMS0xLTA_0c9e1de7-236e-407f-81cd-1c321ee51a5c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YmExYTMxNjBmZWUwNDMzYzllMDZkMTQ4ZDIwYzBkMjUvdGFibGVyYW5nZTpiYTFhMzE2MGZlZTA0MzNjOWUwNmQxNDhkMjBjMGQyNV8wLTItMS0xLTA_8c0b305d-7af2-4792-a4eb-e0a00992a5ed">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg3_dd219e64-4017-4939-86c9-d87e3d9de55b">7 Times Square, Suite 2503,</ix:nonNumeric> <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg4_2a887ddb-52c1-4c32-8b4f-649618dd6e27">New York,</ix:nonNumeric> <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg2_b6d53951-6b85-4c98-9f9d-0c578217954c">NY</ix:nonNumeric> <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8zNjk_50f39422-8377-4aa1-8862-7ca35a95d60b">10036</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8zNzM_bf62bd09-a4f7-4e8f-9de6-ece39ec353a9">(917)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgx_8d753313-6030-41c9-ab5c-d7294dd48799">438-4353</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant's principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTAtMS0xLTA_c0b4d922-ee31-4e0d-a3ad-d13e10547889">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTEtMS0xLTA_d7924ebd-1872-4e4d-ac58-4a58596352bb">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTItMS0xLTA_1f66ca80-55eb-40b6-b63b-7d4e83f2a840">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgy_931da8fe-54c4-48ee-a2d2-55c474943ba8">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgz_1eba7034-3cff-4c6b-8e5c-4df96a5bb3d4">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV8yLTAtMS0xLTA_b2bcc90f-4aa7-4516-b207-840f80b091aa">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV8yLTYtMS0xLTA_7ecba748-8b5a-418c-8440-553e89d901dc">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV80LTItMS0xLTA_17661daf-76ac-4e81-86b4-0367c8fb24a1">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg5_6d75723e-2a55-49bc-b145-77f9a331e805">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;No </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November&#160;13, 2020, SELLAS Life Sciences Group, Inc. had outstanding <ix:nonFraction unitRef="shares" contextRef="i1113bd5f1bec43d2af7664330b6cbdeb_I20201113" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDUz_142ec9da-643f-4e2d-afbb-50b2ad84f62b">9,461,978</ix:nonFraction> shares of common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless stated otherwise, the information contained in these consolidated financial statements gives effect to a one-for-fifty reverse stock split of our shares of common stock effected on November 7, 2019.  See Note 3 under our consolidated financial statements for further information. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_10"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q - Quarterly Report</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended September&#160;30, 2020 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_19">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited <a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_76">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II - OTHER INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_100">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_103">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_106">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_106">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_109">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_112">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_115">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_121">Signatures</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The names &#8220;SELLAS Life Sciences Group, Inc.,&#8221; &#8220;SELLAS,&#8221; the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;will&#8221; and similar statements of a future or forward-looking nature identify forward-looking statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. In addition, while the Company expects the COVID-19 pandemic to have both a direct and an indirect impact on its business operations and financial results, the extent of the impact on the Company&#8217;s clinical development and regulatory efforts, its corporate development objectives, its financial position and the value of and market for its common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the availability of safe and effective vaccines and the uptake thereof. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections captioned &#8220;Risk Factors,&#8221; &#8220;Legal Proceedings,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission ("SEC") on March 13, 2020 ("2019 Annual Report") and in our other public filings with the SEC, all of which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_19"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_22"></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNC0xLTEtMS0w_bf62ef8c-513b-4045-908a-8a5b3b1eacc1">8,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNC0zLTEtMS0w_17d55a6d-e631-4fe9-a02c-1aebe0ed8c42">7,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNS0xLTEtMS0w_6b84d5e6-8772-4422-8fcc-4fe677fe5029">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNS0zLTEtMS0w_1bb69395-8df1-40cf-aebc-9ee96fb228e9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock subscription receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:zerodash" name="gale:StockSubscriptionReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNi0xLTEtMS0w_b43af35a-e352-4ac2-8125-ce58c6549f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:StockSubscriptionReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNi0zLTEtMS0w_8802c8ca-6557-4965-8c24-9d511210cf0d">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfOS0xLTEtMS0w_1c8507a8-60c2-42b6-b756-5d8897c8d761">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfOS0zLTEtMS0w_6dc6c76d-77ed-42cc-b78b-60874143225f">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTEtMS0xLTEtMA_0d29c454-fb6d-49cd-a8e1-46e0fa13ffe7">9,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTEtMy0xLTEtMA_50f3736a-d735-4416-870a-12b471e89498">8,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTMtMS0xLTEtMA_7de2089d-31f0-4e0b-a2f2-31a14c661ac6">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTMtMy0xLTEtMA_6a0d87e6-27a2-4fb8-a2c7-69d394617d87">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:InProcessResearchDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTQtMS0xLTEtMA_230e33db-6712-427f-8aa5-108945e2c166">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gale:InProcessResearchDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTQtMy0xLTEtMA_c1e7d94c-367d-4034-b609-54d7ed980b08">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTgtMS0xLTEtMA_cc215eb8-e6bb-4a87-aaa9-3dc2b2fd1d59">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTgtMy0xLTEtMA_c39605b4-a4b9-4811-aa7d-70b06ae82ad9">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTktMS0xLTEtMA_7b5963e1-fcdc-4309-9a6e-ccd0c226e3b9">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTktMy0xLTEtMA_567575f6-1bf1-4211-aa90-2201bdb87958">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjAtMS0xLTEtMA_6d4ca4b0-d3d2-4589-a7b4-7581454e9a4c">18,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjAtMy0xLTEtMA_9ec971d2-f54d-4179-a03f-e5350e558cf4">16,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjUtMS0xLTEtMA_6da6b234-2c19-4c11-abcb-fd12fb105a8b">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjUtMy0xLTEtMA_bdb8053e-c35a-43bb-bbb4-e14b04a41705">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjYtMS0xLTEtMA_a72c2424-4b81-4ce5-b01e-9d1dd3a4c850">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjYtMy0xLTEtMA_ce91e1ad-ff01-4e5e-8740-b092adb120ad">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjgtMS0xLTEtMA_fda35c57-89b0-4706-9212-8c683bf618b4">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjgtMy0xLTEtMA_2510148e-7158-45af-a26d-27ba5e3e7319">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzAtMS0xLTEtMA_257fb5f4-06b6-4196-b270-d6544c9963d2">4,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzAtMy0xLTEtMA_83102525-0a09-48b5-8b15-7e36d5d955a3">5,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzItMS0xLTEtMA_56eac3fa-a7c2-4123-b7a3-d5512e22fe99">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzItMy0xLTEtMA_39837a8a-0f45-468b-aacf-fe768b062871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzMtMS0xLTEtMA_ba67cecc-e35b-4462-bba1-51381ccc663b">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzMtMy0xLTEtMA_c533992f-c921-4964-9835-756fb7a0b746">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzQtMS0xLTEtMA_00e1695c-48e7-461f-a5d8-7c136a4438e5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzQtMy0xLTEtMA_33ec6f3a-f149-482a-a9e2-dadc2675e0e6">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzUtMS0xLTEtMA_e217603c-7de7-4f06-b712-72932f6eee08">5,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzUtMy0xLTEtMA_5ff53f11-cfb5-4347-b451-72024aa8d9ca">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzctMS0xLTEtMA_531933cb-aaf3-46e3-a866-3ec813f95789">10,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzctMy0xLTEtMA_8782d817-43cd-4279-bb4f-76e71dec6692">10,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzgtMS0xLTEtMA_f18ef9c9-bdaa-4d25-afa9-27f28aa63e10"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzgtMy0xLTEtMA_d72ecdd4-efc1-4d6c-8b4a-a7b9ead3540a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzIx_3fa190ed-5827-4edd-baf4-6de6d6de08b5"><ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzIx_ad007fac-c7ab-4b67-aaf5-03ed9349e697">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzM1_68263aff-7b39-4a2a-914b-23100ecefb2c"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzM1_f56dddfd-4bff-4911-8b69-5e77d31430e2">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; Series A convertible preferred stock, <ix:nonFraction unitRef="shares" contextRef="ic022585050ae4612867b99cbfb4d849b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5Xzk1_4e82cfa8-0fbd-481f-88f5-c86fa4367e80"><ix:nonFraction unitRef="shares" contextRef="i25a23f1f812448a1b0e6a3596e39276e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5Xzk1_9eddf659-5fbc-4e77-aac4-b55f15080c65">17,500</ix:nonFraction></ix:nonFraction> shares designated; <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_18589039-3179-4901-bb2b-ea6cbec8f340"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_5067728e-1363-42d7-b37c-bd4e67ab21d6"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_74387790-42c5-4b2f-aec7-9997676160e2"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_d76b1fb3-ba9c-4d55-8f8f-ee62cda33c0d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMS0xLTEtMA_a258bb94-a578-49d5-b0ad-26722279af5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMy0xLTEtMA_3c6cbe7e-74c2-4286-9f47-9d2db786d2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzE4_3e5606d0-5099-42e4-8bc0-fad4aeba2a46"><ix:nonFraction unitRef="usdPerShare" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzE4_6d987b1d-766b-47fc-a67a-9049c267ca50">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzMy_778293af-ee5f-4999-92b3-dd0dd8423859"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzMy_bafe24b4-ca6f-49d3-a3fb-91284fcea299">350,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzU0_1b0a90fa-8bd4-4830-b082-1d85c6cccc3c"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzU0_68f3ee4f-14d6-4674-a82e-4d4572b5fb51">9,461,978</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzYx_0c94f830-22bd-404f-87fb-628a9394d8e7"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzYx_94523b26-6346-4837-beb7-5281db1502ce">5,080,100</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMS0xLTEtMA_438d42e8-86b2-428f-ad2e-f0df0c4ab63a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMy0xLTEtMA_6c0cedf4-630d-4b5c-bedd-59fe81b34c2c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDItMS0xLTEtMA_98a33377-fbed-4a61-b6dd-f065cf64a677">122,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDItMy0xLTEtMA_1897dfee-b402-4aa4-93fe-9b191abacaad">107,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDMtMS0xLTEtMA_bf00b6ad-df73-4090-afbc-348e2d0e98c3">114,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDMtMy0xLTEtMA_9126a050-cadc-41d5-8337-d773ca636afe">101,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDUtMS0xLTEtMA_cbf26994-f89b-4197-9216-92b78dbb4209">7,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDUtMy0xLTEtMA_1725353a-2096-4861-9970-e03ae6b41f29">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDYtMS0xLTEtMA_eaf3f9c0-2ae2-4eea-8da6-d1c9c9c8c52c">18,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDYtMy0xLTEtMA_57d487dd-de3e-4fac-8279-c834c3fe271d">16,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS0xLTEtMS0w_910b0fbf-ed26-4410-8c8f-2d61ec72c47b">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS0zLTEtMS0w_50a9b687-2a2e-4b8a-83c4-a051c4d57cbb">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS01LTEtMS0w_45cab6f1-1793-44f9-a36b-dbeba9110944">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS03LTEtMS0w_e185d76b-7a26-48bb-b86a-0bdcde2e2a2f">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi0xLTEtMS0w_72ce2cd6-7ebd-4a4e-8688-3c12f95d0ce4">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi0zLTEtMS0w_c6de680a-3b3d-4344-aec4-79d8ffc6daf5">2,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi01LTEtMS0w_b819bbeb-8fc9-4abd-be34-374e03318732">6,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi03LTEtMS0w_7c8de975-6230-41dc-8d12-bfdcf5b32625">7,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC0xLTEtMS0w_283dbc5c-4414-444a-b8c5-4c11af238309">4,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC0zLTEtMS0w_a4aac67a-4431-44c3-8c2a-f31be7cb77c9">4,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC01LTEtMS0w_e4f13850-20e5-413c-b600-7a4f7ef4f773">12,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC03LTEtMS0w_43fd545a-a427-4264-b2c6-14c4e86b76da">12,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItMS0xLTEtMA_5494fe2e-1ada-40d2-aea4-d1cd3013dfa4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItMy0xLTEtMA_b737cfd3-a8e0-4e9e-bb38-e518a7cdf397">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItNS0xLTEtMA_8474c5df-86b3-4308-9e0a-7b2c6d557ce4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItNy0xLTEtMA_cf476927-6d09-47c7-8272-f9e1c7434425">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" name="gale:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtMS0xLTEtMA_f186f57f-251b-4974-bbec-68b8ac1f56af">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" sign="-" name="gale:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtMy0xLTEtMA_05a35ed0-9f25-4e84-8771-093c04c76a7a">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" name="gale:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtNS0xLTEtMA_73908220-d38f-4a46-b122-921fb445c619">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" name="gale:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtNy0xLTEtMA_be9b9817-b744-4493-a364-ddc6f3358956">510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctMS0xLTEtMA_af04a3f5-3d2f-4bb7-8f32-1582f890c6df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctMy0xLTEtMA_3627e5ed-c4ba-46ae-9095-0a62d569dfef">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctNS0xLTEtMA_ad9b99be-5307-4de9-a587-fae06efd7628">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctNy0xLTEtMA_2df1e006-4244-4ea5-8764-be8110bc1a35">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtMS0xLTEtMA_2701c1a9-fcc3-4340-aa6e-72d2fd076499">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtMy0xLTEtMA_c1f9d275-0c07-4f5d-ba2e-8409cad582c0">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtNS0xLTEtMA_7cfbb2b0-494a-4ec6-89d9-4972db8783bb">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtNy0xLTEtMA_d2713fb4-5181-4253-a12e-c561ca808d50">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtMS0xLTEtMA_2fa24e86-59af-4f39-ad5d-3eb592cd1fa9">4,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtMy0xLTEtMA_346a3711-2e69-4e1c-92a8-58d02f7b561d">4,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtNS0xLTEtMA_1ba65774-7211-42b3-946a-021b4a9ab36b">13,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtNy0xLTEtMA_f053c6ce-e534-4d41-97f1-e31817d7ba2e">11,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend arising from warrant modifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="gale:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctMS0xLTEtMA_9e9b78d3-97a3-434d-8250-e68ea5bada13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="gale:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctMy0xLTEtMA_bf29295e-7e05-4d6e-b60e-f47df7e400a1">7,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctNS0xLTEtMA_eb9f045f-60ef-43cb-8fa7-e1eafdba9edf">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="gale:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctNy0xLTEtMA_4f2bd440-51ed-4cf9-8982-53691d102d43">8,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtMS0xLTEtMA_723e25d0-e6c9-46cc-b6c2-dd9550385005">4,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtMy0xLTEtMA_b47a8e48-b38b-4dc0-8717-e2079e7742c2">11,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtNS0xLTEtMA_d5d2ed8c-3063-4553-bd05-413df9157062">13,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtNy0xLTEtMA_b0eae681-a0e5-4c45-b456-ae170c3327c4">20,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtMS0xLTEtMA_1a2b477f-574e-42ae-a36f-9ff8670cb825">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtMy0xLTEtMA_45fa6cfe-d32e-46b3-8dd2-cf23f215834a">2.68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtNS0xLTEtMA_fbdbcc70-790c-4eb4-baae-58ebc100e53f">1.83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtNy0xLTEtMA_6ea443b9-a28a-4731-9ee9-beb8b1814a03">11.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtMS0xLTEtMA_c80ec630-c255-4fdd-ad89-129e0c36d573">8,418,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtMy0xLTEtMA_ff5d74a0-2004-4605-8585-d9646c0725cd">4,281,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtNS0xLTEtMA_60ed6bae-c335-4f33-a92e-00309011fef2">7,174,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtNy0xLTEtMA_9d988c55-e211-4edd-aa05-5042ea981d51">1,805,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88e0e8582c5944e28e652902589c2bc8_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xLTEtMS0w_4d369c65-21e7-4847-8dfd-13995dccd1d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e0e8582c5944e28e652902589c2bc8_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0zLTEtMS0w_3db2bd2b-5b83-499c-a811-13e42b369090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d8e37103bd64af1b9cc06f485522288_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy01LTEtMS0w_38d6295f-c4c3-43cd-9e53-bea2362c411b">6,717,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8e37103bd64af1b9cc06f485522288_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy03LTEtMS0w_d2e0b653-129b-4f8a-ba8e-d226b5f3029e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1497135158547e98a1d099f75b92b6c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy05LTEtMS0w_3ab36bb5-6872-47a0-9a79-c8fe6b41ac22">113,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017b702a13f64d4b98692ac37c6a1053_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xMS0xLTEtMA_ae92d7a2-5dd9-4e67-9185-edc782c0684a">109,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia609730176c14fdab04d34b43a971355_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xNS0xLTEtMA_b2457fbd-08d7-4253-9140-07aa73ab8b1d">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC01LTEtMS0w_83834b70-f98c-442c-8908-30eb7b21cc86">2,744,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930" decimals="-3" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC03LTEtMS0w_2e2aa167-2541-42bf-8d2e-8ea11c9e8f88">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC05LTEtMS0w_1420bd87-09ae-4e1d-9998-4e1951073231">8,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC0xNS0xLTEtMA_e2587cbd-35df-49fe-95ea-e65be427f5d7">8,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfOS05LTEtMS0w_4b3c3ae4-3a15-4ff2-b063-4e9ee0b54794">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfOS0xNS0xLTEtMA_6bec51e2-b087-4be6-bad7-9242b585a66f">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1db2db5213477e963d08ffc4069d65_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTAtMTEtMS0xLTA_35b8ee16-408a-4673-b3f8-9de7e611a165">4,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTAtMTUtMS0xLTA_dbde16d3-3fa5-45bd-825b-959dda62ec1b">4,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17705d1efab94dde907052dd981f02a0_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMS0xLTEtMA_b4b10813-8be1-4eeb-8f5b-c090ee0c2745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17705d1efab94dde907052dd981f02a0_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMy0xLTEtMA_a5210feb-5702-41c1-b3b1-8d67fb679122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtNS0xLTEtMA_ac517912-dfc8-4e96-9265-29603a56c0e9">9,461,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtNy0xLTEtMA_03f1a60a-b582-4d6d-81a0-1c2cbf8b9cf4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448e315df994429faf64be5d9e92cab2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtOS0xLTEtMA_3df87d9a-a963-4e02-8522-3807efd4bf63">122,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic676874210a241b0962cf4ef4c61a42c_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMTEtMS0xLTA_88209505-37bf-48de-b67e-ed0b5cc9438b">114,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMTUtMS0xLTA_957c333d-0f2e-40c5-bdf8-b898ffe954cc">7,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifef9e512b2a5468ebe07f8b90a06af96_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMS0xLTEtMA_162c112d-ac34-40cf-9415-ac41a76787be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef9e512b2a5468ebe07f8b90a06af96_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMy0xLTEtMA_5bd24dd2-6492-423f-b363-973bcbe1e9b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81b1bd6d180f405fa9db296c77b6ed97_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtNS0xLTEtMA_a28956d7-41c7-4c1d-8f4e-348001bb399e">5,080,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b1bd6d180f405fa9db296c77b6ed97_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtNy0xLTEtMA_3ab8fb22-25b8-4a1f-bac0-bce8c3c4a1be">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if021b546b0cf4d20ba09dbffea09d212_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtOS0xLTEtMA_118eae40-bcb1-45ae-a915-68b1d75a3d48">107,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4efe31e6a2740e2a47f900a8411a6ac_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMTEtMS0xLTA_de4f1925-ebac-4f11-9602-d0e5f18de29e">101,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMTUtMS0xLTA_6b0b6721-dd6a-4c14-9810-d0b754d12dbc">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctNS0xLTEtMA_6f80c985-e864-44bb-9960-6f7fc79814cf">3,933,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930" decimals="-3" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctNy0xLTEtMA_651d1809-d350-4ac7-9fd5-6cecf771bd57">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctOS0xLTEtMA_228dacea-0d66-4ad9-86a5-0ad518cfc46b">14,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctMTUtMS0xLTA_2daa0c22-eb1a-4267-ba61-8943c0658c8c">14,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesPrefundedWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtNS0xLTEtMA_e6304003-e9b4-462d-af40-3d264f8ae973">448,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtNy0xLTEtMA_db124974-ca10-41e1-a754-3a272ed2643d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtOS0xLTEtMA_4fbd67ae-a299-4aad-91fc-8c3a12f023e2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtMTUtMS0xLTA_d02498cd-3d9f-4a94-89ca-23a8bb5de257">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzYtOS0xLTEtMA_8b031597-ada2-4c22-88a9-fdf1fabfb2ab">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzYtMTUtMS0xLTA_b1cb72b2-2fad-441a-80df-22ad8b3c36cf">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzctMTUtMS0xLTI5NA_ac28e83e-43d1-44a2-9c82-71d9d6e42f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic656a9beca124dbd893b34aa5140bd0a_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzgtMTEtMS0xLTA_61055b74-755c-4eb3-b847-2a6bfd728e24">13,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzgtMTUtMS0xLTA_6cfa9cbc-7944-44ad-9768-5f71ed040cfb">13,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17705d1efab94dde907052dd981f02a0_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMS0xLTEtMA_559f0ee7-0a4d-412c-925f-e03391965202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17705d1efab94dde907052dd981f02a0_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMy0xLTEtMA_3e0703eb-bc13-444f-9ef7-1ddef76f48d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktNS0xLTEtMA_b6f294b9-969f-434e-b275-ed554670b47c">9,461,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktNy0xLTEtMA_253e70c1-6f7e-4f23-a7c1-849ae4381227">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448e315df994429faf64be5d9e92cab2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktOS0xLTEtMA_e90cb9ba-8bc3-4cb6-9659-f7b821bbefc6">122,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic676874210a241b0962cf4ef4c61a42c_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMTEtMS0xLTA_8f77f039-9c8c-4232-8e2e-3d64ce670907">114,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMTUtMS0xLTA_302b58a6-94b4-4a5e-9e89-4e2b4b95a3fc">7,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic98a9c1849c14b238f015a559fd03855_I20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xLTEtMS0w_81bb5c0b-66c7-469a-99c1-85c59d105808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98a9c1849c14b238f015a559fd03855_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0zLTEtMS0w_819cbaa4-cdff-4434-a5bf-a15603f28402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae50a7116a1f45c48a4530ec81fdf221_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC01LTEtMS0w_86dc2414-4bc2-4c27-ab12-0f2257718cfe">2,002,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae50a7116a1f45c48a4530ec81fdf221_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC03LTEtMS0w_821efd05-7970-4ca4-ae3a-4696890ce8c4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d096b69f27a4dc9b506bd230ab72aa2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC05LTEtMS0w_ed6bdbd1-4967-4522-9c3b-f8e8d1016a38">103,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd470f4d5da4812aa588bd34055fd56_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xMS0xLTEtMA_f974273a-95cb-48f3-9d0a-78ebc688b85a">89,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8251699c639640ee881bf02c2e33e139_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xNS0xLTEtMA_10eb2def-ddea-45b1-a787-ad651b0e3b4d">14,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS01LTEtMS0w_100f71e1-7988-4cf1-9da4-f4f0df7b7c26">2,032,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS03LTEtMS0w_24ba331e-dfff-4da3-8bfb-fe5d695efc2c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS05LTEtMS0w_161584b4-330a-49f5-8db3-5a9c24622916">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS0xNS0xLTEtMA_ff2f2b1c-7610-4f01-a90c-6e66218b0fb1">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesPrefundedWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtNS0xLTEtMA_d46c2948-b70e-445e-993e-e2094bc62598">513,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtNy0xLTEtMA_5f48ca85-80af-4445-93bc-ebcf15b4a98e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtOS0xLTEtMA_6e35418a-ea1c-4d27-8f17-be5c5e85a773">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtMTUtMS0xLTA_7f04c7b1-14fb-4e6b-8073-9151746b62a3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktNS0xLTEtNTc_37e67062-b642-4fef-b311-a1a3f612c225">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktMTUtMS0xLTU3_e37aea47-2bf9-412a-a160-9f93e49d5028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktOS0xLTEtMA_f2da9f93-0ca9-4b33-8d8b-0838fcc4786a">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktMTUtMS0xLTA_c798e7a3-f462-4234-b44a-d4754c18a4a5">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333c91c266364b2eae464c53a8817f07_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjEtMTEtMS0xLTA_70d5288e-9aae-4eff-a736-861ef8a4dc72">4,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjEtMTUtMS0xLTA_66351b84-b0a6-4ca1-8364-f4e064654a6a">4,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMS0xLTEtMA_1cfb4bf0-d63e-47a3-be5b-520462711cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMy0xLTEtMA_686ea433-5976-453f-bba2-6c99cd0cc60a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItNS0xLTEtMA_958975e1-fdad-4499-8225-539ed13e755b">4,549,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItNy0xLTEtMA_8117075f-1e0d-4714-a7a4-7f67824dbe0f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7750e980bf85451d98229836daffbd55_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItOS0xLTEtMA_bd1d4778-3351-44e1-bc46-0f7793e4e22e">104,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMTEtMS0xLTA_715e82b4-5558-4c8b-9496-d980543e1277">93,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3865ec252344ced80fdda5644983129_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMTUtMS0xLTA_5fc98de2-b8eb-49db-9a0e-4a942a5fe35e">10,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12900c59fe2a4ff096fd101b525adf14_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMS0xLTEtMA_f4f477dd-0a5b-4cc8-8f2e-739b34afbd57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12900c59fe2a4ff096fd101b525adf14_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMy0xLTEtMA_4a9c2429-1902-4a48-894c-ed1e7eb876eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86b2f91724d24900ac8e54e3b467f7f3_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctNS0xLTEtMA_395c139e-8c5b-4eb7-8a49-fca30d47e18c">440,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b2f91724d24900ac8e54e3b467f7f3_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctNy0xLTEtMA_8d9f9653-c8af-495f-acc4-4e37c10756ec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f75e0d3fed4888b7432f8ab49025d4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctOS0xLTEtMA_d9bc1b0c-eb57-471b-87f6-33709ab1ad5f">87,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35b97499a01c4bbd86d34124af212071_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMTEtMS0xLTA_cd084bc1-be0c-464f-9fa8-b2e07f026846">81,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8205cb47ed594c60af87958ca345c78a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMTUtMS0xLTA_e4dd9f6a-178d-4fec-a5b5-5255a1dc094f">5,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtNS0xLTEtMA_de99908c-44cb-4677-bf41-b481af9e383b">527,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtOS0xLTEtMA_17a32be4-da50-4e4e-800d-98c406668545">13,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtMTUtMS0xLTA_a772a156-84a1-4f74-b9ae-a2ab6c0543b7">13,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of warrants, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtNS0xLTEtMA_1bb683da-40d2-44a3-8fef-f566200d6d65">2,095,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtNy0xLTEtMA_790a36b4-33fb-4143-a953-c4715b4b1249">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtOS0xLTEtMA_c0cf5e6d-5fb6-471c-80bc-9de087b2c59b">3,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtMTUtMS0xLTA_3e637b15-2fb0-4321-916e-a52a073d2d16">3,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="gale:StockIssuedDuringPeriodSharesPrefundedWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItNS0xLTEtMA_1fa4e4a7-3f17-4847-ac62-4b47fbc7e9fe">1,485,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItNy0xLTEtMA_643d730c-c0bf-4022-b10d-76cdb8c310f1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItOS0xLTEtMA_9fcc665a-f4af-4374-89e2-b24ff2906d81">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="gale:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItMTUtMS0xLTA_794ec22d-83f1-40c5-9765-cf4ad8687c5e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtNS0xLTEtNTA_693669a8-894f-439c-a4b9-3a80a2c5a9bd">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtMTUtMS0xLTUw_5deed578-5b20-4ce3-8713-1df91893a911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtOS0xLTEtMA_e0847f01-62bb-4cd2-af2c-a565d28d2955">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtMTUtMS0xLTA_1e3a02cc-b150-439b-8cf9-2d72f6fe63d4">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of anti-dilution protection on liability-classified warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930" decimals="-3" name="gale:DividendModificationOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDUtOS0xLTEtMA_16015042-90b5-4e1f-8d4f-5bf8c76167a3">243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="gale:DividendModificationOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDUtMTUtMS0xLTA_2189a202-d0da-4b50-a595-40d094e30986">243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifad85cecbb6d478c84dd680e20b243d9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDYtMTEtMS0xLTA_9127ada0-9749-46c3-8c18-94704085f128">11,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDYtMTUtMS0xLTA_080ded35-3e79-48c0-bc42-6da5ce6a5819">11,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMS0xLTEtMA_11e4a701-16de-4c39-9180-45ecb7a38b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMy0xLTEtMA_90298eca-0845-4536-bfb5-d90d1f25aa0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctNS0xLTEtMA_5a7a6a5b-8822-40fa-9fc3-600ed2aae8c8">4,549,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctNy0xLTEtMA_b76643e9-733c-4a41-affd-232cb842257b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7750e980bf85451d98229836daffbd55_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctOS0xLTEtMA_54e914b2-90b5-4fcf-8357-210006b914d7">104,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMTEtMS0xLTA_a498e6d6-6016-4277-8f21-46dcbca0cc5d">93,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3865ec252344ced80fdda5644983129_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMTUtMS0xLTA_b1642e4b-82d6-4e5d-a44e-fcf2516ce541">10,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMy0xLTEtMS0w_301c9c12-9c0a-467e-83c7-9755c8073b69">13,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMy0zLTEtMS0w_691257aa-ad1d-41e8-95a0-bb4aea49b341">11,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTUtMS0xLTEtMA_2e379468-21de-49d2-8e91-a1f5c21b5a3a">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTUtMy0xLTEtMA_aadc0798-beb0-4168-a6d7-2cf8e6e2aa6f">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTYtMS0xLTEtMA_178bbf69-fd69-496a-b147-0da561f95576">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="gale:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTYtMy0xLTEtMA_efec3e80-5ae7-4a57-bb57-5a2ee1a249ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjAtMS0xLTEtMA_fa1d1351-aba0-4652-882e-fb8df05c63b3">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjAtMy0xLTEtMA_acae6ade-2ad3-47ca-b8ff-55a52771753f">1,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" name="gale:ChangeInFairValueOfContingentPurchaseConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjItMS0xLTEtMA_13857269-1593-4082-a120-6606295115df">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" name="gale:ChangeInFairValueOfContingentPurchaseConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjItMy0xLTEtMA_4a772e29-7ee9-44ce-b1ea-c4702a64a98e">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjctMS0xLTEtMA_ff5d4ca2-0dc6-4842-921c-7f36aeb88d0c">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjctMy0xLTEtMA_d43f83f8-9250-4b6c-b131-3267b8e38c00">480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzAtMS0xLTEtMA_4eb19e78-11ad-4d70-ba2d-b280435425be">2,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzAtMy0xLTEtMA_a7ccc05a-7457-4076-af3f-f1117f62c73e">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzEtMS0xLTEtMA_c12d7585-4bf7-4196-9b4c-32da5f336a3b">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzEtMy0xLTEtMA_ad070146-a7fb-4788-bdd5-f39e7b13643b">715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzgtMS0xLTEtMA_ef499a90-e2a3-45b2-b478-3a0490456958">13,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzgtMy0xLTEtMA_9c911be2-ba00-4d5e-925e-e5065ec79ed8">13,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTMtMS0xLTEtMA_098ac3c4-1ff5-4596-8dd2-fec2df56076e">14,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTMtMy0xLTEtMA_211ae15e-788a-413b-aab6-b3219bb12e37">13,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collection of stock subscription receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ProceedsFromStockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTUtMS0xLTEtMA_414e58c0-8f03-41e3-abd3-3a38d6a11d1f">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="gale:ProceedsFromStockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTUtMy0xLTEtMA_455653ab-b768-414a-acba-3db89d76cd79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTYtMS0xLTEtMA_8ecc46f8-8e93-4b43-a6fa-1f4bd4ff9444">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTYtMy0xLTEtMA_36e2ccaf-3978-4d2d-b616-91236a944a55">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjQtMS0xLTEtMA_c3d79d11-6042-448d-8b7a-a3063ae6a9b9">14,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjQtMy0xLTEtMA_8b7614e6-6329-4062-aed0-a9bd6584a33a">17,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjUtMS0xLTEtMA_606262b5-5f2a-466b-a145-4e4c6cc3ed6e">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjUtMy0xLTEtMA_675dd142-d868-4b9c-a3ef-75ed866b2782">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjYtMS0xLTEtMA_562961f0-6d43-48ac-aecf-985d39715019">7,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8205cb47ed594c60af87958ca345c78a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjYtMy0xLTEtMA_87dc18e6-6050-4a47-b428-4eb00f381523">5,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjctMS0xLTEtMA_854f424b-b56e-4cde-afe1-d0ffe973f0f5">8,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3865ec252344ced80fdda5644983129_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjctMy0xLTEtMA_f36e6124-52c2-4aaa-817c-8be5e4c54018">9,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received during the period for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNzAtMS0xLTEtMA_19ffeebd-ccf3-4b87-8a53-52bddaaaea6e">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNzAtMy0xLTEtMA_b6d7c3fa-2d9f-4221-b323-d0725be88e23">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating right of use asset and current and non-current lease liability</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODAtMS0xLTEtMA_8d2d570f-6895-4c3d-a64d-1c9395857535">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODAtMy0xLTEtMA_9a918fd9-b72d-4ced-9fb1-d4d2ce012731">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of anti-dilution protection on liability-classified warrants</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:IncreaseDecreaseInFairValueOfWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODEtMS0xLTEtMA_c8bd9de2-c6f7-435f-a1a1-5069f0930dec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="gale:IncreaseDecreaseInFairValueOfWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODEtMy0xLTEtMA_fff46728-ca20-45f6-a641-d281a63899f4">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offering expenses in accounts payable and accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:NoncashOfferingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODItMS0xLTEtMA_0820db9d-1ace-45d0-93f1-4b3731786ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="gale:NoncashOfferingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODItMy0xLTEtMA_01049cf9-fd11-494f-9f63-3510598cebd1">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities upon exercise</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ReclassificationOfWarrantLiabilityUponExercise" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODQtMS0xLTEtMA_0443a0ad-dd23-44ae-b037-526ed79311af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="gale:ReclassificationOfWarrantLiabilityUponExercise" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODQtMy0xLTEtMA_7e19d762-39ad-474a-9f3c-89ddad732f37">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_37"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zNy9mcmFnOjkxYTFkYzM3Mjc0YTQ5MzU4MDU0Nzk0MWEyMDNlMWVkL3RleHRyZWdpb246OTFhMWRjMzcyNzRhNDkzNTgwNTQ3OTQxYTIwM2UxZWRfMzExNQ_d5ee9561-0334-457e-bef8-ecbf084f1e91" continuedAt="ia186b550942645d88a48cd6e353ac39f" escape="true">Description of Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia186b550942645d88a48cd6e353ac39f" continuedAt="i9b0681bd080e445fae1c1c87bf33d851"><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S ("GPS"), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. In January 2020, the Company commenced a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission. SELLAS&#8217; second product candidate, nelipepimut-S ("NPS"), is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i9b0681bd080e445fae1c1c87bf33d851">On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus as a &#8220;pandemic&#8221;. First identified in late 2019 and known now as COVID-19, the coronavirus outbreak has impacted millions of individuals worldwide and continues to present substantial public health and economic challenges around the world. It is difficult to predict with any certainty the length of time and the full extent to which the pandemic will continue to impact, directly and indirectly, our business and operations. The duration and extent of the impact of the pandemic will depend on future developments, which are highly uncertain, subject to change and cannot be predicted with confidence, including the duration of the outbreak, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, the re-emergence of more severe outbreaks in the fall or winter, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on the Company's business and the Company's financial results. The Company continues to monitor the situation closely, especially the extent to which precautions taken by clinical sites are impacting the timelines for the Company's clinical trials, including the Company's Phase 3 GPS trial, but given the uncertainty, management cannot estimate the impact of the COVID-19 pandemic on the Company's financial statements or operations.</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:LiquidationBasisOfAccountingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNjA2NQ_8ca08561-fc60-46c0-bec4-4e00d6cf5e4b" continuedAt="i345af0be861f47edb9b9d0ab6d8cfcf3" escape="true">Liquidity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i345af0be861f47edb9b9d0ab6d8cfcf3" continuedAt="i4d23b698b8e0434b9cca82955ed7de31"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes. It is likely that additional financing, beyond the financings described below, will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. The Company cannot be certain at this time of the impact of the COVID-19 pandemic on its ability to raise additional capital as needed, or on acceptable terms. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain investors  (the &#8220;PIPE Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), <ix:nonFraction unitRef="shares" contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfOTY3_273ce20b-2091-4d40-bd56-5a2ee4fb36b6">2,744,078</ix:nonFraction> shares of its common stock and accompanying warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTA1Nw_bf5832bd-ae29-4c31-baaf-2e93246317d4">2,744,078</ix:nonFraction> shares of common stock at a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTExNQ_3feac986-05b8-493d-be55-f9da87241164">3.335</ix:nonFraction> per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTIxOQ_c1025834-beb9-4dac-b67d-e28cf6e48c2f">3.30</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" format="ixt-sec:durwordsen" name="gale:ClassofWarrantorRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTI0OA_b7cb883a-9f5f-40ec-889b-23448855bd73">five years</ix:nonNumeric> from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTA5OTUxMTYzNDIyOQ_37041162-fe4f-4f7c-9147-f302f18ab02b">8.5</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January 2020 Registered Offering&#8221;), (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTgzMQ_cb5ee7cf-506d-4fdf-ba15-6e47246a980d">1,189,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" name="gale:OfferingPricePershare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTg4MQ_09ead92f-3956-4ac4-9a59-8deb75fbe3f0">3.9825</ix:nonFraction> per share and (ii) an aggregate of <ix:nonFraction unitRef="shares" contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109" decimals="INF" format="ixt:numdotdecimal" name="gale:ClassOfWarrantOrRightOutstandingExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTkxOQ_f29a4895-8b6d-46bf-b400-706f05f5f79d">448,800</ix:nonFraction> pre-funded warrants exercisable for shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109" decimals="INF" name="gale:OfferingPricePershare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjAzMw_559bd6f5-836f-43d0-9a21-82ad05bf3427">3.9725</ix:nonFraction> per Pre-Funded Warrant, for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109" decimals="-5" format="ixt:numdotdecimal" name="gale:ProceedsFromWarrantExercisesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjA5Ng_c71bc3aa-0f26-411f-9380-c9777cb3fae3">6.5</ix:nonFraction> million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjM0MA_8c660561-0433-49ca-91b5-9d938d02efa1">818,900</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjM5MA_d9371f36-c33e-4661-96a5-a2639324f350">3.93</ix:nonFraction> per share. Each warrant is immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjc0MA_bca39a6a-2dc7-4930-b577-35745fac5a20">6.0</ix:nonFraction> million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i4d23b698b8e0434b9cca82955ed7de31"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or the failure of any of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTU2OQ_2a93336a-b82e-47fd-b2ae-5525dd39e105">8.2</ix:nonFraction> million, and restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTYxNw_1a3d0115-3a0f-48e8-9fda-a0e941d75ab9">0.1</ix:nonFraction> million. The Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTczNw_bc46fb9b-a954-4157-abda-fe9cf1124c63">114.2</ix:nonFraction> million as of September&#160;30, 2020. In addition, the Company had current liabilities of $<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTgwMg_029116f9-11a4-49bd-a29c-1c1e49e6b9ba">4.2</ix:nonFraction> million as of September&#160;30, 2020. The Company expects its cash and cash equivalents as of September&#160;30, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements through the second quarter of 2021.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_46"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzOQ_b8753c9c-0ca9-4a9c-9b0f-b386b25bfb16" continuedAt="ie7f11f1a09754cf58229bd3d9c30620f" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie7f11f1a09754cf58229bd3d9c30620f" continuedAt="ie25203ce2f4840f7a6aae8c0e9582f77"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Summary of Significant Accounting Policies included in the Company's 2019 Annual Report have not materially changed, except as set forth below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzU0MQ_72bfae86-63f9-4558-a4b5-9da1d2c94119" continuedAt="ie8237ce63f4a4bc28e50fcc84ec72b14" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8237ce63f4a4bc28e50fcc84ec72b14">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzMw_db0be2e7-2325-42e3-9973-97670c89c950" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Interim Results </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2019 Annual Report. The accompanying consolidated financial statements at&#160;September&#160;30, 2020&#160;and for the three and nine months ended September 30, 2020 and 2019, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2019 have been derived from the audited financial statements as of that date.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie25203ce2f4840f7a6aae8c0e9582f77" continuedAt="i7e603536f5dc4345b2075cb7392f98ba"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2019, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1 - for - 50 reverse stock split of the Company's outstanding shares of common stock, which became effective on November 7, 2019. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company&#8217;s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans were proportionately adjusted for the reverse stock split.  The reverse stock split reduced the number of shares of the Company&#8217;s common stock that were outstanding at November 8, 2019 from <ix:nonFraction unitRef="shares" contextRef="i9d45ff94435e4d21ba5468a5bebac6bf_I20191107" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfMjgwNA_751bb022-1b15-4131-b890-def380437187">227,800,147</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i4f256c92ebda4e238a9aee699650ec0f_I20191108" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfMjgxMA_816dc64f-f0a3-44b5-92e2-c20618a7b116">4,549,208</ix:nonFraction>, after the cancellation of fractional shares. No fractional shares were issued in connection with the&#160;reverse&#160;stock&#160;split.&#160;Stockholders who otherwise held fractional shares of the Company&#8217;s common stock as a result of the&#160;reverse&#160;stock&#160;split&#160;received a cash payment in lieu of such fractional shares. These consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="gale:RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzU0Mw_922e5447-c5ab-4232-b71b-36b01ab76cfb" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units with Performance and Service Conditions</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the nine months ended September 30, 2020, the Board of Directors granted restricted stock units ("RSUs") to certain employees that vest based on performance and service conditions. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense is recognized for the number of RSUs expected to be earned, provided the requisite service period has been rendered, after assessing the probability that certain performance criteria will be met. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or are not expected to be met, any compensation expense previously recognized to date associated with the RSUs will be reversed.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzNw_16f105f0-ca49-423b-8c01-21caa008ebbf" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzNA_b3a46d71-c9dc-4ddd-b67c-bc604e84137b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib323751cda864ddea7a8246c632828fc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMi0xLTEtMS0w_d688da44-770e-4fcf-943c-0ca587174bcc">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d28b5ddb4f4e639e1959c1669e686e_D20190101-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMi0zLTEtMS0w_7535d630-bcf1-469b-b8e4-50c75b6aa39b">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i236474c05e0144e19db3cd5297f11f83_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMy0xLTEtMS0w_0cf02f71-a1b2-4a36-b0fa-58ecbfd95b91">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7605f1eb40c54e9c842276a939abedd4_D20190101-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMy0zLTEtMS0w_f5e8934e-d12a-4ccf-a3cf-c0fbfc7c2e7e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i336f4731de7d4c87aac9eb314ce2c08f_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNC0xLTEtMS0w_4889e936-4109-473f-b90e-0d2f38f1b5ab">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a636ae8cbfc46d18fa54ecab7fe2024_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNC0zLTEtMS0w_4494bf70-8667-4055-96a1-68579179b70f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNS0xLTEtMS0w_b5be64ed-68de-4beb-a65b-2d9c887dfccc">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNS0zLTEtMS0w_34e471f5-5a0d-4c4e-b14b-0334587d89aa">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7e603536f5dc4345b2075cb7392f98ba"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzOA_17124255-2cc7-4c1c-825a-a6993d333dd0" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, FASB issued No. ASU 2018-13,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU No. 2018-13")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820.&#160;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's disclosures. For the new disclosure regarding our Level 3 instruments, please read Note 4 to these consolidated financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Nonemployee Share-Based Accounting ("ASU No. 2018-07")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. ASU No. 2018-07 supersedes ASC 505-50 and expands the scope of ASC 718, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation (Topic 718) ("ASC 718")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's consolidated financial statements and related disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYxMw_18c32f2a-e5f1-451a-b29f-ec207b07917b" continuedAt="i1ed1772968ca42d3b7db0b883aed6073" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1ed1772968ca42d3b7db0b883aed6073" continuedAt="i592fe230a4f2456089270f0b392a3391"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYyNQ_2874a901-6c3a-458f-be28-72d61ef8840d" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi0xLTEtMS0w_9d9dd3db-f9ef-4326-8dee-53aed0380852">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi0zLTEtMS0w_e332640d-8cdc-4b5f-aaa8-5f6b392b3701">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi01LTEtMS0w_6d8dc1f3-196d-44ab-83d9-0ce32885949f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31133d38f51742738c72afb224c21907_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi03LTEtMS0w_03a9cb3c-4229-4ddd-a0da-8e4538f68447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC0xLTEtMS0w_4c55fbdd-4be1-4965-a929-77cc965c68f2">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC0zLTEtMS0w_628dcb8e-ff07-4f0a-892d-c85ccde1547e">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC01LTEtMS0w_b08b12b4-d921-4cbd-b778-a41888d1b89c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31133d38f51742738c72afb224c21907_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC03LTEtMS0w_ccb31ccb-ce6a-4b49-8a1d-49acb33fa784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi0xLTEtMS0w_4f2cfa87-7bd5-4bf7-85c7-81edcffc5100">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi0zLTEtMS0w_b21c6973-0415-498a-a735-a08cd592917b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi01LTEtMS0w_774b83af-d461-44b0-b3c2-5a91cdc47756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31133d38f51742738c72afb224c21907_I20200930" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi03LTEtMS0w_4a4f6902-5a6b-4fa8-8414-24fe5ae6376e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy0xLTEtMS0w_cf605c2d-ee28-4d5e-84f4-87d0451e6b10">5,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy0zLTEtMS0w_72f7c693-8a4b-43c9-8471-d56fd98d2c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy01LTEtMS0w_926dbbc3-c504-4596-9a91-5e8f931a5a96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31133d38f51742738c72afb224c21907_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy03LTEtMS0w_540caa9b-3011-4c4e-88fd-b1bc030ecfc3">5,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC0xLTEtMS0w_522f88ea-6fd4-43c4-a98b-83cb56815701">5,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC0zLTEtMS0w_aa9ed1ef-ef5a-48c0-89ce-149b508949b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC01LTEtMS0w_8f38e309-5fe1-439f-b451-769686d9d0c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31133d38f51742738c72afb224c21907_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC03LTEtMS0w_fb1e10ab-7c0f-48cc-b789-8a6e3d00aff6">5,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi0xLTEtMS0w_770085c2-0071-49b3-b002-189ccddbd9e1">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi0zLTEtMS0w_34f6a32f-2739-45fb-b7e2-ba2566d235a4">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi01LTEtMS0w_8e5ca5e8-6b3a-45e8-b58d-9daaf8f0bac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi03LTEtMS0w_d6d73805-2b05-47b2-bf66-5684b3f3c4a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC0xLTEtMS0w_1a845617-dec8-4389-9aa0-f7d3578f5357">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC0zLTEtMS0w_4732f767-5f66-49f0-9406-db43374e5574">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC01LTEtMS0w_03b55816-8753-499f-a239-235c41c7b162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC03LTEtMS0w_c0642edd-eef3-4690-b1b5-e5c565e82ddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi0xLTEtMS0w_025bbea1-5c45-44ca-b88e-193e3081beba">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi0zLTEtMS0w_fdf2fd02-5f6b-49c9-8644-98f6f14212d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi01LTEtMS0w_118dfef7-1fbb-4e7f-8a91-7e53c71970d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231" decimals="-3" name="gale:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi03LTEtMS0w_aa49a7d5-7c11-4d8b-80d7-cbc8b2d89401">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy0xLTEtMS0w_b2c5a515-1237-4f1e-a6c3-199328f0a4b8">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy0zLTEtMS0w_db1e69d5-3563-4783-80a2-bf50cc8e9da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy01LTEtMS0w_12c3abba-074c-4907-943e-eedb98d2cf27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy03LTEtMS0w_51a7de86-180a-4603-9e1c-7d2b9b76cb36">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC0xLTEtMS0w_b4805498-35ff-49d9-9e18-d51dc10d4e74">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC0zLTEtMS0w_f0aab80d-eb36-4719-8b8e-d71fa7394530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC01LTEtMS0w_3cb856ca-51ae-4a5c-8ff9-401b95dea5ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC03LTEtMS0w_d37e5279-b9d4-4add-8cab-8809577ad009">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any financial instruments into or out of Level 3 classification during the three or nine months ended September&#160;30, 2020 or during the year ended December 31, 2019.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the nine months ended September&#160;30, 2020. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i592fe230a4f2456089270f0b392a3391"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYxMQ_af761fcc-5a01-4ba5-80a7-6caaa0bbe402" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September&#160;30, 2020 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4007eb8b70cc49a894e1bdf6a68b797d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMS0xLTEtMS0w_126ea475-17e7-4984-bd2f-b6afc44ceda4">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a08e3cbcb5346b484952fa5670010dc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMi0xLTEtMS0w_52a87443-1490-4ac8-ae97-a561fac067b1">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i484453f41b684c819bd4de89fe5e44d7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMy0xLTEtMS0w_034d10c2-bab3-4440-85c4-4e66d8327c7a">5,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib4b789d256a64b4c94443e234118e471_I20111231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfOTY3_1cad0acf-2287-4bb5-8dbd-82e2ceec2f05">32.0</ix:nonFraction> million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s nelipepimut-S ("NPS") product candidate, of which $<ix:nonFraction unitRef="usd" contextRef="ic15be4f3595049579ffb1c76ee6bffb9_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMTEyMA_7929d503-e7ac-4fa5-b142-414e5d2d764d">2.0</ix:nonFraction> million has been paid to date. The remaining contingent consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMTE5NA_61433448-46fc-4b96-8276-35c03f6ef806">30.0</ix:nonFraction> million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of September&#160;30, 2020, estimated future contingent milestone payments related to the Company's business range from <ix:nonFraction unitRef="usd" contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjE2Mg_d6670afa-b770-41ac-9ee0-4456da152fdf">zero</ix:nonFraction>, if no milestone events are achieved, to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjIxOQ_0bd30cac-939a-423f-b4ca-0f737ba92992">30.0</ix:nonFraction> million if all development and commercial milestones are reached. As of September&#160;30, 2020, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of <ix:nonFraction unitRef="number" contextRef="i2a3529684d284f57abc0008fc0964ea3_I20200930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjQwMw_4c30ddc5-16e6-4c74-b1dd-18450f1572d4">11.8</ix:nonFraction>% for development milestones and cost of debt of <ix:nonFraction unitRef="number" contextRef="ic0ed1616c836452e8084ab91d06bef5c_I20200930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjQ1Mw_f6559bc9-7965-41e8-b5d3-e4a7a1888683">5.4</ix:nonFraction>% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4MQ_25e0b964-a33f-48bd-9fac-2954e0ad7f70">five</span> to <ix:nonNumeric contextRef="id8564c243eb44d16943c0ae16d68c94c_D20200101-20200930" format="ixt-sec:durwordsen" name="gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4Nw_251ba717-3482-453c-b726-3a04338ede60">eight years</ix:nonNumeric> as of September&#160;30, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_55"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjE0_f4b2b04e-d3cd-4331-b54f-68ba176e7c00" continuedAt="ib92ddc330d2644628c1a4e1efb30d7c1" escape="true">Balance Sheet Accounts</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib92ddc330d2644628c1a4e1efb30d7c1"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjE3_b533eddf-806c-4c6e-88d4-079f25c55c33" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMS0xLTEtMS0w_52a1dd57-fd76-4fc0-9acb-10b68473a980">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMS0zLTEtMS0w_d8236811-4cdc-4596-afd6-a7a8d18cd206">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:PrepaidResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMi0xLTEtMS0w_1179146f-9618-4921-a40c-65c778c09da7">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:PrepaidResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMi0zLTEtMS0w_18d4382c-797c-4f26-8223-b2222a98cb05">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:PrepaidProfessionalServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMy0xLTEtMS0w_57a7a770-02e2-4cce-aa21-f79694a0b2f5">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:PrepaidProfessionalServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMy0zLTEtMS0w_f8e5fbc4-38a8-4c7a-bf8f-cffd83e38332">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNC0xLTEtMS0w_95794dff-b220-4ab9-ade2-2d01ee98dd4c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNC0zLTEtMS0w_f626f940-ad66-437b-845c-259fce9e36fa">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNS0xLTEtMS0w_9c18cdaf-31eb-49a6-b38e-5860d6255615">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNS0zLTEtMS0w_a7716674-6bfe-4bd3-a536-4d5aa35ee5cd">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjEy_1f3ee3ac-dfb2-45d2-b330-432e45b8b03e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:ContractResearchPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMS0xLTEtMS0w_31d32eda-8105-4011-a608-bd0fa9368792">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:ContractResearchPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMS0zLTEtMS0w_3bff2631-9516-4c06-b714-df20fb7f6872">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMi0xLTEtMS0w_c6797f1c-1bf9-4597-a806-15709013e5d5">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMi0zLTEtMS0w_8c9b88c6-aeaf-4479-a9dd-eafa52cb8f9f">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMy0xLTEtMS0w_48273248-b7b5-438e-b2ef-241eadebf403">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMy0zLTEtMS0w_47f17989-9d89-4389-bd6e-5ca1509897fe">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMTUtMS0xLTEtMA_5fd4cd32-31e5-4d73-b6c5-ca0fcb9940f9">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMTUtMy0xLTEtMA_7ea842a6-b7f2-454f-b499-aced037d67e6">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNjIyMw_6bf15a35-122c-4e03-964c-99630f607d15" continuedAt="ib28dcca46c1247868303a3a05b8856f8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="ib28dcca46c1247868303a3a05b8856f8" continuedAt="ic5a207959434419db1a67203a4d0d8c8"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Space</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, the Company entered into a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The Company recognized a current operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNDAy_9192376d-658e-41f9-be58-f14dac98709c">0.1</ix:nonFraction>&#160;million and a non-current operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNDUy_f4129613-5bfd-490c-b39d-e06f7538465e">0.9</ix:nonFraction>&#160;million with a corresponding right of use asset ("ROU") of $<ix:nonFraction unitRef="usd" contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNTA2_cb2b83c2-f4af-494d-83eb-05fb681e10aa">1.0</ix:nonFraction>&#160;million, which is based on the present value of the minimum rental payments of the lease. The discount rate of the Company's operating lease under ASC 842 is the Company's estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i8c8fdb34b2cc44a58467c8e3974f9096_I20200630" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNzEz_29baf3e3-a4fe-4900-a910-ff66a0d1bc8c">13</ix:nonFraction>%. As of September&#160;30, 2020, the lease has a remaining term of <ix:nonNumeric contextRef="i71b0db59425c4a98acfb161fe0504728_D20200101-20200930" format="ixt-sec:duryear" name="gale:OperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNzcy_24dc0c36-5494-4077-a186-57bda2a1e8df">4.25</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a non-cancelable operating lease for office space in New York, New York, which began on August 1, 2018 with a term through July 31, 2020. The Company adopted ASC 842 in the first quarter of 2019 and as a result of the adoption, the Company recognized a current operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTA4Mw_b282cd03-1f80-46c3-b16b-b23dc3d4d764">0.4</ix:nonFraction> million and a non-current operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTEzMw_1d37e340-6746-4efa-ad1d-74c85452802a">0.2</ix:nonFraction> million with a corresponding ROU of $<ix:nonFraction unitRef="usd" contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTE2NA_062fba28-5cce-40ef-b626-611b3ae57a22">0.6</ix:nonFraction> million, which is based on the present value of the minimum lease payments of the lease. The discount rate used to account for the Company's operating lease under ASC 842 is the Company&#8217;s estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i483df898bc3046c6803892473d43f9dc_I20200930" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTM4Nw_2306bb07-5a9f-4128-a708-264c16851d7d">13</ix:nonFraction>%. The lease expired on July 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to the Company's operating leases was approximately $<ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTU2Mg_3f89806c-c6d8-4a82-8933-84718fdd4230"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTU2Mg_f944eb72-bbdb-473e-8496-be0bb13db970">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended September&#160;30, 2020 and 2019. Rent expense related to the Company's operating leases was approximately $<ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTY5Nw_3bdc7054-8f8e-47ce-95ad-b70f96d6c09c"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTY5Nw_5bee32aa-1ac7-448f-8cb5-cd308e87e2b5">0.3</ix:nonFraction></ix:nonFraction>&#160;million for each of the nine months ended September&#160;30, 2020 and 2019. <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNjIyOA_56bb1feb-e7a2-4f7b-ae3f-6c695f27d462" continuedAt="ice419b746ac44657a526bb3c2119dede" escape="true">Future minimum lease payments under the Company's non-cancelable operating leases are as follows as of September&#160;30, 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ice419b746ac44657a526bb3c2119dede"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMS0yLTEtMS0w_5aba471f-1aee-4b82-9c9e-5c85d77b4f5a">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMi0yLTEtMS0w_510255a4-6dc7-44dd-849b-22d8b15eb8fb">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMy0yLTEtMS0w_b104f453-c9ad-48a4-8493-bded15cef97e">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNC0yLTEtMS0w_efe3fd31-fca0-410a-9798-c56981460876">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNS0yLTEtMS0w_d8984249-26c3-4db1-b0a6-de45b1dfbfdb">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNi0yLTEtMS0w_a797a3bf-20ad-418a-9767-17527575fff9">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNy0yLTEtMS0w_47f3d850-8e43-44c0-a092-e45300d943a2">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfOC0yLTEtMS0w_e11afd95-e8de-419b-bcda-e0783bbac920">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease amortization of the ROU asset was $<ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="gale:OperatingLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTkyNA_37cda2d0-39de-4b43-b573-f7ec87752b54"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="gale:OperatingLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTkyNA_d009ccb2-45d6-4249-9c16-09e99f1c7f59">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended September&#160;30, 2020 and 2019 and $<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="gale:OperatingLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTk3OA_69718df3-3e59-4563-b1e1-20ddd5e7077f"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="gale:OperatingLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTk3OA_ee13efc3-f2cc-4be7-8de7-c14f2b4850ef">0.3</ix:nonFraction></ix:nonFraction>&#160;million for each of the nine months ended September&#160;30, 2020 and 2019.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic5a207959434419db1a67203a4d0d8c8"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss. On December 20, 2019, the lead plaintiffs filed a Second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, certain of the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the two complaints filed in the U.S. District Court for the District of New Jersey.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_61"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk4Mw_b196713d-10ce-499e-aa84-ac51c320e2ae" continuedAt="i4c4a43de6e84410cb6643825c62129a9" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="i4c4a43de6e84410cb6643825c62129a9" continuedAt="i3741d339456c491699d0c1dc1f75f818"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfODI_06c887ec-c727-4b12-b15d-559506b94e79">5,000,000</ix:nonFraction>&#160;shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTEy_fef4cffd-3d13-4ebf-ad3e-14fb5c53cd39">0.0001</ix:nonFraction>&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to <ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjAw_645a5e73-e79e-4478-9cf7-baf73689ae32">350,000,000</ix:nonFraction>&#160;shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjI3_6f200fe8-3675-4d2f-9c32-070bb0181d46">0.0001</ix:nonFraction>&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Maxim Group LLC (the "Agent"), pursuant to which the Company was permitted to offer and sell shares of common stock through the Agent having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029" decimals="-5" format="ixt:numdotdecimal" name="gale:SaleOfStockAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfNTU3_64a690af-07ae-4564-b533-69b00f154ab0">5.0</ix:nonFraction> million in gross proceeds. In connection with such sales, the Agent collected fees equal to <ix:nonFraction unitRef="number" contextRef="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029" decimals="INF" name="gale:SaleOfStockAgentFeePercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfNjQ0_a47be586-67a4-449d-866e-d92a60634861">3</ix:nonFraction>% of the gross sales price of all shares of common stock sold. Sales of the shares under the Distribution Agreement were made in transactions deemed to be "at the market offering" as defined in Rule 415 under the Securities Act of 1933. Shares sold under the Distribution Agreement were offered and sold pursuant to the Company's effective registration statement on Form S-3. During the year ended December 31, 2019, the Company sold&#160;<ix:nonFraction unitRef="shares" contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTA3OQ_fc9d228e-4299-4328-babf-4eed11e54a91">524,097</ix:nonFraction>&#160;shares of common stock pursuant to the Distribution Agreement for net proceeds of&#160;$<ix:nonFraction unitRef="usd" contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTE2NA_778e79d7-e01b-45c9-8fac-c2cd2bf8ae4c">2.7</ix:nonFraction> million. The Distribution Agreement was terminated on January 9, 2020. There were <ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTI0MQ_dbdcdca4-aea1-4b0b-89a8-e9f2a2635e4c">no</ix:nonFraction> shares of common stock sold pursuant to the Distribution Agreement in 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January 2020 Registered Offering&#8221;), (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY1OA_4d53dcb3-7f94-4157-8df5-c7662dd5687f">1,189,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY5NQ_44af0718-b79a-459d-9863-200c0d7ec4d8">0.0001</ix:nonFraction> per share, of the Company, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" name="gale:OfferingPricePershare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTc0OQ_d0b40b1e-6c66-40e6-a41e-28fe4275e0ca">3.9825</ix:nonFraction> per share and (ii) an aggregate of <ix:nonFraction unitRef="shares" contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109" decimals="INF" format="ixt:numdotdecimal" name="gale:ClassOfWarrantOrRightOutstandingExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTc4Nw_07dd8c68-e8ee-4763-91b9-6c779c897bbf">448,800</ix:nonFraction> pre-funded warrants exercisable for shares of common stock  at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109" decimals="INF" name="gale:OfferingPricePershare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTg3NA_31f356d7-7160-4657-adb1-6c079bf13c2b">3.9725</ix:nonFraction> per pre-funded warrant, for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109" decimals="-5" format="ixt:numdotdecimal" name="gale:ProceedsFromWarrantExercisesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTkzNw_caf04f2d-9d6c-4053-a3bd-a16894ea900b">6.5</ix:nonFraction> million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjE4MQ_edb94e84-eacf-42ff-a79f-53f46e35e828">818,900</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjIzMQ_99dead69-bbe7-40e4-81b1-98ada447dab9">3.93</ix:nonFraction> per share. Each warrant was immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, was approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjU2NQ_92300213-37c2-463f-a05e-926f56cad628">6.0</ix:nonFraction> million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain investors  (the &#8220;PIPE Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), <ix:nonFraction unitRef="shares" contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NDk3Mw_c06d4056-a06b-4040-a118-84626b90671c">2,744,078</ix:nonFraction> shares of its common stock and accompanying warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTA2NA_92b0525f-cbc2-43a1-9ab3-4a11b115dda5">2,744,078</ix:nonFraction> shares of common stock at a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTEyMw_4dddbba8-bf34-4c59-b966-3197f35a6b96">3.335</ix:nonFraction> per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTIyOA_84b38e90-670a-48ef-bb3a-7355b523b120">3.30</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" format="ixt-sec:durwordsen" name="gale:ClassofWarrantorRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTI1OA_549cbfc7-e189-495c-a5bf-26f3160d2e49">five years</ix:nonNumeric> from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTA5OTUxMTYzMjY3NA_8341c26f-312c-497e-baf5-7daf39b26f8e">8.5</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The shares of common stock (and shares of common stock underlying the warrants) issued in the July 2020 PIPE Offering were registered under the Securities Act of 1933, as amended, pursuant to a Registration Statement on Form S-3 (333-246333) filed with the Securities and Exchange Commission ("SEC") and declared effective on August 24, 2020. </span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3741d339456c491699d0c1dc1f75f818"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="gale:CommonStockAreReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk3Nw_52ddd188-4ab0-41d0-b6ee-51910381a40a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMC0xLTEtMS0w_f1cf5ea9-0f7f-40a3-802b-1d9d2052930b">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMi0xLTEtMS0w_214c2fe6-da70-4084-b9ec-e6166551f0e5">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMy0xLTEtMS0w_03a0d344-6df5-4277-ac87-bc650a2ec9ee">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNC0xLTEtMS0w_575faaf1-5b72-4fa5-b953-43f2fdc31bae">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNS0xLTEtMS0w_b00e2950-f8c1-41f3-9937-3e8790876413">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNy0xLTEtMS0w_29465096-a566-49a4-80d8-3798c1cf981d">4,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Subscription Receivable</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December 31, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjc2Nw_f5c9adff-dfd8-4ac2-9382-7ab826600753">75,000</ix:nonFraction> shares of common stock for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjgxNQ_adb27684-976d-43e5-b14d-eeacdd4b0ffd">0.3</ix:nonFraction> million. As the gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="id35672082f7945928e2de21782c5ccf4_D20200102-20200102" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjg0OQ_cd02740f-5a61-4c46-8f8b-30e25e7e4fb4">0.3</ix:nonFraction> million were not received until January 2, 2020, the Company recorded a stock subscription receivable of $<ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="gale:StockSubscriptionReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk0OQ_9c674b04-1130-459c-ad37-3f092330478e">0.3</ix:nonFraction> million as of December 31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_67"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwOA_87ae06f2-e199-49d9-a027-0f0755ed0ccb" continuedAt="i08aade12363b44f3ba8fb0ab2acdbb37" escape="true">Warrants to Acquire Shares of Common Stock</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="i08aade12363b44f3ba8fb0ab2acdbb37" continuedAt="i4f8c060c8c0b4b2095c081f69333711d"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Outstanding</span></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="gale:ScheduleOfWarrantActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwMw_17cc0cc5-4bb6-41ef-b945-09c545e168af" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the nine months ended September&#160;30, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if77a8a8ce50a4065b099f3a4946f25d2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0xLTEtMS0zOTE_655daf60-7c2a-4a91-a0bc-2fb8db1d65ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0zLTEtMS0zOTE_3b487bf0-2ff8-4dab-a13f-86111fb1bbb6">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS01LTEtMS0zOTE_0a358893-9e18-4ab9-a0fd-857c43f5e11b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS03LTEtMS0zODc_d2533d3c-08bd-44ba-ab30-eb00395d5ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd662d374f5e4b9b9f63ff15501e6a9b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS05LTEtMS0zODc_52ec9297-9090-46dd-bb22-acab8936b4db">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2003e91715cd42cd807932a074fadd24_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0xLTEtMS0w_4d2061d8-d77b-4c36-82ae-d7ce0c96d293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930" decimals="-3" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0zLTEtMS0w_2df7c229-449d-48fc-9517-d95bd41e54e0">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS01LTEtMS0w_72354da6-d1bc-4204-96ae-25575c8d49a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS03LTEtMS0w_239a206a-b599-4814-b385-541f8b6fa048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64f67ec1048a462997aa215f62c15d3a_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS05LTEtMS0w_4cafecdb-99fc-4ac0-b154-434f5615051c">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-funded January 2020 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4dd7532088040d9b73af1f7afd90860_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi0xLTEtMS0w_e1bfb9dc-10d7-44a6-a791-53d0d90b49a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930" decimals="-3" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi0zLTEtMS0w_f99a5628-7000-485e-add3-8ec012d736f9">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930" decimals="-3" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi01LTEtMS0w_bf36876b-b0c4-4a30-9c2e-94b97a61607b">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi03LTEtMS0w_c9a96e81-175e-4f3a-a1e2-e2d83468dc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27ccbdec896542ac98d4fd115dff1bcf_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi05LTEtMS0w_3c41c1b5-28ec-4c5d-8943-42cd26d82495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39ef75fb2fbe4b15858d159ac382757d_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy0xLTEtMS0w_ff19021a-1383-41ec-b081-dcc3d7a05bae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy0zLTEtMS0w_6174697b-94ed-4034-94b7-987c934c3bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy01LTEtMS0w_14c07857-30d7-4360-870b-23273fb97e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy03LTEtMS0w_f3a54e88-2655-461b-8ca0-1ac38d39e2e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d32eceb309447d9a734885748db45e_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy05LTEtMS0w_a0683777-fcec-4828-b94f-f80b7ff0a3d1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22fb77bdd14a4391afb857bad525ac58_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS0xLTEtMS0w_548ed0f8-3731-4214-85ec-da15c2de95a1">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS0zLTEtMS0w_c8c7d74b-945e-4e12-94f9-485a188aa26b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS01LTEtMS0w_948db8bb-cd2c-4c42-878e-39812aba4a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS03LTEtMS0w_9f9ae6dd-ef10-4f9d-b436-c129b320eccd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if92d800c33d7429d83e6b450093d5217_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS05LTEtMS0w_cf1dd969-adf1-47a7-ad48-8ef85b3f886e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e8dbce17eee4277b5a56ab7ba7dee3b_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi0xLTEtMS0w_16153057-ac90-4af1-b0c2-e8d53b47aa0e">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi0zLTEtMS0w_32bc5186-0fa2-47b4-88a0-8d95339407e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi01LTEtMS0w_a81f8c94-0654-47b6-a0fb-0c875f4ac864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi03LTEtMS0w_62e79588-0a58-4e25-8f8e-fd47eb39efc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f18bc2fcbb74091bfc8098930a1503d_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi05LTEtMS0w_956f83de-a907-4c6b-a1f8-9440602777ca">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC0xLTEtMS0w_2201e20d-901e-461c-8a77-62d496f765be">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC0zLTEtMS0w_cbf30478-1458-49b1-bd3b-67fe084e3818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC01LTEtMS0w_4bd56774-0d8a-4c3d-a1e0-1a7160f5be97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC03LTEtMS0w_550f3a70-3d4d-44df-9dc1-2929401ce91f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC05LTEtMS0w_0e73b9f4-330a-4c59-bfc6-b215c959d5da">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017 Equilibria</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i953ec750bdd64786866ccfc3f7f8baa2_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS0xLTEtMS0w_8bf3475c-b926-4b50-a813-224cc2a594f6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS0zLTEtMS0w_6f2e6b2c-6914-4f57-ab85-b2acc270cc2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS01LTEtMS0w_05d4bce9-614c-4c0f-a5c1-ed4330f05017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS03LTEtMS0w_51e23c5f-7b8d-478c-aade-91d71a3804c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9c5ca7b25c443cab31a8bdd3b02bad6_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS05LTEtMS0w_254dc1e7-1929-4c57-9080-330baa82e51a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtMS0xLTEtMA_8d75b708-cf0e-48c0-8b0b-5260ed8fff44">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtMy0xLTEtMA_c6a7dae9-f8bd-4922-882e-4fec4cd2fae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtNS0xLTEtMA_8bf47d22-ebeb-4154-8618-07837a9d79b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtNy0xLTEtMA_71e2ab39-3b64-412e-936c-b5b20a3f2fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtOS0xLTEtMA_c68d254f-0648-437c-bff8-3ee65069e5b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtMS0xLTEtMA_4eca72d3-9dee-4074-92ab-11b82b1bbb9e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtMy0xLTEtMA_b063b639-74a1-49a0-89a3-61e8f45041b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtNS0xLTEtMA_e75d64fc-de54-4472-a19c-c3b510ddd170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930" decimals="-3" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtNy0xLTEtMA_847565a1-d686-4935-a604-ad9148ab4f65">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3b14755124449839e31591a62b76734_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtOS0xLTEtMA_14852efd-2312-4f7a-9148-5c76eb8e6a83">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtMS0xLTEtMA_3a0ed3d4-ff2f-4cbb-8d29-5293e81addb9">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="gale:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtMy0xLTEtMA_8696a08c-ef8b-4116-bb16-0ad8f5795863">4,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtNS0xLTEtMA_cc9bcce7-ea1b-4c70-91c9-44b00899043c">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtNy0xLTEtMA_715ac4ad-47ee-4703-91ac-28cfc4206c07">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtOS0xLTEtMA_a7024a4f-c6a8-4ed2-b61c-4f73d202919d">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i4f8c060c8c0b4b2095c081f69333711d" continuedAt="i2899c12d3666412bb145453fb8a5f590"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Liabilities </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for Series A Convertible Preferred Stock, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined not to be indexed to the Company&#8217;s common stock. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDE5OQ_9dd3db0f-0e9e-4e3f-8c9a-15b8c6be8c2a" continuedAt="i97c813fa9f164c3d91c58880041d65de" escape="true">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i97c813fa9f164c3d91c58880041d65de"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy0xLTEtMS0w_4f1e9410-de3e-473b-9632-e76762d48283">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="INF" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy0zLTEtMS0w_d90b19de-2e17-4ae7-bcf9-b183488868d5">7.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy01LTEtMS0w_80599139-94e4-4b4e-aabb-ec4ebf4eabc0">3.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy03LTEtMS0w_6162b7ed-de00-466c-bb05-cd636d335626">131.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy05LTEtMS0w_18253e9b-7561-4c84-a282-872b982b80ad">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC0xLTEtMS0w_b5a5b772-68bd-4567-ab2c-ee4998c7e9f8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="INF" format="ixt:numdotdecimal" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC0zLTEtMS0w_f5d015ec-3eb0-4da2-b663-f7f60a42d760">1,650.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC01LTEtMS0w_7ee7d889-a925-46d4-8792-9994518006da">1.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC03LTEtMS0w_fb191b17-aa8d-4d8b-ba6a-bce43085115a">135.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC05LTEtMS0w_3c2fd750-35a2-4fcb-9d83-03bbb2953d60">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3b14755124449839e31591a62b76734_I20200930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS0xLTEtMS0w_b6a51555-a613-4786-93af-270b2b43a3e3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3b14755124449839e31591a62b76734_I20200930" decimals="INF" format="ixt:numdotdecimal" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS0zLTEtMS0w_75ba9fd9-277e-4b47-b826-bd8c30ecc85e">30,901.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS01LTEtMS0w_808d1b8d-04ec-4051-8ce4-2c1fca967111">1.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3b14755124449839e31591a62b76734_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS03LTEtMS0w_eb772154-861e-449c-84e5-7babaef60f90">135.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3b14755124449839e31591a62b76734_I20200930" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS05LTEtMS0w_95ecf282-11bc-47ed-b9c3-831ccc35ac8c">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItMS0xLTEtMA_d001f274-d701-4724-b497-5ada230c8260">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="INF" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItMy0xLTEtMA_c1408998-d7ee-400d-8bf0-289a1ff89d77">7.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib03011f148cb4758a40c754e531e9467_D20190101-20191231" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItNS0xLTEtMA_b64992f6-78ed-4b8f-8eda-439a20492567">3.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItNy0xLTEtMA_819385e2-d52e-45aa-ab08-43bf19d8ef08">112.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItOS0xLTEtMA_613e765c-aff7-4350-9ca1-9fbba8e1a1c1">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtMS0xLTEtMA_ebe86dd9-b9d0-4e02-8c1e-b90188ae59b6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="INF" format="ixt:numdotdecimal" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtMy0xLTEtMA_1cde35a4-e607-4565-98ab-9c87e078f6f0">1,650.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc95b8a4af8c45868a82d2bdc59aba55_D20190101-20191231" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtNS0xLTEtMA_6a9f0842-01ed-4353-9dd4-75b131e7f5ca">2.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtNy0xLTEtMA_2c582184-59f5-4cdf-b8db-6dc1ce811c6f">114.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtOS0xLTEtMA_d482f123-2c4f-4dba-a90a-3d8329cdcb72">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtMS0xLTEtMA_093f81c9-14db-4934-be9d-30b7321a8a24">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231" decimals="INF" format="ixt:numdotdecimal" name="gale:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtMy0xLTEtMA_c22f3ca1-25a4-4155-b3c2-84a1a1626864">41,494.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i454630a01309432fa2cd4d7cff6dfe26_D20190101-20191231" format="ixt-sec:duryear" name="gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtNS0xLTEtMA_ff2a9b2b-0e8c-4db2-ae92-a5febf67d2a4">1.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtNy0xLTEtMA_5efdcc32-8070-4f23-a75a-aea1c86b5bcd">114.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231" decimals="4" name="gale:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtOS0xLTEtMA_858d64fe-ded7-4b40-a0b7-19ccaab22d67">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the <ix:nonFraction unitRef="number" contextRef="i057e07bc9bcb479399b79efcba85a739_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMTU5Ng_5e9a2e1a-5429-4f1b-b321-f72902094a42">zero</ix:nonFraction> coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is <ix:nonFraction unitRef="number" contextRef="if56a535a800d461ab07716bd1239fb0f_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMTY5Ng_0c5dd025-f791-4d40-bf8d-9ebbfc078687">zero</ix:nonFraction>, because the Company has no present intention to pay cash dividends.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwNw_c67b8337-5892-4d53-9393-b7d1184fbbee" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the nine months ended September 30, 2020 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to exercise price of warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9131a32521e475eab282e97afd922ad_I20191231" decimals="-3" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0xLTEtMS0w_acbc5c06-e5b5-4596-8441-fe436e699666">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueofWarrantsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0zLTEtMS0w_684dac00-7c69-4e2c-86ec-65907c865485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsCanceled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS01LTEtMS0w_44e0217c-7047-476d-a08a-f45f4f822def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsExercisePriceAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS03LTEtMS0w_00d141ff-6003-4d9a-8c1a-3c5a7f4e6c95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930" decimals="-3" name="gale:ChangeInFairValueOfWarrantLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS05LTEtMS0w_cb4b900c-ea20-4aa2-87c0-374abca13a2e">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930" decimals="-3" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0xMS0xLTEtMA_7574f34f-81bf-43b0-9ca5-6f7728046a30">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0xLTEtMS0w_9afeeaa9-4121-45d0-a877-17447a605bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueofWarrantsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0zLTEtMS0w_1fed7196-6dae-43bf-8c8b-c7db5f65e5ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsCanceled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi01LTEtMS0w_c6642ca2-638b-4656-bfc1-5bc27216f0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsExercisePriceAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi03LTEtMS0w_36431bc0-5ac6-4f02-a333-62e30981a551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ChangeInFairValueOfWarrantLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi05LTEtMS0w_91160f3c-bbb2-41df-80b0-090deab19b72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0xMS0xLTEtMA_d9f1c8dd-c0e5-42b3-8ad3-6ae3848376f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0xLTEtMS0w_c7d74f14-7734-4196-ac83-d714b78992c6">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueofWarrantsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0zLTEtMS0w_c3985c3e-fcd0-40e4-8aea-3d72d401d85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsCanceled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC01LTEtMS0w_40c3d25d-d70e-4e53-b926-32312d1f6ac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:FairValueOfWarrantsExercisePriceAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC03LTEtMS0w_bac70c40-fc23-4223-944d-250216b112fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="gale:ChangeInFairValueOfWarrantLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC05LTEtMS0w_29465c34-3d22-4621-8593-efabcc62de2d">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="gale:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0xMS0xLTEtMA_22138af6-e7fa-49bd-8a37-1d1e42eae6d0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i2899c12d3666412bb145453fb8a5f590"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Equity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the January 2020 Offering and concurrent private placement and the warrants to acquire shares of common stock issued during the July 2020 PIPE Offering were recorded as equity upon issuance. During its evaluation of equity classification of these pre-funded warrants and common stock purchase warrants, the Company considered the conditions as prescribed within ASC 815-40,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,&#160;Contracts in an Entity&#8217;s own Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Modification</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company entered into a Warrant Exercise Agreement (the "March 2019 Exercise Agreement") with one of the holders of the Company's warrants issued in July 2018. Pursuant to the March 2019 Exercise Agreement, new warrants to purchase up to an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzQwNg_64c4c0e4-bf5e-4121-89c1-9711231b1a8b">76,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzQ1Ng_50c475fe-750f-49e6-8ee5-4c170fa64e93">70.00</ix:nonFraction> per share ("March 2019 Exercise Agreement Warrants") were issued on a share-for-share basis in an amount equal to the number of the warrants issued in 2018 that were cash exercised by the warrant holder prior to May 31, 2019. On January 2, 2020, the Company amended the March 2019 Exercise Agreement Warrants to provide for an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idcee970816de4898aab068f1436dc88c_I20200102" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzgwNA_98abfc38-7fc5-4b66-a72d-b7f8dc959772">7.50</ix:nonFraction> per share (subject to adjustment for stock splits and the like). The reduced exercise price of the <ix:nonFraction unitRef="shares" contextRef="ie359a0832f7942bdbf02a2c59e430ed4_D20200102-20200102" decimals="-3" format="ixt:numdotdecimal" name="gale:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzkwNg_75e54866-f11e-4337-a527-074fd69190bc">63,000</ix:nonFraction> March 2019 Exercise Agreement Warrants increased the fair value of these warrants by approximately $<ix:nonFraction unitRef="usd" contextRef="ic21ba327b68645e39db322f2b5490a05_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDAwOA_62a5c9f7-0171-4bad-93b4-c637b3b86782">0.1</ix:nonFraction> million during the nine months ended September 30, 2020, which is recorded as a deemed dividend increasing the net loss attributable to common stockholders and additional paid-in-capital.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwNA_749b7aef-1347-4360-9a7e-0a7cc8f61887" continuedAt="ic9fc220618d349c984def42bd159fa69" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic9fc220618d349c984def42bd159fa69" continuedAt="iaf0ce2c4ef9b4180b05848dd8b37c721"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of <ix:nonFraction unitRef="shares" contextRef="ic7c4d8cbc2a54d81bb75603f21e71592_I20171229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjIw_2029afab-6732-4c37-a932-2b2e3659486a">24,204</ix:nonFraction> shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to (i) <ix:nonFraction unitRef="shares" contextRef="i5e452b96408744e7b8df56fd8bb09e82_I20190910" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNzQ4_37bab700-8edc-4136-9d71-ddf17e92f5f3">454,005</ix:nonFraction> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) <ix:nonFraction unitRef="shares" contextRef="i2016b111d5d5438a9afb8026836b746a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfOTc3_3468f82b-2ed9-4d26-bcc4-7775deaf7932">2,684</ix:nonFraction> shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than <ix:nonNumeric contextRef="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTMxOQ_153322b4-4cb7-41e3-8397-16c0de4f0acc">four years</ix:nonNumeric>, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTQ0MA_31503786-dad9-470e-831c-200302e6dbc0">5</ix:nonFraction>% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="ie0346c87fde44172b58c4033836ca055_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTYyOQ_ce57177d-07d8-4900-8f84-f8958e0e104c">100,689</ix:nonFraction> shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYxNA_f2adcf1e-03f2-4303-be9d-e29ef359b61b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0326b4a15fb4f79b56050d8f382451e_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi0xLTEtMS0w_3fbd4604-4b01-46b9-bf4e-843b4af8f370">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e7017a8cdc4a0282dd6943f37e6465_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi0zLTEtMS0w_6cf343e1-29a2-4f79-8d3d-26c226c760a6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7978d211d17840e58f2b8d3d7d3796a0_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi01LTEtMS0w_372e5faf-aae5-44bd-b6f6-9a9ffa6b80b8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fa5608939c04c9f8ee26f0aac67c972_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi03LTEtMS0w_381c358d-73a6-43da-b0a8-81d14ee72169">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37be4be95af44ceaaaa2b49b0947ba57_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy0xLTEtMS0w_492f50f1-7eb4-4d1f-a3c2-62df4178786d">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c151f4f312b4f67ae012e478ef3df7e_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy0zLTEtMS0w_fde215b3-2bae-4e8c-9204-7caae42976f3">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcce4f272d22498990237677ea1747bc_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy01LTEtMS0w_20381012-ff73-4938-9c26-84f695c6b43c">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26e5d011619471ead5000df2785d4af_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy03LTEtMS0w_e80dee2e-54ad-45ec-a985-7e3a876775f9">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC0xLTEtMS0w_a44474d4-7504-4a50-ba67-2440e6058a9f">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC0zLTEtMS0w_fb4d921b-620c-43fd-93ce-6f87eb12a5fb">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC01LTEtMS0w_9b1ecc61-6e64-42df-8fdb-3cb8e330440b">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC03LTEtMS0w_30561a30-6aa4-4c0b-b41b-d8dd06151f91">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to Purchase Shares of Common Stock </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwMQ_282c087a-2f32-4304-a64f-6f1d7a11f9cd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the nine months ended September 30, 2020 and 2019, respectively, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMi01LTEtMS0w_ba478698-3bf2-4162-bd35-dbb1f5a9f44e">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMi03LTEtMS0w_c345abbb-fff1-4857-86af-adb0d3371357">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMy01LTEtMS0w_c39d0032-1dee-4e72-a9d2-49b0c65b64a0">106.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMy03LTEtMS0w_25d6f210-ede6-4cc9-9dd5-be2ff4a3d810">96.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNC01LTEtMS0w_b2201cc0-2ece-4250-9b77-9f5c199779a6">6.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNC03LTEtMS0w_0dd3e9b7-d762-4ce1-a967-ca7c77c60644">6.20</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNS01LTEtMS0w_bb18f877-37d4-4ae7-85ad-428b78987b78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNS03LTEtMS0w_5452d3a4-81d5-434b-abfb-d109cd1d01f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usdPerShare" contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjI3NQ_6633efc3-ca54-4646-b699-5b6cd699276d"><ix:nonFraction unitRef="usdPerShare" contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjI3NQ_b5947c7f-20a7-427f-aa24-ff014fb7f911">no</ix:nonFraction></ix:nonFraction> options granted during the three months ended September 30, 2020 and 2019. The weighted-average grant date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjQ1NA_b23acd7a-c86a-4031-9833-46dba7be2b3c">1.53</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjQ2MQ_7cbce498-8c2c-4cb2-ab0f-f1ca0800c449">54.00</ix:nonFraction>, respectively. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iaf0ce2c4ef9b4180b05848dd8b37c721"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjgyOQ_00712fa4-56b2-40f1-9120-857d8dd8933c">ten years</ix:nonNumeric> with the average vesting term of <ix:nonNumeric contextRef="i670c721655b24536abbe20f1d9e66a1e_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjg2NQ_1bb0d081-d9c1-414a-9e19-63470cd041d1">four years</ix:nonNumeric> for an average of approximately <ix:nonNumeric contextRef="i046188f82f2c42d1b09d3e35bf7d8bf5_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjkwMA_816109d8-2187-4a8c-9143-b71f00bf2f93">six years</ix:nonNumeric>. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is <ix:nonFraction unitRef="number" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzAzNw_751577b7-f344-4167-8c03-a3b003f1ae1f">zero</ix:nonFraction> because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzMxMA_c6fda687-732e-457e-8ebe-79db897f5be7">0.8</ix:nonFraction> million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:duryear" name="gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzUwMw_177a8d53-24ec-4713-9d36-e2cda69219e6">2.12</ix:nonNumeric> years.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYyMw_a1469ae2-e007-4df1-8536-b4be62ec426f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS0xLTEtMS0w_b394b987-e797-44ed-8bdb-3d20cc82c850">21,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS0zLTEtMS0w_9853d785-e80b-4b52-bedb-0a6aa874cd14">112.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS01LTEtMS0w_dbc808f0-48e7-4957-8cb4-361ff8ca5164">8.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS03LTEtMS0w_8b6212cb-9edf-436a-b17b-24bde9bd8165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi0xLTEtMS0w_c9f80769-7050-4363-9e23-1d12a441f068">186,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi0zLTEtMS0w_8d090d0a-4249-43a1-b1f4-107da3e4c4a2">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi03LTEtMS0w_f7685d52-4af4-4260-8308-61e09c3795dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS0xLTEtMS0w_fe550d3d-86df-4a15-8d40-69c2229d812c">207,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS0zLTEtMS0w_69ef6613-790f-465b-b336-6756045edf55">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS01LTEtMS0w_8a126f26-24b2-4711-b638-ec245a28fd16">9.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS03LTEtMS0w_714c81f0-7c5f-4a5a-99e5-ab39d4b24623">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi0xLTEtMS0w_8473241d-b8ab-48b2-b794-1ed1b7f36b5e">10,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi0zLTEtMS0w_1a6b0e37-bb5b-4a8e-95c5-1675e20c99dc">129.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi01LTEtMS0w_ad6bf8fd-14a9-46cb-ae42-d42122cf0be5">8.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi03LTEtMS0w_9ff34411-1524-4d54-b270-2b7d0f4d2801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of outstanding and exercisable stock options at September&#160;30, 2020 were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on September&#160;30, 2020 of $<ix:nonFraction unitRef="usdPerShare" contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930" decimals="INF" name="gale:ClosingPriceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzgwNA_367bb35d-ca85-4fc6-8927-a2ed0bdd14d2">2.65</ix:nonFraction> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs with Performance and Service Conditions </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted RSUs subject to both performance-based and service-based vesting conditions to certain of its employees&#160;pursuant to the Company's 2019 Equity Incentive Plan that will settle in shares of common stock. These RSUs vest based on&#160;the achievement of certain clinical and regulatory milestones and the respective employee's continued employment with the Company. As of September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDQ1OQ_66d895ae-9b2a-404d-8410-e9a65a0915da">0.3</ix:nonFraction> million of unrecognized compensation cost related to outstanding RSUs.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwMg_6e7cef16-7c17-4ddd-9a43-358ab8a26878" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97541f70c99c4d0d99f8987a97e11b2d_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMS0xLTEtMS0w_fca10be4-eb16-42f2-8cf1-aea1f33d7249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97541f70c99c4d0d99f8987a97e11b2d_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMS0zLTEtMS0w_45bf4c16-60a7-47cd-bbdb-0f7f47502a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMi0xLTEtMS0w_24245ae4-10e1-41bc-8cc3-aa8d122b7bdf">170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMi0zLTEtMS0w_c9cdf42d-54c4-4885-87ae-b854dd8d4d82">1.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMy0xLTEtMS0w_f8906885-c42e-4bdf-a9ea-a8a773f90a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMy0zLTEtMS0w_2b067a75-b037-4a93-8b4a-3c6b70fb89a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfNC0xLTEtMS0w_6e6e490e-0512-433c-84ba-d141a1abf156">170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfNC0zLTEtMS0w_f52e7a85-22bb-4664-93fe-a5ab667987fd">1.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ibab9091ab18243cd80fc8b0fdb9ba8dc_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183My9mcmFnOjJmMWU0YWYyNWY0NjRkNDU5M2VjZTJmOGNkYjkwZDFlL3RleHRyZWdpb246MmYxZTRhZjI1ZjQ2NGQ0NTkzZWNlMmY4Y2RiOTBkMWVfMTc4Mw_5f9327e1-d3b3-4ce4-8c5e-ac8494af73f7" continuedAt="icf037411f9654abfbf78362bb88f2765" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf037411f9654abfbf78362bb88f2765">The Company evaluated all events or transactions that occurred after September&#160;30, 2020 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of financial condition as of September&#160;30, 2020 and results of operations for the three and nine months ended September 30, 2020 and 2019, respectively, should be read in conjunction with Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in the 2019 Annual Report, and our other public reports filed with the SEC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_79"></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galinpepimut-S, or GPS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we commenced an investigator-sponsored clinical trial, or IST, of GPS in combination with Bristol-Myers Squibb&#8217;s anti-PD-1 therapy, Opdivo&#174; (nivolumab), in patients with malignant pleural mesothelioma, or MPM, which is being conducted at MSK. This Phase 1 open-label clinical study is enrolling patients with MPM who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy with the study drug provided by both us and Bristol-Myers Squibb. We expect initial data from this IST by the end of 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we commenced a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission, or CRem2, following successful completion of second-line antileukemic therapy. We expect this study, the Regal study, will be used as the basis for a Biologics License Application, or BLA, submission, subject to a statistically significant and clinically meaningful data outcome and agreement with the U.S. Food &amp; Drug Administration, or the FDA. The study is expected to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe and is contemplated to have a planned interim safety and futility analysis after 80 events (deaths) which we expect to occur by the end of 2021 or early 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we initiated a Phase 1/2 multi-arm (&#8216;basket&#8217; type) clinical study of GPS in combination with Merck &amp; Co., Inc.&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab).  We plan to enroll up to approximately 90 patients at up to 20 centers in the United States. The primary indication currently being studied in ovarian cancer (second or third line) with initial data from this study expected in the first half of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GPS was granted Orphan Drug Product Designations from the FDA, as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nelipepimut-S or NPS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor, or HER2, expressing cancers. Following positive data for the patients in the TNBC cohort received in 2018 from our Phase 2b clinical trial of the combination of trastuzumab (Herceptin&#174;) plus NPS in HER2 low expressing 1+ or 2+ per immunohistochemistry, or IHC) breast cancer patients in the adjuvant setting to prevent recurrences and subsequent discussions with the FDA, and based upon written feedback from the FDA and the totality of clinical, safety and translational NPS data to date, we have finalized the design and plan for a Phase 3 registration-enabling study of NPS in combination with trastuzumab for the treatment of patients with TNBC in the adjuvant setting after standard treatment. If successful, we believe this study may be considered as the basis for a BLA submission to the FDA.  We are seeking out-licensing opportunities to fund and conduct the future clinical development of NPS in order to maximize the potential of the program and we do not plan to conduct and fund a Phase 3 program for NPS on our own.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FBP-targeting bivalent vaccine (GALE-301/-302)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to prioritize development of our core assets, we have determined to cease development of GALE-301 and GALE-302, cancer immunotherapies that target the E39 peptide derived from the folate binding protein, or FBP, which were licensed in from The Henry M. Jackson Foundation, or HJF, and the MD Anderson Cancer Center, or MDACC.  We are currently negotiating a termination of the license agreement with HJF and MDACC.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus to be a &#8220;pandemic&#8221;. The COVID-19 pandemic continues to present substantial public health and economic challenges around the world which have impacted, and will continue to impact, millions of individuals and business worldwide. As we have historically functioned operationally as a semi-virtual company, the transition to &#8220;work-from-home&#8221; for our employees has not materially altered our business operations. We have implemented a return-to-work policy in compliance with federal, state and local requirements and guidance which provides for a hybrid of remote and in-office work, and we expect to operate on such a semi-virtual basis for the remainder of 2020 and into early 2021. We are continuously monitoring the impact of the pandemic on our clinical development programs. Our Phase 3 REGAL study is progressing, with the necessary work to activate additional sites in the United States and Europe has continued. During the third quarter of 2020, we initiated additional sites as planned. However, we are observing that clinical site initiations and patient enrollment may be delayed due to prioritization of hospital resources towards the COVD-19 pandemic. Clinicians and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt operations at sites. Accordingly, we are uncertain at this time the extent to which these newly initiated sites will be fully operational, which we believe could have an impact on the projected timing of the REGAL study. Additionally, several European Union countries in which we plan to initiate clinical sites, including Germany, France, and Italy, have imposed new "lockdown" restrictions in response to the recent surge in coronavirus cases throughout the European Union. Accordingly, we now believe that planned interim safety and futility analysis for the REGAL study may occur by the end of 2021 or early 2022. Screening is ongoing at the majority of the sites in the GPS + pembrolizumab combination study and we continue to expect initial clinical data from the basket study in the first half of 2021. We believe that the COVID-19 pandemic has not materially impacted our efforts to out-license NPS. The full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and cannot be predicted with confidence, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat COVID-19, the overall duration of the outbreak, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, and the re-emergence of more severe outbreaks in the fall or winter, among others. In particular, the continued spread of the coronavirus globally could adversely impact our clinical trial operations and could have an adverse impact on our business and the financial results.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing expenses; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control and quality assurance services;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">outsourced professional scientific development services; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments made under our license agreements, under which we acquired certain intellectual property; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses relating to certain regulatory activities, including filing fees paid to regulatory agencies; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory materials and supplies used to support our research activities; and </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses, utilities and other facility-related costs. </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of our clinical trials, which vary significantly over the life of a project as a result of many factors, including, but not limited to: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of clinical sites included in the trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the length of time required to enroll suitable patients; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients that ultimately participate in the trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of doses patients receive; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the duration of patient follow-up; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the results of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the expenses associated with manufacturing; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the receipt of marketing approvals; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of current and future product candidates; and</span></div><div style="padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the COVID-19 pandemic.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials due to the COVID-19 pandemic or otherwise, we could be required to expend significant additional financial resources and time on the completion of clinical development. Cancer immunotherapy product commercialization may take several years and millions of dollars in development costs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Cancer immunotherapy product candidates in the later stages of clinical development generally have higher development costs than those in the earlier stages of clinical development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase for the foreseeable future as we conduct and complete our ongoing early and late stage clinical trials and initiate additional clinical trials. </span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses, fees for outside legal counsel, and director and officer insurance premiums. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, accounting, consulting, legal and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC reporting requirements, investor relations costs, and other expenses associated with being a public company.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we believe that regulatory approval of a product candidate appears likely, we anticipate that an increase in general and administrative expenses will occur as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of such product candidate. </span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating (Expense) Income, Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating (expense) income, net consists of changes in fair value of our warrant liability, changes in fair value of our contingent consideration, and interest income, net.  Interest income, net primarily reflects interest earned from our cash and cash equivalents.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 2019 Annual Report, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no material changes to these policies since December&#160;31, 2019 that are not included in Note 3 of the accompanying consolidated financial statements for the three and nine months ended September&#160;30, 2020. Readers are encouraged to read the 2019 Annual Report in conjunction with this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September&#160;30, 2020 and 2019 </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:51.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,184)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,473)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,202)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:51.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,562)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,041)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,873)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further analysis of the changes and trends in our operating results are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $2.4 million for the three months ended September 30, 2020 compared to $1.8 million for the three months ended September 30, 2019. The $0.6 million increase was primarily attributable to a $0.3 million increase in clinical trial expenses primarily due to the initiation of our Phase 3 trial of GPS in AML in 2020, a $0.2 million increase in outsourced clinical and regulatory consulting services in support of our clinical programs, and a $0.1 million increase in personnel related expenses due to increased headcount. We anticipate that our research and development expenses will increase in the future as we continue to advance the development of GPS, including our Phase 3 trial of GPS in AML and the ongoing basket trial of GPS in combination with pembrolizumab.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $6.5 million for the nine months ended September 30, 2020 compared to $5.0 million for the nine months ended September 30, 2019. The $1.5 million increase was primarily attributable to a $1.1 million increase in clinical trial expenses primarily due to the initiation of our Phase 3 trial of GPS in AML in 2020, a $0.7 million increase in outsourced clinical and regulatory consulting services in support of our clinical programs, and a $0.2 million increase in personnel related expenses due to increased headcount. These increases were partially offset by a $0.2 million decrease in manufacturing expenses and a $0.3 million decrease in licensing fees per our license agreements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.1 million for the three months ended September 30, 2020 compared to $2.4 million for the three months ended September 30, 2019. The $0.3 million decrease was primarily due to a $0.2&#160;million decrease in legal fees, a $0.2 million decrease in personnel related expenses due to reduced headcount, and a $0.1 million decrease in other general and administrative expenses. These decreases were partially offset by a $0.2 million increase in insurance premiums due to hardening insurance markets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $6.3 million for the nine months ended September 30, 2020 compared to $7.5 million for the nine months ended September 30, 2019. The $1.2 million decrease was primarily due to a $1.4 million decrease in legal fees, a $0.5 million decrease in personnel related expenses due to reduced headcount, and a $0.2 million decrease in professional services. These decreases were partially offset by a $0.7 million increase in insurance premiums due to hardening insurance markets and $0.2 million in outsourced professional services and public company costs.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income (Expense), Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense), net for the three and nine months ended September 30, 2020 and 2019, respectively, was as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(907)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-operating income (expense) was nominal for the three months ended September 30, 2020 and 2019.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-operating expense of $0.2 million during the nine months ended September 30, 2020 was primarily due to the increase in the change in the fair value of the contingent consideration liability partially offset by a slight decrease in the change in the fair value of the warrant liability and nominal interest income. The change in the fair value of contingent consideration liability reflect the interest component of contingent consideration related to the passage of time. The decrease in the estimated fair value of our warrant liability was primarily due to a decrease in our common stock price.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-operating income of $0.7 million during the nine months ended September 30, 2019 was primarily due to a $1.1 million gain arising from the decrease in the fair value of liability-classified warrants to acquire shares of common stock, partially offset by a $0.5 million increase in the fair value of the contingent consideration liability. The decreases in the estimated fair value of our warrant liability were primarily due to decreases in our common stock price.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consisted of interest earned from our cash and cash equivalents.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of warrant liability and change in fair value of contingent consideration are non-cash in nature.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no income tax expense for the three and nine months ended September 30, 2020 and 2019. We continue to maintain a full valuation allowance against our net deferred tax assets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_85"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales or collaboration and licensing agreements during the three and nine months ended September&#160;30, 2020 and 2019. Since inception, we have incurred net losses, used net cash from our operations, and have funded substantially all of our operations through proceeds of the sale of equity securities and convertible notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, we entered into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain investors named therein (the &#8220;PIPE Investors&#8221;), pursuant to which we agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), 2,744,078 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,744,078 shares of common stock at a combined purchase price of $3.335 per share and accompanying warrant. The warrants are immediately exercisable at an exercise price of $3.30 per share and will expire five years from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to us from the July 2020 PIPE Offering, after deducting the placement agent fee and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$8.5&#160;million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we entered into a Securities Purchase Agreement, or the Purchase Agreement, with certain investors named therein, or the Investors, pursuant to which we agreed to issue and sell, in a registered direct offering by us directly to the Investors, or the January 2020 Registered Direct Offering, (i) an aggregate of 1,189,000 shares of our common stock at an offering price of $3.9825 per share and (ii) an aggregate of 448,800 pre-funded warrants exercisable for shares of our common stock, or the Pre-Funded Warrants, at an offering price of $3.9725 per Pre-Funded Warrant, for gross proceeds of approximately $6.5 million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, we issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share. Each warrant is immediately exercisable and will expire five and one-half years from the issuance date. The net proceeds to us from the January 2020 Registered Direct Offering, after deducting the placement agent fee and related offering expenses, and excluding the exercise of any warrants, was approximately&#160;$6.0 million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had an accumulated deficit of $114.2 million, cash and cash equivalents of $8.2 million, and restricted cash and cash equivalents of $0.1 million. In addition, we had accounts payable and accrued expenses and other current liabilities of $4.2 million as of September&#160;30, 2020. These matters raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This going concern assumption is based on management&#8217;s assessment of the sufficiency of our current and future sources of liquidity, considering whether or not it is probable we will be able to meet our obligations as they become due for at least one year from the date our consolidated financial statements are available to be issued, and if not, whether our liquidation is imminent. Our management believes that our cash and cash equivalents of $8.2 million as of September&#160;30, 2020 will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2021. We will require additional financing to fund our operations thereafter and to commercially develop any current or future product candidates. We may be required to delay, scale back or eliminate some or all of our research and development programs and place certain activities on hold or cease operations if we are unable to raise funds as needed. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. Our management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, payments from potential strategic research and development collaborations, and licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to engage in active discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to our pipeline candidates. To the extent that we raise additional capital through the sale of our common stock, the interests of our current stockholders may be diluted. If we issue additional preferred stock or convertible debt securities, it could affect the rights of our common stockholders or reduce the value of our common stock or any outstanding classes of preferred stock. There can be no assurance that these future funding efforts will be successful. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. An extended period of economic disruption could materially affect our access to sources of liquidity and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing transactions discussed above, (ii)&#160;our ability to complete revenue-generating partnerships with pharmaceutical companies, (iii)&#160;the success of our research and development activities, (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v)&#160;regulatory approval and market acceptance of our proposed future products. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows from operating and financing activities for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Flow from Operating Activities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $13.8 million during the nine months ended September&#160;30, 2020 was primarily attributable to our net loss of $13.0 million and a $1.6 million net change in our operating assets and liabilities, which was offset by various net non-cash charges of $0.8 million. The net change in our operating assets and liabilities of $1.6 million is primarily attributable to an increase in prepaid expenses and other current assets of $0.6 million and a $1.0 million decrease in accounts payable and accrued expenses and other current liabilities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $13.5 million during the nine months ended September 30, 2019 was primarily attributable to our net loss of $11.9 million. This amount was impacted by a non-cash gain of $1.1 million from the decrease in the fair value of liability-classified warrants, partially offset by various net non-cash charges of $0.9 million, which was comprised of $0.5 million increase in the fair value of our contingent consideration liability, and a $0.4 million increase in stock-based compensation. The net change in our operating assets and liabilities of $1.4 million is primarily attributable to an increase in prepaid expenses of $0.5 million, and a $0.9 million decrease in our accounts payable and accrued expenses and other current liabilities as we paid down longer outstanding payables during the nine months ended September 30, 2019.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Flow from Financing Activities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated $14.8 million of net cash from financing activities for the nine months ended September&#160;30, 2020. We received $14.5 million in aggregate net proceeds from our January 2020 Registered Offering and July 2020 PIPE Offering through the sale of securities and $0.3 million from the collection of our stock subscription receivable in January 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated $17.3 million of net cash from financing activities for the nine months ended September 30, 2019. We received $13.7 million in net proceeds from our June 2019 Offering through the sale of shares of common stock, pre-funded warrants to acquire shares of common stock, and accompanying common stock warrants to acquire shares of common stock. As of September 30, 2019, we had $0.2 million of offering expenses from the June 2019 Offering in accounts payable and accrued expenses that were paid in the fourth quarter of 2019. In addition, during the nine months ended September 30, 2019, we received $3.6 million in net proceeds from the exercise of warrants and pre-funded warrants.</span></div><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_88"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet financing arrangements as of September&#160;30, 2020.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_94"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and our principal financial officer (the &#8220;Certifying Officer&#8221;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this Quarterly Report on Form 10-Q:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_100"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 6 (Commitments and Contingencies) to our consolidated financial statements contained in Part I, Item 1 (Financial Statements) of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_103"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to our note on forward-looking statements on page 2 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in our 2019 Annual Report. The risks described in such 2019 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, operating results and stock price.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_109"></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_112"></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_115"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>#</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 13, 2018</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm">Amended and Restated By-Laws of the Registrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 5, 2018</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/tm2026370d1_ex4-1.htm">Form of Warrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/tm2026370d1_ex10-1.htm">Form of Purchase Agreement</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/tm2026370d1_ex10-2.htm">Form of Registration Rights Agreement</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls20200930ex103.htm">First Amendment to Amended and Restated Exclusive License Agreement between SLSG Limited LLC and Memorial Sloan Kettering Cancer Center, effective as of September 29, 2020**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls20200930ex311.htm">Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls20200930ex312.htm">Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls20200930ex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.*</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plans or arrangements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ibab9091ab18243cd80fc8b0fdb9ba8dc_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Angelos M. Stergiou</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 13, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>sls20200930ex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ibdb711aec9764d53847846ea3aa10bbc_32"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IRST AMENDMENT TO AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXCLUSIVE LICENSE AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">              This First Amendment to Amended and Restated Exclusive License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), effective as of September 29, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), is entered into by and between </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SLSG Limited LLC </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(together with its affiliates, hereinafter collectively &#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Company</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), a Delaware limited liability company with a place of business at 15 West 38</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, 10</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Floor, New York, New York 10018, and </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Memorial Sloan Kettering Cancer Center</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a New York not-for-profit corporation with a principal office address at 1275 York Avenue, New York, New York 10065 (&#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MSK</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, the Company is a wholly-owned subsidiary of Sellas Life Sciences Group Ltd., an exempted limited company incorporated under the laws of Bermuda with offices at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (&#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sellas Limited</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59; and</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, Sellas Limited is a wholly-owned subsidiary of SELLAS Life Sciences Group, Inc., a Delaware corporation with a place of business at 15 West 38</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, 10</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Floor, New York, New York 10018&#59; and</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, Sellas Limited and MSK entered into that certain Amended and Restated Exclusive License Agreement, dated as of October 10, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59; and</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, Sellas Limited assigned all of its right, title and interest in and to the Agreement to the Company pursuant to that certain Assignment of License dated as of June 28, 2019 by and between Sellas Limited, as assignor, and the Company, as assignee (the &#8220;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Assignment</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59; and</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, following and as a result of the execution of the Assignment, the Company is the successor-in-interest to Sellas Limited under the Agreement and is as of the Effective Date a Party and the Licensee under and pursuant to the Agreement&#59; and</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, the Parties to the Agreement desire to, and hereby do, amend the Agreement in accordance with the terms hereof.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NOW, THEREFORE, in exchange for the promises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the Parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">              1.           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Capitalized terms used, but otherwise not defined herein shall have the meanings given to such terms in the Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Original Patent Rights &#8211; Exhibit A</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to the Agreement is hereby amended by deleting such </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in its entirety and substituting in place thereof the copy of </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> attached hereto as </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Appendix 1</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to this Amendment and made a part hereof.  The definition of Original Patent Rights is automatically and without any further action by the Parties amended to include all of the patents and patent applications included within </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as amended by this Amendment.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Additional Patent Rights &#8211; Exhibit B</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to the Agreement is hereby amended by deleting such </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in its entirety and substituting in place thereof the copy of </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> attached hereto as </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Appendix 2</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to this Amendment and made a part hereof.  The definition of Additional Patent Rights is automatically and without any further action by the Parties amended to include all of the patents and patent applications included within </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as amended by this Amendment.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  The validity, enforcement, construction, and interpretation of this Amendment are governed by the laws of the State of New York and the federal laws of the United States of America, excluding the laws of those jurisdictions pertaining to resolution of conflicts with laws of other jurisdictions.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">              5.           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   This Amendment is binding on, and inures to the benefit of, the Parties, their authorized and permitted heirs, successors and assigns. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Counterparts&#59; Effective Date</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">  </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Parties may execute this Amendment by facsimile or other electronic transmission, in pdf file format or otherwise, and in counterparts. Each executed counterpart of this </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment will constitute an original document, and all executed counterparts, together, will constitute the same agreement.   This Amendment will become effective as of the Effective Date. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">              </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">           </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Complete Agreement&#59; Ratification and Confirmation</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The headings of the Sections of this Amendment are solely for convenient reference and neither constitutes a part of this Amendment nor affect its meaning, interpretation, or effect.  This Amendment, together with the Agreement, records the entire understanding of the Parties with respect to the terms of this Amendment and the Agreement and the restrictions and subject matter stated in it and them, and supersedes any previous or contemporaneous agreement, representation, or understanding, oral or written, by either of them.  The Agreement, as amended by this Amendment, is in full force and effect, and is hereby ratified and confirmed by the Parties in every respect.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing Amendment is executed as of the Effective Date. </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SLSG LIMITED LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Angelos Stergiou </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos Stergiou, M.D., ScD. h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 West 38th Street, 10th Floor</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, NY 10018</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEMORIAL SLOAN KETTERING CANCER CENTER</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Gregory Raskin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregor Raskin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Technology Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1275 York Avenue, Box 524</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, NY 10065</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Appendix 1 to the Amendment</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EXHIBIT A</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Original Patent Rights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:8pt;text-decoration:underline">SK1074 Synthetic HLA Binding Peptide Analogues and Uses Thereof</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Reference Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application&#47;Patent Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-01</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Provisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">60&#47;525,955</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Dec 1, 2003</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-03</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2004&#47;040347</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 30, 2004</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Canada</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">CA 2,548,135</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">May 31, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-02</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Europe</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">France</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">United Kingdom</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Germany</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Italy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Switzerland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Spain</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP 1708732</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Jun 29, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-05</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Australia</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">AU 2004294345</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Jul 6, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1074-06</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - United States</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">7,488,718</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 30, 2004</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">SK1219 WT1 HLA Class II-Binding Peptides and Compositions and Methods Comprising Same</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Reference Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application&#47;Patent Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-01</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Provisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">60&#47;726,608</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Oct 17, 2005</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-02</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Provisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">60&#47;728,304</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Oct 20, 2005</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-03</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2006&#47;040719</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Oct 17, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Europe</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">France</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">United Kingdom</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Germany</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Ireland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Italy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Switzerland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Spain</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP 1951281</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 17, 2008</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-09</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Europe - Divisional</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">France</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">United Kingdom</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Germany</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Ireland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Italy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Switzerland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Spain</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP 2565201</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Jun 14, 2012</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-06</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - United States</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8,765,687</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sep 27, 2009</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-10</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">9,233,149</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sep 16, 2013</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-27</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">10,221,224</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Jan 8, 2016</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1276-27</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">16&#47;270,444</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Feb 7, 2019</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-07</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Canada</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2,626,238</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 17, 2008</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-18</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National -Canada - Divisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2,900,087</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Oct 17, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1219-08</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Australia</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2006304573</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 17, 2008</font></div></td></tr></table></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">SK1225 Synthetic HLA Binding Peptide Analogues and Uses Thereof</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Reference Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application&#47;Patent Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1225-01</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">7,598,221</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sep 12, 2005</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Immunogenic WT-1 Peptides and Methods of Use Thereof</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Reference Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application&#47;Patent Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-01</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Provisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">60&#47;790,526</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 10, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-02</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Provisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">60&#47;852,009</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Oct 17, 2006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-03</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2007&#47;008853</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 10, 2007</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-06</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Canada</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">CA 2645766</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 9, 2008</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-05</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Europe</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Austria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Belgium</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Finland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">France</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">United Kingdom</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Germany</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Greece</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Ireland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Italy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Netherlands</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Poland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Romania</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Switzerland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Spain</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Turkey</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP 2010209</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 10, 2008</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-08</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Europe - Divisional</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">16173687.1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Apr 10, 2007</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-25</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Extension &#8211; Hong Kong</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">17107134.3</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Jul 17, 2017</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - United States</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">9,265,816</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Dec 2, 2009</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK1233-26</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">16&#47;359,897</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mar 20, 2019</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Appendix 2 to the Amendment</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EXHIBIT B</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Additional Patent Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Immunogenic WT-1 Peptides and Methods of Use Thereof</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Pearl Cohen Ref.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Ref.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application&#47;Patent Number</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-USP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-02</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">US Provisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">61&#47;752,799</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2013</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-US</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-04</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; US</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">9,919,037</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">July 14, 2015</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-US2</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-10</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Continuation</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">15&#47;920,335</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">March 13, 2018</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-PC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-03</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2014&#47;011711</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-AU</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-05</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Australia</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2014207615</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-AU1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-11</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Australia - Divisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2018241209</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-CA</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-06</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Canada</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2,898,099</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-CN</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-08</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; China</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">201480010289.3</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-MO</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-14</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Extension &#8211; Macau</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">J&#47;003740</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">July 1, 2019</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-CN1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-12</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - China - Divisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">201910196887.9</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-HK</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-15</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Extension &#8211; Hong Kong</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">42020002109.5</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 31, 2020</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-EP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-09</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Europe</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP14741142.5</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-EP1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(unknown)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Europe &#8211; Divisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EP20193303.3</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">August 28, 2020</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-JP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-07</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Japan</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">6486278</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-76807-JP1</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2011-072-13</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National - Japan - Divisional</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2019027238</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">January 15, 2014</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">2. Methods and Compositions for Treating Cancer</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:18.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Pearl Cohen Ref.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">MSK Ref.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application Number</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-USP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(unknown)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">US Provisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">62&#47;258,134</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 20, 2015</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-PC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-02</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2016&#47;062865</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-US</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-03</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; US</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">15&#47;777,514</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">May 18, 2018</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-AU</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-09</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Australia</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2016356708</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-CA</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-04</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Canada</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3,005,896</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-CN</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-05</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; China</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">201680077975.1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-HK</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(unknown)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Extension &#8211; Hong Kong</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">19119785.4</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Feb 21, 2019</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-EP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-08</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Europe</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">16867262.4</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-JP</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-06</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; Japan</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2018-526090</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">P-79550-KR</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SK2015-113-07</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">National &#8211; South Korea</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">10-2018-7017393</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Nov 18, 2016</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">3. Multi-Valent Immunotherapy Composition and Methods of Use for Treating WT1-Positive Cancers</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:20.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">SLE Ref.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Type of Filing</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Application Number</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Date of Filing</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SEL.102P</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">US Provisional</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">62&#47;832,244</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">April 10, 2019</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SEL.102XC1PCT</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PCT&#47;US2020&#47;027681</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">April 10, 2020</font></div></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sls20200930ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i40c84e73d2e74e898f3681621fd6ae29_32"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Angelos M. Stergiou, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.  The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;13, 2020</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sls20200930ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i37256b19cb4b44f8a31554925bd2f524_32"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Angelos M. Stergiou, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;13, 2020 </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sls20200930ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ide9886328eee41a9b64581b69047ae17_32"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report of SELLAS Life Sciences Group, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;13, 2020</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by&#160;Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gale-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gale="http://www.galenabiopharma.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.galenabiopharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.galenabiopharma.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.galenabiopharma.com/role/Liquidity">
        <link:definition>2102102 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityDetails" roleURI="http://www.galenabiopharma.com/role/LiquidityDetails">
        <link:definition>2403401 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2109104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2310302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails">
        <link:definition>2411404 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccounts" roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccounts">
        <link:definition>2114105 - Disclosure - Balance Sheet Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsTables" roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables">
        <link:definition>2315303 - Disclosure - Balance Sheet Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2416407 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2417408 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingencies">
        <link:definition>2118106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>2319304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2420409 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2122107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2323305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2424411 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails">
        <link:definition>2425412 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStock" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock">
        <link:definition>2126108 - Disclosure - Warrants to Acquire Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockTables" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables">
        <link:definition>2327306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails">
        <link:definition>2428413 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails">
        <link:definition>2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails">
        <link:definition>2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2132109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2333307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2434417 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockbasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails">
        <link:definition>2435418 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails">
        <link:definition>2436419 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2437420 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUActivityDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails">
        <link:definition>2438421 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2139110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gale_July2020PIPEOfferingMember" abstract="true" name="July2020PIPEOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_OfficeSpaceLeaseExpiringJuly312020Member" abstract="true" name="OfficeSpaceLeaseExpiringJuly312020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_FairValueofWarrantsGranted" abstract="false" name="FairValueofWarrantsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_DividendArisingFromWarrantModifications" abstract="false" name="DividendArisingFromWarrantModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" abstract="false" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ClassofWarrantorRightCanceledOrExpired" abstract="false" name="ClassofWarrantorRightCanceledOrExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_July2019OfferingMember" abstract="true" name="July2019OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" abstract="false" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gale_ClassofWarrantorRightFairValueRollForward" abstract="true" name="ClassofWarrantorRightFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gale_July2018OfferingMember" abstract="true" name="July2018OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_OperatingLeaseRightOfUseAssetAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" abstract="false" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_PIPEInvestorsMember" abstract="true" name="PIPEInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_WarrantExerciseAgreementMember" abstract="true" name="WarrantExerciseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_DividendModificationOfWarrants" abstract="false" name="DividendModificationOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_MeasurementInputWeightedAverageCostOfCapitalMember" abstract="true" name="MeasurementInputWeightedAverageCostOfCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gale_ContractResearchPayable" abstract="false" name="ContractResearchPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_MeasurementInputCostOfDebtMember" abstract="true" name="MeasurementInputCostOfDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" abstract="false" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_February2017WarrantsMember" abstract="true" name="February2017WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_ClassOfWarrantOrRightOutstandingExercisable" abstract="false" name="ClassOfWarrantOrRightOutstandingExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_ClosingPriceOfCommonStock" abstract="false" name="ClosingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="gale_TwoThousandAndSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_OfficeSpaceLeaseExpiringDecember312024Member" abstract="true" name="OfficeSpaceLeaseExpiringDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_StockIssuedDuringPeriodValuePreFundedWarrant" abstract="false" name="StockIssuedDuringPeriodValuePreFundedWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ProceedsFromStockSubscriptionReceivable" abstract="false" name="ProceedsFromStockSubscriptionReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_Warrants2020Member" abstract="true" name="Warrants2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" abstract="false" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gale_ProceedsFromWarrantExercisesGross" abstract="false" name="ProceedsFromWarrantExercisesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_StockIssuedDuringPeriodValueCommonStockandWarrants" abstract="false" name="StockIssuedDuringPeriodValueCommonStockandWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_FairValueOfWarrantsLiabilities" abstract="false" name="FairValueOfWarrantsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_AptheraInc.Member" abstract="true" name="AptheraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" abstract="false" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_Warrants2019Member" abstract="true" name="Warrants2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_EqcWarrantsMember" abstract="true" name="EqcWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gale_PrepaidResearchAndDevelopment" abstract="false" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_SeriesAConvertiblePreferredWarrantsMember" abstract="true" name="SeriesAConvertiblePreferredWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_TwoThousandAndNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" abstract="false" name="StockIssuedDuringPeriodSharesCommonStockandWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_ScheduleOfWarrantActivityTableTextBlock" abstract="false" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gale_DistributionAgreementMember" abstract="true" name="DistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_WarrantStrikePrice" abstract="false" name="WarrantStrikePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="gale_ClassofWarrantorRightTerm" abstract="false" name="ClassofWarrantorRightTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" abstract="false" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" abstract="false" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ClassofWarrantorRightOutstandingRollForward" abstract="true" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" abstract="false" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" abstract="false" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_StockSubscriptionReceivableCurrent" abstract="false" name="StockSubscriptionReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" abstract="false" name="RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" abstract="false" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gale_FairValueOfWarrantsExercisePriceAdjustment" abstract="false" name="FairValueOfWarrantsExercisePriceAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_StockIssuedDuringPeriodSharesPrefundedWarrant" abstract="false" name="StockIssuedDuringPeriodSharesPrefundedWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_ChangeInOperatingLeaseRightOfUseAssets" abstract="false" name="ChangeInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" abstract="false" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gale_InProcessResearchDevelopment" abstract="false" name="InProcessResearchDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" abstract="false" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gale_OfferingPricePershare" abstract="false" name="OfferingPricePershare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="gale_SaleOfStockAgentFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAgentFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gale_FairValueOfWarrantsCanceled" abstract="false" name="FairValueOfWarrantsCanceled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gale_January2020OfferingMember" abstract="true" name="January2020OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_PrepaidProfessionalServices" abstract="false" name="PrepaidProfessionalServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_IncreaseDecreaseInFairValueOfWarrantLiability" abstract="false" name="IncreaseDecreaseInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_OtherWarrantIssuesMember" abstract="true" name="OtherWarrantIssuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_PreFundedJune2019OfferingMember" abstract="true" name="PreFundedJune2019OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gale_ChangeInFairValueOfWarrantLiabilities" abstract="false" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gale_NoncashOfferingExpense" abstract="false" name="NoncashOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>gale-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Cover" xlink:type="simple" xlink:href="gale-20200930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_432ab562-c04d-46a6-9d58-27e1f43f674f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:to="loc_us-gaap_AssetsCurrent_432ab562-c04d-46a6-9d58-27e1f43f674f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_57fef1c2-18cd-48f2-ac1a-89b5d2789324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_57fef1c2-18cd-48f2-ac1a-89b5d2789324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_InProcessResearchDevelopment_bbec0d6d-8025-467d-a0d6-1dfa6dd9899d" xlink:href="gale-20200930.xsd#gale_InProcessResearchDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:to="loc_gale_InProcessResearchDevelopment_bbec0d6d-8025-467d-a0d6-1dfa6dd9899d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5045cc6b-d138-492e-8884-5266742a1062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:to="loc_us-gaap_Goodwill_5045cc6b-d138-492e-8884-5266742a1062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_9adc6ea3-56bf-4055-92d1-28ec05946940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ae61856f-a447-4be9-9c75-8ae2a7639c92" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_9adc6ea3-56bf-4055-92d1-28ec05946940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4df8cd0a-e555-4701-b091-6cbdff4b433c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_739e77eb-5f34-478a-aa3d-359e175f26ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df8cd0a-e555-4701-b091-6cbdff4b433c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_739e77eb-5f34-478a-aa3d-359e175f26ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bcc2698f-a150-433e-a8a6-e7d5a550abcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df8cd0a-e555-4701-b091-6cbdff4b433c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bcc2698f-a150-433e-a8a6-e7d5a550abcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6668d7c5-e933-44fe-8b88-582f6bc63424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df8cd0a-e555-4701-b091-6cbdff4b433c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6668d7c5-e933-44fe-8b88-582f6bc63424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockSubscriptionReceivableCurrent_7b1f6ec7-22de-44e6-b521-a8275898c54f" xlink:href="gale-20200930.xsd#gale_StockSubscriptionReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df8cd0a-e555-4701-b091-6cbdff4b433c" xlink:to="loc_gale_StockSubscriptionReceivableCurrent_7b1f6ec7-22de-44e6-b521-a8275898c54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_82733f5b-b81b-4b6e-b3c9-fcba60b0ef5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b54b0fa9-d737-4a9f-8235-06d9121b3756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_82733f5b-b81b-4b6e-b3c9-fcba60b0ef5d" xlink:to="loc_us-gaap_Liabilities_b54b0fa9-d737-4a9f-8235-06d9121b3756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48113631-a940-40e3-93e0-a99f4ecd4fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_82733f5b-b81b-4b6e-b3c9-fcba60b0ef5d" xlink:to="loc_us-gaap_StockholdersEquity_48113631-a940-40e3-93e0-a99f4ecd4fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f8b72e06-5685-43fd-bcb4-151b65ec1772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_82733f5b-b81b-4b6e-b3c9-fcba60b0ef5d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f8b72e06-5685-43fd-bcb4-151b65ec1772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_399a1f92-2244-4308-b21d-447175644d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:to="loc_us-gaap_LiabilitiesCurrent_399a1f92-2244-4308-b21d-447175644d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_abb46136-8356-44ac-b032-bb62beaf6fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_abb46136-8356-44ac-b032-bb62beaf6fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_461314bb-a30c-44de-859c-f077b44a5ed0" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_461314bb-a30c-44de-859c-f077b44a5ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_5bedcd87-a3e0-4bb3-b0d0-f4dec9795f45" xlink:href="gale-20200930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_5bedcd87-a3e0-4bb3-b0d0-f4dec9795f45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5a56d11-c926-443f-810b-c34f47caa546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_01501186-1479-45a7-8de4-cb5f1899cb7d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5a56d11-c926-443f-810b-c34f47caa546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f11bc4f4-5741-4d1e-8665-7bcd733955af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_089f09ca-69b8-4779-be26-dbae3a89b481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f11bc4f4-5741-4d1e-8665-7bcd733955af" xlink:to="loc_us-gaap_PreferredStockValue_089f09ca-69b8-4779-be26-dbae3a89b481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fa31770e-bec4-42ef-9711-a53a1e91af2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f11bc4f4-5741-4d1e-8665-7bcd733955af" xlink:to="loc_us-gaap_CommonStockValue_fa31770e-bec4-42ef-9711-a53a1e91af2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6afaee28-4b72-4f74-a80e-10bd19e777b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f11bc4f4-5741-4d1e-8665-7bcd733955af" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6afaee28-4b72-4f74-a80e-10bd19e777b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae40d278-771c-4ea8-8b2f-cea187c20c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f11bc4f4-5741-4d1e-8665-7bcd733955af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae40d278-771c-4ea8-8b2f-cea187c20c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fca15340-befc-4409-9311-5b4ece9fff7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8c010e54-eba0-4018-af56-e85f6240694b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fca15340-befc-4409-9311-5b4ece9fff7c" xlink:to="loc_us-gaap_AccountsPayableCurrent_8c010e54-eba0-4018-af56-e85f6240694b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4eae9fcb-b43d-4014-8e5f-bd984e03aba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fca15340-befc-4409-9311-5b4ece9fff7c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4eae9fcb-b43d-4014-8e5f-bd984e03aba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_56bb8d31-08a8-42f1-ac4b-3ca7601f268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fca15340-befc-4409-9311-5b4ece9fff7c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_56bb8d31-08a8-42f1-ac4b-3ca7601f268a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e345d8d-8f2a-4686-a8c7-985fae206641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81ec72d1-3c97-40db-acb1-2aa1552fc841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e345d8d-8f2a-4686-a8c7-985fae206641" xlink:to="loc_us-gaap_NetIncomeLoss_81ec72d1-3c97-40db-acb1-2aa1552fc841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendArisingFromWarrantModifications_c8a61e8c-f67b-4d00-9a0f-236959bedcd2" xlink:href="gale-20200930.xsd#gale_DividendArisingFromWarrantModifications"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e345d8d-8f2a-4686-a8c7-985fae206641" xlink:to="loc_gale_DividendArisingFromWarrantModifications_c8a61e8c-f67b-4d00-9a0f-236959bedcd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c9f735ab-e7e8-4f67-9e48-5f910377ad06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8642b44e-9787-4a61-ab4d-e4cf72683d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c9f735ab-e7e8-4f67-9e48-5f910377ad06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8642b44e-9787-4a61-ab4d-e4cf72683d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e6d43d2b-09dd-4cb8-847a-97263bed8bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c9f735ab-e7e8-4f67-9e48-5f910377ad06" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e6d43d2b-09dd-4cb8-847a-97263bed8bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_cfa3f14c-dc7c-4485-8382-42a0187d4d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3ff7c38a-1a3d-45d6-b2ad-358baa92e4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_cfa3f14c-dc7c-4485-8382-42a0187d4d77" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3ff7c38a-1a3d-45d6-b2ad-358baa92e4aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_81e1b6e4-28e4-4c8f-ad4c-55d036bb4f1b" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_cfa3f14c-dc7c-4485-8382-42a0187d4d77" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_81e1b6e4-28e4-4c8f-ad4c-55d036bb4f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_237899c0-29f0-4192-acc0-6307dec3034f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_cfa3f14c-dc7c-4485-8382-42a0187d4d77" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_237899c0-29f0-4192-acc0-6307dec3034f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14825aa5-6632-4c4e-bd73-f7992dbaaec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_43de3ea7-6abf-4d38-ac7c-bdd78ff65e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14825aa5-6632-4c4e-bd73-f7992dbaaec4" xlink:to="loc_us-gaap_CostsAndExpenses_43de3ea7-6abf-4d38-ac7c-bdd78ff65e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a58eab07-cdbd-41ff-86cd-5e0c5432f723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14825aa5-6632-4c4e-bd73-f7992dbaaec4" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a58eab07-cdbd-41ff-86cd-5e0c5432f723" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c3bec5b-ea55-4e27-8b17-3c49d5cf8c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d72d013-a3ea-4001-a8e3-1a1e583f306c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c3bec5b-ea55-4e27-8b17-3c49d5cf8c4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d72d013-a3ea-4001-a8e3-1a1e583f306c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e0a0320b-0357-4a9f-b58d-6426f686294a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c3bec5b-ea55-4e27-8b17-3c49d5cf8c4c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e0a0320b-0357-4a9f-b58d-6426f686294a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromStockSubscriptionReceivable_ef123ab3-c12f-4a3c-99dc-93da537c76d2" xlink:href="gale-20200930.xsd#gale_ProceedsFromStockSubscriptionReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c3bec5b-ea55-4e27-8b17-3c49d5cf8c4c" xlink:to="loc_gale_ProceedsFromStockSubscriptionReceivable_ef123ab3-c12f-4a3c-99dc-93da537c76d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e140e924-164a-4135-9513-030380d05176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e140e924-164a-4135-9513-030380d05176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bcb6aaed-1f6e-47b6-8d95-db731e2f1277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_us-gaap_ShareBasedCompensation_bcb6aaed-1f6e-47b6-8d95-db731e2f1277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_934e718f-8348-4fc9-bcf4-4092ddce847b" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_934e718f-8348-4fc9-bcf4-4092ddce847b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_812465e5-956d-4a61-846b-82a2a80baad7" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_812465e5-956d-4a61-846b-82a2a80baad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b03c47e-1cf4-416b-9f7e-a5a92f1fa8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b03c47e-1cf4-416b-9f7e-a5a92f1fa8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe4b8377-eed4-443a-8307-d6b427b4e784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe4b8377-eed4-443a-8307-d6b427b4e784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6f130af3-3bd0-466e-8315-5c0a04352df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6f130af3-3bd0-466e-8315-5c0a04352df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInOperatingLeaseRightOfUseAssets_caba5d21-28da-4d3e-8d79-abef9ef014ec" xlink:href="gale-20200930.xsd#gale_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48129191-dc47-4e37-8fd2-9e34c49742bf" xlink:to="loc_gale_ChangeInOperatingLeaseRightOfUseAssets_caba5d21-28da-4d3e-8d79-abef9ef014ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9884fce7-1094-43d6-9d3f-f5fed7af8f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e06401f-a321-4d16-97b5-3ca4994d96ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9884fce7-1094-43d6-9d3f-f5fed7af8f54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e06401f-a321-4d16-97b5-3ca4994d96ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2763687-e584-4bfc-b74c-2b946a3aae69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9884fce7-1094-43d6-9d3f-f5fed7af8f54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2763687-e584-4bfc-b74c-2b946a3aae69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gale-20200930.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:type="simple" xlink:href="gale-20200930.xsd#Liquidity"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#LiquidityDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fbdd2ac0-c83d-4bfc-b95b-ee72b44f16a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477faf76-381e-4813-82f8-745af72cae33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fbdd2ac0-c83d-4bfc-b95b-ee72b44f16a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_477faf76-381e-4813-82f8-745af72cae33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8d4a34a8-538f-4c5b-8dd3-57d5c737787e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_972c1013-aa22-4184-b1a9-2a031f1b43df" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8d4a34a8-538f-4c5b-8dd3-57d5c737787e" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_972c1013-aa22-4184-b1a9-2a031f1b43df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d437e90-4faa-4f1d-a510-42ec0f9dd7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8d4a34a8-538f-4c5b-8dd3-57d5c737787e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d437e90-4faa-4f1d-a510-42ec0f9dd7e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccounts"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9bcf4e-cd78-49db-8537-20643336ab30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_e4f325e0-549b-42ee-b21c-2c6c96da33cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9bcf4e-cd78-49db-8537-20643336ab30" xlink:to="loc_us-gaap_PrepaidInsurance_e4f325e0-549b-42ee-b21c-2c6c96da33cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidResearchAndDevelopment_b113450b-41e4-45d7-a1af-18c2b4fa26e2" xlink:href="gale-20200930.xsd#gale_PrepaidResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9bcf4e-cd78-49db-8537-20643336ab30" xlink:to="loc_gale_PrepaidResearchAndDevelopment_b113450b-41e4-45d7-a1af-18c2b4fa26e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidProfessionalServices_a1d8341a-49bc-4d1b-a9ce-d871812702c8" xlink:href="gale-20200930.xsd#gale_PrepaidProfessionalServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9bcf4e-cd78-49db-8537-20643336ab30" xlink:to="loc_gale_PrepaidProfessionalServices_a1d8341a-49bc-4d1b-a9ce-d871812702c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_dbf6c545-0bb0-499f-a77f-022943af30a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9bcf4e-cd78-49db-8537-20643336ab30" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_dbf6c545-0bb0-499f-a77f-022943af30a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ca4b746a-d984-4d58-88c9-e3f77419fd09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e31ce6f5-ccdd-4b9f-b40a-32dbdf600002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ca4b746a-d984-4d58-88c9-e3f77419fd09" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e31ce6f5-ccdd-4b9f-b40a-32dbdf600002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContractResearchPayable_5c0b51f0-8512-4731-b836-a672b9d7e7be" xlink:href="gale-20200930.xsd#gale_ContractResearchPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ca4b746a-d984-4d58-88c9-e3f77419fd09" xlink:to="loc_gale_ContractResearchPayable_5c0b51f0-8512-4731-b836-a672b9d7e7be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1f756d6e-d547-4930-aa08-44c7ded228af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ca4b746a-d984-4d58-88c9-e3f77419fd09" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1f756d6e-d547-4930-aa08-44c7ded228af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0921f3ec-18d0-4eb3-a762-e7a27508913c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0921f3ec-18d0-4eb3-a762-e7a27508913c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f9a43f73-a6f1-4f4b-bdb1-72d1cea54b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f9a43f73-a6f1-4f4b-bdb1-72d1cea54b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_45c04c71-47c8-494c-95d4-aebb8435409b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_45c04c71-47c8-494c-95d4-aebb8435409b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f78c2e31-d9b4-47ad-9baf-fb57cc9392ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f78c2e31-d9b4-47ad-9baf-fb57cc9392ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_44b84107-7049-4686-9a1c-6287b0518261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2796bed2-2dfa-4ad0-9e82-deca5b79b8a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_44b84107-7049-4686-9a1c-6287b0518261" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d81df2b-aec1-4a3f-ab61-6a967f828bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_85a38920-6590-45f4-bd42-ec165353f376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d81df2b-aec1-4a3f-ab61-6a967f828bbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_85a38920-6590-45f4-bd42-ec165353f376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c4cd8d42-65d5-48fe-adb5-9a2ba73589c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d81df2b-aec1-4a3f-ab61-6a967f828bbc" xlink:to="loc_us-gaap_OperatingLeaseLiability_c4cd8d42-65d5-48fe-adb5-9a2ba73589c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_fcad798c-a5f0-4401-a1a5-a6b85c9c8516" xlink:href="gale-20200930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_fcad798c-a5f0-4401-a1a5-a6b85c9c8516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_305d02c1-e84f-4311-aef9-fc98482013c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_305d02c1-e84f-4311-aef9-fc98482013c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_bea121c8-4d03-4fdb-878f-2003223fd2d2" xlink:href="gale-20200930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_bea121c8-4d03-4fdb-878f-2003223fd2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bd5a8de6-6851-4130-aa9e-948034f00750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bd5a8de6-6851-4130-aa9e-948034f00750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0f93026-b682-45c9-8611-fac1ad64c21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7af6b3f3-3881-4c19-b49d-6b33af6f955f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0f93026-b682-45c9-8611-fac1ad64c21b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStock"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAllocatedStockbasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gale-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>gale-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Cover" xlink:type="simple" xlink:href="gale-20200930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Cover" xlink:type="extended" id="i34172fd58bdb4013819a6842169d8663_Cover"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ic47a70be84604c1e9ecc6709946d6b69_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i6e565225e3b04ccd96944f9eedb203a3_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a95a43c-6b8b-4055-b2ea-0094c1134ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a95a43c-6b8b-4055-b2ea-0094c1134ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9d94cfe5-6936-453d-95da-1ac00a559950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9d94cfe5-6936-453d-95da-1ac00a559950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6cb837f-5cd7-4518-b8d8-ab2d1c88a963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6cb837f-5cd7-4518-b8d8-ab2d1c88a963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ce8d432e-8f4b-4557-a488-48f9ea2637f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ce8d432e-8f4b-4557-a488-48f9ea2637f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb3ba62b-2281-4c13-86b9-f68732653654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb3ba62b-2281-4c13-86b9-f68732653654" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7c9bdcbf-1195-4787-bf75-c9831b3e57bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7c9bdcbf-1195-4787-bf75-c9831b3e57bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_297d6135-14a1-4c72-a80b-298b868e2a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesIssued_297d6135-14a1-4c72-a80b-298b868e2a14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_53a89f47-f50c-441c-9001-3277dd09e42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_53a89f47-f50c-441c-9001-3277dd09e42e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ad10316-a912-41f7-a3f0-54a513610ef8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:to="loc_us-gaap_ClassOfStockDomain_3ad10316-a912-41f7-a3f0-54a513610ef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:to="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2bb8bd8a-3bf2-4a56-8bc7-66ca8dec40cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2bb8bd8a-3bf2-4a56-8bc7-66ca8dec40cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ia8bf93686210455593f5b70ab6166061_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i9a97bc2ca7fa40bf991410b9c0f36738_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1fcc893d-529a-4034-ba4d-92ec0c6e1326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_SharesOutstanding_1fcc893d-529a-4034-ba4d-92ec0c6e1326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09b8591f-0fb8-4818-8b1a-fc59941c79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09b8591f-0fb8-4818-8b1a-fc59941c79cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_0544c52b-593a-4005-9690-1932e17206b8" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_0544c52b-593a-4005-9690-1932e17206b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_c617e5af-58d5-483d-9355-280d5011dce1" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_c617e5af-58d5-483d-9355-280d5011dce1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b10eb42-01cd-4f17-8803-be99c9f82c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b10eb42-01cd-4f17-8803-be99c9f82c54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2201dae1-cde3-4f1b-9037-2b69b870e725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2201dae1-cde3-4f1b-9037-2b69b870e725" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_c9c9fc3d-b140-49f3-8f06-9781d3757251" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_c9c9fc3d-b140-49f3-8f06-9781d3757251" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant_2a59c86d-c27f-4fdf-9b3b-ccfe231102ad" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant_2a59c86d-c27f-4fdf-9b3b-ccfe231102ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ea3f3a26-4a35-49bb-b6b8-4ddcf3580fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ea3f3a26-4a35-49bb-b6b8-4ddcf3580fdb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_943f9791-18d2-40d6-9c2b-48dbc87561e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_943f9791-18d2-40d6-9c2b-48dbc87561e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_616f2c7d-953d-4437-b49b-2ddeb0591a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_616f2c7d-953d-4437-b49b-2ddeb0591a60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b4776e2-feb1-4e11-a3ea-930fc617fd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b4776e2-feb1-4e11-a3ea-930fc617fd6a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendModificationOfWarrants_9091fb3e-ba28-4fa2-8021-c8c4632500a1" xlink:href="gale-20200930.xsd#gale_DividendModificationOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_DividendModificationOfWarrants_9091fb3e-ba28-4fa2-8021-c8c4632500a1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e7e8e03-25f3-4d7d-a5da-7f30dcb31cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_NetIncomeLoss_0e7e8e03-25f3-4d7d-a5da-7f30dcb31cdc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0fd1430b-48e4-4d16-8ce6-affe5194c914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8c8738e-53d5-42d1-b9a2-9cd4c89fe856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:to="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0dd4335f-c943-4c33-82fb-aa2d893ec628_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:to="loc_us-gaap_EquityComponentDomain_0dd4335f-c943-4c33-82fb-aa2d893ec628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:to="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_795490cc-7fff-4b43-8fe3-f53048683786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_PreferredStockMember_795490cc-7fff-4b43-8fe3-f53048683786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_793804f1-e0e8-43cc-bdc6-035328915c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_CommonStockMember_793804f1-e0e8-43cc-bdc6-035328915c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a37bf42-a344-4f2e-a0a2-2fdf508f930e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a37bf42-a344-4f2e-a0a2-2fdf508f930e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_737688d0-8d03-413c-96ca-152563c68307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_RetainedEarningsMember_737688d0-8d03-413c-96ca-152563c68307" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i0117543b6d9346118115983c48ce2de1_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gale-20200930.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="extended" id="i4c4591ec009c4b848571817db982a584_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:type="simple" xlink:href="gale-20200930.xsd#Liquidity"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended" id="idbeb158273584a58968a3f6e4dcc391f_Liquidity"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#LiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended" id="id4e875c46f5d4c0cbc69e91bfe7237d5_LiquidityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a2b6166f-1ca3-4778-9508-0b7bd48983aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a2b6166f-1ca3-4778-9508-0b7bd48983aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c00fcd88-b49b-42c7-b6f5-df61293ca93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c00fcd88-b49b-42c7-b6f5-df61293ca93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d01ac6de-2f19-4be7-a22f-63be537c97f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d01ac6de-2f19-4be7-a22f-63be537c97f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eee6340a-9fc9-4196-86e3-156252594a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eee6340a-9fc9-4196-86e3-156252594a08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightTerm_0668b947-0ee7-4229-843f-49eea068590a" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ClassofWarrantorRightTerm_0668b947-0ee7-4229-843f-49eea068590a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df8c0126-ccf5-413c-b782-48ff785ca244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df8c0126-ccf5-413c-b782-48ff785ca244" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_418a5a05-5d7f-4d63-856b-8540c2dbfe9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SharesIssued_418a5a05-5d7f-4d63-856b-8540c2dbfe9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfferingPricePershare_4a23a8eb-6e8b-439a-90d0-cfc90c87950a" xlink:href="gale-20200930.xsd#gale_OfferingPricePershare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_OfferingPricePershare_4a23a8eb-6e8b-439a-90d0-cfc90c87950a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_8eb0cec8-7772-4e64-962b-09966ee8b0f1" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_8eb0cec8-7772-4e64-962b-09966ee8b0f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromWarrantExercisesGross_0d17b0aa-39fc-40f1-a224-ccaee0bc1a6e" xlink:href="gale-20200930.xsd#gale_ProceedsFromWarrantExercisesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ProceedsFromWarrantExercisesGross_0d17b0aa-39fc-40f1-a224-ccaee0bc1a6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de221794-8028-420c-8db2-fbafc8273ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de221794-8028-420c-8db2-fbafc8273ec7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_eb72dac7-bb3b-4e1b-97c7-96b0f667cb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_eb72dac7-bb3b-4e1b-97c7-96b0f667cb99" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_363b1510-5fb0-492a-bf66-3c0392e475f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_363b1510-5fb0-492a-bf66-3c0392e475f4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93cd5dcc-c2da-49e1-90c5-d16ab05d7a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93cd5dcc-c2da-49e1-90c5-d16ab05d7a7e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c46e815e-56cf-43c0-9b35-8946ac3971d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:to="loc_us-gaap_RelatedPartyDomain_c46e815e-56cf-43c0-9b35-8946ac3971d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:to="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PIPEInvestorsMember_6f170e04-23e6-480e-b2f6-4f699dcfb8e7" xlink:href="gale-20200930.xsd#gale_PIPEInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:to="loc_gale_PIPEInvestorsMember_6f170e04-23e6-480e-b2f6-4f699dcfb8e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_9f650e3f-b7b0-4baf-b34f-82cb950284cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:to="loc_us-gaap_InvestorMember_9f650e3f-b7b0-4baf-b34f-82cb950284cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4b81862-373f-407a-a2a8-88263375008c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:to="loc_us-gaap_EquityComponentDomain_e4b81862-373f-407a-a2a8-88263375008c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:to="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedWarrantsMember_fd9fe869-fb0e-46d6-aa81-57d2e85e2da6" xlink:href="gale-20200930.xsd#gale_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:to="loc_gale_PreFundedWarrantsMember_fd9fe869-fb0e-46d6-aa81-57d2e85e2da6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended" id="i4c10517d1fdc447691c29ed8298be00f_BasisofPresentationandSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic35ec9095569499b8872efbd845f97c4_BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended" id="if89bdcd045d545139d68ed7425c4e7e1_BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i7e8caefa65064539abd36a42366ac358_BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i57e65f5db71f4581bdd7b7a670654dfa_BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76ec7a27-0871-435f-988e-f4c8eea75620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76ec7a27-0871-435f-988e-f4c8eea75620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b5a1132-b869-4dbf-bc2f-748af4c9095b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b5a1132-b869-4dbf-bc2f-748af4c9095b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_41cf2082-3d8f-455e-80b5-a615fb61eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_WarrantMember_41cf2082-3d8f-455e-80b5-a615fb61eac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c193d5da-595a-4bfc-81ac-a49262700cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c193d5da-595a-4bfc-81ac-a49262700cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bd7e347b-8310-49af-bd58-1e58a699bf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bd7e347b-8310-49af-bd58-1e58a699bf8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" id="i42f60f57e2bd4584a9216c72c3f507c4_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i4c8d4a751e934896a10c38943a93b5e7_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended" id="i9649c75bf9d04c0fb3be0822aadc617d_FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c44feb-617e-41e4-b035-4f41f8544634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c44feb-617e-41e4-b035-4f41f8544634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b682e75a-bd97-4dd1-a4eb-7e80a25e19c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b682e75a-bd97-4dd1-a4eb-7e80a25e19c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_2b311185-e599-4343-83dd-a4cb1a4d6298" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_2b311185-e599-4343-83dd-a4cb1a4d6298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_08c1f3d1-533e-4d24-a2b7-7e5aaedd5b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_08c1f3d1-533e-4d24-a2b7-7e5aaedd5b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_30c11d5d-ccb7-428d-9d6a-4c42b00e1d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_30c11d5d-ccb7-428d-9d6a-4c42b00e1d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a4f4cc3d-3b37-4f4f-9360-f18a238ea603_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a4f4cc3d-3b37-4f4f-9360-f18a238ea603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9e78fe0e-1576-4ae2-887d-29da7623ea01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9e78fe0e-1576-4ae2-887d-29da7623ea01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_769bf19d-5dce-4367-b97e-d96ce928223b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_769bf19d-5dce-4367-b97e-d96ce928223b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab5f6c4a-33e2-4d05-a8bd-72e48812121a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab5f6c4a-33e2-4d05-a8bd-72e48812121a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c13b54a1-8b9a-4b2e-9dab-1508c34398e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c13b54a1-8b9a-4b2e-9dab-1508c34398e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4e62c389-5e2d-465a-8060-0cfc65e9df6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4e62c389-5e2d-465a-8060-0cfc65e9df6e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="extended" id="i76e8550bf43e448ea10b115a14385c1a_FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_021806db-86ec-4620-9317-f1ed2bdb865e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_021806db-86ec-4620-9317-f1ed2bdb865e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_95f42ea2-2298-4cfb-9fd5-a5acf27f46ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_95f42ea2-2298-4cfb-9fd5-a5acf27f46ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e14a8057-a95a-4187-93b3-31ea93407dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73070ade-5b28-43ef-ad12-de32d8d582f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73070ade-5b28-43ef-ad12-de32d8d582f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eacba9b1-e9ab-42df-b52a-76dc601407b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eacba9b1-e9ab-42df-b52a-76dc601407b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i745c0c445d554c4aa1abf017cb5a4b77_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_229401c2-b1cd-4541-ac04-af9071dfd069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_229401c2-b1cd-4541-ac04-af9071dfd069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f39b3ee5-2e1f-4b76-967a-0d308edf5576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f39b3ee5-2e1f-4b76-967a-0d308edf5576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2464796e-9bfd-4db5-b746-d5c67670efa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2464796e-9bfd-4db5-b746-d5c67670efa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_becba808-ca50-49ec-bb1a-665cbef61537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_becba808-ca50-49ec-bb1a-665cbef61537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c830db67-8307-430a-b071-d79ca8ab6f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c830db67-8307-430a-b071-d79ca8ab6f6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_6a4560a3-0207-4f46-bdeb-2320fc2a2a12" xlink:href="gale-20200930.xsd#gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_6a4560a3-0207-4f46-bdeb-2320fc2a2a12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_AptheraInc.Member_8cfd0568-6702-4510-a6b9-3701dae307b2" xlink:href="gale-20200930.xsd#gale_AptheraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:to="loc_gale_AptheraInc.Member_8cfd0568-6702-4510-a6b9-3701dae307b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_73476e4f-42d8-4639-b940-8070842b3cd6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_73476e4f-42d8-4639-b940-8070842b3cd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember_13eeb53f-5267-4da8-ad11-e56798703009" xlink:href="gale-20200930.xsd#gale_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:to="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember_13eeb53f-5267-4da8-ad11-e56798703009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputCostOfDebtMember_97c536e9-7851-45cf-a363-f772033dbe38" xlink:href="gale-20200930.xsd#gale_MeasurementInputCostOfDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:to="loc_gale_MeasurementInputCostOfDebtMember_97c536e9-7851-45cf-a363-f772033dbe38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bdd515f-c542-4ff2-ba77-61323f7b52b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:to="loc_srt_RangeMember_6bdd515f-c542-4ff2-ba77-61323f7b52b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:to="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50bf7927-4c70-4a2d-882a-35edc09101f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:to="loc_srt_MinimumMember_50bf7927-4c70-4a2d-882a-35edc09101f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ae4fd35-d9e2-445e-b11c-4d102f3f5dc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:to="loc_srt_MaximumMember_2ae4fd35-d9e2-445e-b11c-4d102f3f5dc6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccounts"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="extended" id="ica52df71f1f643b785230a8cd0213b84_BalanceSheetAccounts"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="extended" id="if8705aa70426421797ff323a23eab317_BalanceSheetAccountsTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i81b8819c6419425c96455888b0441c54_BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="i51af0acce3e44469b6f1c84a2f18ff85_BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="ib0d2b00a714b4ee69eec114eac3bf8c5_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i9687a1b3ca504c3e94262fbf903285d9_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="icd4a8535b8f04bebbae6dad374c3b19d_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecae99d9-1730-42a7-82be-e1ee08a58fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecae99d9-1730-42a7-82be-e1ee08a58fb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bce595ec-f955-46dd-b30b-29fc5cb71520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bce595ec-f955-46dd-b30b-29fc5cb71520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1805f02-b614-4a2c-b9ec-ccf0b8233ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1805f02-b614-4a2c-b9ec-ccf0b8233ca8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_628bc674-40ec-4e55-9a73-799b3abebe37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_628bc674-40ec-4e55-9a73-799b3abebe37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRemainingLeaseTerm_bf3a41c1-bc31-4015-952e-08a6bfdd63cb" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_gale_OperatingLeaseRemainingLeaseTerm_bf3a41c1-bc31-4015-952e-08a6bfdd63cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_dff2bf94-9f4c-4d29-bbd2-8586175b27e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseExpense_dff2bf94-9f4c-4d29-bbd2-8586175b27e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRightOfUseAssetAmortization_4181e464-f79b-4307-92fa-fb04f85c0877" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_gale_OperatingLeaseRightOfUseAssetAmortization_4181e464-f79b-4307-92fa-fb04f85c0877" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_58eb58a8-3baa-4e1f-a866-e218bb02af71_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:to="loc_us-gaap_TypeOfAdoptionMember_58eb58a8-3baa-4e1f-a866-e218bb02af71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_491bb6ea-5cc6-4361-8b7f-92b363ebd96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_491bb6ea-5cc6-4361-8b7f-92b363ebd96f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:to="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_6eb018ae-0560-40c4-9c76-03769ddda1a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_6eb018ae-0560-40c4-9c76-03769ddda1a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member_0dea7673-5153-48f9-ba28-81d43bb71c7f" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:to="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member_0dea7673-5153-48f9-ba28-81d43bb71c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member_aefc97c1-0214-4997-bdbc-dcac38d53a8a" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringJuly312020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:to="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member_aefc97c1-0214-4997-bdbc-dcac38d53a8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="extended" id="ibadd213ccc6c4c0699c8c0fcde49fbbc_CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" id="ia31b100c43ee4baca8be00d6abc12ea5_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" id="ifb8bee2fcf134eecbbc9d27a69b2729a_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i40b00752967c404480036e1e23bc935e_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cc12de36-b097-44ce-b40f-6829c115b2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cc12de36-b097-44ce-b40f-6829c115b2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d5cb2aa-37de-42b6-921c-48d88f194069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d5cb2aa-37de-42b6-921c-48d88f194069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45fab622-362b-4805-8778-dcb7e8e147ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_45fab622-362b-4805-8778-dcb7e8e147ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_236ac899-f5da-4eb6-80a9-e506e86c2ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_236ac899-f5da-4eb6-80a9-e506e86c2ca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAuthorizedAmount_fac69992-66d6-493c-ba79-f4a7eb435e77" xlink:href="gale-20200930.xsd#gale_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_SaleOfStockAuthorizedAmount_fac69992-66d6-493c-ba79-f4a7eb435e77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_90dc37c5-4add-46c1-93ee-e89f725d9adc" xlink:href="gale-20200930.xsd#gale_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_90dc37c5-4add-46c1-93ee-e89f725d9adc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5df850d-5965-4135-b816-9652d9460eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5df850d-5965-4135-b816-9652d9460eaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd8ac080-0ed6-482b-83b2-ec385de30053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd8ac080-0ed6-482b-83b2-ec385de30053" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ecd1801e-0656-4cc1-a67e-5eba0dc78319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SharesIssued_ecd1801e-0656-4cc1-a67e-5eba0dc78319" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfferingPricePershare_fc8b128f-a9b2-44a2-bdf8-6dd8c1099223" xlink:href="gale-20200930.xsd#gale_OfferingPricePershare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_OfferingPricePershare_fc8b128f-a9b2-44a2-bdf8-6dd8c1099223" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_4681c8ca-b4cb-4a04-aa94-6f1afd680734" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_4681c8ca-b4cb-4a04-aa94-6f1afd680734" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromWarrantExercisesGross_962bef32-ae94-4c28-b267-1974a3a788c5" xlink:href="gale-20200930.xsd#gale_ProceedsFromWarrantExercisesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ProceedsFromWarrantExercisesGross_962bef32-ae94-4c28-b267-1974a3a788c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cc445938-cba0-4553-9d63-b197fa02908f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cc445938-cba0-4553-9d63-b197fa02908f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e03571e-a635-4f62-b33b-2366ee0cb465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e03571e-a635-4f62-b33b-2366ee0cb465" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightTerm_dace3738-517e-4351-83ab-48f0f8a9af17" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ClassofWarrantorRightTerm_dace3738-517e-4351-83ab-48f0f8a9af17" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8947b079-9c97-4cb0-8c6e-994439d01730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8947b079-9c97-4cb0-8c6e-994439d01730" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockSubscriptionReceivableCurrent_96e6396c-1692-42e3-bbc1-9531f3d05d9b" xlink:href="gale-20200930.xsd#gale_StockSubscriptionReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_StockSubscriptionReceivableCurrent_96e6396c-1692-42e3-bbc1-9531f3d05d9b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd4a13e9-de7d-4301-bde8-f476fd6d2484_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd4a13e9-de7d-4301-bde8-f476fd6d2484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DistributionAgreementMember_b790b206-ed31-4ee8-bfcd-9aca325fe6fc" xlink:href="gale-20200930.xsd#gale_DistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:to="loc_gale_DistributionAgreementMember_b790b206-ed31-4ee8-bfcd-9aca325fe6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bcd55b50-9fc0-4cb0-b89a-2684f2aab598_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:to="loc_us-gaap_RelatedPartyDomain_bcd55b50-9fc0-4cb0-b89a-2684f2aab598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:to="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_0cecc9c1-6cb2-42bc-a4a2-5d7408cd4acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:to="loc_us-gaap_InvestorMember_0cecc9c1-6cb2-42bc-a4a2-5d7408cd4acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PIPEInvestorsMember_6e69c1c1-55d7-4aec-9bbd-5b369807509d" xlink:href="gale-20200930.xsd#gale_PIPEInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:to="loc_gale_PIPEInvestorsMember_6e69c1c1-55d7-4aec-9bbd-5b369807509d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dc5be395-dbb4-4d65-ac4e-2be5252b5d43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:to="loc_us-gaap_EquityComponentDomain_dc5be395-dbb4-4d65-ac4e-2be5252b5d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:to="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedWarrantsMember_c6b69b83-767e-425c-a55e-d7cb6e8001f1" xlink:href="gale-20200930.xsd#gale_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:to="loc_gale_PreFundedWarrantsMember_c6b69b83-767e-425c-a55e-d7cb6e8001f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended" id="i277b587fc3c64aa48b9398f27b77d02c_StockholdersEquityCommonStockareReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f97149eb-fafd-4fc4-8691-b71a63503b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f97149eb-fafd-4fc4-8691-b71a63503b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ebd159b9-212e-4d80-8476-09ccc8eaa5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ebd159b9-212e-4d80-8476-09ccc8eaa5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a046d51-cb6f-42e7-8a35-b11bf67142e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a046d51-cb6f-42e7-8a35-b11bf67142e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_aea6b622-e547-4e13-9e2e-9d102d70ccba" xlink:href="gale-20200930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_aea6b622-e547-4e13-9e2e-9d102d70ccba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_5442ef3c-de27-4144-929e-05d894d4ffa4" xlink:href="gale-20200930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_5442ef3c-de27-4144-929e-05d894d4ffa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1a7c33cd-f286-456b-a188-b3d56cdd213f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1a7c33cd-f286-456b-a188-b3d56cdd213f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:to="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19bd7f4a-9328-42b5-bab4-5d394d0e8e10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19bd7f4a-9328-42b5-bab4-5d394d0e8e10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d6e256c-076a-4a11-810f-e3eef3e21838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d6e256c-076a-4a11-810f-e3eef3e21838" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStock"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="extended" id="ifde43a4b7838453296872168677e298d_WarrantstoAcquireSharesofCommonStock"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="extended" id="i4b806a5b92384f1e94f9d33a4e939568_WarrantstoAcquireSharesofCommonStockTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="extended" id="i84506fe7e15f4428af2e9beccf2ba780_WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_893b054a-d563-4543-9841-1ad99efa653e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_893b054a-d563-4543-9841-1ad99efa653e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_08eb1883-4f11-42a6-a123-8f4330eb4af6" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_08eb1883-4f11-42a6-a123-8f4330eb4af6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_2d9eef5b-38dc-40b7-b976-cd7b48009c7c" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_2d9eef5b-38dc-40b7-b976-cd7b48009c7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_4a012b7d-5f93-48f7-8a95-29e928b3e217" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightCanceledOrExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_4a012b7d-5f93-48f7-8a95-29e928b3e217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f133913d-a091-4595-b3f3-acf2afebe786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2020PIPEOfferingMember_9bc6aa79-1cf5-4051-a232-9c571abb3805" xlink:href="gale-20200930.xsd#gale_July2020PIPEOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2020PIPEOfferingMember_9bc6aa79-1cf5-4051-a232-9c571abb3805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_January2020OfferingMember_dbfa8769-9791-463f-90e7-cb77a1ab4664" xlink:href="gale-20200930.xsd#gale_January2020OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_January2020OfferingMember_dbfa8769-9791-463f-90e7-cb77a1ab4664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedJune2019OfferingMember_86cfdab7-ead6-484c-aede-f7a7cdc2aece" xlink:href="gale-20200930.xsd#gale_PreFundedJune2019OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_PreFundedJune2019OfferingMember_86cfdab7-ead6-484c-aede-f7a7cdc2aece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2019OfferingMember_350abcef-4d94-431a-a2f9-d1fa2a8b0d88" xlink:href="gale-20200930.xsd#gale_July2019OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2019OfferingMember_350abcef-4d94-431a-a2f9-d1fa2a8b0d88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantExerciseAgreementMember_af264bef-4a41-4893-bf2b-bb93ef7f0f0f" xlink:href="gale-20200930.xsd#gale_WarrantExerciseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_WarrantExerciseAgreementMember_af264bef-4a41-4893-bf2b-bb93ef7f0f0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2018OfferingMember_c983f92d-0601-4a9b-a85e-7bd8c811aa5f" xlink:href="gale-20200930.xsd#gale_July2018OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2018OfferingMember_c983f92d-0601-4a9b-a85e-7bd8c811aa5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5354fe5a-6d3b-49f2-8337-63ec04d4520b" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5354fe5a-6d3b-49f2-8337-63ec04d4520b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EqcWarrantsMember_84e7de92-c76b-47c3-b406-445ce83ad683" xlink:href="gale-20200930.xsd#gale_EqcWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_EqcWarrantsMember_84e7de92-c76b-47c3-b406-445ce83ad683" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_47846d0a-3816-4a7e-9b2f-fcbc8e88e1ae" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_February2017WarrantsMember_47846d0a-3816-4a7e-9b2f-fcbc8e88e1ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OtherWarrantIssuesMember_1471f628-6eb3-4b9a-ad9e-21e8d8985463" xlink:href="gale-20200930.xsd#gale_OtherWarrantIssuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_OtherWarrantIssuesMember_1471f628-6eb3-4b9a-ad9e-21e8d8985463" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" id="i9252a6c6da0a49efa65c9f586d8ef72b_WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d616872f-7114-4fe9-8cd0-9be8bcbb5d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d616872f-7114-4fe9-8cd0-9be8bcbb5d38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantStrikePrice_928fa5d8-10ea-477a-bbb5-dac151c95697" xlink:href="gale-20200930.xsd#gale_WarrantStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantStrikePrice_928fa5d8-10ea-477a-bbb5-dac151c95697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_73553fc6-32c2-46fe-b829-c2ee8f44af83" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_73553fc6-32c2-46fe-b829-c2ee8f44af83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_8fbed9a7-5a85-48be-8f0d-537614a7ce40" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_8fbed9a7-5a85-48be-8f0d-537614a7ce40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_0f0c2072-c2d0-4ce6-8eab-775d6dcfe02d" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_0f0c2072-c2d0-4ce6-8eab-775d6dcfe02d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b31cbebf-9ad2-445a-a868-031fb7e3f7f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b31cbebf-9ad2-445a-a868-031fb7e3f7f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_7daf53cf-fe9d-4151-b4b0-3ca34ff704c9" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_7daf53cf-fe9d-4151-b4b0-3ca34ff704c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_7803ff60-152a-4c28-9e24-06241b051109" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_February2017WarrantsMember_7803ff60-152a-4c28-9e24-06241b051109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OtherWarrantIssuesMember_09f0fe3e-2a79-43dc-8b68-671ca8dabbb3" xlink:href="gale-20200930.xsd#gale_OtherWarrantIssuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_OtherWarrantIssuesMember_09f0fe3e-2a79-43dc-8b68-671ca8dabbb3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="extended" id="if1866d8ddc7544b98f1176ac21d58613_WarrantstoAcquireSharesofCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_efaabc11-fbfc-46fa-a334-8242d430bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_efaabc11-fbfc-46fa-a334-8242d430bc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6ca2f6a-5aa0-48ef-8ca2-40766424f61b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6ca2f6a-5aa0-48ef-8ca2-40766424f61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ccff6220-7095-4dfb-8180-bba67b4d2ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ccff6220-7095-4dfb-8180-bba67b4d2ce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_293b1b49-ba33-4f94-ac5a-050a2b6fb438" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_293b1b49-ba33-4f94-ac5a-050a2b6fb438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_258ba564-668c-40ba-80dd-bf0de832546e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_258ba564-668c-40ba-80dd-bf0de832546e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cf3c53da-5936-4859-9f8d-c735bc85cc03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cf3c53da-5936-4859-9f8d-c735bc85cc03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_577e397f-398a-41d9-86b6-608a590d5125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_577e397f-398a-41d9-86b6-608a590d5125" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_41654dd6-9357-48bd-9e84-d1ea1fcb1ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_41654dd6-9357-48bd-9e84-d1ea1fcb1ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_616b32a4-5023-4896-9a27-30a459eb22fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_616b32a4-5023-4896-9a27-30a459eb22fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_39176642-8951-419a-a5eb-36e48037f478" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_39176642-8951-419a-a5eb-36e48037f478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2019Member_1a006d05-2bf6-4719-a44f-9c07e238f06b" xlink:href="gale-20200930.xsd#gale_Warrants2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_Warrants2019Member_1a006d05-2bf6-4719-a44f-9c07e238f06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2020Member_bdba8268-87f6-4021-94d8-fd7d6c6dac2c" xlink:href="gale-20200930.xsd#gale_Warrants2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_Warrants2020Member_bdba8268-87f6-4021-94d8-fd7d6c6dac2c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="extended" id="i70f1f1053e6e4f78a9a0f1b628cad830_WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_dd970e39-557a-4cc6-bd3a-517e53ae9a06" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_dd970e39-557a-4cc6-bd3a-517e53ae9a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueofWarrantsGranted_9a5e1f22-a4b1-4268-a400-adf1022e38c4" xlink:href="gale-20200930.xsd#gale_FairValueofWarrantsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueofWarrantsGranted_9a5e1f22-a4b1-4268-a400-adf1022e38c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsCanceled_24a0d4c0-783f-43dc-b8bc-c49292209cf6" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsCanceled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsCanceled_24a0d4c0-783f-43dc-b8bc-c49292209cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_eeada418-af76-43fe-93e7-6d7103eb0f39" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_eeada418-af76-43fe-93e7-6d7103eb0f39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_b1dab659-df5c-4142-a066-d0fbfbda147c" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfWarrantLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_b1dab659-df5c-4142-a066-d0fbfbda147c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_48bfe310-d001-4ebc-a6de-e6e4415b944b" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1783f974-b670-4262-b4b2-b25a2770145d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1783f974-b670-4262-b4b2-b25a2770145d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_b028cb7a-4aa2-4a31-b799-1b655f394c32" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_b028cb7a-4aa2-4a31-b799-1b655f394c32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_cd61e65f-74ce-40ef-baf3-bf00d1265568" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:to="loc_gale_February2017WarrantsMember_cd61e65f-74ce-40ef-baf3-bf00d1265568" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" id="i34010a80660842079d31747a0d825a72_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" id="i80ab6302bdf8403c9b8dac7f1b6aa1b2_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i0a5f55eaefa641a3a4f623e7c8c7d609_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40d9d3d7-872d-4be9-a37e-5fee8ba5593b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40d9d3d7-872d-4be9-a37e-5fee8ba5593b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e7b9c5a8-c633-4ba2-89b0-cd9f788e4458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e7b9c5a8-c633-4ba2-89b0-cd9f788e4458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e37d153e-c3cb-45f5-b74e-c54e9a1f683b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e37d153e-c3cb-45f5-b74e-c54e9a1f683b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0ff6d2ef-4704-456f-853f-68325b083745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0ff6d2ef-4704-456f-853f-68325b083745" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d2d4383-ae2f-45c8-a1d1-cfa4d422a902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d2d4383-ae2f-45c8-a1d1-cfa4d422a902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_044fa654-fe98-4c6e-967d-c3933cff075e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_044fa654-fe98-4c6e-967d-c3933cff075e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e18fb376-bcb7-4ab2-84b4-8aae82dd69b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e18fb376-bcb7-4ab2-84b4-8aae82dd69b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87470114-261e-4426-a388-de4d51e3303e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87470114-261e-4426-a388-de4d51e3303e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32180bee-1876-406a-8cc1-6b93d1e837eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32180bee-1876-406a-8cc1-6b93d1e837eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_2d99bc8c-81f5-4f82-a854-33833301fb30" xlink:href="gale-20200930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_2d99bc8c-81f5-4f82-a854-33833301fb30" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClosingPriceOfCommonStock_26975aa6-1e31-4194-8906-95e938641d75" xlink:href="gale-20200930.xsd#gale_ClosingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_gale_ClosingPriceOfCommonStock_26975aa6-1e31-4194-8906-95e938641d75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e852608c-5e27-446c-a575-5b4bc4d4564e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e852608c-5e27-446c-a575-5b4bc4d4564e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1b786992-77b2-4b07-8e93-2ea267fe308d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:to="loc_us-gaap_PlanNameDomain_1b786992-77b2-4b07-8e93-2ea267fe308d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:to="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_7a265a0a-9e76-4a5b-af66-f5d5def878b8" xlink:href="gale-20200930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_7a265a0a-9e76-4a5b-af66-f5d5def878b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember_bc0cebfa-6a35-4fc0-9a51-f134642be239" xlink:href="gale-20200930.xsd#gale_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:to="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember_bc0cebfa-6a35-4fc0-9a51-f134642be239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34a12e71-18fe-434e-b5f6-e5976cf81290_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:to="loc_srt_RangeMember_34a12e71-18fe-434e-b5f6-e5976cf81290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:to="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00666b64-cea0-4ba3-bfa1-a9e4f37ab58c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:to="loc_srt_MaximumMember_00666b64-cea0-4ba3-bfa1-a9e4f37ab58c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1f7fa6ca-ba3e-455e-b39b-0b89e9598866" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:to="loc_srt_MinimumMember_1f7fa6ca-ba3e-455e-b39b-0b89e9598866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_093cc6d3-7e8d-4d65-b56b-8b2c02c79bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_093cc6d3-7e8d-4d65-b56b-8b2c02c79bb4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAllocatedStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="extended" id="i26f655f123974174b96ee883bc9f7ca7_StockBasedCompensationAllocatedStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d741e2da-4d58-46f6-a895-c280e79dbc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d741e2da-4d58-46f6-a895-c280e79dbc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5bf83a42-d726-4896-8540-6f957276a9d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5bf83a42-d726-4896-8540-6f957276a9d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_181f3f7c-5205-4ec5-9d27-0f0a766888d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_181f3f7c-5205-4ec5-9d27-0f0a766888d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df5263f9-dc7e-4e95-8756-094de5ac249c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df5263f9-dc7e-4e95-8756-094de5ac249c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="extended" id="i74f59ef29d1b4aa0b8a9aa312bfc6002_StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i47d62b352a524ca89ed3af732f0e7dc3_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended" id="i21b591e908f341d3b448cfdcdb00bbac_StockBasedCompensationSummaryofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e92938bb-9f24-4a2f-924f-9731b722d0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e92938bb-9f24-4a2f-924f-9731b722d0e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1549252e-8f3f-461a-a8e0-bbd09d5748a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1549252e-8f3f-461a-a8e0-bbd09d5748a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2956d9d8-d840-4036-a4f1-e4548ece36b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2956d9d8-d840-4036-a4f1-e4548ece36b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b783d9b-9310-45d9-bec6-2fe39a173d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_17da0c5a-fd65-4f30-8b28-782a1f4a9a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_17da0c5a-fd65-4f30-8b28-782a1f4a9a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feeb254a-c545-47f4-b32b-be69ff9718a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feeb254a-c545-47f4-b32b-be69ff9718a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b12fdfd3-13d7-42a6-a405-b9308817621a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b12fdfd3-13d7-42a6-a405-b9308817621a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a76afc5a-a1a4-4508-8e77-37cf4e70f9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:to="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_64a4d01c-120f-450a-b997-cf6da464df76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_64a4d01c-120f-450a-b997-cf6da464df76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0087f8-c7b3-4d84-83b2-8840c7f21e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0087f8-c7b3-4d84-83b2-8840c7f21e66" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gale-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" id="i65c73b4653684902b742092e7bc8b941_SubsequentEvents"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gale-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f948b0ac-e7dc-47f1-8e3b-cc4dc3b5047a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_55bc9a89-f202-4849-aee4-d438763b74e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b15c9ca8-1091-4285-8503-28d5f0982d2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6f2232fe-1c2d-4b7d-8580-b0b2c6db0d60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2b7cb7cc-adbf-44b8-8c0d-8d5f0b8b4b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8a5518aa-ebc4-40aa-b577-67d92b8cd732_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ceaf34a-a01a-4abb-a44a-88614506f704_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_89e8e795-8cfc-490b-8c94-6dbcad5dc9f6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bbe948fe-599a-444d-8cc9-01e4531dcb83_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_79b795df-2661-465f-b9b8-41351b4c815a_negatedLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_e578f5ef-f18a-48bf-a8e0-061fe11100b3_verboseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3662f24-c975-4a5e-9dd4-8b334b21a119_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2c7529ac-443f-4a8a-8349-db5a4fb90c58_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses and operating loss</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bd57aa37-c30e-4215-98c6-bfad7000e9be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e3faf25b-4f7d-4cc3-ab10-e4e9f5756c18_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_PreFundedWarrantsMember_e74e1c77-b99a-4fae-a215-69e0c49f173e_terseLabel_en-US" xlink:label="lab_gale_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_gale_PreFundedWarrantsMember_label_en-US" xlink:label="lab_gale_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_gale_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_gale_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedWarrantsMember" xlink:href="gale-20200930.xsd#gale_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreFundedWarrantsMember" xlink:to="lab_gale_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_DividendModificationOfWarrants_b7a44d2c-e745-4937-99de-b16d99a15b25_negatedTerseLabel_en-US" xlink:label="lab_gale_DividendModificationOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_label_en-US" xlink:label="lab_gale_DividendModificationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_documentation_en-US" xlink:label="lab_gale_DividendModificationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendModificationOfWarrants" xlink:href="gale-20200930.xsd#gale_DividendModificationOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendModificationOfWarrants" xlink:to="lab_gale_DividendModificationOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f86eb5e-c4c3-4ae2-b6d7-264009f0bfae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d6224969-53e5-4d7f-9114-630a1fa89a98_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9ae3358e-8bb6-4367-9807-11215871daa5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable&#160; Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_843bcd29-8d0f-4c89-8d99-419da37932a6_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_c0ade652-2134-4d1e-a337-7559f55d0b59_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, ending balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsLiabilities" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities" xlink:to="lab_gale_FairValueOfWarrantsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7a105987-9551-4da2-81a9-890bf9a1e1c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_January2020OfferingMember_55c3f4a0-b5a5-431c-8977-da335323bec8_terseLabel_en-US" xlink:label="lab_gale_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering</link:label>
    <link:label id="lab_gale_January2020OfferingMember_label_en-US" xlink:label="lab_gale_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering [Member]</link:label>
    <link:label id="lab_gale_January2020OfferingMember_documentation_en-US" xlink:label="lab_gale_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_January2020OfferingMember" xlink:href="gale-20200930.xsd#gale_January2020OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_January2020OfferingMember" xlink:to="lab_gale_January2020OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_36e3a080-6d72-4296-afd5-f5c93f646b4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_b01bdf41-2075-4a63-9243-c143ce7bc192_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e7520066-0553-48fd-852c-771a647c2bf4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e7c3a7ba-da94-46d6-8a2b-3097edd613ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00206ddc-5f82-4e3c-bf50-898e20f4f10e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_7bcec33a-9d1c-4b5c-afdc-73cc6b4068cc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_93025cbc-e16a-4b33-88c1-884f82ef1062_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_3365ac09-fc00-4e18-a677-c6ee71bbca72_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fbf45a14-1d91-4f0a-9710-70c26635c36f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40a248de-3cce-4976-9107-c5185a801d07_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_e581cf8a-4b45-4e9d-bf2f-a696904aaac0_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_df8e4e6b-e222-4af3-ba72-952b4106dbb2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d447b054-0a57-4b08-a5b5-38c233fc20a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_9eb10e06-88d7-4f48-a9e5-60f1402fa2a0_terseLabel_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_label_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_documentation_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:href="gale-20200930.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:to="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a5323bb6-1b42-4765-bd37-1af6e31e44b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5cb6936d-ca46-4a86-b06b-091819dea409_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_Warrants2019Member_07eb7c82-d5ed-4d9c-9b14-e13aa82ca56e_terseLabel_en-US" xlink:label="lab_gale_Warrants2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2019</link:label>
    <link:label id="lab_gale_Warrants2019Member_label_en-US" xlink:label="lab_gale_Warrants2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2019 [Member]</link:label>
    <link:label id="lab_gale_Warrants2019Member_documentation_en-US" xlink:label="lab_gale_Warrants2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2019Member" xlink:href="gale-20200930.xsd#gale_Warrants2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Warrants2019Member" xlink:to="lab_gale_Warrants2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_28566e36-e305-4b97-a04a-cae2a1e11ab0_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:href="gale-20200930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_48d06d44-a1f2-416d-868b-439812f33de5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OtherWarrantIssuesMember_cad8c501-08ce-4f97-8b94-41edaf6f742e_terseLabel_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galena Other</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_label_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_documentation_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OtherWarrantIssuesMember" xlink:href="gale-20200930.xsd#gale_OtherWarrantIssuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OtherWarrantIssuesMember" xlink:to="lab_gale_OtherWarrantIssuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_b48f7a1f-df58-4b80-b0af-8cca902e33ee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_13897d44-2102-446c-8b99-45935532f3bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b975514c-1ec1-4842-ba0d-761cf4c165d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_f7072f06-c1f7-4b91-a2e1-41c1e7ff6cbe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86fdaff2-8762-4f21-8034-b3d1c6fe965e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85ea4028-26dd-4d20-ae64-f1e9d831158c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7c25fae2-2964-42eb-9853-de4125e50a3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b3dd1f32-d9c2-4c38-9d23-854541f6d1db_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60809b18-f12c-4263-8750-d00c26146251_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_58600476-ece0-4ee9-ab5d-e2ad6d267a4c_negatedTerseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants exercised</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsCanceled" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsCanceled" xlink:to="lab_gale_FairValueOfWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4902ceab-cc81-46fa-94a3-27c712decdd3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6bdfa7c0-681a-4723-a232-eb0da48f7319_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_201117b1-5c6f-4e6a-8b47-3baede668d25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9904539c-25bf-4a78-969a-40bab57e4afb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7acc4dca-c22b-49a9-ac80-32f4ed232c78_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0c956691-47b3-43da-9c27-b57ae3940b78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_48d96501-de9d-42df-8106-e680eff8994d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4cdfa8f8-e5e1-4c8b-a113-5890e27f0a36_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_af8b519f-4215-44c8-91b3-ee65c311f356_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dbffd58a-d91a-447f-8da3-1cc2b2819f28_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_1a62c691-3774-46ce-afcf-8640c8882403_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage gross proceeds from the sale of share (as a percent)</link:label>
    <link:label id="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:href="gale-20200930.xsd#gale_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:to="lab_gale_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_852f3d3f-7b3f-4a3c-9f05-30188431f006_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueofWarrantsGranted_dbf7fe29-fc35-4fec-8e3f-bf32cbb2aa87_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueofWarrantsGranted" xlink:href="gale-20200930.xsd#gale_FairValueofWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted" xlink:to="lab_gale_FairValueofWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9ef5fc15-c7c9-4d19-8c5a-f1791f73a1ad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8ac541c9-4aca-41fe-b82a-bbc33b40cf76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_ab54ab1b-ebf0-4ec5-a1eb-1f2b2fc8d11c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6dc7f2b0-9656-43b2-9b72-cca4241b143c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23eb6616-d7f2-478f-827d-f30ffbbd928c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e1194a9c-26a4-4ceb-b127-b97fc1517042_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c9b31b2b-4cf7-4d74-bab7-d99f22d615dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20640241-a036-44da-b69f-b4028022f1ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c2df874-4959-41ce-a81d-9e7cdd9a4383_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_535da7d7-af00-496c-a8a7-d33c198bb02e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b12c3082-575d-46b2-b158-bb6f5a308a3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_26c695b8-6043-49eb-acb7-70fa37bb58b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_dae4addc-25a5-4d56-b012-74aea6d62491_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_12c6bc08-1a38-42fa-9553-f5584fd10d45_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f33a289c-afdb-4813-a18c-fcd19e69dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ContractResearchPayable_51393c9c-f11f-4033-8e0f-1e682ea9a4fc_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_label_en-US" xlink:label="lab_gale_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContractResearchPayable" xlink:href="gale-20200930.xsd#gale_ContractResearchPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable" xlink:to="lab_gale_ContractResearchPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_52b954b8-4e73-4088-8ba8-9c7b296291d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_PreFundedJune2019OfferingMember_f9c12428-be33-49a6-83b3-985fc27fa1fe_terseLabel_en-US" xlink:label="lab_gale_PreFundedJune2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded January 2020 Offering</link:label>
    <link:label id="lab_gale_PreFundedJune2019OfferingMember_label_en-US" xlink:label="lab_gale_PreFundedJune2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded June 2019 Offering [Member]</link:label>
    <link:label id="lab_gale_PreFundedJune2019OfferingMember_documentation_en-US" xlink:label="lab_gale_PreFundedJune2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded June 2019 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedJune2019OfferingMember" xlink:href="gale-20200930.xsd#gale_PreFundedJune2019OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreFundedJune2019OfferingMember" xlink:to="lab_gale_PreFundedJune2019OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1eb6a118-dd4a-4db5-9efe-9f6c80a4373a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_1b86317b-615d-48cb-aa35-0497fa7f6499_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_368240f9-e658-4315-b164-3849fd4e9196_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fa03794f-1ecf-43a8-9055-38b1eae79365_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5242d528-94ef-4e52-9527-c258378404ea_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_9d2832d3-7399-40a9-a71b-ed91d5e5f141_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:href="gale-20200930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_InProcessResearchDevelopment_c73e8bf4-507c-4736-bc5c-8433ab5bc770_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_InProcessResearchDevelopment" xlink:href="gale-20200930.xsd#gale_InProcessResearchDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment" xlink:to="lab_gale_InProcessResearchDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d4c95fed-2aca-4001-a1ca-3b237d131f90_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_81870136-c643-4bdc-9e3d-a2c38671973b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_69847351-6aa9-4e0c-ba8e-e2523ef1a329_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_38f48179-5be1-41cf-aea6-c0e215fac089_terseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:href="gale-20200930.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5c916f0-24c4-4285-b57b-e428f94748c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_5cf883f9-f629-4b0b-9998-21aa3ce9a278_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_554eeba6-5bad-415c-ba10-f311dfca5152_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f1ffa30f-3da7-4a87-9940-2b96c6d93374_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_63603aa9-634f-45e1-84a5-3aab4e153eac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b0feef1e-09d4-47a0-8f20-32b1ea3da8b5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_d14c70ff-c65f-49a4-acfe-eb4816778faf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4eecd3df-b948-42ad-b97e-7b5f23013451_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9d3d9465-56b2-4f22-9e63-9e08e58e9623_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bbfe5b08-f937-47df-9993-80b77e5031df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_73d095f9-618e-45ed-b065-c38f2d506391_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable&#160; Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b0d53ab6-d099-4ade-9337-129919ab0ed0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e4e3056-db2c-46ae-957b-f6fb234c5e47_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_918abf27-fc8b-48d5-b4d1-a9a38251e7f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2a59ca28-d864-42f9-ac0b-85efa0b6f4ae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_50bce94a-da8e-44e7-8f98-d7ab65f1f779_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_30f4cfd9-7f13-4c4b-9d5d-df3fc0d57d2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_July2020PIPEOfferingMember_f614c53b-eb5e-4a32-98ab-a6d210e72cab_terseLabel_en-US" xlink:label="lab_gale_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering</link:label>
    <link:label id="lab_gale_July2020PIPEOfferingMember_label_en-US" xlink:label="lab_gale_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering [Member]</link:label>
    <link:label id="lab_gale_July2020PIPEOfferingMember_documentation_en-US" xlink:label="lab_gale_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2020PIPEOfferingMember" xlink:href="gale-20200930.xsd#gale_July2020PIPEOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2020PIPEOfferingMember" xlink:to="lab_gale_July2020PIPEOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75e719f1-02f7-4615-ba56-2445de6d9612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0ba9ed49-66b8-4051-b599-a02cc5c513be_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c25172dd-5a31-4248-b3dc-3973942ed517_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c3468e65-4def-4cb7-a5f2-8a405d2b4b7f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_95b9dd54-25ea-45d2-95f9-1d36b85029bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares available for future issuance under stock based awards (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_71cd7773-72d1-4852-8b9a-62f1374d7063_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:href="gale-20200930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_feaeeeac-a9ae-432b-8bf9-62e48abac69f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f70e8014-c3e5-41e3-878c-a3c28337fc26_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_28eed18e-bd57-406a-8327-4674bf4576ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8b1ea0cc-dd45-4bf2-8103-1aab8827d24f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0404032f-04ee-490a-aea1-f314c5d53d66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a86b91c2-8675-4ea4-9e58-e4c858316135_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_5c66766b-cef5-4e26-861b-01b164079a96_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ProceedsFromWarrantExercisesGross_173f1966-384e-4998-94d5-14f70e71a902_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromWarrantExercisesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_gale_ProceedsFromWarrantExercisesGross_label_en-US" xlink:label="lab_gale_ProceedsFromWarrantExercisesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises, Gross</link:label>
    <link:label id="lab_gale_ProceedsFromWarrantExercisesGross_documentation_en-US" xlink:label="lab_gale_ProceedsFromWarrantExercisesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromWarrantExercisesGross" xlink:href="gale-20200930.xsd#gale_ProceedsFromWarrantExercisesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromWarrantExercisesGross" xlink:to="lab_gale_ProceedsFromWarrantExercisesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_297c90de-4ee3-417d-b501-a1d4ce5f2f91_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7f4a064a-2d51-415b-bc54-1ab81f321573_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_21dd4375-6ba7-4d3b-9758-1213674bcdf2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd797ff2-35fc-4348-a00d-74a67e789a3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_fc05ca1a-2559-41db-bba7-ff0413c39bda_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b388edae-20c1-49e8-a1a3-c65114013232_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_99435077-26a0-4752-9a57-67efbef0ec74_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_Warrants2020Member_1eaea99c-9541-433d-881e-7d14c0b9bfb7_terseLabel_en-US" xlink:label="lab_gale_Warrants2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2020</link:label>
    <link:label id="lab_gale_Warrants2020Member_label_en-US" xlink:label="lab_gale_Warrants2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2020 [Member]</link:label>
    <link:label id="lab_gale_Warrants2020Member_documentation_en-US" xlink:label="lab_gale_Warrants2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2020Member" xlink:href="gale-20200930.xsd#gale_Warrants2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Warrants2020Member" xlink:to="lab_gale_Warrants2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f88e11fb-dcbf-49b6-9cb8-8ffd9de02413_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d587c482-ae48-4d76-a973-cae3bb671830_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_005fd986-d518-4b01-9c50-c2d443fc65b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_df84f9b5-a1c9-4f3a-86f7-92fdfa9e85f6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9d08d223-1a53-4bd6-b073-96d2dc2f1322_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_8cbbae83-e96f-41a0-8bcf-9b2b0c1cd557_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received during the period for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_024870c4-6f9e-4d2b-89a7-b5f07b17cda1_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_439e184a-1f5f-416c-b39e-6cd606b89d61_terseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:href="gale-20200930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:to="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0a20ea35-6e0f-41d8-95c5-78d29cb02a68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 9,461,978 and 5,080,100&#160;shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b6300f86-f687-45be-a995-f1f2495f2597_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_64c27b39-2da1-4b7f-8e88-4f0a67b19eaf_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ceeafef0-5c50-4f8e-96fd-f543279a5a48_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_db336687-4bb6-4659-8f39-5429047f0f3f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_NoncashOfferingExpense_1675881d-ace3-4427-8e9e-3b4eaadcf09a_terseLabel_en-US" xlink:label="lab_gale_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses in accounts payable and accrued expenses and other current liabilities</link:label>
    <link:label id="lab_gale_NoncashOfferingExpense_label_en-US" xlink:label="lab_gale_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Offering Expense</link:label>
    <link:label id="lab_gale_NoncashOfferingExpense_documentation_en-US" xlink:label="lab_gale_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_NoncashOfferingExpense" xlink:href="gale-20200930.xsd#gale_NoncashOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NoncashOfferingExpense" xlink:to="lab_gale_NoncashOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_14eb507b-82d6-4ad5-9071-dd3c4f732946_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember_70e441bd-538d-41c9-928a-b7ad7854314c_terseLabel_en-US" xlink:label="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:href="gale-20200930.xsd#gale_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="lab_gale_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17274ebc-6208-4534-8aa2-63dedc544723_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c7e18993-8250-4bbe-9ca0-8d334dfcfc7c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_PIPEInvestorsMember_5a7dd544-2f90-4d89-95fb-7b8cd1462de8_terseLabel_en-US" xlink:label="lab_gale_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors</link:label>
    <link:label id="lab_gale_PIPEInvestorsMember_label_en-US" xlink:label="lab_gale_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors [Member]</link:label>
    <link:label id="lab_gale_PIPEInvestorsMember_documentation_en-US" xlink:label="lab_gale_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PIPEInvestorsMember" xlink:href="gale-20200930.xsd#gale_PIPEInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PIPEInvestorsMember" xlink:to="lab_gale_PIPEInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f457b7c8-64bd-4127-ba31-558979fdc65d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_423a6280-75dd-49ec-8d77-d45328704c92_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_88bcf6b7-d729-446b-a13d-39858c0148eb_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:to="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_February2017WarrantsMember_08457b2b-e56b-4948-a211-9ea3262366b5_terseLabel_en-US" xlink:label="lab_gale_February2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galena February 2017</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_label_en-US" xlink:label="lab_gale_February2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_documentation_en-US" xlink:label="lab_gale_February2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_February2017WarrantsMember" xlink:to="lab_gale_February2017WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fdb7d373-b654-4fb0-a17f-50abaf8692cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ProceedsFromStockSubscriptionReceivable_e4d1da28-9f17-4755-bab8-2b9ce8656021_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collection of stock subscription receivable</link:label>
    <link:label id="lab_gale_ProceedsFromStockSubscriptionReceivable_label_en-US" xlink:label="lab_gale_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Subscription Receivable</link:label>
    <link:label id="lab_gale_ProceedsFromStockSubscriptionReceivable_documentation_en-US" xlink:label="lab_gale_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Subscription Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromStockSubscriptionReceivable" xlink:href="gale-20200930.xsd#gale_ProceedsFromStockSubscriptionReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromStockSubscriptionReceivable" xlink:to="lab_gale_ProceedsFromStockSubscriptionReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e71ea2c9-ec8e-4028-a03f-eaab383305ab_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_de0f6a13-3a74-44d7-8746-a84060d357d9_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/Expired (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightCanceledOrExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightCanceledOrExpired" xlink:to="lab_gale_ClassofWarrantorRightCanceledOrExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_StockSubscriptionReceivableCurrent_93f17223-bf13-4d9b-9154-52eecb1ab81f_terseLabel_en-US" xlink:label="lab_gale_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription receivable</link:label>
    <link:label id="lab_gale_StockSubscriptionReceivableCurrent_label_en-US" xlink:label="lab_gale_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable, Current</link:label>
    <link:label id="lab_gale_StockSubscriptionReceivableCurrent_documentation_en-US" xlink:label="lab_gale_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockSubscriptionReceivableCurrent" xlink:href="gale-20200930.xsd#gale_StockSubscriptionReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockSubscriptionReceivableCurrent" xlink:to="lab_gale_StockSubscriptionReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0fbd9657-2f8e-495f-bc3c-552c67e70f48_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_f492b421-43f1-4545-b6d5-ce0d43ba6e2d_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_PrepaidProfessionalServices_db99b119-b69f-4225-85e0-b9da8ee07f3b_terseLabel_en-US" xlink:label="lab_gale_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_gale_PrepaidProfessionalServices_label_en-US" xlink:label="lab_gale_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Professional Services</link:label>
    <link:label id="lab_gale_PrepaidProfessionalServices_documentation_en-US" xlink:label="lab_gale_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Professional Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidProfessionalServices" xlink:href="gale-20200930.xsd#gale_PrepaidProfessionalServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrepaidProfessionalServices" xlink:to="lab_gale_PrepaidProfessionalServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_084ce6be-5848-4c77-83db-cdc21552de0b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, December 31, 2019</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2e0d93de-59e0-4080-afee-996e4ff493bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, September 30, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a0954a16-2bf7-490d-a9fe-d5d8f57790c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a2917382-9f1c-4e48-ac04-a130616e0a75_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c99a347c-8b61-40bd-bf5b-e76996d580ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa0d3e92-68bd-4c60-9bf3-37d25c63dd68_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4f7c05b2-8601-494d-916e-3327cb9cb2eb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_72af2095-380d-43ca-b96a-867b87639cb7_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity Table</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:href="gale-20200930.xsd#gale_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_a166ddde-df14-4647-86f8-cd4886ac40b1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fcfc0099-d87e-420b-9b30-448d0e8433b5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Accounts</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_845428d4-3556-4dba-b256-75696d5081d2_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_81c95c83-5638-47da-93b8-a2de55640cb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and non-current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7047896-07d5-46ec-9bc6-d6d6cdeb4acc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a94e743d-3c03-4f90-8825-6960b4149492_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c9965ed7-eeca-49d6-8125-b66237d369ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_347df23c-3595-44d7-9f7c-716adbc35588_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember_981c05d9-6b01-4ea2-a436-f27421aca2a5_terseLabel_en-US" xlink:label="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average cost of capital</link:label>
    <link:label id="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember_label_en-US" xlink:label="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital [Member]</link:label>
    <link:label id="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember_documentation_en-US" xlink:label="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:href="gale-20200930.xsd#gale_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:to="lab_gale_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangeInOperatingLeaseRightOfUseAssets_92920f92-fe70-490e-b8a2-636d20091c2a_terseLabel_en-US" xlink:label="lab_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating lease right of use assets</link:label>
    <link:label id="lab_gale_ChangeInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_gale_ChangeInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:href="gale-20200930.xsd#gale_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="lab_gale_ChangeInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_148507d7-a834-4e00-abed-6498aaec6c90_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2fc3ae2d-8bff-4c3c-94ca-6c72cdbbda24_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_636c9866-d53a-496f-8199-cc35086b570f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e96f2f89-b882-45d5-acba-66b40d3fb3c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_76df563c-6ce4-40e2-bf43-e5a6aec16f93_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_48d647c3-db68-4cbc-a30c-d00f09b9b089_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_47022f4d-7ba8-483d-ad1c-21fca0b46eac_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_73d7c725-7cbe-487f-8973-a5ad7630ce02_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9fa14b76-4722-4ebf-a0b8-0c71f3df589d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6911e83-0448-46b2-b1be-8c1fe7600b08_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f056a3d2-6947-49dd-97da-4ad33830f94e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member_cc2d57c8-adc5-4182-a531-4588e438f961_terseLabel_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring July 31, 2020</link:label>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member_label_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring July 31, 2020 [Member]</link:label>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member_documentation_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring July 31, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringJuly312020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:to="lab_gale_OfficeSpaceLeaseExpiringJuly312020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_ed07030c-bfe4-4b80-9885-f5a0c435f694_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfWarrantLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OfferingPricePershare_e989106d-fb89-4605-923a-b29c1ab89ebc_terseLabel_en-US" xlink:label="lab_gale_OfferingPricePershare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_gale_OfferingPricePershare_label_en-US" xlink:label="lab_gale_OfferingPricePershare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Price Per share</link:label>
    <link:label id="lab_gale_OfferingPricePershare_documentation_en-US" xlink:label="lab_gale_OfferingPricePershare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Price Per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfferingPricePershare" xlink:href="gale-20200930.xsd#gale_OfferingPricePershare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OfferingPricePershare" xlink:to="lab_gale_OfferingPricePershare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a25e6611-043b-408b-8215-d3b309643070_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_a5fb82e4-aab6-4dea-a54c-b072c893dc3f_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to Acquire Shares of Common Stock</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_08261d89-0a79-4fd1-9924-53a2735d57c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_48a8a75b-405c-4da2-9434-52d9b5cba8f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_da24268b-aa2c-4f6e-b7c4-09776f2e868e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a9c82b2b-0ea6-43d8-9ef1-b34eb06f4d7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fe18c3fa-6eea-4070-8cef-b1e58cb972e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_83e90620-c9d6-4652-8c67-8c491bfdea0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12feddcd-7c36-4f6d-b272-381c8633624e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_75e8f9b3-2061-422f-91d4-c43be449cb17_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_d64f4e95-2f2e-47af-983f-e09a552884eb_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9f470fd8-7c78-461f-aea0-4fbc307458d2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a0c25f36-ce8d-4f31-b63c-5891c617481d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2070cfff-a2c9-4130-9dc4-51e5bf56724f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_2d5c7f2c-7f92-470b-811f-4db998813365_terseLabel_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_label_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_documentation_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:to="lab_gale_SeriesAConvertiblePreferredWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8c0b509f-b230-4214-8b31-6bd1535ff2ec_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ac8c02d3-093f-40e4-8f35-efa80d07ad64_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b47e73bf-4bde-4ca4-9ab0-e21db3030336_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1986775e-501f-4136-9ccd-998599c07a80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_d07205c7-ac74-470e-a4e1-0b181ed8ad88_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value Of Warrant Liability [Table Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:href="gale-20200930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_DividendArisingFromWarrantModifications_0973c854-acba-4376-9bcd-14c8625405da_negatedLabel_en-US" xlink:label="lab_gale_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend arising from warrant modifications</link:label>
    <link:label id="lab_gale_DividendArisingFromWarrantModifications_label_en-US" xlink:label="lab_gale_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Arising From Warrant Modifications</link:label>
    <link:label id="lab_gale_DividendArisingFromWarrantModifications_documentation_en-US" xlink:label="lab_gale_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Arising From Warrant Modifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendArisingFromWarrantModifications" xlink:href="gale-20200930.xsd#gale_DividendArisingFromWarrantModifications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendArisingFromWarrantModifications" xlink:to="lab_gale_DividendArisingFromWarrantModifications" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OperatingLeaseRemainingLeaseTerm_bb842493-4829-4b91-95c7-80fc5c96cc7b_terseLabel_en-US" xlink:label="lab_gale_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining term</link:label>
    <link:label id="lab_gale_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_gale_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_gale_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_gale_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRemainingLeaseTerm" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_gale_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_847fc482-ffeb-42cb-baf0-bf3475e777d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f824e43c-3f8a-4027-af9c-7ced36d23943_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b800feda-6db7-424a-99c0-13bb3812ef8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_90303411-de09-435e-a8ac-a9bb109b1b32_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_929ad361-ede2-4864-a328-400d82877252_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5b84d268-32f5-4bc2-8279-5f9450c83c22_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of warrants, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_ca6091ad-c85e-424d-b090-b7eda898fe36_terseLabel_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Plan</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:href="gale-20200930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_15a9bf18-7555-4d28-8777-b187c40ffae7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_75314082-277a-4019-bffc-f180e40cb9af_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_10cb5007-0ea0-4477-a7d4-cfbb1376be99_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fc096724-3c24-4083-9190-b8e97c502201_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b4cd0104-398b-4459-9505-bcda73ec9e2a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d4587993-99fc-4090-b719-7ab72c6093fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_EqcWarrantsMember_61f1d1ae-d886-4a04-bdc8-776d94c18b52_terseLabel_en-US" xlink:label="lab_gale_EqcWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equilibria</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_label_en-US" xlink:label="lab_gale_EqcWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_documentation_en-US" xlink:label="lab_gale_EqcWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EqcWarrantsMember" xlink:href="gale-20200930.xsd#gale_EqcWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EqcWarrantsMember" xlink:to="lab_gale_EqcWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e2d1235-3451-42d8-ad13-f3bfed1bf5b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114ff4d2-2b43-4c11-a4a8-65782e0118df_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_519bfea8-b675-44b4-920e-375c8810a173_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5835f990-2bcb-499c-aec2-ba1b164bd909_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a8a4b77-3c9b-426f-bc09-3bac81396aff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_6fca9a85-5ce6-4cfa-9e87-ffce8030bdd1_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Issued</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="lab_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_189212ac-de36-43e4-8a54-b83f19ec79f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_977c732e-6342-4f57-8b32-c97a16bbe377_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25212a81-78bf-4e94-9811-65984c80fc06_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_AptheraInc.Member_33d2b98d-a758-48ab-9abc-4af3c594dcd0_terseLabel_en-US" xlink:label="lab_gale_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc.</link:label>
    <link:label id="lab_gale_AptheraInc.Member_label_en-US" xlink:label="lab_gale_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:label id="lab_gale_AptheraInc.Member_documentation_en-US" xlink:label="lab_gale_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_AptheraInc.Member" xlink:href="gale-20200930.xsd#gale_AptheraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AptheraInc.Member" xlink:to="lab_gale_AptheraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_363d494e-d509-4e18-9b11-896fd51ad8f6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_38d00f0a-4cea-459b-b0e2-5f9d1877454a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_730f15e5-ca8d-4d6b-b97d-ff80e6def3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cf1e26af-63e4-4988-b70d-88935af43a9d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock to be called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_30de71d3-8bd0-4012-b2b6-35699eaf1a69_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_223cf113-876f-4bd1-9f6a-8d694b7a49f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55a9ead3-500f-45d8-a8e1-a27388498c93_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3272de7e-55d0-4434-9b65-501d56ad34fd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fc38b2ae-5762-4871-ab7b-9f8f42a9ea8e_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f9f60c3d-e030-42b8-a05a-b2aaaf4cc959_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f395f2cd-367b-460c-8889-b11fad530308_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a01748a7-98bf-43bd-8c08-46fa4513edc4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fed0edb5-e7e6-441c-a637-45d7da1da983_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_94de4e99-533e-434e-91d9-f0075465d6e7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9445531b-12af-401e-9a4a-86b8e89b6115_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9ea145ce-bb75-45da-a570-33e4193405b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76f6a7b3-d851-4bf0-b760-7b72e8602cef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_MeasurementInputCostOfDebtMember_7f83aac7-608e-49fd-a79f-c3f0cb2f8fef_terseLabel_en-US" xlink:label="lab_gale_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_gale_MeasurementInputCostOfDebtMember_label_en-US" xlink:label="lab_gale_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Cost Of Debt [Member]</link:label>
    <link:label id="lab_gale_MeasurementInputCostOfDebtMember_documentation_en-US" xlink:label="lab_gale_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Cost Of Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputCostOfDebtMember" xlink:href="gale-20200930.xsd#gale_MeasurementInputCostOfDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MeasurementInputCostOfDebtMember" xlink:to="lab_gale_MeasurementInputCostOfDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5128f035-404b-43f7-8d21-b674dd5f8c99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_29408e82-bbd7-4180-984d-47ab91981b42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_280464d5-9668-470f-b567-1986e9d67501_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8155848a-25dc-46a1-9657-7a962684b9a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_71e8ddfe-ba46-4c69-afbc-7ec5a35b9637_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the estimated fair value of the contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0ffdcc37-bf03-41f8-9ff5-cf21e1346656_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices&#160;In Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_c578078b-2f0e-4017-ae5d-632d4dc75aba_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Common Stock and Warrants</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:to="lab_gale_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_75eacc98-9c04-4351-8d98-fff1602b2275_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_589dffd6-d26a-46f8-8d55-bbbe0f2144fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member_7ae71606-4c56-472b-a1f3-c68328bd081e_terseLabel_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024</link:label>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member_label_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024 [Member]</link:label>
    <link:label id="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member_documentation_en-US" xlink:label="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:to="lab_gale_OfficeSpaceLeaseExpiringDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_July2019OfferingMember_be18d12e-e5b1-4d81-8e9f-18faf5484e9a_terseLabel_en-US" xlink:label="lab_gale_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2019 Offering</link:label>
    <link:label id="lab_gale_July2019OfferingMember_label_en-US" xlink:label="lab_gale_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Offering [Member]</link:label>
    <link:label id="lab_gale_July2019OfferingMember_documentation_en-US" xlink:label="lab_gale_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2019OfferingMember" xlink:href="gale-20200930.xsd#gale_July2019OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2019OfferingMember" xlink:to="lab_gale_July2019OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538bb1e7-358e-41e0-a1ef-689ce4545b52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_29ca83c7-5663-473a-a649-26bad2822dc5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_b08ab384-474d-4ba2-bb35-12be2078740f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9b364692-63b2-4c02-8b3f-69a312ff93ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_798f3bfc-7472-47ae-bb09-8ca0fb5f2d62_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Are Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:href="gale-20200930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3d7a7e4b-7aab-43fd-82aa-13d1b7a78200_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of warrants, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_0fa66a19-61e0-4a56-9e69-cd74e21b4d0b_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan (in shares)</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:href="gale-20200930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_0406ffd8-f3e7-4756-8c76-3077f5c16a52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_68ff8356-08b1-4c70-b5ba-be98679057c1_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, timing of development milestones</link:label>
    <link:label id="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_label_en-US" xlink:label="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</link:label>
    <link:label id="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_documentation_en-US" xlink:label="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:href="gale-20200930.xsd#gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:to="lab_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_3698b7d4-14c9-4316-917a-d1474d6459bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable, minimum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e545a8f1-db68-41fa-b49b-b35b6e18d228_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_d2b246b8-362a-42db-85e1-2b284393f84f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b33acac6-6429-4190-8262-a823d4b6bfb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_WarrantStrikePrice_ddefc784-ab77-424c-aa73-5bfe0f736461_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_label_en-US" xlink:label="lab_gale_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantStrikePrice" xlink:href="gale-20200930.xsd#gale_WarrantStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice" xlink:to="lab_gale_WarrantStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e22a343e-e80b-49e5-bc8d-c66bb770198a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_cb52cbfb-9f0f-4a6e-9c37-29b430e73d67_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5fa1c74f-b586-443a-b465-d49a1681925d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5e734aef-2eb5-4a57-a3ee-2e9bc35aed31_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_11b0a1e0-2c2f-4e32-a84d-765dc04e2919_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c2298f39-e3bf-4898-b350-829c131dace6_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6405ed8e-878e-4ff5-a7de-8f2043218d80_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48812fce-3a27-48a0-be09-63fb71b58ef6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c7fe9b1a-868f-4fcf-a88a-7ed7d73e3825_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_583a40e8-670b-4202-b9bf-3c1eb7b2d838_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_PrepaidResearchAndDevelopment_accfa65e-a1a4-40c2-9b9c-c6fcab742d79_terseLabel_en-US" xlink:label="lab_gale_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_PrepaidResearchAndDevelopment_label_en-US" xlink:label="lab_gale_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:label id="lab_gale_PrepaidResearchAndDevelopment_documentation_en-US" xlink:label="lab_gale_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidResearchAndDevelopment" xlink:href="gale-20200930.xsd#gale_PrepaidResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrepaidResearchAndDevelopment" xlink:to="lab_gale_PrepaidResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_07052f36-672f-4306-a8cc-941e28914c37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2afb3fa0-b25b-41da-97ed-856698497fbc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_4a785682-ac26-4c9a-88f3-08205bdbd826_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Exercisable</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:to="lab_gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_5048c8c3-1995-4562-9fd9-483bd60c5318_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightTerm" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm" xlink:to="lab_gale_ClassofWarrantorRightTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05cc3f7f-eee1-4710-8ed7-f541a0768ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1fe1c5d3-77b7-4099-8861-c944167ec0bf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_58de7a9b-e8e2-4ac4-9458-247f51eb87d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379d351c-e478-4b61-a534-cd3e6ce9516b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3263f0e-436e-4498-894d-00d7812bca4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3e3682fa-c6ef-4617-86e1-3d485370ef76_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_SaleOfStockAuthorizedAmount_36b85b38-086e-46c0-b8fc-35ae1adc124b_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares, common stock gross proceeds</link:label>
    <link:label id="lab_gale_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_gale_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_gale_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_gale_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAuthorizedAmount" xlink:href="gale-20200930.xsd#gale_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockAuthorizedAmount" xlink:to="lab_gale_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b705a416-5576-4d43-bd36-523c7d86bd0d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d268e7f3-2286-46e1-b53f-d2a863ed49a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f3f5c43f-6afa-423d-af69-7409eece7b5a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_d8f4face-4165-4e0d-a726-d287a5da8b32_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_d2ccb488-7d0a-4faa-a938-6f3565a08442_terseLabel_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_label_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6631cfc1-5b93-4fc9-a826-bca388c5ff55_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0eb1aba-a881-409c-a127-ed4e2ff7db54_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ef2e649d-74f7-43fb-afa0-64cf04fe1a8b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right of use asset and current and non-current lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8b538c9a-41f5-4baf-837f-4b48be50a186_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3218fb8e-5a40-4a5a-8f57-b11cb7e2b11a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_072f91d7-b155-4f46-9590-d25e7315087e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_88cbd23e-30ce-42f5-9cdc-fff21a92ccef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_296c8eac-6036-4259-8c5c-78d95caad25c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51271483-65d9-4e2f-be19-e5767c5622a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1a55802-06cc-41cc-aa71-5b9d05efdd46_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a6422db9-a0ca-4fc1-a7a3-1d760eca6e18_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_14192818-a136-4cee-98c9-884c7eeecdb9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in warrant fair value</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d94d30e4-221d-463f-84c7-4088c3013ab1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7bd6dd31-7ac8-44b4-a6a2-8ce7189e6444_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1dcd3052-dff3-4b86-945c-8ad71ba06cc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cfd7312a-bf99-4518-a7ff-4eaaedc2b604_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_de69d68b-c552-429e-8a03-640c54d2145d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_July2018OfferingMember_36dd20f4-2215-4e78-8b97-7036ed2b8c25_verboseLabel_en-US" xlink:label="lab_gale_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering</link:label>
    <link:label id="lab_gale_July2018OfferingMember_label_en-US" xlink:label="lab_gale_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:label id="lab_gale_July2018OfferingMember_documentation_en-US" xlink:label="lab_gale_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2018OfferingMember" xlink:href="gale-20200930.xsd#gale_July2018OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2018OfferingMember" xlink:to="lab_gale_July2018OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_49a4f5a5-94db-41fb-a21f-67a7b6c4d0cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant_4f12b6db-479f-4a36-bff6-c96499d0fe2a_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value, Pre-Funded Warrant</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value, Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:to="lab_gale_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_DistributionAgreementMember_dcd8cb96-ab29-4812-8fbb-3fb1510bf7ff_verboseLabel_en-US" xlink:label="lab_gale_DistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Agreement</link:label>
    <link:label id="lab_gale_DistributionAgreementMember_label_en-US" xlink:label="lab_gale_DistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Agreement [Member]</link:label>
    <link:label id="lab_gale_DistributionAgreementMember_documentation_en-US" xlink:label="lab_gale_DistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DistributionAgreementMember" xlink:href="gale-20200930.xsd#gale_DistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DistributionAgreementMember" xlink:to="lab_gale_DistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_73b7322a-bcd7-4be5-9a2f-8a2f038f2822_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding, measurement input coupon rate</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15d3f92c-2cd1-45ab-8f3d-27b8919064df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0c5d5cd6-c217-45ed-a84c-8460e91e10c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9ea91cb-4d18-46ed-8a44-52041e46f462_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_cbe5f9b6-8a30-4245-a706-f2ba5fa12b5e_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:href="gale-20200930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_f2ef1b30-82c0-42ae-898e-2c8e31f20949_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to exercise price of warrants</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:to="lab_gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_94ad1b97-5d9f-48ab-9c31-d725aa7d4329_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4a56c385-3b8f-4daf-812a-bc154e6bc8cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable, maximum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1827889f-4965-45f7-b8b9-862ab85a8312_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a997c428-d4e5-4491-ad8f-4b61ae75990a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_OperatingLeaseRightOfUseAssetAmortization_4189ba95-9d59-4afa-aea0-a9c3e994d867_terseLabel_en-US" xlink:label="lab_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease amortization</link:label>
    <link:label id="lab_gale_OperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_gale_OperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_gale_OperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0f85bb8d-0051-4ca7-a712-5a6059a90fa2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_19de7b7a-5725-4ab7-a5e3-6fb7046b4d2d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ba4763c6-6b71-466e-bbb6-27bc9cc20053_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_e8ab3b90-3e35-43f6-8efd-2bd70d2040e0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f27b4b7-9e73-4578-9f7c-51e99f6b5155_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c19aeb9a-27fe-4dd1-b827-c09ff68d9f9e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d38526ae-17cd-476c-92b9-56e8f229ea3d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_46aa7e08-c215-4526-a721-525d75ecf018_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:href="gale-20200930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c4864d11-0130-49e2-beae-68e748dae3ff_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_769ddb9d-fa85-4f37-aae9-028464cc7177_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2841bea4-926f-40aa-97ed-261525dee8e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dd7342b5-7b5b-45da-bb75-83460191ff2a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_50fa801c-7677-462e-8d72-e3f75604ab0b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_cbea6233-d15e-4837-85a0-e4728ce33315_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_278073de-4e84-496f-9cec-37e25e1f39e8_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_be8729c8-28cc-483c-934c-63d67d4f5f74_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_828cf526-2dba-40e3-9bc6-0f163d1fbb5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_df034946-27a6-4875-86e2-ec8e27147b99_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_4e8dc619-616f-49c7-9c42-07386140aa83_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of the Company's common stock (in dollars per share)</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClosingPriceOfCommonStock" xlink:href="gale-20200930.xsd#gale_ClosingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock" xlink:to="lab_gale_ClosingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18521a67-0e4f-44cf-9ab3-ef8685f6746e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1833457-7e8f-4047-90e1-43250c3d6c76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_d7b5f3df-9eae-4d1a-9149-185e268e00e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ce6b5d54-efe9-457d-943f-e036b6ca687f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05172cf7-a037-4062-901b-bf6883ea151f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_674f7527-4aa4-406a-9a07-ec457295eba6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_887ddee7-7f37-4be6-885d-fd43c5fb40dc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_70e4e2d1-d295-4dab-8c31-f05b02cbd501_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Common Stock and Warrants</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:to="lab_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_35164722-09d8-4194-a7c6-2f6d8c07f3c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_41f253d7-84bf-42f0-b0ba-70800d0b79f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f60ccf7d-9a51-4f7d-8b2a-4110adbbeaea_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_bf4edf62-37a6-4800-868b-057caedd8ca7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_3094994b-7a8a-43f1-a6b0-fa021b1e4a12_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c3d2a448-c4ab-492d-bb04-77e28334d7e9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d987a89b-ab8b-456e-80de-eda0a03e4678_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock_8d23b958-c768-4ef8-9765-740586229d94_terseLabel_en-US" xlink:label="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units with Performance and Service Conditions</link:label>
    <link:label id="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock_label_en-US" xlink:label="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Performance And Service Conditions [Policy Text Block]</link:label>
    <link:label id="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock_documentation_en-US" xlink:label="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Performance And Service Conditions [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:href="gale-20200930.xsd#gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:to="lab_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_WarrantExerciseAgreementMember_234f07a9-8582-48d3-8ff1-1cec1d26a315_verboseLabel_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Exercise Agreement</link:label>
    <link:label id="lab_gale_WarrantExerciseAgreementMember_label_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Agreement [Member]</link:label>
    <link:label id="lab_gale_WarrantExerciseAgreementMember_documentation_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantExerciseAgreementMember" xlink:href="gale-20200930.xsd#gale_WarrantExerciseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExerciseAgreementMember" xlink:to="lab_gale_WarrantExerciseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_ace39a60-ed1b-45cf-95c6-0eefb8f5e614_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1b54c64f-05db-48eb-a4c1-092884f4949a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Adopted an Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_dc9abd28-121c-48f6-87fd-b27199625844_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_902d222a-26ed-4643-8c0f-27244cca9f34_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_18de88aa-4ab9-4197-8896-8940add50452_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gale-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2e7a0093-5db0-44f6-b483-1ef83a9e73fd,g:e4277140-7cd7-42d9-8716-563b01e01457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Cover" xlink:type="simple" xlink:href="gale-20200930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a89225f1-9f20-4140-b569-3d01d50d233d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentType_a89225f1-9f20-4140-b569-3d01d50d233d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c900f82a-cacc-461b-9ffb-c0ddcf85d721" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentQuarterlyReport_c900f82a-cacc-461b-9ffb-c0ddcf85d721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_88bf3ab3-7f13-4c00-ac8b-9583365be1ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentPeriodEndDate_88bf3ab3-7f13-4c00-ac8b-9583365be1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c1fbb9be-f97c-4f45-98bf-69db27b3d4c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentTransitionReport_c1fbb9be-f97c-4f45-98bf-69db27b3d4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_81446977-fbf4-4464-8100-3dff93de889b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityFileNumber_81446977-fbf4-4464-8100-3dff93de889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c82a3966-ea21-4e49-8e0c-aecc19f8ce9c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityRegistrantName_c82a3966-ea21-4e49-8e0c-aecc19f8ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a35590c-bf52-40f1-b071-d2b62e812bc9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a35590c-bf52-40f1-b071-d2b62e812bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9ff22cde-03cf-43d7-9615-a3ed3bbd1f8a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityTaxIdentificationNumber_9ff22cde-03cf-43d7-9615-a3ed3bbd1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4c316e82-bf55-4a16-906f-7a28c1e24977" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityAddressAddressLine1_4c316e82-bf55-4a16-906f-7a28c1e24977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ad98f3ce-f171-47cc-ad81-9604a7f6c44e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityAddressCityOrTown_ad98f3ce-f171-47cc-ad81-9604a7f6c44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d2f258ec-468b-4fce-9925-654d2431bb0a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityAddressStateOrProvince_d2f258ec-468b-4fce-9925-654d2431bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_818143a9-db44-4e33-b9b6-cd7f488ba81d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityAddressPostalZipCode_818143a9-db44-4e33-b9b6-cd7f488ba81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fcb7aa79-1cec-42a4-ac1b-140f383e2858" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_CityAreaCode_fcb7aa79-1cec-42a4-ac1b-140f383e2858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a03731b5-6c8b-4403-af19-b357e336e336" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_LocalPhoneNumber_a03731b5-6c8b-4403-af19-b357e336e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5584d089-800e-41e4-8d94-806be07d04c2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_Security12bTitle_5584d089-800e-41e4-8d94-806be07d04c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cab5139b-ce2a-4d25-9eb7-72f526c4e19a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_TradingSymbol_cab5139b-ce2a-4d25-9eb7-72f526c4e19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2be9fd5e-1bb1-4298-b9ab-9011d5b70c1e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_SecurityExchangeName_2be9fd5e-1bb1-4298-b9ab-9011d5b70c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a7fe9cc6-8cd6-46d4-ba0d-64f4e286c8b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityCurrentReportingStatus_a7fe9cc6-8cd6-46d4-ba0d-64f4e286c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b966472e-d66b-4580-b63e-859460e5f969" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityInteractiveDataCurrent_b966472e-d66b-4580-b63e-859460e5f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bfc41cd5-f207-49a5-aeea-a9bfd875ebdb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityFilerCategory_bfc41cd5-f207-49a5-aeea-a9bfd875ebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6831b2d1-27de-44dc-b53f-a264a5b74cb1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntitySmallBusiness_6831b2d1-27de-44dc-b53f-a264a5b74cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a7b4c08b-1ef7-42bf-b6ec-fd975f9f30a2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityEmergingGrowthCompany_a7b4c08b-1ef7-42bf-b6ec-fd975f9f30a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5c7dc128-42e8-41dd-8046-9c5e83759782" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityShellCompany_5c7dc128-42e8-41dd-8046-9c5e83759782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3cb245df-7fbb-4833-b637-ad127b6726a9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3cb245df-7fbb-4833-b637-ad127b6726a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6c4ec8a6-fded-4f47-90e3-2f319516794b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_EntityCentralIndexKey_6c4ec8a6-fded-4f47-90e3-2f319516794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ebe71c28-75da-4f30-91bd-9fb3f7c2b537" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_CurrentFiscalYearEndDate_ebe71c28-75da-4f30-91bd-9fb3f7c2b537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0b47b131-26a1-4d22-8b0f-50a778157145" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentFiscalYearFocus_0b47b131-26a1-4d22-8b0f-50a778157145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d043fb6c-cf81-4268-a7ab-91877ef59dbe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d043fb6c-cf81-4268-a7ab-91877ef59dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e43ade02-14ad-45f6-9541-18d01f071902" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4bdf4d4d-1ffe-4fc3-b2c3-257549362bae" xlink:to="loc_dei_AmendmentFlag_e43ade02-14ad-45f6-9541-18d01f071902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75a128f5-b7d8-4f0a-8fe8-abfcb09c7f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75a128f5-b7d8-4f0a-8fe8-abfcb09c7f42" xlink:to="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_561609c8-dd7a-4c97-adb0-e1372d852617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_561609c8-dd7a-4c97-adb0-e1372d852617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a0544020-ab4f-4aa7-8efc-0c6a7f682066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a0544020-ab4f-4aa7-8efc-0c6a7f682066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockSubscriptionReceivableCurrent_1ce5562d-05ba-4244-9d2d-ecc7a67cbcb0" xlink:href="gale-20200930.xsd#gale_StockSubscriptionReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:to="loc_gale_StockSubscriptionReceivableCurrent_1ce5562d-05ba-4244-9d2d-ecc7a67cbcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72d78998-bfc1-4f2f-a753-0f0a770f1206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72d78998-bfc1-4f2f-a753-0f0a770f1206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e153c9e3-81c5-4d99-a5d5-72d81ed76411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd5e9ae8-4e0a-47d7-b563-ac5b402d44cd" xlink:to="loc_us-gaap_AssetsCurrent_e153c9e3-81c5-4d99-a5d5-72d81ed76411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfb01de0-1ea3-4da3-8637-33a62b6201a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfb01de0-1ea3-4da3-8637-33a62b6201a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_InProcessResearchDevelopment_e4ec2c31-22a9-4280-be0e-74d76f268901" xlink:href="gale-20200930.xsd#gale_InProcessResearchDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_gale_InProcessResearchDevelopment_e4ec2c31-22a9-4280-be0e-74d76f268901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_17d8e196-282f-40de-9ee5-609b00ed3dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_us-gaap_Goodwill_17d8e196-282f-40de-9ee5-609b00ed3dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_88a22af7-bd58-4200-9b70-cddf55580563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_88a22af7-bd58-4200-9b70-cddf55580563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_98bc3ba1-7b9e-4dbd-bb40-2e1d13803e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edcd24a7-9bba-4d13-b74b-14b199919daa" xlink:to="loc_us-gaap_Assets_98bc3ba1-7b9e-4dbd-bb40-2e1d13803e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75a128f5-b7d8-4f0a-8fe8-abfcb09c7f42" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_97874e5b-7ef4-4f0e-8628-c2bebfdf2074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:to="loc_us-gaap_AccountsPayableCurrent_97874e5b-7ef4-4f0e-8628-c2bebfdf2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1c9fd27b-95aa-438b-8009-3359038bbf2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1c9fd27b-95aa-438b-8009-3359038bbf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a044567-da61-44c2-b5f9-2ee514ae2c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a044567-da61-44c2-b5f9-2ee514ae2c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_13258606-1acf-4904-9bac-e5d344929105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_204fee9d-8382-4d40-9cf7-6c141cc82294" xlink:to="loc_us-gaap_LiabilitiesCurrent_13258606-1acf-4904-9bac-e5d344929105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebc62ba-8057-4485-a298-e24025f808bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebc62ba-8057-4485-a298-e24025f808bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7480ac60-3cc2-4b74-b1d5-d93271f2b1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7480ac60-3cc2-4b74-b1d5-d93271f2b1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_5a3cf70c-de12-4195-b2db-d73453c021a4" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_5a3cf70c-de12-4195-b2db-d73453c021a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d55275b6-0d29-4a58-ab2c-cad765d9a661" xlink:href="gale-20200930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d55275b6-0d29-4a58-ab2c-cad765d9a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2d3cb41f-77ee-4fcf-ab65-0d813e7baa1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_Liabilities_2d3cb41f-77ee-4fcf-ab65-0d813e7baa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bf12501c-166b-44c1-b9d5-262d59ea561b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bf12501c-166b-44c1-b9d5-262d59ea561b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_54f4bbd7-ef49-45d7-bd68-bd470bce76d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:to="loc_us-gaap_PreferredStockValue_54f4bbd7-ef49-45d7-bd68-bd470bce76d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d99c9bb2-65b3-4c53-a9e8-e54288b5d072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:to="loc_us-gaap_CommonStockValue_d99c9bb2-65b3-4c53-a9e8-e54288b5d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b7aa63a7-dc4b-4f83-bc75-0ecfaa9d53b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b7aa63a7-dc4b-4f83-bc75-0ecfaa9d53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f447ae77-f264-43eb-9fbf-ba2571a361e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f447ae77-f264-43eb-9fbf-ba2571a361e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4646a7e0-f396-44d5-9583-2ee70c5e1d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a058d4c7-b06f-4c9b-b243-a4c612d1f88d" xlink:to="loc_us-gaap_StockholdersEquity_4646a7e0-f396-44d5-9583-2ee70c5e1d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58152645-f79d-4ad1-b440-4c4434444760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_039a3413-5fc8-4fac-8ee1-93dcedea6dc5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58152645-f79d-4ad1-b440-4c4434444760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_daa371f0-9c80-4974-bda2-561462f6c4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_daa371f0-9c80-4974-bda2-561462f6c4b2" xlink:to="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3ad10316-a912-41f7-a3f0-54a513610ef8" xlink:to="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2bb8bd8a-3bf2-4a56-8bc7-66ca8dec40cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_828e185a-cfa2-40b1-9b89-98e624da5b87" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2bb8bd8a-3bf2-4a56-8bc7-66ca8dec40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bdf6308c-1d8a-4deb-909b-bdd4e34c75ed" xlink:to="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a95a43c-6b8b-4055-b2ea-0094c1134ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a95a43c-6b8b-4055-b2ea-0094c1134ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9d94cfe5-6936-453d-95da-1ac00a559950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9d94cfe5-6936-453d-95da-1ac00a559950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6cb837f-5cd7-4518-b8d8-ab2d1c88a963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6cb837f-5cd7-4518-b8d8-ab2d1c88a963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ce8d432e-8f4b-4557-a488-48f9ea2637f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ce8d432e-8f4b-4557-a488-48f9ea2637f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb3ba62b-2281-4c13-86b9-f68732653654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb3ba62b-2281-4c13-86b9-f68732653654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7c9bdcbf-1195-4787-bf75-c9831b3e57bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7c9bdcbf-1195-4787-bf75-c9831b3e57bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_297d6135-14a1-4c72-a80b-298b868e2a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesIssued_297d6135-14a1-4c72-a80b-298b868e2a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_53a89f47-f50c-441c-9001-3277dd09e42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95e017fa-9ff3-490c-87c0-a34f3d156867" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_53a89f47-f50c-441c-9001-3277dd09e42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f5d0e54f-bf86-440c-8538-631e005deb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f5d0e54f-bf86-440c-8538-631e005deb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_79a98a94-f9ef-483d-99d2-cb37ed94ad86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f5d0e54f-bf86-440c-8538-631e005deb23" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_79a98a94-f9ef-483d-99d2-cb37ed94ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9fea8109-0afd-4ac6-8cfc-42fcb7fb52f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f5d0e54f-bf86-440c-8538-631e005deb23" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9fea8109-0afd-4ac6-8cfc-42fcb7fb52f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c68c34b0-bd64-4138-b29d-961b20c4e103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f5d0e54f-bf86-440c-8538-631e005deb23" xlink:to="loc_us-gaap_CostsAndExpenses_c68c34b0-bd64-4138-b29d-961b20c4e103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_900ed8e4-e871-409a-9c16-4f26b7391d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_900ed8e4-e871-409a-9c16-4f26b7391d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_cafc96c5-bd11-430b-91a8-581f5d26e6d2" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_cafc96c5-bd11-430b-91a8-581f5d26e6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_168112b6-8a2f-429e-80d9-ab9203a092bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_168112b6-8a2f-429e-80d9-ab9203a092bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_e3a7eb0a-3bc3-4db4-9a6a-6e8b5dd9c147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bc213155-6f68-49f0-911c-02d767106b30" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_e3a7eb0a-3bc3-4db4-9a6a-6e8b5dd9c147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c5dc1d3-d881-4a5b-81a1-65c42f86a4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_us-gaap_NetIncomeLoss_7c5dc1d3-d881-4a5b-81a1-65c42f86a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendArisingFromWarrantModifications_e426ca56-fb5a-4e10-8814-8c5fb993e02a" xlink:href="gale-20200930.xsd#gale_DividendArisingFromWarrantModifications"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_gale_DividendArisingFromWarrantModifications_e426ca56-fb5a-4e10-8814-8c5fb993e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_60824bea-f993-44e9-9ff1-9616d76e44d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_60824bea-f993-44e9-9ff1-9616d76e44d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_654a28c7-b592-4457-a766-7f138df82c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e49d72fb-0109-41d3-a620-6265be159ef7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_654a28c7-b592-4457-a766-7f138df82c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_03e12b89-ac7e-4cdc-bf37-3505c1287225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_654a28c7-b592-4457-a766-7f138df82c94" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_03e12b89-ac7e-4cdc-bf37-3505c1287225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c0ac521a-a9a9-47be-9c40-97b563cb5277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_654a28c7-b592-4457-a766-7f138df82c94" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c0ac521a-a9a9-47be-9c40-97b563cb5277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_67db15f1-e1b6-4911-9ab6-9b80f585973b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_67db15f1-e1b6-4911-9ab6-9b80f585973b" xlink:to="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0dd4335f-c943-4c33-82fb-aa2d893ec628" xlink:to="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_795490cc-7fff-4b43-8fe3-f53048683786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_PreferredStockMember_795490cc-7fff-4b43-8fe3-f53048683786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_793804f1-e0e8-43cc-bdc6-035328915c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_CommonStockMember_793804f1-e0e8-43cc-bdc6-035328915c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a37bf42-a344-4f2e-a0a2-2fdf508f930e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a37bf42-a344-4f2e-a0a2-2fdf508f930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_737688d0-8d03-413c-96ca-152563c68307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82100394-b276-487c-8b3d-baffeb3131ab" xlink:to="loc_us-gaap_RetainedEarningsMember_737688d0-8d03-413c-96ca-152563c68307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95fb7800-2f64-4b92-b5b4-ffe59a5dbf84" xlink:to="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54ccd757-06a4-432b-a929-04a69925b699" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1fcc893d-529a-4034-ba4d-92ec0c6e1326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_SharesOutstanding_1fcc893d-529a-4034-ba4d-92ec0c6e1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09b8591f-0fb8-4818-8b1a-fc59941c79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09b8591f-0fb8-4818-8b1a-fc59941c79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_0544c52b-593a-4005-9690-1932e17206b8" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants_0544c52b-593a-4005-9690-1932e17206b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_c617e5af-58d5-483d-9355-280d5011dce1" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodValueCommonStockandWarrants_c617e5af-58d5-483d-9355-280d5011dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b10eb42-01cd-4f17-8803-be99c9f82c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b10eb42-01cd-4f17-8803-be99c9f82c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2201dae1-cde3-4f1b-9037-2b69b870e725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2201dae1-cde3-4f1b-9037-2b69b870e725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_c9c9fc3d-b140-49f3-8f06-9781d3757251" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_c9c9fc3d-b140-49f3-8f06-9781d3757251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant_2a59c86d-c27f-4fdf-9b3b-ccfe231102ad" xlink:href="gale-20200930.xsd#gale_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_StockIssuedDuringPeriodValuePreFundedWarrant_2a59c86d-c27f-4fdf-9b3b-ccfe231102ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ea3f3a26-4a35-49bb-b6b8-4ddcf3580fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ea3f3a26-4a35-49bb-b6b8-4ddcf3580fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_943f9791-18d2-40d6-9c2b-48dbc87561e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_943f9791-18d2-40d6-9c2b-48dbc87561e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_616f2c7d-953d-4437-b49b-2ddeb0591a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_616f2c7d-953d-4437-b49b-2ddeb0591a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b4776e2-feb1-4e11-a3ea-930fc617fd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b4776e2-feb1-4e11-a3ea-930fc617fd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DividendModificationOfWarrants_9091fb3e-ba28-4fa2-8021-c8c4632500a1" xlink:href="gale-20200930.xsd#gale_DividendModificationOfWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_gale_DividendModificationOfWarrants_9091fb3e-ba28-4fa2-8021-c8c4632500a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e7e8e03-25f3-4d7d-a5da-7f30dcb31cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_NetIncomeLoss_0e7e8e03-25f3-4d7d-a5da-7f30dcb31cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0fd1430b-48e4-4d16-8ce6-affe5194c914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_SharesOutstanding_0fd1430b-48e4-4d16-8ce6-affe5194c914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8c8738e-53d5-42d1-b9a2-9cd4c89fe856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81a69438-bff1-42ac-88fd-3dac77054028" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8c8738e-53d5-42d1-b9a2-9cd4c89fe856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gale-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcac7767-5546-43db-be73-e49a1148c69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcac7767-5546-43db-be73-e49a1148c69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ddab4ea7-103a-45ad-8342-2c057605be43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcac7767-5546-43db-be73-e49a1148c69f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ddab4ea7-103a-45ad-8342-2c057605be43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcac7767-5546-43db-be73-e49a1148c69f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_08c8a5cb-3982-4afb-bb98-f606761b949e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:to="loc_us-gaap_ShareBasedCompensation_08c8a5cb-3982-4afb-bb98-f606761b949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInOperatingLeaseRightOfUseAssets_c038fd94-9d15-4ec7-ae3a-d4d5a46dd8ab" xlink:href="gale-20200930.xsd#gale_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:to="loc_gale_ChangeInOperatingLeaseRightOfUseAssets_c038fd94-9d15-4ec7-ae3a-d4d5a46dd8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_496db7c2-d244-43f9-9027-7682303cdcb6" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_496db7c2-d244-43f9-9027-7682303cdcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_33e8bd26-a1f6-4863-ac6a-ff02a63040c4" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_33e8bd26-a1f6-4863-ac6a-ff02a63040c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ead79fd8-f7b9-49f3-ac61-283e78e63079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e03295c-b647-4e95-93a3-886ee5d9f3a4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ead79fd8-f7b9-49f3-ac61-283e78e63079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5dea03d0-fe6a-450d-9ee7-ad352272f3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ead79fd8-f7b9-49f3-ac61-283e78e63079" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5dea03d0-fe6a-450d-9ee7-ad352272f3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f566041c-35bc-4906-be9f-b98b1b7903a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ead79fd8-f7b9-49f3-ac61-283e78e63079" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f566041c-35bc-4906-be9f-b98b1b7903a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_96231394-d2ca-4f1a-942e-4cd6ab6b3b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ead79fd8-f7b9-49f3-ac61-283e78e63079" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_96231394-d2ca-4f1a-942e-4cd6ab6b3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef282c02-2c41-444c-9388-c8a2e7515354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcac7767-5546-43db-be73-e49a1148c69f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef282c02-2c41-444c-9388-c8a2e7515354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3813cb31-e45d-4352-af6a-fec1c596c595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3813cb31-e45d-4352-af6a-fec1c596c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromStockSubscriptionReceivable_608a9d21-cbb6-4ca6-80c1-0dbc36e236cb" xlink:href="gale-20200930.xsd#gale_ProceedsFromStockSubscriptionReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:to="loc_gale_ProceedsFromStockSubscriptionReceivable_608a9d21-cbb6-4ca6-80c1-0dbc36e236cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7e434291-a7e2-485f-90f6-c613a2f121ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7e434291-a7e2-485f-90f6-c613a2f121ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_553b52f0-6fe5-42da-b650-f9b8cd650aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f57f699-0f19-416d-8632-9204d9309ed3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_553b52f0-6fe5-42da-b650-f9b8cd650aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f76808d4-b12c-4a6e-bda4-32676b47a327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f76808d4-b12c-4a6e-bda4-32676b47a327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab01390c-bedf-4636-9f31-4dd96b8e556c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab01390c-bedf-4636-9f31-4dd96b8e556c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3674fdae-1628-41d5-a59d-fd66c5d2e2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3674fdae-1628-41d5-a59d-fd66c5d2e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_18574b99-b6cc-485e-9816-b8ecae38e5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_18574b99-b6cc-485e-9816-b8ecae38e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_d338f306-2b30-4466-a79c-f176b11945f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_18574b99-b6cc-485e-9816-b8ecae38e5cd" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_d338f306-2b30-4466-a79c-f176b11945f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9454348-e67d-4965-a249-b9b5de0ac1ac" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7a6df239-8aad-45a9-8906-6b324fbe9caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7a6df239-8aad-45a9-8906-6b324fbe9caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_6ba7a30e-cd18-46ab-856b-1491cce30977" xlink:href="gale-20200930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_6ba7a30e-cd18-46ab-856b-1491cce30977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_NoncashOfferingExpense_1511ccf0-4bbf-4a33-ba80-8389acf7a815" xlink:href="gale-20200930.xsd#gale_NoncashOfferingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:to="loc_gale_NoncashOfferingExpense_1511ccf0-4bbf-4a33-ba80-8389acf7a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_0cf09d07-976e-47a5-b809-76c948fca63e" xlink:href="gale-20200930.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b473ba48-0d1b-4e51-b5ef-0a15fdb13a66" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_0cf09d07-976e-47a5-b809-76c948fca63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gale-20200930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50e2306c-9701-457a-839f-23f13c8671db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_eeb24ea6-8cf8-4704-8fb8-ccaae999b289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50e2306c-9701-457a-839f-23f13c8671db" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_eeb24ea6-8cf8-4704-8fb8-ccaae999b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:type="simple" xlink:href="gale-20200930.xsd#Liquidity"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22d637f3-77dc-485d-9314-664cddb32853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_1f7a41c0-5c77-4ed8-8527-3e79713def1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22d637f3-77dc-485d-9314-664cddb32853" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_1f7a41c0-5c77-4ed8-8527-3e79713def1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#LiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45ac98f1-4eec-40f7-8cf9-3067810f6142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45ac98f1-4eec-40f7-8cf9-3067810f6142" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c46e815e-56cf-43c0-9b35-8946ac3971d6" xlink:to="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PIPEInvestorsMember_6f170e04-23e6-480e-b2f6-4f699dcfb8e7" xlink:href="gale-20200930.xsd#gale_PIPEInvestorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:to="loc_gale_PIPEInvestorsMember_6f170e04-23e6-480e-b2f6-4f699dcfb8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_9f650e3f-b7b0-4baf-b34f-82cb950284cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_816963de-e244-4d01-b1ef-c21e7fb24a30" xlink:to="loc_us-gaap_InvestorMember_9f650e3f-b7b0-4baf-b34f-82cb950284cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e4b81862-373f-407a-a2a8-88263375008c" xlink:to="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedWarrantsMember_fd9fe869-fb0e-46d6-aa81-57d2e85e2da6" xlink:href="gale-20200930.xsd#gale_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9cac62-0764-4b01-a39b-f9535d928100" xlink:to="loc_gale_PreFundedWarrantsMember_fd9fe869-fb0e-46d6-aa81-57d2e85e2da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bcc7fa44-f58c-4c3e-b7cf-7e18b350bbc6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a2b6166f-1ca3-4778-9508-0b7bd48983aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a2b6166f-1ca3-4778-9508-0b7bd48983aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c00fcd88-b49b-42c7-b6f5-df61293ca93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c00fcd88-b49b-42c7-b6f5-df61293ca93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d01ac6de-2f19-4be7-a22f-63be537c97f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d01ac6de-2f19-4be7-a22f-63be537c97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eee6340a-9fc9-4196-86e3-156252594a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eee6340a-9fc9-4196-86e3-156252594a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightTerm_0668b947-0ee7-4229-843f-49eea068590a" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ClassofWarrantorRightTerm_0668b947-0ee7-4229-843f-49eea068590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df8c0126-ccf5-413c-b782-48ff785ca244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df8c0126-ccf5-413c-b782-48ff785ca244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_418a5a05-5d7f-4d63-856b-8540c2dbfe9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_SharesIssued_418a5a05-5d7f-4d63-856b-8540c2dbfe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfferingPricePershare_4a23a8eb-6e8b-439a-90d0-cfc90c87950a" xlink:href="gale-20200930.xsd#gale_OfferingPricePershare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_OfferingPricePershare_4a23a8eb-6e8b-439a-90d0-cfc90c87950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_8eb0cec8-7772-4e64-962b-09966ee8b0f1" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_8eb0cec8-7772-4e64-962b-09966ee8b0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromWarrantExercisesGross_0d17b0aa-39fc-40f1-a224-ccaee0bc1a6e" xlink:href="gale-20200930.xsd#gale_ProceedsFromWarrantExercisesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_gale_ProceedsFromWarrantExercisesGross_0d17b0aa-39fc-40f1-a224-ccaee0bc1a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de221794-8028-420c-8db2-fbafc8273ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de221794-8028-420c-8db2-fbafc8273ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_eb72dac7-bb3b-4e1b-97c7-96b0f667cb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_eb72dac7-bb3b-4e1b-97c7-96b0f667cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_363b1510-5fb0-492a-bf66-3c0392e475f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_363b1510-5fb0-492a-bf66-3c0392e475f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93cd5dcc-c2da-49e1-90c5-d16ab05d7a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a339232c-337d-4181-8f34-8ee694c6a272" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93cd5dcc-c2da-49e1-90c5-d16ab05d7a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eb334e7d-9eac-401b-9912-5be365ad6250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_084ac3fc-f3e7-4f26-8638-bbe6a8f304f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb334e7d-9eac-401b-9912-5be365ad6250" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_084ac3fc-f3e7-4f26-8638-bbe6a8f304f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_078f8a70-14dd-4392-9035-ee0ea7d63c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_078f8a70-14dd-4392-9035-ee0ea7d63c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_715bd229-4555-45ef-8ac4-e9eb8d550058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_715bd229-4555-45ef-8ac4-e9eb8d550058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock_f82cae13-01c0-4fdf-b7a4-147d8bd9e7cd" xlink:href="gale-20200930.xsd#gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:to="loc_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock_f82cae13-01c0-4fdf-b7a4-147d8bd9e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_da4d3df7-2e51-4972-a921-aff515a5040c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_da4d3df7-2e51-4972-a921-aff515a5040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7915a95b-fb34-4c57-976a-bd78a8c6a1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db3e5cb7-4b2f-45e7-a418-527917b3b6d3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7915a95b-fb34-4c57-976a-bd78a8c6a1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c60990bf-18c2-477e-8f12-8d7b126b909f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6c9f3502-2d5d-41bd-a064-0443b62ceca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c60990bf-18c2-477e-8f12-8d7b126b909f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6c9f3502-2d5d-41bd-a064-0443b62ceca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aea80775-9703-4b4a-946f-7f40f0c4ccbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f1ba56a4-0ab7-4036-b2b5-8743cd054b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aea80775-9703-4b4a-946f-7f40f0c4ccbd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f1ba56a4-0ab7-4036-b2b5-8743cd054b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_993758d3-55e5-4200-8929-badcd642c73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aea80775-9703-4b4a-946f-7f40f0c4ccbd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_993758d3-55e5-4200-8929-badcd642c73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_acb5ba64-2395-4c7d-9b57-ae8166b59998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_acb5ba64-2395-4c7d-9b57-ae8166b59998" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b5a1132-b869-4dbf-bc2f-748af4c9095b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_41cf2082-3d8f-455e-80b5-a615fb61eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_WarrantMember_41cf2082-3d8f-455e-80b5-a615fb61eac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c193d5da-595a-4bfc-81ac-a49262700cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c193d5da-595a-4bfc-81ac-a49262700cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bd7e347b-8310-49af-bd58-1e58a699bf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_731d5032-f223-45d9-bdc0-e82a03f61f39" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bd7e347b-8310-49af-bd58-1e58a699bf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3681bb6d-efb4-42cf-80d6-0015ef7d8f37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76ec7a27-0871-435f-988e-f4c8eea75620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b60a92a-39aa-4a7b-894f-38d4d012cc9b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76ec7a27-0871-435f-988e-f4c8eea75620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e503f9f8-3547-4a77-a13c-d01d9dc348ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_28a9aca3-9fb8-4120-b84d-6b39e160e990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e503f9f8-3547-4a77-a13c-d01d9dc348ce" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_28a9aca3-9fb8-4120-b84d-6b39e160e990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54468300-def0-4eff-a7f5-e54256cf94f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dec1cac7-d86c-4b06-bae4-0f78798f511f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54468300-def0-4eff-a7f5-e54256cf94f3" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dec1cac7-d86c-4b06-bae4-0f78798f511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456a6dd7-0d5d-479e-a0be-36dfe2b9d73e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54468300-def0-4eff-a7f5-e54256cf94f3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_456a6dd7-0d5d-479e-a0be-36dfe2b9d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_47af45ee-56fa-4163-b2f3-7cbcdaf8cd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_47af45ee-56fa-4163-b2f3-7cbcdaf8cd6a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a4f4cc3d-3b37-4f4f-9360-f18a238ea603" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9e78fe0e-1576-4ae2-887d-29da7623ea01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f817464-242b-416a-8c55-a32a9e97f1d2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9e78fe0e-1576-4ae2-887d-29da7623ea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_769bf19d-5dce-4367-b97e-d96ce928223b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab5f6c4a-33e2-4d05-a8bd-72e48812121a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab5f6c4a-33e2-4d05-a8bd-72e48812121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c13b54a1-8b9a-4b2e-9dab-1508c34398e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c13b54a1-8b9a-4b2e-9dab-1508c34398e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4e62c389-5e2d-465a-8060-0cfc65e9df6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4888a3bd-7deb-482d-bf64-d5441cfdd6de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4e62c389-5e2d-465a-8060-0cfc65e9df6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7012c909-2dfe-4757-82f8-14b0ef6630cd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c44feb-617e-41e4-b035-4f41f8544634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c44feb-617e-41e4-b035-4f41f8544634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b682e75a-bd97-4dd1-a4eb-7e80a25e19c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4e5bc2d1-fc6d-4817-ac30-25159447624b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b682e75a-bd97-4dd1-a4eb-7e80a25e19c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77a2fac4-dafa-4669-8bc2-3db27afb3c43" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_2b311185-e599-4343-83dd-a4cb1a4d6298" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_2b311185-e599-4343-83dd-a4cb1a4d6298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_08c1f3d1-533e-4d24-a2b7-7e5aaedd5b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_08c1f3d1-533e-4d24-a2b7-7e5aaedd5b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_30c11d5d-ccb7-428d-9d6a-4c42b00e1d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b187444a-5285-4e8a-8caa-06309184ca69" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_30c11d5d-ccb7-428d-9d6a-4c42b00e1d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28f05a1c-c5ed-438f-83de-730abe49271a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28f05a1c-c5ed-438f-83de-730abe49271a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_73070ade-5b28-43ef-ad12-de32d8d582f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eacba9b1-e9ab-42df-b52a-76dc601407b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6784d8e9-5077-4551-9bc7-d83de6316ff2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eacba9b1-e9ab-42df-b52a-76dc601407b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21aafbf4-0d84-4718-9cbd-c74d0bcb1ab6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_08dbc3ae-2a32-403b-b05f-91fe55c29025" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_021806db-86ec-4620-9317-f1ed2bdb865e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_021806db-86ec-4620-9317-f1ed2bdb865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_95f42ea2-2298-4cfb-9fd5-a5acf27f46ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_95f42ea2-2298-4cfb-9fd5-a5acf27f46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e14a8057-a95a-4187-93b3-31ea93407dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_938cb022-a437-4db4-96ed-b401797d7a1c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e14a8057-a95a-4187-93b3-31ea93407dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_61dd0ac7-9fd9-4a5a-8e52-c8dc0485c4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61dd0ac7-9fd9-4a5a-8e52-c8dc0485c4bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a0e4110-0f88-46b9-9be6-ff5bbaa9a532" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_AptheraInc.Member_8cfd0568-6702-4510-a6b9-3701dae307b2" xlink:href="gale-20200930.xsd#gale_AptheraInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_328706fa-7850-4665-948d-fc5e4aae4c05" xlink:to="loc_gale_AptheraInc.Member_8cfd0568-6702-4510-a6b9-3701dae307b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_73476e4f-42d8-4639-b940-8070842b3cd6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember_13eeb53f-5267-4da8-ad11-e56798703009" xlink:href="gale-20200930.xsd#gale_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:to="loc_gale_MeasurementInputWeightedAverageCostOfCapitalMember_13eeb53f-5267-4da8-ad11-e56798703009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_MeasurementInputCostOfDebtMember_97c536e9-7851-45cf-a363-f772033dbe38" xlink:href="gale-20200930.xsd#gale_MeasurementInputCostOfDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_79b6dc44-7e1b-4dc7-b4f5-6e16306ea306" xlink:to="loc_gale_MeasurementInputCostOfDebtMember_97c536e9-7851-45cf-a363-f772033dbe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6bdd515f-c542-4ff2-ba77-61323f7b52b8" xlink:to="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50bf7927-4c70-4a2d-882a-35edc09101f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:to="loc_srt_MinimumMember_50bf7927-4c70-4a2d-882a-35edc09101f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ae4fd35-d9e2-445e-b11c-4d102f3f5dc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f615793e-9310-4ee3-a3aa-dc1e0519f17e" xlink:to="loc_srt_MaximumMember_2ae4fd35-d9e2-445e-b11c-4d102f3f5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5b7fb5d-8acb-4413-8a11-5b1b9c80b124" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_229401c2-b1cd-4541-ac04-af9071dfd069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_229401c2-b1cd-4541-ac04-af9071dfd069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f39b3ee5-2e1f-4b76-967a-0d308edf5576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f39b3ee5-2e1f-4b76-967a-0d308edf5576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2464796e-9bfd-4db5-b746-d5c67670efa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2464796e-9bfd-4db5-b746-d5c67670efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_becba808-ca50-49ec-bb1a-665cbef61537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_becba808-ca50-49ec-bb1a-665cbef61537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c830db67-8307-430a-b071-d79ca8ab6f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c830db67-8307-430a-b071-d79ca8ab6f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_6a4560a3-0207-4f46-bdeb-2320fc2a2a12" xlink:href="gale-20200930.xsd#gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03ca1c2e-a51a-42e0-b3ac-895741828a94" xlink:to="loc_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_6a4560a3-0207-4f46-bdeb-2320fc2a2a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccounts"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f6dca0b-590d-41fb-a18b-099e578cd09d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2274b322-edf8-4fa2-8aa1-a971063975f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f6dca0b-590d-41fb-a18b-099e578cd09d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2274b322-edf8-4fa2-8aa1-a971063975f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4fc0709-baa8-4349-8a1f-8cac2945ccb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9ba4349d-7e16-426d-ba88-ec0ed160be7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4fc0709-baa8-4349-8a1f-8cac2945ccb0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9ba4349d-7e16-426d-ba88-ec0ed160be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_effc33e8-5c4d-4848-83af-fa7e95837b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4fc0709-baa8-4349-8a1f-8cac2945ccb0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_effc33e8-5c4d-4848-83af-fa7e95837b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_86d56238-0f93-4e15-9b1f-7e8fb035137d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:to="loc_us-gaap_PrepaidInsurance_86d56238-0f93-4e15-9b1f-7e8fb035137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidResearchAndDevelopment_a656c588-cd75-4faf-8424-5ed775ede4a2" xlink:href="gale-20200930.xsd#gale_PrepaidResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:to="loc_gale_PrepaidResearchAndDevelopment_a656c588-cd75-4faf-8424-5ed775ede4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PrepaidProfessionalServices_d76ac434-323a-4db3-ba43-53eabbe0c0b0" xlink:href="gale-20200930.xsd#gale_PrepaidProfessionalServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:to="loc_gale_PrepaidProfessionalServices_d76ac434-323a-4db3-ba43-53eabbe0c0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f023f1db-524f-400f-ae41-ddfc84656b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f023f1db-524f-400f-ae41-ddfc84656b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45f0e2a2-7195-4d59-a824-39a6c2ae6cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de4e8905-d572-4596-8c5f-0bcdb0051a05" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45f0e2a2-7195-4d59-a824-39a6c2ae6cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_975f7f4c-d9e9-4178-a48c-45d524d9d150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ContractResearchPayable_f55e2758-7a67-4999-a2ee-73a3c0df93ab" xlink:href="gale-20200930.xsd#gale_ContractResearchPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_975f7f4c-d9e9-4178-a48c-45d524d9d150" xlink:to="loc_gale_ContractResearchPayable_f55e2758-7a67-4999-a2ee-73a3c0df93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a230fe1b-a6bb-42ed-aa57-01f82c8e84a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_975f7f4c-d9e9-4178-a48c-45d524d9d150" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a230fe1b-a6bb-42ed-aa57-01f82c8e84a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5c20a457-d8b0-4873-8440-e4297621a16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_975f7f4c-d9e9-4178-a48c-45d524d9d150" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5c20a457-d8b0-4873-8440-e4297621a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_989d6321-09d7-4cb1-bdbe-051a4078a86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_975f7f4c-d9e9-4178-a48c-45d524d9d150" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_989d6321-09d7-4cb1-bdbe-051a4078a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8064d3bc-a32f-4ab4-9673-09a13fcbc348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aa1838eb-5798-4f58-a107-fbc6c10bc709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8064d3bc-a32f-4ab4-9673-09a13fcbc348" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aa1838eb-5798-4f58-a107-fbc6c10bc709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1dc7518-df0c-4287-8e80-0020a8d3aeff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43305a49-528a-4357-b2bb-99873f93e35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1dc7518-df0c-4287-8e80-0020a8d3aeff" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43305a49-528a-4357-b2bb-99873f93e35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ab32003a-5903-484b-b710-e8bcf3cadd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ab32003a-5903-484b-b710-e8bcf3cadd21" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_58eb58a8-3baa-4e1f-a866-e218bb02af71" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_491bb6ea-5cc6-4361-8b7f-92b363ebd96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0c660a9a-9d0d-4e1f-ade1-e85f369284d7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_491bb6ea-5cc6-4361-8b7f-92b363ebd96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:to="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_6eb018ae-0560-40c4-9c76-03769ddda1a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member_0dea7673-5153-48f9-ba28-81d43bb71c7f" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:to="loc_gale_OfficeSpaceLeaseExpiringDecember312024Member_0dea7673-5153-48f9-ba28-81d43bb71c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member_aefc97c1-0214-4997-bdbc-dcac38d53a8a" xlink:href="gale-20200930.xsd#gale_OfficeSpaceLeaseExpiringJuly312020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_3bb000c1-6a55-40f3-a36e-a2be9f459203" xlink:to="loc_gale_OfficeSpaceLeaseExpiringJuly312020Member_aefc97c1-0214-4997-bdbc-dcac38d53a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4bb5d86e-023b-4092-a778-60034e802aee" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecae99d9-1730-42a7-82be-e1ee08a58fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecae99d9-1730-42a7-82be-e1ee08a58fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bce595ec-f955-46dd-b30b-29fc5cb71520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bce595ec-f955-46dd-b30b-29fc5cb71520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1805f02-b614-4a2c-b9ec-ccf0b8233ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1805f02-b614-4a2c-b9ec-ccf0b8233ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_628bc674-40ec-4e55-9a73-799b3abebe37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_628bc674-40ec-4e55-9a73-799b3abebe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRemainingLeaseTerm_bf3a41c1-bc31-4015-952e-08a6bfdd63cb" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_gale_OperatingLeaseRemainingLeaseTerm_bf3a41c1-bc31-4015-952e-08a6bfdd63cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_dff2bf94-9f4c-4d29-bbd2-8586175b27e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_us-gaap_OperatingLeaseExpense_dff2bf94-9f4c-4d29-bbd2-8586175b27e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OperatingLeaseRightOfUseAssetAmortization_4181e464-f79b-4307-92fa-fb04f85c0877" xlink:href="gale-20200930.xsd#gale_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fe70b162-b2b1-49ac-866e-64a271217018" xlink:to="loc_gale_OperatingLeaseRightOfUseAssetAmortization_4181e464-f79b-4307-92fa-fb04f85c0877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_682f6829-6348-4df1-9ff4-f5a59ffbf9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_682f6829-6348-4df1-9ff4-f5a59ffbf9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_724ca547-fdf5-4983-95b2-509c87cdc35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_724ca547-fdf5-4983-95b2-509c87cdc35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f2a5438-0050-444d-9eff-061e8b35d60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f2a5438-0050-444d-9eff-061e8b35d60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b49175c-15a4-4b3a-b8fd-56d30af94d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b49175c-15a4-4b3a-b8fd-56d30af94d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8a2158a2-c76b-4ecf-8f8e-004ac848071e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8a2158a2-c76b-4ecf-8f8e-004ac848071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03aa76ea-9efe-4773-a5db-44c0ae71c163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03aa76ea-9efe-4773-a5db-44c0ae71c163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_792a0fb5-7855-49af-aefd-f29dd0bb7bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_792a0fb5-7855-49af-aefd-f29dd0bb7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8589286d-327b-485c-b7e4-d43ff83ed1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5119c7ae-ab5f-41ea-8362-6650e533fa22" xlink:to="loc_us-gaap_OperatingLeaseLiability_8589286d-327b-485c-b7e4-d43ff83ed1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="simple" xlink:href="gale-20200930.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0e429287-5789-40fe-a4a1-e235e2e771a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bcc9b53c-29db-448e-b4d9-d9b55b8c44f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0e429287-5789-40fe-a4a1-e235e2e771a6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bcc9b53c-29db-448e-b4d9-d9b55b8c44f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_abcfcd36-45dd-4b87-8ccf-14fa9d01cad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_43cbdf4d-ab7a-43b4-839c-a4eec02f6feb" xlink:href="gale-20200930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_abcfcd36-45dd-4b87-8ccf-14fa9d01cad8" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_43cbdf4d-ab7a-43b4-839c-a4eec02f6feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_23b022ed-f7f8-4a5a-832a-8a0d41457df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23b022ed-f7f8-4a5a-832a-8a0d41457df0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd4a13e9-de7d-4301-bde8-f476fd6d2484" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_DistributionAgreementMember_b790b206-ed31-4ee8-bfcd-9aca325fe6fc" xlink:href="gale-20200930.xsd#gale_DistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9cb6c7d-2b66-49df-9309-a88bbcc80feb" xlink:to="loc_gale_DistributionAgreementMember_b790b206-ed31-4ee8-bfcd-9aca325fe6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bcd55b50-9fc0-4cb0-b89a-2684f2aab598" xlink:to="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_0cecc9c1-6cb2-42bc-a4a2-5d7408cd4acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:to="loc_us-gaap_InvestorMember_0cecc9c1-6cb2-42bc-a4a2-5d7408cd4acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PIPEInvestorsMember_6e69c1c1-55d7-4aec-9bbd-5b369807509d" xlink:href="gale-20200930.xsd#gale_PIPEInvestorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10f89f48-40cc-42b6-a849-0a634a77f878" xlink:to="loc_gale_PIPEInvestorsMember_6e69c1c1-55d7-4aec-9bbd-5b369807509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc5be395-dbb4-4d65-ac4e-2be5252b5d43" xlink:to="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedWarrantsMember_c6b69b83-767e-425c-a55e-d7cb6e8001f1" xlink:href="gale-20200930.xsd#gale_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1c6f5404-b840-4d46-83c0-42a8c508ca70" xlink:to="loc_gale_PreFundedWarrantsMember_c6b69b83-767e-425c-a55e-d7cb6e8001f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fa4ac9e3-9fc5-41d9-a125-894aae0b4cec" xlink:to="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cc12de36-b097-44ce-b40f-6829c115b2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cc12de36-b097-44ce-b40f-6829c115b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d5cb2aa-37de-42b6-921c-48d88f194069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4d5cb2aa-37de-42b6-921c-48d88f194069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45fab622-362b-4805-8778-dcb7e8e147ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_45fab622-362b-4805-8778-dcb7e8e147ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_236ac899-f5da-4eb6-80a9-e506e86c2ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_236ac899-f5da-4eb6-80a9-e506e86c2ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAuthorizedAmount_fac69992-66d6-493c-ba79-f4a7eb435e77" xlink:href="gale-20200930.xsd#gale_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_SaleOfStockAuthorizedAmount_fac69992-66d6-493c-ba79-f4a7eb435e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_90dc37c5-4add-46c1-93ee-e89f725d9adc" xlink:href="gale-20200930.xsd#gale_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_SaleOfStockAgentFeePercentageOfGrossProceeds_90dc37c5-4add-46c1-93ee-e89f725d9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5df850d-5965-4135-b816-9652d9460eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5df850d-5965-4135-b816-9652d9460eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd8ac080-0ed6-482b-83b2-ec385de30053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd8ac080-0ed6-482b-83b2-ec385de30053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ecd1801e-0656-4cc1-a67e-5eba0dc78319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SharesIssued_ecd1801e-0656-4cc1-a67e-5eba0dc78319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OfferingPricePershare_fc8b128f-a9b2-44a2-bdf8-6dd8c1099223" xlink:href="gale-20200930.xsd#gale_OfferingPricePershare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_OfferingPricePershare_fc8b128f-a9b2-44a2-bdf8-6dd8c1099223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_4681c8ca-b4cb-4a04-aa94-6f1afd680734" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_4681c8ca-b4cb-4a04-aa94-6f1afd680734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ProceedsFromWarrantExercisesGross_962bef32-ae94-4c28-b267-1974a3a788c5" xlink:href="gale-20200930.xsd#gale_ProceedsFromWarrantExercisesGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ProceedsFromWarrantExercisesGross_962bef32-ae94-4c28-b267-1974a3a788c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cc445938-cba0-4553-9d63-b197fa02908f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cc445938-cba0-4553-9d63-b197fa02908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e03571e-a635-4f62-b33b-2366ee0cb465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e03571e-a635-4f62-b33b-2366ee0cb465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightTerm_dace3738-517e-4351-83ab-48f0f8a9af17" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_ClassofWarrantorRightTerm_dace3738-517e-4351-83ab-48f0f8a9af17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8947b079-9c97-4cb0-8c6e-994439d01730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8947b079-9c97-4cb0-8c6e-994439d01730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_StockSubscriptionReceivableCurrent_96e6396c-1692-42e3-bbc1-9531f3d05d9b" xlink:href="gale-20200930.xsd#gale_StockSubscriptionReceivableCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f9e5c397-4244-40e0-b838-11affbaee532" xlink:to="loc_gale_StockSubscriptionReceivableCurrent_96e6396c-1692-42e3-bbc1-9531f3d05d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c54c1c68-eb28-4b2d-851b-137b11db58ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c54c1c68-eb28-4b2d-851b-137b11db58ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:to="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_19bd7f4a-9328-42b5-bab4-5d394d0e8e10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d6e256c-076a-4a11-810f-e3eef3e21838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e81b5ed7-17b6-4ab8-92dc-f974f330ed13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d6e256c-076a-4a11-810f-e3eef3e21838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d5fea-6608-4669-9291-1a04810eb7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f97149eb-fafd-4fc4-8691-b71a63503b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f97149eb-fafd-4fc4-8691-b71a63503b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ebd159b9-212e-4d80-8476-09ccc8eaa5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ebd159b9-212e-4d80-8476-09ccc8eaa5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a046d51-cb6f-42e7-8a35-b11bf67142e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a046d51-cb6f-42e7-8a35-b11bf67142e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_aea6b622-e547-4e13-9e2e-9d102d70ccba" xlink:href="gale-20200930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_aea6b622-e547-4e13-9e2e-9d102d70ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_5442ef3c-de27-4144-929e-05d894d4ffa4" xlink:href="gale-20200930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_5442ef3c-de27-4144-929e-05d894d4ffa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1a7c33cd-f286-456b-a188-b3d56cdd213f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cc136ff-ee76-43e2-b4c5-4c2a533ad095" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1a7c33cd-f286-456b-a188-b3d56cdd213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStock"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_ec46c013-de3a-4e45-9baf-1510d3063d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_e84d4fe2-41de-4753-9cce-12a921704889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_ec46c013-de3a-4e45-9baf-1510d3063d6f" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_e84d4fe2-41de-4753-9cce-12a921704889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_86945b7e-fa37-43ee-8c08-e2c60166d282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock_eeb39462-10a2-4956-9992-32711430c2e2" xlink:href="gale-20200930.xsd#gale_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_86945b7e-fa37-43ee-8c08-e2c60166d282" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTextBlock_eeb39462-10a2-4956-9992-32711430c2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_bd399fce-e612-437a-af3b-79c2b2407d1b" xlink:href="gale-20200930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_86945b7e-fa37-43ee-8c08-e2c60166d282" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_bd399fce-e612-437a-af3b-79c2b2407d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_98770490-4f89-4879-8fff-5457a9cdcc07" xlink:href="gale-20200930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_86945b7e-fa37-43ee-8c08-e2c60166d282" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_98770490-4f89-4879-8fff-5457a9cdcc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_7ef0d4e7-b0e3-4f02-884f-012d9684c11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_7ef0d4e7-b0e3-4f02-884f-012d9684c11b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5a4ca087-b2ca-48bc-a9f8-2e8880a4850a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2020PIPEOfferingMember_9bc6aa79-1cf5-4051-a232-9c571abb3805" xlink:href="gale-20200930.xsd#gale_July2020PIPEOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2020PIPEOfferingMember_9bc6aa79-1cf5-4051-a232-9c571abb3805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_January2020OfferingMember_dbfa8769-9791-463f-90e7-cb77a1ab4664" xlink:href="gale-20200930.xsd#gale_January2020OfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_January2020OfferingMember_dbfa8769-9791-463f-90e7-cb77a1ab4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_PreFundedJune2019OfferingMember_86cfdab7-ead6-484c-aede-f7a7cdc2aece" xlink:href="gale-20200930.xsd#gale_PreFundedJune2019OfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_PreFundedJune2019OfferingMember_86cfdab7-ead6-484c-aede-f7a7cdc2aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2019OfferingMember_350abcef-4d94-431a-a2f9-d1fa2a8b0d88" xlink:href="gale-20200930.xsd#gale_July2019OfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2019OfferingMember_350abcef-4d94-431a-a2f9-d1fa2a8b0d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantExerciseAgreementMember_af264bef-4a41-4893-bf2b-bb93ef7f0f0f" xlink:href="gale-20200930.xsd#gale_WarrantExerciseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_WarrantExerciseAgreementMember_af264bef-4a41-4893-bf2b-bb93ef7f0f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_July2018OfferingMember_c983f92d-0601-4a9b-a85e-7bd8c811aa5f" xlink:href="gale-20200930.xsd#gale_July2018OfferingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_July2018OfferingMember_c983f92d-0601-4a9b-a85e-7bd8c811aa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5354fe5a-6d3b-49f2-8337-63ec04d4520b" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5354fe5a-6d3b-49f2-8337-63ec04d4520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EqcWarrantsMember_84e7de92-c76b-47c3-b406-445ce83ad683" xlink:href="gale-20200930.xsd#gale_EqcWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_EqcWarrantsMember_84e7de92-c76b-47c3-b406-445ce83ad683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_47846d0a-3816-4a7e-9b2f-fcbc8e88e1ae" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_February2017WarrantsMember_47846d0a-3816-4a7e-9b2f-fcbc8e88e1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OtherWarrantIssuesMember_1471f628-6eb3-4b9a-ad9e-21e8d8985463" xlink:href="gale-20200930.xsd#gale_OtherWarrantIssuesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_799816e4-8125-4ad2-ad46-db21616cb085" xlink:to="loc_gale_OtherWarrantIssuesMember_1471f628-6eb3-4b9a-ad9e-21e8d8985463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0d201147-6f5d-4373-b6fb-dc95a7c5c1da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9163b331-c4d0-4a93-be9e-428dddae9ca1" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_893b054a-d563-4543-9841-1ad99efa653e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_893b054a-d563-4543-9841-1ad99efa653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_08eb1883-4f11-42a6-a123-8f4330eb4af6" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued_08eb1883-4f11-42a6-a123-8f4330eb4af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_2d9eef5b-38dc-40b7-b976-cd7b48009c7c" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_2d9eef5b-38dc-40b7-b976-cd7b48009c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_4a012b7d-5f93-48f7-8a95-29e928b3e217" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightCanceledOrExpired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_4a012b7d-5f93-48f7-8a95-29e928b3e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f133913d-a091-4595-b3f3-acf2afebe786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_102753f4-06e0-4f2e-8582-8be270dadf26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f133913d-a091-4595-b3f3-acf2afebe786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_6722cb8c-8d17-4bd9-8d51-e1af0d8758fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_6722cb8c-8d17-4bd9-8d51-e1af0d8758fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b31cbebf-9ad2-445a-a868-031fb7e3f7f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_7daf53cf-fe9d-4151-b4b0-3ca34ff704c9" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_7daf53cf-fe9d-4151-b4b0-3ca34ff704c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_7803ff60-152a-4c28-9e24-06241b051109" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_February2017WarrantsMember_7803ff60-152a-4c28-9e24-06241b051109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_OtherWarrantIssuesMember_09f0fe3e-2a79-43dc-8b68-671ca8dabbb3" xlink:href="gale-20200930.xsd#gale_OtherWarrantIssuesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ca5881-cff2-4ffc-a6c1-2ed77d902bc4" xlink:to="loc_gale_OtherWarrantIssuesMember_09f0fe3e-2a79-43dc-8b68-671ca8dabbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_650c1742-49f4-47c8-aec4-049451c69f9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d616872f-7114-4fe9-8cd0-9be8bcbb5d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d616872f-7114-4fe9-8cd0-9be8bcbb5d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantStrikePrice_928fa5d8-10ea-477a-bbb5-dac151c95697" xlink:href="gale-20200930.xsd#gale_WarrantStrikePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantStrikePrice_928fa5d8-10ea-477a-bbb5-dac151c95697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_73553fc6-32c2-46fe-b829-c2ee8f44af83" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_73553fc6-32c2-46fe-b829-c2ee8f44af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_8fbed9a7-5a85-48be-8f0d-537614a7ce40" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_8fbed9a7-5a85-48be-8f0d-537614a7ce40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_0f0c2072-c2d0-4ce6-8eab-775d6dcfe02d" xlink:href="gale-20200930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d717f1d8-5d8d-4a92-a40a-9f2da2bf3ed4" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_0f0c2072-c2d0-4ce6-8eab-775d6dcfe02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_62f9c46a-fa51-486d-ae98-ff96758199e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_62f9c46a-fa51-486d-ae98-ff96758199e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cf3c53da-5936-4859-9f8d-c735bc85cc03" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_577e397f-398a-41d9-86b6-608a590d5125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_577e397f-398a-41d9-86b6-608a590d5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_41654dd6-9357-48bd-9e84-d1ea1fcb1ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6029f167-4bf2-4316-9eb5-ca8bc6c5bcf2" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_41654dd6-9357-48bd-9e84-d1ea1fcb1ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_616b32a4-5023-4896-9a27-30a459eb22fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_39176642-8951-419a-a5eb-36e48037f478" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_39176642-8951-419a-a5eb-36e48037f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2019Member_1a006d05-2bf6-4719-a44f-9c07e238f06b" xlink:href="gale-20200930.xsd#gale_Warrants2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_Warrants2019Member_1a006d05-2bf6-4719-a44f-9c07e238f06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_Warrants2020Member_bdba8268-87f6-4021-94d8-fd7d6c6dac2c" xlink:href="gale-20200930.xsd#gale_Warrants2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ab28ea6-7bc7-4063-b942-1e678db5b381" xlink:to="loc_gale_Warrants2020Member_bdba8268-87f6-4021-94d8-fd7d6c6dac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_102cdc99-449d-4d97-84ba-9f76673001c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_efaabc11-fbfc-46fa-a334-8242d430bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_efaabc11-fbfc-46fa-a334-8242d430bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6ca2f6a-5aa0-48ef-8ca2-40766424f61b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6ca2f6a-5aa0-48ef-8ca2-40766424f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ccff6220-7095-4dfb-8180-bba67b4d2ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ccff6220-7095-4dfb-8180-bba67b4d2ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_293b1b49-ba33-4f94-ac5a-050a2b6fb438" xlink:href="gale-20200930.xsd#gale_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised_293b1b49-ba33-4f94-ac5a-050a2b6fb438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_258ba564-668c-40ba-80dd-bf0de832546e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bb0ec085-05ee-48b8-8568-41a5d44bf4b7" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_258ba564-668c-40ba-80dd-bf0de832546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2ec6cdfc-6a0f-472d-b8c7-543eb368590d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2ec6cdfc-6a0f-472d-b8c7-543eb368590d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1783f974-b670-4262-b4b2-b25a2770145d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_b028cb7a-4aa2-4a31-b799-1b655f394c32" xlink:href="gale-20200930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_b028cb7a-4aa2-4a31-b799-1b655f394c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_February2017WarrantsMember_cd61e65f-74ce-40ef-baf3-bf00d1265568" xlink:href="gale-20200930.xsd#gale_February2017WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4c0cf2-21d8-4a27-9ba3-12bd6b960207" xlink:to="loc_gale_February2017WarrantsMember_cd61e65f-74ce-40ef-baf3-bf00d1265568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b03a1ec9-8dd9-4ac1-a883-970e135297b6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:href="gale-20200930.xsd#gale_ClassofWarrantorRightFairValueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ef8902a9-c486-4eb1-bd16-04867e8fac9a" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_dd970e39-557a-4cc6-bd3a-517e53ae9a06" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_dd970e39-557a-4cc6-bd3a-517e53ae9a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueofWarrantsGranted_9a5e1f22-a4b1-4268-a400-adf1022e38c4" xlink:href="gale-20200930.xsd#gale_FairValueofWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueofWarrantsGranted_9a5e1f22-a4b1-4268-a400-adf1022e38c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsCanceled_24a0d4c0-783f-43dc-b8bc-c49292209cf6" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsCanceled"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsCanceled_24a0d4c0-783f-43dc-b8bc-c49292209cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_eeada418-af76-43fe-93e7-6d7103eb0f39" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_eeada418-af76-43fe-93e7-6d7103eb0f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_b1dab659-df5c-4142-a066-d0fbfbda147c" xlink:href="gale-20200930.xsd#gale_ChangeInFairValueOfWarrantLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_b1dab659-df5c-4142-a066-d0fbfbda147c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_48bfe310-d001-4ebc-a6de-e6e4415b944b" xlink:href="gale-20200930.xsd#gale_FairValueOfWarrantsLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_6fea3154-b06a-488f-80ac-ca0d39a0d1b0" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_48bfe310-d001-4ebc-a6de-e6e4415b944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b817d34e-0e54-48b9-b29a-66aab2773c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6dfacd14-0946-4c4e-9ccc-09d4a097091a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b817d34e-0e54-48b9-b29a-66aab2773c0a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6dfacd14-0946-4c4e-9ccc-09d4a097091a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0035b9e4-441e-402c-912e-65a7b4040b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9dfa5171-be65-4675-b940-5839be6d49a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0035b9e4-441e-402c-912e-65a7b4040b29" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9dfa5171-be65-4675-b940-5839be6d49a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b11d5948-225c-40bd-b7f4-5cfc4aaf3ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0035b9e4-441e-402c-912e-65a7b4040b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b11d5948-225c-40bd-b7f4-5cfc4aaf3ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0aab608-64b8-46dd-a1f0-ffe8e296ed9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0035b9e4-441e-402c-912e-65a7b4040b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0aab608-64b8-46dd-a1f0-ffe8e296ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d4d6dfb0-c3d5-41ae-add3-6dea328b672d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0035b9e4-441e-402c-912e-65a7b4040b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d4d6dfb0-c3d5-41ae-add3-6dea328b672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09b2ab33-ef07-421f-9c36-7048d2f0a94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09b2ab33-ef07-421f-9c36-7048d2f0a94c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1b786992-77b2-4b07-8e93-2ea267fe308d" xlink:to="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_7a265a0a-9e76-4a5b-af66-f5d5def878b8" xlink:href="gale-20200930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_7a265a0a-9e76-4a5b-af66-f5d5def878b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember_bc0cebfa-6a35-4fc0-9a51-f134642be239" xlink:href="gale-20200930.xsd#gale_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e3e1d686-95d4-42d5-bd44-f4239f934836" xlink:to="loc_gale_TwoThousandAndNineteenEquityIncentivePlanMember_bc0cebfa-6a35-4fc0-9a51-f134642be239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_34a12e71-18fe-434e-b5f6-e5976cf81290" xlink:to="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00666b64-cea0-4ba3-bfa1-a9e4f37ab58c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:to="loc_srt_MaximumMember_00666b64-cea0-4ba3-bfa1-a9e4f37ab58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1f7fa6ca-ba3e-455e-b39b-0b89e9598866" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_accb542f-d5cb-48d0-941a-fab76d5d8b87" xlink:to="loc_srt_MinimumMember_1f7fa6ca-ba3e-455e-b39b-0b89e9598866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_af1f6a7b-66a7-4713-b12c-ed9ba7ae2c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_093cc6d3-7e8d-4d65-b56b-8b2c02c79bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e069e8de-422e-4317-bd16-108573bf9c51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_093cc6d3-7e8d-4d65-b56b-8b2c02c79bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a3352a62-c7c7-4755-88a6-821a29e4a247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40d9d3d7-872d-4be9-a37e-5fee8ba5593b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40d9d3d7-872d-4be9-a37e-5fee8ba5593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e7b9c5a8-c633-4ba2-89b0-cd9f788e4458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e7b9c5a8-c633-4ba2-89b0-cd9f788e4458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e37d153e-c3cb-45f5-b74e-c54e9a1f683b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e37d153e-c3cb-45f5-b74e-c54e9a1f683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0ff6d2ef-4704-456f-853f-68325b083745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0ff6d2ef-4704-456f-853f-68325b083745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d2d4383-ae2f-45c8-a1d1-cfa4d422a902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d2d4383-ae2f-45c8-a1d1-cfa4d422a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_044fa654-fe98-4c6e-967d-c3933cff075e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_044fa654-fe98-4c6e-967d-c3933cff075e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e18fb376-bcb7-4ab2-84b4-8aae82dd69b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e18fb376-bcb7-4ab2-84b4-8aae82dd69b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87470114-261e-4426-a388-de4d51e3303e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87470114-261e-4426-a388-de4d51e3303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32180bee-1876-406a-8cc1-6b93d1e837eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32180bee-1876-406a-8cc1-6b93d1e837eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_2d99bc8c-81f5-4f82-a854-33833301fb30" xlink:href="gale-20200930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_2d99bc8c-81f5-4f82-a854-33833301fb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ClosingPriceOfCommonStock_26975aa6-1e31-4194-8906-95e938641d75" xlink:href="gale-20200930.xsd#gale_ClosingPriceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_gale_ClosingPriceOfCommonStock_26975aa6-1e31-4194-8906-95e938641d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e852608c-5e27-446c-a575-5b4bc4d4564e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d499880-b0ac-47dc-8738-2fd0e50f3322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e852608c-5e27-446c-a575-5b4bc4d4564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAllocatedStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40fdc988-ca24-4e55-9272-1e9d263e4375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40fdc988-ca24-4e55-9272-1e9d263e4375" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5bf83a42-d726-4896-8540-6f957276a9d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_181f3f7c-5205-4ec5-9d27-0f0a766888d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_181f3f7c-5205-4ec5-9d27-0f0a766888d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df5263f9-dc7e-4e95-8756-094de5ac249c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea8cf156-097d-4841-87a0-2549aef6948c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df5263f9-dc7e-4e95-8756-094de5ac249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a1f34e-7ed3-46f3-b122-95dc26d4fb3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d741e2da-4d58-46f6-a895-c280e79dbc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f5790e8-745b-4b03-aeb3-718c8116019c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d741e2da-4d58-46f6-a895-c280e79dbc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b479a580-01c5-4be4-afdb-9f46eb06b4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c789e4a7-bc23-45ac-9789-19dc41e3fdc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b479a580-01c5-4be4-afdb-9f46eb06b4fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c789e4a7-bc23-45ac-9789-19dc41e3fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_289021de-6ec2-466b-b3b6-3208f24ecea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b479a580-01c5-4be4-afdb-9f46eb06b4fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_289021de-6ec2-466b-b3b6-3208f24ecea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_be21b102-cc38-49d6-ba33-31784a3566fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b479a580-01c5-4be4-afdb-9f46eb06b4fd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_be21b102-cc38-49d6-ba33-31784a3566fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_08d1b13b-1ae7-441d-81a3-8436dd1e0b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b479a580-01c5-4be4-afdb-9f46eb06b4fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_08d1b13b-1ae7-441d-81a3-8436dd1e0b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18557c1f-9b68-470f-816e-1f6f6b33f11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18557c1f-9b68-470f-816e-1f6f6b33f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1bf0239-c9e5-49f2-bd5a-2ea1242babf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18557c1f-9b68-470f-816e-1f6f6b33f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1bf0239-c9e5-49f2-bd5a-2ea1242babf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce046d64-56c9-4975-8c40-18f1a52ccc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18557c1f-9b68-470f-816e-1f6f6b33f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce046d64-56c9-4975-8c40-18f1a52ccc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_faabd8ae-caf4-4f65-a761-1c83dcb6c6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18557c1f-9b68-470f-816e-1f6f6b33f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_faabd8ae-caf4-4f65-a761-1c83dcb6c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3767601e-b759-4cba-b219-d832ec22257c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3767601e-b759-4cba-b219-d832ec22257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b44db27-50e9-43e2-9e5e-ced9e1f137f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b44db27-50e9-43e2-9e5e-ced9e1f137f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_612fbf30-7584-4b08-ba53-d99e7e1f4e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b44db27-50e9-43e2-9e5e-ced9e1f137f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_612fbf30-7584-4b08-ba53-d99e7e1f4e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_967a0e55-7b0b-4180-a934-14a0aa6ab0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b44db27-50e9-43e2-9e5e-ced9e1f137f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_967a0e55-7b0b-4180-a934-14a0aa6ab0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f460792-8811-4b97-ba46-4f18470de2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b44db27-50e9-43e2-9e5e-ced9e1f137f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f460792-8811-4b97-ba46-4f18470de2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9cfdaf2b-c65e-45ad-900a-ad08a6435320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9cfdaf2b-c65e-45ad-900a-ad08a6435320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4afdf240-dd3b-46ce-86ea-91556a915e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4afdf240-dd3b-46ce-86ea-91556a915e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0596377d-53a8-4a1b-8491-f0de46177f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0596377d-53a8-4a1b-8491-f0de46177f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_64a108cd-d78c-43f7-817a-589a19885cb0" xlink:href="gale-20200930.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_64a108cd-d78c-43f7-817a-589a19885cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_777ace32-4e2e-42a8-86e0-da8c0027c913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_64a108cd-d78c-43f7-817a-589a19885cb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_777ace32-4e2e-42a8-86e0-da8c0027c913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_464617c1-07f2-4e32-8b57-221deab941bf" xlink:href="gale-20200930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_64a108cd-d78c-43f7-817a-589a19885cb0" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_464617c1-07f2-4e32-8b57-221deab941bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db6da1ee-5961-462e-ad3b-a11fe17632ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_64a108cd-d78c-43f7-817a-589a19885cb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db6da1ee-5961-462e-ad3b-a11fe17632ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_99a05e1c-032f-4739-bf01-30587848c2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82089ee0-e650-4891-b03b-bd176d06aba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_99a05e1c-032f-4739-bf01-30587848c2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="gale-20200930.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b5c706c-3fd5-4d2c-8061-c1be55e6eb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b5c706c-3fd5-4d2c-8061-c1be55e6eb65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:to="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_64a4d01c-120f-450a-b997-cf6da464df76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0087f8-c7b3-4d84-83b2-8840c7f21e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0657b6a-4ed9-4fe7-adf4-b743de5a2644" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d0087f8-c7b3-4d84-83b2-8840c7f21e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e885db61-458f-46a1-8293-ff5de0b8444d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e92938bb-9f24-4a2f-924f-9731b722d0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e92938bb-9f24-4a2f-924f-9731b722d0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1549252e-8f3f-461a-a8e0-bbd09d5748a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1549252e-8f3f-461a-a8e0-bbd09d5748a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2956d9d8-d840-4036-a4f1-e4548ece36b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2956d9d8-d840-4036-a4f1-e4548ece36b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b783d9b-9310-45d9-bec6-2fe39a173d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56b20bcd-afe2-48c1-a09d-afc8bc18d9a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b783d9b-9310-45d9-bec6-2fe39a173d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43825b67-4164-49de-9a2c-704ca82a255e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_17da0c5a-fd65-4f30-8b28-782a1f4a9a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_17da0c5a-fd65-4f30-8b28-782a1f4a9a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feeb254a-c545-47f4-b32b-be69ff9718a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feeb254a-c545-47f4-b32b-be69ff9718a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b12fdfd3-13d7-42a6-a405-b9308817621a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b12fdfd3-13d7-42a6-a405-b9308817621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a76afc5a-a1a4-4508-8e77-37cf4e70f9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a8ad4ef3-1046-46ba-9a90-0752a7c66aa8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a76afc5a-a1a4-4508-8e77-37cf4e70f9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gale-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_446fa6c9-77e8-4894-aa1f-f831bf39f187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9b27942f-d0cd-4705-a63f-1ae2386cd151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_446fa6c9-77e8-4894-aa1f-f831bf39f187" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9b27942f-d0cd-4705-a63f-1ae2386cd151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gale-20200930_g1.jpg
<TEXT>
begin 644 gale-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "L @D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP_X*Y_\
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MAMJECI=PH>*[UF:'2UD4]&5)V61E/4,JD$=Z]%_XAZOVFO\ H6_#O_@_MO\
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M/_G^O_ 9?_(GI_ZBYY_SX?\ X%'_ .2/RAHK]7O^(6;7_P#HLFC_ /A.2?\
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MOB/_ -"%?UP5[_BKOAO^W_\ VP^?\*=L5_VY_P"WA1117Y&?KP4444 %%%%
M!1110!\F?\%KOVI/^&7?V ?%D]G<>1KWC)1X9TO#8<-<JPF<=P4MUF8,.C;.
MF17\XU?U1?M&_L??#;]K>STFW^(WA:U\46^AO))8QW$\T:P-(%#MB-UR2$49
M.<<XQDY\O3_@C=^S)&FT?"'P]QZSW)/Y^;7Z1PGQ=E^48-T:E.3G)MMJUNR6
MK6R_%L_->+N#\PS?&*M3J1C"*22;=^[>B:U?X)'S#_P;/_LM?\(-\ ?$_P 5
MM0M]M_XXO/[,TMV7E;&U8AV4^DEP74C_ *=EK].*P_AM\-M"^#_@32_#/AG2
M[71=!T6 6]E96ZXCMXQDX&>>I)))))))YK<KXS/,TEF&.J8N7VGHNR6B7W'V
MF1Y7'+L#3P<?LK5]V]6_O_ *\ _X*@_LP?\ #77[#WCOPC;V_P!HUI;(ZIHP
M"Y?[;;?O8E7T,FUHL^DIKW^BN+"8J>'KPQ%/XHM->J=SNQ>%AB:$\/5^&2:?
MHU8_D3(P:_4+_@V7_:@_X1#XW>+OA/J%QML_&%F-8TI&;@7ML,2HH_O20$L?
M:V%?*_\ P5\_9@_X91_;X\;:):V_V?0]<G_X2'1P%VI]FNBSE%']V.831#VB
MKQ_]F+XZ:A^S-^T)X.\?:9O:Z\*ZK#?F-3M^T1*W[V$GTDC+H?9S7])9EAZ>
M<Y/*-/:I%./KNOQT?S/YIRW$5,ESB,JF].34O39_AJOD?U945G>#_%FG^/?"
M6EZYI-PEYI>M6D5]9SI]V:&5 Z./8JP/XUHU_,THM.S/Z=C)-76P4444AGXM
M_P#!:#_@BQJW@3Q7K'Q:^$>CRZEX9U%WO=>T"RBW3Z/*<M)<01KRUNQRS(HS
M$22!Y?\ J_RWK^NROD_]K;_@BY\"/VN]4NM7U'P[<>$_$MXQDFU?PY(MG+<.
M>2TL15H9&)Y+&/>?[U?JG#?B)]7I+#9DG)+126KMYKKZK7R>Y^4\2^'/UBK+
M%9:U%O5Q>BO_ '7T]'IYK8_G#HK]>/%W_!K+&]\[Z#\9VCMF)V0W_AK?(H[9
MD2Y /_? K%_XA9M?_P"BR:/_ .$Y)_\ )%?=1XZR-J_M_P#R67_R)\'+@//4
M[>P_\FC_ /)'Y0T5^KW_ !"S:_\ ]%DT?_PG)/\ Y(J*^_X-:O$T=JS6OQ@T
M*:;'RI+H,L:D^["9B/R-5_KQD?\ S_7_ (#+_P"1)_U%SS_GP_\ P*/_ ,D?
MG!\(OVG/B+\ ]1CNO!?CCQ5X8DB((73M2EAB?'9HPVQU_P!E@0?2OTF_8#_X
M./=7T_6+'PU\>K6'4--F98E\5Z=;"*XMCTW75N@VR+ZM"JLH'W')X^3_ -L;
M_@C'\;_V,M!NM>U;1[+Q1X5LP7N-8\/S-=0VB_WIHV598U ZN4*#^]TKY/K?
M$9;E&>4.>T9I_:C;F3]5JGY/YHQPV99QD6(Y+R@U]F5^5KT>C7FODS^M[POX
MHTWQMX<L=8T>_L]4TK4X$N;2\M95EAN8G&5='4D,I!!!%7J_%'_@WB_X**7W
MP]^*4/P-\47\DWAGQ0\DGAMYGS_9E_@NT"D](YP&(7H)0,#,C&OVNK\$XAR.
MKE6,>&J:K>+[I]?7H_,_?N'<\I9K@UBJ:L]I+LUT].J\@K'^(7Q T;X4^!M6
M\2^(M0M]*T/0[62]OKN<X2")%+,Q[G@< <DX R36Q7XF_P#!P-_P4T_X6_XU
MF^"/@G4-_A?PW<AO$MW _P NJ7\9XM@1UB@8?-V:4=/W:DG#N1U<UQD<-#2.
M\GV77Y]%YD\19Y2RK!RQ-366T5W?^75^7F?)/_!2O]O36?\ @H%^TA?>*+K[
M19^&M-W6/AS3';BQM W#,!QYTI&]SSSA<E47'SW17Z2_\$$O^"7W_#0GCV'X
MP^.-/W^!_"]U_P 26SN$_=ZY?QG[Y!^]!"PR>SR +R$=:_H;&8K!Y+E_.URP
MIJR7=]$O-_YM]3^><'A<9G>8\B?-.H[MOHNK?DO\DNA]<?\ !"/_ ()??\,M
M?#5/BCXVT_R_B%XNM1]AM;A,2:!8/@A"#]V>489^ZKM3@^8#^A]%%?S=FV:5
M\PQ4L57>LON2Z)>2_K4_I+*<KH9?A8X3#K2/WM]6_-_\#8****\X](**** "
MOYM_^"U'_*4#XM?]A"V_](;>OZ2*_FW_ ."U'_*4#XM?]A"V_P#2&WK]*\+_
M /D95?\  _\ TJ)^:>*/_(MI?]?%_P"DR.;_ ."57_*1KX-_]C/:_P#H5?TV
M5_,G_P $JO\ E(U\&_\ L9[7_P!"K^FRM/%'_?J/^#]69>%O^XUO\?\ [:@H
MHHK\Q/U **** "BBB@ HHHH ^+?^#@3_ )1?^-/^PAI?_I=#7\\M?T-?\' G
M_*+_ ,:?]A#2_P#TNAK^>6OWCPS_ .13+_&__28GX)XG?\C:/_7M?^E2/WD_
MX-J/^4?&K?\ 8YWW_I-9U^A%?GO_ ,&U'_*/C5O^QSOO_2:SK]"*_*.+/^1Q
MB/\ $S]9X3_Y$^'_ ,*"BBBOGCZ(**** "BBB@ K\&O^#E?_ )2#Z3_V)EC_
M .E-Y7[RU^#7_!RO_P I!])_[$RQ_P#2F\K[WPX_Y''_ &[+]#X'Q(_Y$S_Q
M1_4^!/#_ /R'K'_KXC_]"%?UP5_(_P"'_P#D/6/_ %\1_P#H0K^N"O?\5=\-
M_P!O_P#MA\_X4[8K_MS_ -O"BBBOR,_7@HHHH **** "BBOC3_@MY^W=??L4
M?LF>3X;OFL?''CR=M*TB>-L2V,2J&N;I/]I$944CE7F1NU=N78&KC<3#"T?B
MD[+]7Z):LXLQQ]+!8:>*K?#%7?\ DO-O1'U?K?Q-\-^&=0^R:EX@T/3[KC]S
M<WT44G/3Y68&FK\5/"[J&7Q)H)4\@C4(N?\ QZOY-]1U*XUC4)KN\N)KJZNI
M&EFFF<R22NQR69CR23R2>34-?JB\*X6UQ+O_ (/_ +8_*'XK3OIAE;_'_P#:
MG]9W_"TO#/\ T,6@_P#@?%_\51_PM+PS_P!#%H/_ ('Q?_%5_)C13_XA7#_H
M)?\ X!_]L'_$5I_] R_\#_\ M3^L[_A:7AG_ *&+0?\ P/B_^*H_X6EX9_Z&
M+0?_  /B_P#BJ_DQHH_XA7#_ *"7_P" ?_;!_P 16G_T#+_P/_[4_9S_ (.4
M/@YH7Q0^!WA/XF:'J6D7FK>#;TZ9J"V]U')))8W)&QB 22(YU4 ?]/#&OQCH
MHK] X?RF66X-8-U.=1;L[6T>MMWUN?GO$&;QS/&2QBI\CDE=7OJM+[+I8_?[
M_@WK_:@_X7K^PM;^%[ZX\[6_AC=G1Y S9=K-\RVCG_9"F2(>UO7W=7\_'_!O
MU^U!_P *#_;QT_P[>W'DZ'\3+8Z%,&;"+=@^9:/[L9 8A_U\&OZ!Z_#>.,K^
MI9M/E7NU/>7SW_&_RL?NW N:?7<IAS/WJ?N/Y;?A;YW"BBBOCS[ **** "BB
MB@ HHHH ;/ ES"\<B+)'(I5E895@>"".X-?SK?\ !;[]CS1_V//VW;VS\,VL
M=AX8\8:?'XAL+.(8CL#)))'- @[*)8F95'"K(JCI7]%=?B1_P=!?\G5?#O\
M[%0_^EDU??>'&*J0S;V47[LHNZ]%=?=_F?G_ (D86G4RGVLE[T)*S]79_?\
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M@:*^?O\ AZO^SC_T63P+_P"# 4?\/5_V<?\ HLG@7_P8"OS?^R<=_P ^9_\
M@+_R/TG^U\#_ ,_H?^!1_P SZ!HKY^_X>K_LX_\ 19/ O_@P%'_#U?\ 9Q_Z
M+)X%_P#!@*/[)QW_ #YG_P" O_(/[7P/_/Z'_@4?\SZ!HKY^_P"'J_[./_19
M/ O_ (,!1_P]7_9Q_P"BR>!?_!@*/[)QW_/F?_@+_P @_M? _P#/Z'_@4?\
M,^@:***\\] ^+?\ @X$_Y1?^-/\ L(:7_P"ET-?SRU_0U_P<"?\ *+_QI_V$
M-+_]+H:_GEK]X\,_^13+_&__ $F)^">)W_(VC_U[7_I4C]Y/^#:C_E'QJW_8
MYWW_ *36=?H17Y2?\$#_ -M[X1_L[?L3:EH/CCX@^&?"^LR^*KR\2SO[H12M
M"UO:JKX_NDHPS_LFOMK_ (>K_LX_]%D\"_\ @P%?FO%&6XR>;8B<*4FG)V:B
MVOR/TSA?,\'3RG#PG5BFHJZ<DG^9] T5\_?\/5_V<?\ HLG@7_P8"C_AZO\
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M:I[*S^9Q\$\&X/'8%XO'Q;YG:.K6BT;T:W=U\C\8/^(7#QM_T5?PM_X*I_\
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M?#%E7J(_$5K(WY*Y/Z4O[-QG_/J7_@+_ ,A_VG@_^?L?_ E_F>W5\M_MX_\
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M.UU=>JFO'J_J7_:L_8I^&O[:O@Z+1?B)X9M=:CM"S65VK-!>Z>S=3%,A#KG
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MTMQI_BKXE:3;R,6%JE]:31Q>RE[<MC_>+'WK/_XA@_@Y_P!#Y\3/^_\ 8_\
MR/7[)'Q$R9J_-+_P%GXQ+PYSI.W+'_P)'X>T5^X7_$,'\'/^A\^)G_?^Q_\
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M8J2OPC,,;/%XJIBJF\VW]_3Y;'[UEV!A@\+3PM/:"2^[K\]PHHHKC.P****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[]LSQ]\$/V(K[XW?$KQ-XD\;77B#6DT/PIH<^IO9V\H0L9[AVC7<?]7,HR"
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M#*2I!/IU<E:C4HU'2JIJ2=FGNF=="O3K4U5I-2C)736S045\[^$/V\W\5?\
M!27Q5^S[_P (LL">&O#:>(!KO]H[C<;A:GROL_E#;C[3][S#]SISQ]$5>(PE
M6@XJJK<R4EML]4]/^'(PV+I8A2=)WY9.+WW6C6O;[@HKY3_;(_X*R^#?V7_B
M'#\/_#N@Z]\5OBI=8$?A?PY&99;<D;E$\BJWEDKSM5'<#!*A2"?+;_\ X*1?
MM7^#K(ZYKG['^IR>'5'F/#IVOK<:A''W/EHCN2!SCRAT[5Z6'X>QM6G&IRJ*
MEMS2C%R]%)IOUV/,Q'$6!I5)4N9R<?BY8RDH^KBFEZ;GW]17D/[$_P"V;X8_
M;J^"H\:>%[35]-@M[Z32[ZQU. 17%C=Q*C21-@E6 $B$,#R#S@@@>4_\%%_^
M"ENN?L0_%'X<^$?#GPRF^)&M?$;[0EG;0ZQ]AE$L;Q(L:KY$N\N9?5<8[YXY
MJ.4XNKBG@HP_>*]TVE:RN[MM+1*^YTULVPE+"K&RG^[=K-)N]W9:)-ZMVV/K
M2BO@G_AZ!^TQ_P!&5>+_ /PI?_N.OMGX7^)M2\:?#3P[K&LZ--X=UC5M,MKR
M^TF63S)-+GDB5Y+=FPNXQL2A.!DKG Z48[*L1A(J5;EU[3C+_P!)D[?,,#FV
M'Q<G&CS:=X3C_P"E15_D;M%?)/[:_P#P5(_X9Z^->G_"7X=> =8^+7Q8U*W%
MT^C6$WDP:9$PW*\\@5B"5^?;@ (0S.@*YY'X/_\ !63QIX8_: \-_#G]H+X-
M:I\)M0\;3BUT#5H;T7^GWD[$*L+,HPIW,JEE=]I==RHIW5TT^'\=.BJ\8*S7
M,ES1YG%=5&_,UYI'/4X@P,*SH2F[I\K?++E4GT<K<J?DV?<E%%%>*>T%%!.!
M7Q+\;O\ @M%H]O\ %6\^'_P/^'_B3X\>,=/8I>'1"8]*LB#M.ZY"2;@IX+!1
M'V\S.<=V!RW$XR3CAXWMJWHDEW;=DOFSAQV98;!Q4L1*U]$M6V^R2NW\D?;5
M%?GYKG_!5']HCX#63:[\5OV4]<T_P?#^\O-0T'6$OI=.BZF1T4.N .N]HQZL
M*^O/V7/VL? O[8_PNM_%W@'6H=7TN1O*GC(\NYL)L F&>,\QN,]#P1@J64@G
M;&9+B\+3]M42<-N:,HR5^S<6TGY,PP6=83%5/8TVU/?EE&496[I22;7FKGH]
M%>>_M7?'1OV9?V;_ !G\0%TL:TWA+2Y=1%B;C[/]JV#.SS-K;<^NT_2OBGPI
M_P %Q?B5=_#JQ\<:Q^RCX\C^']Y!]L_M[2-5;4(TM^<R[?LJ+M&#\S.HXZBJ
MP.28S&4W5P\4XIVUE%:VO9)M-OT%CL\P>#JJCB)-2:OI&3TO:[:325^Y^C%%
M><_LK?M4^#?VRO@W8>.? NH27VCWKM#)'-'Y=S8SIC?!,F3MD7(. 2"&5@2K
M GT*[NXK"UDGGDCAAA0R222,%6-0,DDG@ #G)KS:U&I2J.E434D[-/=,]*C6
MIU::JTVG%JZ:V:)**^%_B#_P6C;QY\1=0\(_L[_"KQ-\=-2TE_*O=6LW-GHM
MJW(R)]C;UR" S>6C=59AS6+J_P#P5G^.'[.T:ZI\;/V7?$F@>$5(-WK7A_4D
MU)=.3^](B@H![O+&/KFO:CPSF$DKQ2D]HN45)_\ ;K:E^%SPY<3Y>F[2;BMY
M*,G%?]O)./SO8_0*BN(_9Z_:,\&_M4?"ZQ\8^!=<M==T&^RHEBRLD$@QNBE0
MX:.1<C*L >0>A!.M\7/'?_"KOA3XG\3"U^W'P[I-UJ@MO,\O[1Y$+R[-V#MW
M;<9P<9S@]*\>6'J1J^QDFI7M9Z._;4]J.(IRI>VBTXVO=:JW=6.AHKQ3_@GS
M^U\W[=/[+FB_$AO#Z^%VU>XNH/[/%]]L$7DSO%GS/+CSNV9QM&,XYZUT_P"U
MK\>6_9?_ &;/&7Q!72QK;>$]-?4!8&Y^S?:MN/D\S:^W.>NT_2M9X&O#$_4Y
M1_><W+:ZWO:U]M^M[&5/'4)X98R+_=N/->SVM>]M]NEKGHE%>=_LE?'EOVH/
MV;/!OQ!;2QHC>+--34#8"Y^T_9=V?D\S:F[&.NT?2O#?^"B?_!2_7?V)OBU\
M/?!GAOX8S?$G6_B&D_V.WAUC[#*)8WC58U7R)-Y;?ZC&.]:X?*\37Q+P=./O
MJ]U=+X;WU;2TL^IEB,TPU#"K&5)?NW:SLW\5K:)-ZW70^MJ*^#O#_P#P6QO_
M (=>.M'TGX\? KQU\$]-UZX6TM==O)C?::LI_P">DAABPHZG9O*CDC&2/N'_
M (2O2_\ H):?_P"!"?XT8W*\5A''V\;*6S34D[;V<6T[==0P.:X7%J7L)7<=
MTTXM7VNI)-7Z:'\V_P 1/^2@:[_V$+C_ -&-7UE_P1-\.VNG_M'>*/B!JB_\
M2OX:^%;W5I)?^>;LNSKVS";CGVKY.^(HQ\0=>_["-Q_Z,:OKS]FX'X%?\$AO
MC-XP;]QJ'Q(U>V\+61/'FPH!YF#Z%)KH?5*_JKBB3EE7U6.]9PIK_M]I/_R6
M[/XHX.BHYU]<FO=PZJ57_P!PXN4?OERKYF]_P1VU6%?BY\9OC9XINOLUMX5T
M&XO+N],)F\F>[E:9I%3J[;8)0%!YWX[BK/\ P3J^!OPMUS]NKPIK'@OQUK_C
M4>'+;4/$&LOJFA_V;':*D8CBDW&1MQ,TZMVQL]ZYGPH#\"/^")WB#4&_<ZA\
M8?%L=A XX9K2W.3^&ZUN%)_Z:8[TG_!/4?\ "E_V#_VCOBE)^ZGGTR+PGIDP
MX9)I_EDQ[AKBV;VVYKY7,J<ZL,?BJ,W'GE'#QBK6>BI]F])3FU9K;4^TRFM3
MHU,MP=>G&7LX2Q4Y/FNG=U>DDM80@GS)[Z6+G_!-2Z7]I3_@JAKWQ&U(XT_2
MVU?Q;.TOW(4<M'$#Z;/M"$#_ *9^U>2?LU6<W[8?_!2_0;RZC:9?%7C"37+N
M)AG]PDKWDB'V\M&7V%>G_L' _!3_ ()V?M%?$QOW=QJUK#X/TV3HRO, DNWW
M'VJ%O;R\U!_P1ATN'PA\3?B/\4KZ-7T_X7^#[N_RW03R*2@S[Q13C'4YKMQE
M;V"S'%T?^7<(4(>O+>W_ (%4BOD>=@:+Q#RK!5_^7U2>(J?X7*UW_P!N4I/Y
MGT=H_@GX4_M3_P#!6Z7Q#:^/M>U7Q9X8U/SSH8T I8VYTU%BP+HR<J)8P^X+
M\S-QP<UY?^PEXGM?CK_P59^*'Q<U"3=H?@^WU?7([@\JD(_T6 ?46S,1_N5Q
M_P#P2_U*X^'7PE_:*^-5Y(WV_1?#4FFV5R_66]NV9\Y]?-2WSW_>5!^R6#\#
MO^"4OQX\=-^YOO'%W;>$+$GAI(\!9MI]"EU-GU,7M7C8C+W1CB,)"HY6C1PT
M6[:<[3FE9+11:>MWIJSZ##9HL1/"8ZI3C"\Z^+FES:^S34&^:3U<HM:66NB/
MD+X@>,KKXC>/=;\07QW7NO7\^HW!SG,DTC2-^K&OLC_@@)_R>OK'_8I7?_I5
M:5\/U]P_\$ U+?MK:U@?=\(W9/M_I5G7VO&D8PR#$QCLH-'Y[X?U)3XGPDY.
M[=1-_B?L?1117\C']S'YY?LS?\K&'[17_8D:?_Z3:)7Z&U^>7[,W_*QA^T5_
MV)&G_P#I-HE?H;7T7$G\6A_UYI?^D(^<X:_A5_\ K]5_]+9^>/[9G_*?#]F+
M_L7[[_T7J%?H=7YX_MF?\I\/V8O^Q?OO_1>H5^AU&>?[O@_^O7_M\QY%_O&,
M_P"OO_MD#\=_^"8G_!2SX2_L-^*/CKH_Q$UC4=,OM<\>7=Y:);:;-=!XU=T)
M)C4@?,.AK](/V/OV^_AI^W79:]<?#G5+[5(_#3P1WYN;"6T\LS"0QX\P#=GR
MWZ=,>]?)/_!"'PCI/B.7]HB34-+TZ_DC^(MTJ-<VR2E1\_ + XK]$-%\,:;X
M:60:=I]CIXFP9!;0+%OQTSM SC)Z^M>AQ94P7UNK%4Y>U]WWN9<OPQ^SRWV_
MO;Z^1YW"-/'?4Z4G4C[+WO=Y7S?%+[7-;?\ N[:>9^>/_!R/JD.A_L^_">]N
M&*V]GX\@GE(&2%6VG8\?05Z)_P 1!W[,7_0V:]_X3]W_ /$5P?\ P<9HLGP0
M^#ZLH96^(-J""."/L\U?>W_"K?#/_0N:#_X+XO\ XFB=3!1RC"_6X2EK4MRR
M4;:QO>\97_ 5.GC9YQB_JE2,=*=^:+E?1VM:4;?B4?@9\:_#_P"T9\)M$\;>
M%;F:\\/^(8#<64TL#0O(@9D)*, R\J>M=94.GZ?;Z39QV]K!#;6\0PD42!$0
M>P' J:OD*CBYMTU97TOJ[=+O2_W(^QIJ:@E4=W;5K17ZV6MOO9G^+= 'BOPI
MJFEM-);KJ5I+:F5/O1"1"NX>XSFORY_8"_:P_P"'.5MJ'P(_: \,ZGX5TUM9
MN+[1/&=G9O<Z5JJ2;02S("Q'R@AE#,H8*Z(4R?TV^*WQ4T'X(_#K5_%GBC4%
MTKP_H,!NKZ[:*246\8(!;;&K,>HZ FL/P[K'@#]LWX$:?JD=KH_C;P+XNM%N
M8([^R$UO=QG(^:*5>&!!!#*&5@1P17LY;C%1PTZ6)I.5";5VM&I*]K2LU>S>
MC3NCQ<RP;K8FG5PU50KP3LGJG%VO>-T[72U35GWV-7X7>,_!_P 5=$_X2[P=
MJ'A_7;'7$0-JVER13+>! 0JM(F=Q3)&UCE<D8'->2?\ !4K]IC4/V2/V%/'O
MC31I/)UZ"UCL-+D Y@N;F5(%E';,?F&09X)CQ7R+\)/AK8_\$^/^"Y/AWX8?
M"N\O;?X?_%/PY/JVN>'#<-/;:5,D-XZ,FXDKAK6,J6.X+,RYVLHKZP_X*R?L
MYZE^U-^P'\0/"NAP/=:\+6+4].@09>XFM9DG\I1W:18W11_><5U_V?AL-F6&
MYY<U&IR2NU9\KE9J2UVLT[:-:HY/[0Q.)RS$^SCRUJ?/&T7=<RC=.+TWNFKZ
MIZ,P/^"0?[&>C?LK?LC^'=4:VCN?''CZP@U[Q%JTPWW5Q+<*)E@+G+;(E<+C
M."^]^K&OJNOE[_@D5^V%H?[67[&7A06UW$/%'@W3K?0O$&GLV+BUG@C$2RLO
M79*J;U/3)9>J,!]0UYF>/$/'UOK5^?F=[_A;RMMTM:VAZ61_5UE]'ZI;DY5:
MWIK?SOOUO>^IG^'_  KIGA..Z32]/L].2^N9+VX6VA6)9IY.7E8* "[$9+=2
M>3S7P#^V9_RGP_9B_P"Q?OO_ $7J%?H+IVLV>L?:/LEU;77V69K>?R90_DRK
MC<C8/RL,C(/(S7Y]?MF?\I\/V8O^Q?OO_1>H5Z'#=WB:O-O[*K_Z0SAXDLL/
M2Y=O:TO_ $M'Z'5^._\ P3$_X*6?"7]AOQ1\=='^(FL:CIE]KGCR[O+1+;39
MKH/&KNA),:D#YAT-?L17YP_\$(?".D^(Y?VB)-0TO3K^2/XBW2HUS;)*5'S\
M L#BMLCE0CE^+>)BY1_=Z)I/XGU:?Y'/GL:\LQP:PTE&7[S5IM?"NB:_,^B_
MV7/^"LOP5_;%^*D?@WP)KVJ:AKTEK+>+#/I,]LGEQXWG>Z@<9'%7?^"LG_*-
M[XQ?]BY/_-:]RTGP1HN@7?VBQT?2[*XP5\R"TCC?!ZC*@&O#?^"LG_*-[XQ?
M]BY/_-:X<'/#RS.@\+%QCS0TDU)WYEU2C^1Z&+AB8Y976*DI2Y9ZQ3BK<KZ-
MR_,_//\ 9X_9U^(G[!W[,OPT_:?^""WFO:7JOAVWG^(W@R25GCU&!=V^ZB')
M^498D M$<L T;2(/U'_9,_:R\&_MH?!C3O&_@G4/M>G7G[NYMI,+=:;<  O;
MSH"=LBY'J&!#*2K G@_^"3HW?\$W?@Z#R#X<AR/Q:OFC]K']E7QE_P $Q?C)
MJ/[0W[/>GM>>#[P^;X_\ Q96VF@!+/=6Z*#L"Y9OE!,))8 Q%T7W,?5IYKBJ
MN%KM1KQE)0D]%))NT)/OTC+Y/HSP<OIU,JPE+%4$Y4)1BYQ6KBVE><5VZRC\
MUU1H_"+_ )60?BE_V3F#_P!!TNOJW]OO]H:X_92_8V^(7C^R5&U+P_I3&PWK
MN1;J5E@@9AW42RH2.X!%?"G[ O[2/AG]K?\ X+H^-/'_ (1N)IM$U[X:1.BS
MQ^7-;R)_9B20R+V='5E."0<9!(()^X_^"B7[/UY^U)^Q+\1_ NFJ'U76M)9M
M/C)VB:Z@=+B!">VZ2)%SVW9K'-J,:>8X2EC%9*%)23Z)6YK_ (F^45IU,NQE
M7!N[<ZSBUU;ORV_ \:_X(H?LBZ=\%_V4](^(FJI_:OQ&^+5LOB/6=;NOWMU+
M#<GSH8A(?FVE&21N<M([$YPH'V;7QS_P1+_:UTGX_P#[&7AWPC-,+/QM\+;.
M/PWK6DS_ +NYMX[<>5;R[#AMK1HJDXX='7MS]C5XW$/M_P"TJWUGXN9_=TMY
M6M;RL>SP[]7_ +-H_5OAY5]_6_G>]_.YGZ'X5TSPS/J$NFZ?9V,FKW1OKYK>
M%8S=W!1$,LF!\SE(T4L>2$'I7YL?\%L?BMHOP,_X* _LI>,/$4\MKH7AN_N[
M^^ECB:5XXDGM"Q"+DL<=AS7Z7V&L6>J3W4=K=6]Q)83?9[E(I0[6\NQ7V. ?
ME;8Z-@X.'4]"*_.__@J_90ZE_P %1OV.;>XABN()M:N%DCD0,C@W%IP0>"*[
M>%)+^T;U+M<E2_>WLY==>FQQ<6)_V;:E9/GIV[7]I'IIUW/0/^(@[]F+_H;-
M>_\ "?N__B*^QO!?BZQ\?^#M)U[3)&FTW6[.&_M'9"C/%*@D0E3R"58<'D53
M_P"%6^&?^A<T'_P7Q?\ Q-;D$"6L"1QHL<<:A411A5 X  [ 5Y6.J8&27U2G
M*+Z\TE+[K1C;\3UL#3QT&_K=2,ETY8N/WWE*_P"!^9_[1=]XL_X)??\ !43Q
MA^T'JG@W5O&GPE^)FE0:?JFI:5%YUWX;9$ME;>#@!=ULI&XJC*X ?<F#]K?L
MX_M<?"/]MC2;76O OB/0?%%QI)^T"!T":CI+,I0LT,@$L1(9DWX 8%@"0:UO
M@C^U5\/?VF]8\7:3X-UZ'7KKP3??V5KD'V:6$VDYWC81*B[AE'7<N5)1ADX-
M?GY_P6M_9I\'_L0Z5X2_:$^$L5O\.?B18>)8+/RM)46]IK(DCED</;KA-W[L
M[MH D1G#AL@CZ&C"GF=6G@<5&5/$**A&71I+W5.+U6EES)[:M'SM:53+*53'
M864:N'<G.4>J;?O.$EH];OE:WT3/U)HJKH=[-J.BV=Q<0-:W%Q DDD)ZQ,5!
M*_@>/PJU7QKTT/LT[JY\5_\ !=W]HG7O@C^Q6FA^%9IK7Q#\3=9@\+0SQ/LD
MAAE21YBK=BZH(L]0)B1@C(]X_8F_8[\+?L0? +1_!/AFSMUDMX4?5=06,+-J
M]X5'F3R-U.6SM!^XNU1P*^?O^"^?P'UOXM?L/IXB\-Q23:S\,=:M_% 2)=TC
M6\:21S$#_8$BRG_9A:OHO]C;]JWPY^V?^SWX?\>>&[J"2/4K=5O[1'W2:9>!
M1YUM(.H9&/&?O*589# GZ;$<RR.E['X>>7/;^:RY+^5KV\[GS&'Y7GM7V_Q<
MD?9W_EN^>WG>U_*QZDRAU*L,J>"#WKRSX _L6_#7]E_QMXR\0>!O#5KH&H>.
MKI+K5/(9A#E <)%'G;%'N9WVJ -TC=@H7SK]M#_@E%\+OV[OB7I_BSQO<>+(
M=4TO3$TF$:7J2VT/DI++*,J8VRVZ9^<],>E?$G_!+O\ 9L\$^'_^"R/CAOA'
M=:OK'PV^%^AR6<NK7=V+N.XU"94A9%D555@6-P%(&"+=B"0028#+Z-7!5JE+
M$2BXPYIQY?==FK1<N;6[M;3Y!F&85J6.HTZN'C)2GRPESWDKIWDH\NEE>_O?
M/4^\O^"J_P#RCD^,G_8L77\A7C'_  3X_;Q^#/[/G_!,WX9_\)=\2O!NEW>C
M^'U^U::=4AFU%6#.=@M48S,_^R$SS7L__!5?_E')\9/^Q8NOY"ORLB_8NT?]
MF?\ 9F^ /[4FF^!]+\>>$X].@3XA>&M1MEO(95>1T%ZBR94$Y"G^%9%B)!5I
M*];(<#AL9EGL,3)J]7W;6]Z7)I&[T5]D^]CR,_QV)P>:?6,-%.U+WKW]V//K
M*RU=MVNUS[2_X-]/".H+\%_BCXV_LFXT+PK\0/&ESJ7ARQEC\M5M1D;T4<;,
MD1@CC,![ 5I?\%W_ (N>(HOA5\.?@SX4O&TW6/CQXDC\/2W*DC_1 \*21\8.
M'DN( W/*;U/#&OL;X(?$CPO\7OA%X=\2^"[FSNO"NL6,<^F/:H(XUAQ@($'W
M"F"A3 *E2I (Q7Q;_P %ZOAWKVC^ ?A3\;?#ME)J5Y\#/%46LW-LN>+9Y8',
MAQ_"LMM K<<+(2> :Y<!C%B^(8UZT>5N3LGTDHM03OUYDK^9UYA@WA.'94*$
MN9**O)=8N2<VK=.5RMY'V!^S7^SCX5_90^#6B^!_!VG1:?H^CPA"P4"6\EP-
M]Q,P^_*Y&68_08  '<W%O'>6\D,T:2Q2J4='7<KJ>""#U!]*Y#X ?'KPQ^TU
M\(M$\;>#]2AU/0]=MUGA=2-\+?QQ2#^&1&RK*>00:[)F"*68X4<DGM7RF)=9
MUI.O?GN[WWOUOYW/J\*J*HQ5"W)96MM;I;RL?FK\-/"D?_!-?_@M?9^!?"R_
M8?AA^T!I,E^FD1G;;:7J$:S,/*7^'#PLH P EV%QA%Q]T_M:?\FJ_$S_ +%3
M5/\ TCEKX6\->+H/^"BG_!<?1_$GA*0:C\._V>]'EMKK5X?FMKZ_D$ZA8W'#
M R2\8X9;21@2&4G[X_:+\.W/B_\ 9\\=Z39QM->:IX>U"T@C499Y)+:1% 'J
M217TN>-K$X65?^)R0Y^][NU_/DY;W/F<CBGAL5&A_#YY\EMK65^7RY^:UCY?
M_P"#?O\ Y1?^"_\ L(:I_P"ETU>F?\%9/^4;WQB_[%R?^:UY#_P;Q>*+/7?^
M":FAV=O-')<:'K6I6=VBMEH9&G,X##ME)D/T->E?\%D/%MGX._X)H_%B:\GC
MA%YI*V$(<X,LLTT<:*H[G+9X[ GH#58R$O\ 6:4;:^V_]O#!5(_ZLQE?3V/_
M +8:G_!)O_E&]\'?^Q<@_FU?,O\ P5D\2Z=X/_X*E?LBZIJ^H66EZ98ZA<S7
M-W>3K!!;H)X,L[L0JJ/4D"OJ?_@EWX?NO#'_  3P^#EI>1-#<?\ "+6<Y1AA
ME61/,7(_W7%?)7_!8GX<Z)\7O^"E?[*'ACQ)I\6JZ#KEW=6E]9R,RI<1-/!N
M4E2#S[$5T90X//:SE\/[Z]NW+/8Y\V4UD%%1^+]SOWYH;FM_P6Y_;@^$?Q(_
M8OUKX:^&?%'A[X@^.?&5[8VVCZ;H%U'JDMO*EW%(9&,)8(VU615SO<R  $%B
M/D/_ (<[?M:_]!*[_P#!JO\ \57ZX? [_@GK\$_V;O$:ZSX*^&OAC1-8CR(K
M\6YGNH,C!\N64LZ9'!VD9%>R4L+Q7'+J"PN60O&[;=1)MMV6B6B22[NX8KA.
M695WBLSG:5E%*FVDDKO5M7;;?96/Q#_X*M_L'Z]^S/\ ';6O%%AI]Q=> O%5
M])?6=[#&6BL)IF+O:RX^X0Y.S/#)C!)# =5_P4<L9?@=^R?^S_\  JVC?^V+
M?3SXDUFS09D%Y<EA&N.I822W:^N *_8R_L(-4LY+>ZAAN+>8;9(I4#HX]"#P
M:X#Q?^R3\-_'_P 5+3QMK7@_2=3\56,D,MOJ-PC/+$T)!B(&=ORD CC@\U[^
M!\29-86.84W+V%W=/XI<O+!M/:R;N];NSL?&YCX21B\9+*ZJA]9Y4U)/W(\_
M/-1:O?F:BDFE973;/RJ_X*W74/P?\&?!;X(VDB;OA_X:2[U41'Y7O;@*&)]\
MQR/])_>I/VL5_P"&;_\ @E?\&_AO_P >^N>/[R3QCJT8X;R2"85<=LK+ .><
MVY],5^GWQ&_87^$?Q<\8WGB#Q-X#T/6]:U!D:XO+I&>68JJJN3NZ!550.F !
MTJ_\4OV/OAC\;/$=KJWBSP5H?B#4+&W2TMY;R(R>3"A++&JYVA068X QR?6M
M<+Q_@J='"4:E.;5*3J3V]Z;NTUKMS2;U[+Y88SPPS"K7QV(I581=:$:5/XO<
MIKE33TWY(*.FFLOG^67[9:_\,X_\$RO@C\+O]1K7B^63QEK$8^5PK F%9!])
MT7'K;>U'A)/^&:/^",7B#4I?]'USXX>(4L;0])#86[?,2/[I\FX&>F)U]0:_
M4KXK_L<?"_XY^)(]8\7^"]%\0:E#;K:1SW:,[10J25C7G"J"S' XRQ/>F_$'
M]C/X7_%7PYX?T?Q!X+TC4M)\*VYM=(LW#I!I\9"@K&BL ,A%!.,G:*5+Q P?
MU>E1JTY?Q75J-6]Y\SDDM=E+E6MM(CK>&&/^M5L10JP7[E4:2?-[JY5!R>F[
MCSO2_O2W/RW^+:?\,T?\$</ _A=O]'USXSZZ_B&[B/WGLHMC1GUP0EDP'3YS
M1_P4*3_AGC]A7X"?!K_4ZK/:/XOUR#H\<TV_RP_KAIKA/^V(K]3/B+^Q]\,O
MBWJVBWOB3P;H^L3>';>.TTP3HQBLHD.51(P0@4''&.0 #D "JOQ:_8C^%/QV
M\82>(/&'@O2]?UB2)(#=732,PC0850 P  YX '))ZDT87Q P<:U*I7IR=JE2
MK*UM9R3C!+7:,7UZI:!CO##,)4*U'#58+FI4J,&^;2$6I5&[+><U>RTLWJ?S
MRQ1M-(J(K,[$*JJ,DD]A7Z]_\$3/V%-<_9\\*ZQ\0?&%C-I>O>++9+/3]/G3
M9/9V082,TJGE6E=4.P\J(QGEL#ZE^%_[%OPG^"^L1ZEX8^'WA;2=2A.8KQ+%
M'N8C_L2/EU_ BO3JGC#Q*>:85X'!TW"$OB;:NTM;)+1*^^KOMH5P'X1K)L:L
MRQ]55*D;\JBGRIM6NV]6[/165M]=+%%%%?E)^V'P7\?/^"6_QA\0?MV>.OC5
M\+?C1IOP[O/&EG::?)$=&^US+!#:VL3(Q<E2&DM5?(4$<#/7/OW[$?P/^,7P
M6L/$4?Q<^*T/Q1FU"2W;3)(]+2Q_LY4$GFCY0-V\LG7IL]Z]VHKUL1G>)KT%
MAZO*TDHI\D>:T;67-;FZ=SR,-DF&P^(>)I<R;;DUSRY;RO=\M^7KV/FOXX?L
M):A\6O\ @HA\*?C;#XAL[/3_ (=:=<6,VEO;,TUZ9%N5#+(#A<>>."#]T^M?
M2E%%<>(QE6M&$*CNH+E7DKM_FV=N'P=*A*<Z:LYOF?F[)?DD?-G_  3L_82U
M#]B+_A9G]H>(+/7O^$^\32Z_#]GMFA^R(^?W;;B=Q&>HQ7TG112QF,JXJLZ]
M9WD[7Z;*W3R08/!TL+15"BK16W7=WZ^;/E__ (*F_L":S_P4#^%?A70=#\46
M/A.^\,Z\FM+=7-HURK%89(PH52.07!R<CBO*?^&%?VSO^CMK/_PEH/\ XFOO
M:BO1PV?8JA0CAXJ+C&]N:$96OOK)-ZGGXK(<+7KRQ$G)2E:_+.4;VVNHM+0X
M7]FKP1XP^''P1T/1?'WBI/&_BZQ24:AK:VJVPOBTTCH?+4 +MC9$XZ[,]Z[J
MBBO)JU'4FZCM=MO166O9+1+R6AZU&FJ<%3C>R26K;>G=O5OS>K,WQGX.TOXA
M^$-4T'6K*'4M'UJTEL;ZTF&8[F"1"CHWL5)'XU\ ^&?^"7'[1W[(TFH:#^SU
M^T!I^C_#V^N9+FVT?Q-IB7<FE%SDB)VAF4\DDE5C#$Y*D_,?T0HKNP.;5\)&
M4*=G&5KQE%2BVMG9IJZ[G#C\IP^+E&I4NI1O:49.,DGNKIIV?;8^4_V#/^"9
M:?LM?$37_B9XY\8ZA\3OB]XJC,-_K]Y'Y<=K"=N8H$))&=B*6)'RHJJJ+D'Z
MLHHKGQN.K8NK[:N[O;LDELDEHDNB1O@L#1PE+V.'5EOU;;>[;>K;ZMGQ;^T[
M_P $>-/\:?&:X^*?P9\=:U\$_B5>,TM[=:4A?3]5=CN<RP!EVER 7P2C'EHV
M8DGD;_\ 8H_;@^)=@V@^*/VGO#>D^'[@>5<7F@Z$D6I.G0X:."!E;']V5?K7
MZ 45Z=/B+&1A&$^6?+HG*$9->C:;TZ7V/,J<-X.4Y3AS0YM9*$Y13]5%I:];
M6N>5_L9?LFZ+^Q5\!]/\":'J>K:U!:SS7EQ?ZE(KW%W<3/OE<[0  6/ Y('4
ML<D^?_'#]A+4/BU_P40^%/QMA\0V=GI_PZTZXL9M+>V9IKTR+<J&60'"X\\<
M$'[I]:^E**X(9EB8UIXA2]^:DF]-5)-/[T_\CT)Y;AI488?E]R#BTM='%IQ^
MYK_,*_-_P#_P2-_:&^ _BWQG=_#7]HC2_!^F>,=;GUFYM(_#ZSY>1V*[FDW<
MA2!Q@<=*_2"BM,OS;$8-3C1M:5KJ48R3MMI)-&>893A\:X2K7O"]G&4HM7WU
MBTSY0_93_98_:3^%OQGL=8^)'[05O\0/"<$,R7&C)H45H9W:,K&WF*H(VL0V
M.^*]E_;#^!-Q^T[^S#XV^']IJ$.DW/BS3)+".\FB,D=N6Q\Q4$$CCH#7I5%3
M6S*M4Q$<3:*E&UN6,8K1W6B27X%4<MHT\/+#7E*,KWYI2D]59ZMM_B>:_L>?
M FX_9B_9A\$_#^[U"'5KGPGID=A)>0Q&..X*Y^8*22!ST)KTIE#J01D'@@]Z
M**XZU:=6I*K/>3;?J]6==&C"E3C2AM%)+T6B/E#X'_\ !+CPW^S'_P %!M4^
M+_@3[-I/AWQ1X>O-.U+047;'97LEQ;2B6V X6)Q$^Z/@(V-ORMM3ZOHHK?&8
MZOBI*=>7,TDKO>RVOW,,'@:&%C*&'CRIMNRVN][=CX[_ &NO^"0VB?&GXO-\
M4OAGXPUKX-?%8DO-K&B@FWU)C]XSPJR'<V &96 8$EUD-<+<_L:_MT>+[%M"
MUG]I[PKIVARCRI=0TO08TU,Q],@I;Q,K>ZRJ?]JOOZBO1H\18R%.-.?+/ETB
MYPC)Q]')-V71;(\ZMP[@YU)5(<T'+62A.45+U46E?N]V>-_L,_L9Z3^PU\%I
MO"6FZ[KGB:XU+4YM:U35=5D#7%]>3+&LDF!]U2(UP"6/4EF)S7DG_!27_@G/
MXS_;(^+WPQ\:>!_']AX#USX;&XEM;F?3S=OYTCPNCJ,[?E\KHP(.:^OZ*Y:.
M;XJEBWC8RO4=[MI.]U9Z-6V=MCKK91A:N$6!E&U-6LDVK6::U3ONK[GP3_PP
MK^V=_P!';6?_ (2T'_Q-?;/POT36/#/PT\.Z;XBU9=>\0:?IEM;:GJ8B$0U&
MZ2)5EGV#A=[AFVCINQ6[12QV:5<5%1J1BK?RPC'[^5*X8'*Z6%DY4Y2=_P":
M<I?=S-V/B+]HO_@ECXSTW]I75OC%^SO\31\+?&?B8'^W]/N[,76E:O(2"TK*
M5<*S$;F#1N"Q+ H2<YGPV_X)1?$3XR_'+P]\0/VGOBM%\3I_!\PN=%\.:99"
MUTB"8,&$DBA(U89525$2E]BAW905/WA179'B/'1IJ":NERJ7+'G4=K<]N:UM
M-[V..7#>!E4=1IV;YG'FER.5[W<+\M[Z[6OT"BBBO"/>&S0I<0M'(JR1R JR
ML,JP/4$5\(_$C_@C3JGPP^*FI>.OV:/BEJOP5U?5G\V^T00?:]#NVR2,1$X1
M022$=)57)"A!Q7WA17?@<SQ&#;="6DM&FDXM>:=T_N//Q^5X;&)*O'6.J:;4
MD_*2::^3/SY\0_\ !._]KC]I"R;P_P#%C]IC3K'P?.-E[:^$M(6VN+^,\-&[
MI%;X##@ABZ\_</0_7/[)O[(G@;]BKX2V_@WP'I?V#38W\ZYN)F\R[U&<@!II
MY,#>Y  X 50 %"@ #TVBML9G.)Q-/V,K1A>_+&*BK]VHI7?K<QP62X;#5/;Q
MO*=K<TI.4K=DY-V7I8\Y_:\^!UQ^TO\ LR>-_ -KJ$.E7/BS2I=.CNY8S(EN
M7&-Q4$$@>@-9/[+O[+EO\$_V./#7PE\126'BBSTK16T;4"UOMM]1B?>'4QL3
M\K*Y!!->N45R1QE94/JR?N\W-\[6O??8[)8*BZ_UEKWN7E_[=O>UMMSY9_X)
MX?L#^)_V O$'C/0++QM;^(/A3K-[)J&@Z-<V\@OM!D9A\HE+%75DX88&617&
MTLX/T]K&D6GB'2;K3[^UM[ZQOH7M[BWGC$D4\;@JR.K9#*P)!!X(-6**>,QU
M;%5GB*SO)VN[)7MUTZ]WUW%@\#1PM%8>BK05[*[=K]->G9=-CX%\1_\ !'#Q
M=^S_ ./]2\3?LO\ QBU;X3KJTIGNO#5_#_:&C._JJON  ' $D<K#) 8#BJFO
M_P#!.+]JO]INT;0_C)^TM:VO@Z?Y+W3O!^E):RZA$>&C>18H.&'4.)%_V#7Z
M"T5ZL>)L=I*7+*:VDX1<U_V\U>_F[L\J7#&!UC'FC![P4Y*#_P"W4[?)61YU
M^RY^RIX'_8Y^$]IX-\!Z.FEZ3;L99G9O,N;^8@!IYY#R\C8'/0 !5"J !Z+1
M17AUJU2K-U*K;D]6WJV>Y1HTZ4%2I)1BM$EHDCX1^*'_  24\;?"CXUZY\0O
MV8_BM)\*=1\43&XU?P]>V@N]%NY22Q=4*NJ#+,0K1/M+ML9%PM9NG?\ !);X
MJ?M0>.M'U;]J3XS?\+ T'0+@75MX4T&S%CIEQ(.AE*I$",94XBWE6($B@G/Z
M 45[<>)L>H[KF2LI\L>=+:W/;FVZWOYGARX9P#D]'RMW<.:7(WO?DOR[]+6\
MB.SLX=.M(K>WBC@MX$$<<<:A4C4# 4 <  < "OFW]K#]@W4?VC?VQ/@G\3[7
MQ%9:7:?"F[DN;BPEMFDDU -)&^$<, N-F.0>M?2U%>5A,95PU3VM%V=FN^DD
=T]_)GK8O!TL33]E65U=/MK%IK;S2"BBBN4ZC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>gale-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:gale="http://www.galenabiopharma.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gale-20200930.xsd" xlink:type="simple"/>
    <context id="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1113bd5f1bec43d2af7664330b6cbdeb_I20201113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-11-13</instant>
        </period>
    </context>
    <context id="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i526ba136e5e243d480e699d976eac2a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic022585050ae4612867b99cbfb4d849b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25a23f1f812448a1b0e6a3596e39276e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i25819b81a08a4c37884c9892590906c8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5157db189dde4c2695638890e78b8126_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic25846bafe5d48b2be3621585891630c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i88e0e8582c5944e28e652902589c2bc8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1d8e37103bd64af1b9cc06f485522288_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib1497135158547e98a1d099f75b92b6c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i017b702a13f64d4b98692ac37c6a1053_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia609730176c14fdab04d34b43a971355_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c1db2db5213477e963d08ffc4069d65_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17705d1efab94dde907052dd981f02a0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i645c600a848a471a83b9b22bb3e706b1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i448e315df994429faf64be5d9e92cab2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic676874210a241b0962cf4ef4c61a42c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifef9e512b2a5468ebe07f8b90a06af96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81b1bd6d180f405fa9db296c77b6ed97_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if021b546b0cf4d20ba09dbffea09d212_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4efe31e6a2740e2a47f900a8411a6ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic656a9beca124dbd893b34aa5140bd0a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic98a9c1849c14b238f015a559fd03855_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iae50a7116a1f45c48a4530ec81fdf221_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8d096b69f27a4dc9b506bd230ab72aa2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iabd470f4d5da4812aa588bd34055fd56_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8251699c639640ee881bf02c2e33e139_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i333c91c266364b2eae464c53a8817f07_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i789a0f37c09142ab985c13adff90f7a2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6e733b367c614849b02a9fd90805dcb2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7750e980bf85451d98229836daffbd55_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if3865ec252344ced80fdda5644983129_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i12900c59fe2a4ff096fd101b525adf14_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i86b2f91724d24900ac8e54e3b467f7f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i84f75e0d3fed4888b7432f8ab49025d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i35b97499a01c4bbd86d34124af212071_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8205cb47ed594c60af87958ca345c78a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifad85cecbb6d478c84dd680e20b243d9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:PIPEInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i9fe21654d5bd481094895b468bb60e02_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:PIPEInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i354bd279ed2542818d5f6d96946a39b1_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="iea994a777cf84044889ade0f0cfca5c7_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gale:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gale:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="i28c703bfbd66411799afac37b66ff593_D20200109-20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="i9d45ff94435e4d21ba5468a5bebac6bf_I20191107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-11-07</instant>
        </period>
    </context>
    <context id="i4f256c92ebda4e238a9aee699650ec0f_I20191108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-11-08</instant>
        </period>
    </context>
    <context id="ib323751cda864ddea7a8246c632828fc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57d28b5ddb4f4e639e1959c1669e686e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i236474c05e0144e19db3cd5297f11f83_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7605f1eb40c54e9c842276a939abedd4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i336f4731de7d4c87aac9eb314ce2c08f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a636ae8cbfc46d18fa54ecab7fe2024_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie6b0a09ffc074f6a9ca8dbb88f9820a5_D20191107-20191107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2019-11-07</startDate>
            <endDate>2019-11-07</endDate>
        </period>
    </context>
    <context id="i111eee7793154c7cbef26ee3f9b7f76f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i27de7fe30b534200ba87bbfcddc0e6df_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i31133d38f51742738c72afb224c21907_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i52f4af32287b4eebbb3e4bb756720009_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i312df3f093ec493b8184ebf1b42c5b63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4007eb8b70cc49a894e1bdf6a68b797d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a08e3cbcb5346b484952fa5670010dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i484453f41b684c819bd4de89fe5e44d7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib4b789d256a64b4c94443e234118e471_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="ic15be4f3595049579ffb1c76ee6bffb9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2a3529684d284f57abc0008fc0964ea3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">gale:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic0ed1616c836452e8084ab91d06bef5c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">gale:MeasurementInputCostOfDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i784b47aa030d491fb2d324b3fc9ef92a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8564c243eb44d16943c0ae16d68c94c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8c8fdb34b2cc44a58467c8e3974f9096_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i71b0db59425c4a98acfb161fe0504728_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65906fccb4494d56a3acf5118e25adbf_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringJuly312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i483df898bc3046c6803892473d43f9dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gale:OfficeSpaceLeaseExpiringJuly312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:DistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="id35672082f7945928e2de21782c5ccf4_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="if77a8a8ce50a4065b099f3a4946f25d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a06969186f544b098f9823b6f201beb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd662d374f5e4b9b9f63ff15501e6a9b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2003e91715cd42cd807932a074fadd24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id011ae33db9a49bfa4332611238d7399_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64f67ec1048a462997aa215f62c15d3a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie4dd7532088040d9b73af1f7afd90860_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27ccbdec896542ac98d4fd115dff1bcf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:PreFundedJune2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i39ef75fb2fbe4b15858d159ac382757d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11d32eceb309447d9a734885748db45e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i22fb77bdd14a4391afb857bad525ac58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if92d800c33d7429d83e6b450093d5217_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9e8dbce17eee4277b5a56ab7ba7dee3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f18bc2fcbb74091bfc8098930a1503d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id9131a32521e475eab282e97afd922ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i953ec750bdd64786866ccfc3f7f8baa2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic9c5ca7b25c443cab31a8bdd3b02bad6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13c6c834d79b43b2b4810fe704177d48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icde95ad8907947079b64dbecdb9a5118_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3b14755124449839e31591a62b76734_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib03011f148cb4758a40c754e531e9467_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc95b8a4af8c45868a82d2bdc59aba55_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i454630a01309432fa2cd4d7cff6dfe26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i057e07bc9bcb479399b79efcba85a739_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if56a535a800d461ab07716bd1239fb0f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="idcee970816de4898aab068f1436dc88c_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="ie359a0832f7942bdbf02a2c59e430ed4_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Warrants2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="ic21ba327b68645e39db322f2b5490a05_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Warrants2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic7c4d8cbc2a54d81bb75603f21e71592_I20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="i5e452b96408744e7b8df56fd8bb09e82_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i2016b111d5d5438a9afb8026836b746a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-10</startDate>
            <endDate>2019-09-10</endDate>
        </period>
    </context>
    <context id="ie0346c87fde44172b58c4033836ca055_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0326b4a15fb4f79b56050d8f382451e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02e7017a8cdc4a0282dd6943f37e6465_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7978d211d17840e58f2b8d3d7d3796a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8fa5608939c04c9f8ee26f0aac67c972_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37be4be95af44ceaaaa2b49b0947ba57_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c151f4f312b4f67ae012e478ef3df7e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcce4f272d22498990237677ea1747bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if26e5d011619471ead5000df2785d4af_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i670c721655b24536abbe20f1d9e66a1e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i046188f82f2c42d1b09d3e35bf7d8bf5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97541f70c99c4d0d99f8987a97e11b2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl80LTEtMS0xLTA_642ddf2a-ddff-4ac7-be0c-80a962b5339b">0001390478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl81LTEtMS0xLTA_4b37cf7e-bb2a-40b4-b0d2-5ff3dea821e6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl85LTEtMS0xLTA_743aad66-747f-481d-a9ef-4993b97a9980">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl8xMC0xLTEtMS0w_e18f8f2c-af2c-4365-b11d-f29ba5d106ee">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180L2ZyYWc6MjI4NjcyMTZmYzFmNGQzMTkwMDA0ZmRhMzMxZWQ4YjMvdGFibGU6ZjRkODFjOWQwYWJiNGE4YmExYzVhNGZmMjBhNWEwYzIvdGFibGVyYW5nZTpmNGQ4MWM5ZDBhYmI0YThiYTFjNWE0ZmYyMGE1YTBjMl8xMS0xLTEtMS0w_53dc4268-0cc8-43af-b32d-76b3768dc92f">false</dei:AmendmentFlag>
    <gale:ClassofWarrantorRightTerm
      contextRef="i28c703bfbd66411799afac37b66ff593_D20200109-20200109"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180My9mcmFnOmM4NGQ2NzA3ZTJjYjQ1YjZiN2E5MzljN2EzYzJjZjk5L3RleHRyZWdpb246Yzg0ZDY3MDdlMmNiNDViNmI3YTkzOWM3YTNjMmNmOTlfMTEw_6b4c3a93-098a-44f9-a8cc-e889960cdcf5">P5Y6M</gale:ClassofWarrantorRightTerm>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ie6b0a09ffc074f6a9ca8dbb88f9820a5_D20191107-20191107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180OS9mcmFnOjFjOTZiYThkN2U3ODRmYmViNzJhMGFmZTkxYzZhZWYyL3RhYmxlOjE0Mzg5YWJmNTA3YjQ3NGRhYTVkZTI3MTc1NGU2NGUzL3RhYmxlcmFuZ2U6MTQzODlhYmY1MDdiNDc0ZGFhNWRlMjcxNzU0ZTY0ZTNfMS0xLTEtMS0w_29fd6e08-f0a9-45ae-b475-d47a81450c0c"
      unitRef="number">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones
      contextRef="i784b47aa030d491fb2d324b3fc9ef92a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4MQ_25e0b964-a33f-48bd-9fac-2954e0ad7f70">P5Y</gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones>
    <gale:ClassofWarrantorRightTerm
      contextRef="i28c703bfbd66411799afac37b66ff593_D20200109-20200109"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182NC9mcmFnOjNiNmM3ZTcxMjYwNjQ3ZTY4ZjEzYTE5NDRkYmYzZjIyL3RleHRyZWdpb246M2I2YzdlNzEyNjA2NDdlNjhmMTNhMTk0NGRiZjNmMjJfMTEy_6b4c3a93-098a-44f9-a8cc-e889960cdcf5">P5Y6M</gale:ClassofWarrantorRightTerm>
    <dei:DocumentType
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg1_6eea6bad-ab29-484b-a625-7e10272792f9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6OTU4ZmVlMjEyNTQzNGY4MDhkMGMwNzY5ZmFkYjJmNGQvdGFibGVyYW5nZTo5NThmZWUyMTI1NDM0ZjgwOGQwYzA3NjlmYWRiMmY0ZF8wLTAtMS0xLTA_78c11148-ec7a-49a9-95b5-5087bedfdc8e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8xOTI_ee79290e-7bda-40e6-a410-38bce413abfb">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YWUzMDNkMDU3Y2FjNGYwMWFjN2UwMjU2MDkxYzEzNzYvdGFibGVyYW5nZTphZTMwM2QwNTdjYWM0ZjAxYWM3ZTAyNTYwOTFjMTM3Nl8wLTAtMS0xLTA_00ca64f4-2e40-417c-9c4c-b1acbe5a7dfb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDkx_08844eba-74ae-41ea-beea-db51b8a2941a">001-33958</dei:EntityFileNumber>
    <dei:EntityFileNumber
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDkx_8d7de0b5-372e-4e6e-b870-3b44252bc560">001-33958</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDky_a1ba84a0-d110-4725-a01a-899dd02d76f4">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDky_bf0a4329-b785-4a6f-a189-ed083074b414">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YmExYTMxNjBmZWUwNDMzYzllMDZkMTQ4ZDIwYzBkMjUvdGFibGVyYW5nZTpiYTFhMzE2MGZlZTA0MzNjOWUwNmQxNDhkMjBjMGQyNV8wLTAtMS0xLTA_0c9e1de7-236e-407f-81cd-1c321ee51a5c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6YmExYTMxNjBmZWUwNDMzYzllMDZkMTQ4ZDIwYzBkMjUvdGFibGVyYW5nZTpiYTFhMzE2MGZlZTA0MzNjOWUwNmQxNDhkMjBjMGQyNV8wLTItMS0xLTA_8c0b305d-7af2-4792-a4eb-e0a00992a5ed">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg3_dd219e64-4017-4939-86c9-d87e3d9de55b">7 Times Square, Suite 2503,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg4_2a887ddb-52c1-4c32-8b4f-649618dd6e27">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg2_b6d53951-6b85-4c98-9f9d-0c578217954c">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8zNjk_50f39422-8377-4aa1-8862-7ca35a95d60b">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8zNzM_bf62bd09-a4f7-4e8f-9de6-ece39ec353a9">(917)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgx_8d753313-6030-41c9-ab5c-d7294dd48799">438-4353</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTAtMS0xLTA_c0b4d922-ee31-4e0d-a3ad-d13e10547889">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTEtMS0xLTA_d7924ebd-1872-4e4d-ac58-4a58596352bb">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6ZmEzMThhYTQzNjdkNDU1OTlhNGJhMzkxZDQwZDJlYTYvdGFibGVyYW5nZTpmYTMxOGFhNDM2N2Q0NTU5OWE0YmEzOTFkNDBkMmVhNl8xLTItMS0xLTA_1f66ca80-55eb-40b6-b63b-7d4e83f2a840">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgy_931da8fe-54c4-48ee-a2d2-55c474943ba8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDgz_1eba7034-3cff-4c6b-8e5c-4df96a5bb3d4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV8yLTAtMS0xLTA_b2bcc90f-4aa7-4516-b207-840f80b091aa">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV8yLTYtMS0xLTA_7ecba748-8b5a-418c-8440-553e89d901dc">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGFibGU6NmYyMWVmZGJiZTcyNDZmMmI3Y2QzOGM1ZTkyMjQ4MjkvdGFibGVyYW5nZTo2ZjIxZWZkYmJlNzI0NmYyYjdjZDM4YzVlOTIyNDgyOV80LTItMS0xLTA_17661daf-76ac-4e81-86b4-0367c8fb24a1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDg5_6d75723e-2a55-49bc-b145-77f9a331e805">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1113bd5f1bec43d2af7664330b6cbdeb_I20201113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18xL2ZyYWc6N2I3ZGQ1NGU5Yjk4NDI4YjhkMmViYzg3NDM0MWM3N2YvdGV4dHJlZ2lvbjo3YjdkZDU0ZTliOTg0MjhiOGQyZWJjODc0MzQxYzc3Zl8yMDUz_142ec9da-643f-4e2d-afbb-50b2ad84f62b"
      unitRef="shares">9461978</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNC0xLTEtMS0w_bf62ef8c-513b-4045-908a-8a5b3b1eacc1"
      unitRef="usd">8203000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNC0zLTEtMS0w_17d55a6d-e631-4fe9-a02c-1aebe0ed8c42"
      unitRef="usd">7277000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNS0xLTEtMS0w_6b84d5e6-8772-4422-8fcc-4fe677fe5029"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNS0zLTEtMS0w_1bb69395-8df1-40cf-aebc-9ee96fb228e9"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gale:StockSubscriptionReceivableCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNi0xLTEtMS0w_b43af35a-e352-4ac2-8125-ce58c6549f9f"
      unitRef="usd">0</gale:StockSubscriptionReceivableCurrent>
    <gale:StockSubscriptionReceivableCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNi0zLTEtMS0w_8802c8ca-6557-4965-8c24-9d511210cf0d"
      unitRef="usd">308000</gale:StockSubscriptionReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfOS0xLTEtMS0w_1c8507a8-60c2-42b6-b756-5d8897c8d761"
      unitRef="usd">1030000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfOS0zLTEtMS0w_6dc6c76d-77ed-42cc-b78b-60874143225f"
      unitRef="usd">557000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTEtMS0xLTEtMA_0d29c454-fb6d-49cd-a8e1-46e0fa13ffe7"
      unitRef="usd">9333000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTEtMy0xLTEtMA_50f3736a-d735-4416-870a-12b471e89498"
      unitRef="usd">8242000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTMtMS0xLTEtMA_7de2089d-31f0-4e0b-a2f2-31a14c661ac6"
      unitRef="usd">911000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTMtMy0xLTEtMA_6a0d87e6-27a2-4fb8-a2c7-69d394617d87"
      unitRef="usd">217000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gale:InProcessResearchDevelopment
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTQtMS0xLTEtMA_230e33db-6712-427f-8aa5-108945e2c166"
      unitRef="usd">5700000</gale:InProcessResearchDevelopment>
    <gale:InProcessResearchDevelopment
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTQtMy0xLTEtMA_c1e7d94c-367d-4034-b609-54d7ed980b08"
      unitRef="usd">5700000</gale:InProcessResearchDevelopment>
    <us-gaap:Goodwill
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTgtMS0xLTEtMA_cc215eb8-e6bb-4a87-aaa9-3dc2b2fd1d59"
      unitRef="usd">1914000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTgtMy0xLTEtMA_c39605b4-a4b9-4811-aa7d-70b06ae82ad9"
      unitRef="usd">1914000</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTktMS0xLTEtMA_7b5963e1-fcdc-4309-9a6e-ccd0c226e3b9"
      unitRef="usd">651000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMTktMy0xLTEtMA_567575f6-1bf1-4211-aa90-2201bdb87958"
      unitRef="usd">536000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjAtMS0xLTEtMA_6d4ca4b0-d3d2-4589-a7b4-7581454e9a4c"
      unitRef="usd">18509000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjAtMy0xLTEtMA_9ec971d2-f54d-4179-a03f-e5350e558cf4"
      unitRef="usd">16609000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjUtMS0xLTEtMA_6da6b234-2c19-4c11-abcb-fd12fb105a8b"
      unitRef="usd">1779000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjUtMy0xLTEtMA_bdb8053e-c35a-43bb-bbb4-e14b04a41705"
      unitRef="usd">3902000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjYtMS0xLTEtMA_a72c2424-4b81-4ce5-b01e-9d1dd3a4c850"
      unitRef="usd">2304000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjYtMy0xLTEtMA_ce91e1ad-ff01-4e5e-8740-b092adb120ad"
      unitRef="usd">1171000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjgtMS0xLTEtMA_fda35c57-89b0-4706-9212-8c683bf618b4"
      unitRef="usd">136000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMjgtMy0xLTEtMA_2510148e-7158-45af-a26d-27ba5e3e7319"
      unitRef="usd">217000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzAtMS0xLTEtMA_257fb5f4-06b6-4196-b270-d6544c9963d2"
      unitRef="usd">4219000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzAtMy0xLTEtMA_83102525-0a09-48b5-8b15-7e36d5d955a3"
      unitRef="usd">5290000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzItMS0xLTEtMA_56eac3fa-a7c2-4123-b7a3-d5512e22fe99"
      unitRef="usd">873000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzItMy0xLTEtMA_39837a8a-0f45-468b-aacf-fe768b062871"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzMtMS0xLTEtMA_ba67cecc-e35b-4462-bba1-51381ccc663b"
      unitRef="usd">262000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzMtMy0xLTEtMA_c533992f-c921-4964-9835-756fb7a0b746"
      unitRef="usd">262000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzQtMS0xLTEtMA_00e1695c-48e7-461f-a5d8-7c136a4438e5"
      unitRef="usd">27000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzQtMy0xLTEtMA_33ec6f3a-f149-482a-a9e2-dadc2675e0e6"
      unitRef="usd">52000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzUtMS0xLTEtMA_e217603c-7de7-4f06-b712-72932f6eee08"
      unitRef="usd">5180000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
    <gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzUtMy0xLTEtMA_5ff53f11-cfb5-4347-b451-72024aa8d9ca"
      unitRef="usd">4912000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
    <us-gaap:Liabilities
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzctMS0xLTEtMA_531933cb-aaf3-46e3-a866-3ec813f95789"
      unitRef="usd">10561000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzctMy0xLTEtMA_8782d817-43cd-4279-bb4f-76e71dec6692"
      unitRef="usd">10516000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzgtMS0xLTEtMA_f18ef9c9-bdaa-4d25-afa9-27f28aa63e10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfMzgtMy0xLTEtMA_d72ecdd4-efc1-4d6c-8b4a-a7b9ead3540a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzIx_3fa190ed-5827-4edd-baf4-6de6d6de08b5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzIx_ad007fac-c7ab-4b67-aaf5-03ed9349e697"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzM1_68263aff-7b39-4a2a-914b-23100ecefb2c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzM1_f56dddfd-4bff-4911-8b69-5e77d31430e2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic022585050ae4612867b99cbfb4d849b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5Xzk1_4e82cfa8-0fbd-481f-88f5-c86fa4367e80"
      unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i25a23f1f812448a1b0e6a3596e39276e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5Xzk1_9eddf659-5fbc-4e77-aac4-b55f15080c65"
      unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_18589039-3179-4901-bb2b-ea6cbec8f340"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_5067728e-1363-42d7-b37c-bd4e67ab21d6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_74387790-42c5-4b2f-aec7-9997676160e2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjRkOTRmYmJjMzkxMjRiNDRiNjM0YzI0NzcwNzVkZTc5XzExNw_d76b1fb3-ba9c-4d55-8f8f-ee62cda33c0d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMS0xLTEtMA_a258bb94-a578-49d5-b0ad-26722279af5d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDAtMy0xLTEtMA_3c6cbe7e-74c2-4286-9f47-9d2db786d2ff"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzE4_3e5606d0-5099-42e4-8bc0-fad4aeba2a46"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzE4_6d987b1d-766b-47fc-a67a-9049c267ca50"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzMy_778293af-ee5f-4999-92b3-dd0dd8423859"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzMy_bafe24b4-ca6f-49d3-a3fb-91284fcea299"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzU0_1b0a90fa-8bd4-4830-b082-1d85c6cccc3c"
      unitRef="shares">9461978</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzU0_68f3ee4f-14d6-4674-a82e-4d4572b5fb51"
      unitRef="shares">9461978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzYx_0c94f830-22bd-404f-87fb-628a9394d8e7"
      unitRef="shares">5080100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjZmNGMxYzBkMDZiYTQ0MWFhNTU3Y2NjNDcwMzhiYjgwXzYx_94523b26-6346-4837-beb7-5281db1502ce"
      unitRef="shares">5080100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMS0xLTEtMA_438d42e8-86b2-428f-ad2e-f0df0c4ab63a"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDEtMy0xLTEtMA_6c0cedf4-630d-4b5c-bedd-59fe81b34c2c"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDItMS0xLTEtMA_98a33377-fbed-4a61-b6dd-f065cf64a677"
      unitRef="usd">122126000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDItMy0xLTEtMA_1897dfee-b402-4aa4-93fe-9b191abacaad"
      unitRef="usd">107235000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDMtMS0xLTEtMA_bf00b6ad-df73-4090-afbc-348e2d0e98c3"
      unitRef="usd">-114188000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDMtMy0xLTEtMA_9126a050-cadc-41d5-8337-d773ca636afe"
      unitRef="usd">-101147000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDUtMS0xLTEtMA_cbf26994-f89b-4197-9216-92b78dbb4209"
      unitRef="usd">7948000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDUtMy0xLTEtMA_1725353a-2096-4861-9970-e03ae6b41f29"
      unitRef="usd">6093000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDYtMS0xLTEtMA_eaf3f9c0-2ae2-4eea-8da6-d1c9c9c8c52c"
      unitRef="usd">18509000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yMi9mcmFnOmZlMmU3NDU2MzgxOTQ5NDk5MDM2ODYzMmUyYmZjZmQ5L3RhYmxlOjE0OWM5Nzg0NDIzOTRlMTI5NWUzNWY5NWYxZDJjYWQ5L3RhYmxlcmFuZ2U6MTQ5Yzk3ODQ0MjM5NGUxMjk1ZTM1Zjk1ZjFkMmNhZDlfNDYtMy0xLTEtMA_57d487dd-de3e-4fac-8279-c834c3fe271d"
      unitRef="usd">16609000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS0xLTEtMS0w_910b0fbf-ed26-4410-8c8f-2d61ec72c47b"
      unitRef="usd">2367000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS0zLTEtMS0w_50a9b687-2a2e-4b8a-83c4-a051c4d57cbb"
      unitRef="usd">1799000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS01LTEtMS0w_45cab6f1-1793-44f9-a36b-dbeba9110944"
      unitRef="usd">6511000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNS03LTEtMS0w_e185d76b-7a26-48bb-b86a-0bdcde2e2a2f"
      unitRef="usd">5039000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi0xLTEtMS0w_72ce2cd6-7ebd-4a4e-8688-3c12f95d0ce4"
      unitRef="usd">2125000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi0zLTEtMS0w_c6de680a-3b3d-4344-aec4-79d8ffc6daf5"
      unitRef="usd">2385000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi01LTEtMS0w_b819bbeb-8fc9-4abd-be34-374e03318732"
      unitRef="usd">6312000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfNi03LTEtMS0w_7c8de975-6230-41dc-8d12-bfdcf5b32625"
      unitRef="usd">7523000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC0xLTEtMS0w_283dbc5c-4414-444a-b8c5-4c11af238309"
      unitRef="usd">4492000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC0zLTEtMS0w_a4aac67a-4431-44c3-8c2a-f31be7cb77c9"
      unitRef="usd">4184000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC01LTEtMS0w_e4f13850-20e5-413c-b600-7a4f7ef4f773"
      unitRef="usd">12823000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfOC03LTEtMS0w_43fd545a-a427-4264-b2c6-14c4e86b76da"
      unitRef="usd">12562000</us-gaap:CostsAndExpenses>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItMS0xLTEtMA_5494fe2e-1ada-40d2-aea4-d1cd3013dfa4"
      unitRef="usd">-6000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItMy0xLTEtMA_b737cfd3-a8e0-4e9e-bb38-e518a7cdf397"
      unitRef="usd">49000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItNS0xLTEtMA_8474c5df-86b3-4308-9e0a-7b2c6d557ce4"
      unitRef="usd">-25000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTItNy0xLTEtMA_cf476927-6d09-47c7-8272-f9e1c7434425"
      unitRef="usd">-1108000</us-gaap:FairValueAdjustmentOfWarrants>
    <gale:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtMS0xLTEtMA_f186f57f-251b-4974-bbec-68b8ac1f56af"
      unitRef="usd">13000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <gale:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtMy0xLTEtMA_05a35ed0-9f25-4e84-8771-093c04c76a7a"
      unitRef="usd">-28000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <gale:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtNS0xLTEtMA_73908220-d38f-4a46-b122-921fb445c619"
      unitRef="usd">-268000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <gale:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTQtNy0xLTEtMA_be9b9817-b744-4493-a364-ddc6f3358956"
      unitRef="usd">-510000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctMS0xLTEtMA_af04a3f5-3d2f-4bb7-8f32-1582f890c6df"
      unitRef="usd">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctMy0xLTEtMA_3627e5ed-c4ba-46ae-9095-0a62d569dfef"
      unitRef="usd">59000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctNS0xLTEtMA_ad9b99be-5307-4de9-a587-fae06efd7628"
      unitRef="usd">25000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTctNy0xLTEtMA_2df1e006-4244-4ea5-8764-be8110bc1a35"
      unitRef="usd">91000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtMS0xLTEtMA_2701c1a9-fcc3-4340-aa6e-72d2fd076499"
      unitRef="usd">19000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtMy0xLTEtMA_c1f9d275-0c07-4f5d-ba2e-8409cad582c0"
      unitRef="usd">-18000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtNS0xLTEtMA_7cfbb2b0-494a-4ec6-89d9-4972db8783bb"
      unitRef="usd">-218000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMTgtNy0xLTEtMA_d2713fb4-5181-4253-a12e-c561ca808d50"
      unitRef="usd">689000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtMS0xLTEtMA_2fa24e86-59af-4f39-ad5d-3eb592cd1fa9"
      unitRef="usd">-4473000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtMy0xLTEtMA_346a3711-2e69-4e1c-92a8-58d02f7b561d"
      unitRef="usd">-4202000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtNS0xLTEtMA_1ba65774-7211-42b3-946a-021b4a9ab36b"
      unitRef="usd">-13041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjQtNy0xLTEtMA_f053c6ce-e534-4d41-97f1-e31817d7ba2e"
      unitRef="usd">-11873000</us-gaap:NetIncomeLoss>
    <gale:DividendArisingFromWarrantModifications
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctMS0xLTEtMA_9e9b78d3-97a3-434d-8250-e68ea5bada13"
      unitRef="usd">0</gale:DividendArisingFromWarrantModifications>
    <gale:DividendArisingFromWarrantModifications
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctMy0xLTEtMA_bf29295e-7e05-4d6e-b60e-f47df7e400a1"
      unitRef="usd">7268000</gale:DividendArisingFromWarrantModifications>
    <gale:DividendArisingFromWarrantModifications
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctNS0xLTEtMA_eb9f045f-60ef-43cb-8fa7-e1eafdba9edf"
      unitRef="usd">78000</gale:DividendArisingFromWarrantModifications>
    <gale:DividendArisingFromWarrantModifications
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjctNy0xLTEtMA_4f2bd440-51ed-4cf9-8982-53691d102d43"
      unitRef="usd">8659000</gale:DividendArisingFromWarrantModifications>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtMS0xLTEtMA_723e25d0-e6c9-46cc-b6c2-dd9550385005"
      unitRef="usd">-4473000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtMy0xLTEtMA_b47a8e48-b38b-4dc0-8717-e2079e7742c2"
      unitRef="usd">-11470000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtNS0xLTEtMA_d5d2ed8c-3063-4553-bd05-413df9157062"
      unitRef="usd">-13119000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMjgtNy0xLTEtMA_b0eae681-a0e5-4c45-b456-ae170c3327c4"
      unitRef="usd">-20532000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtMS0xLTEtMA_1a2b477f-574e-42ae-a36f-9ff8670cb825"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtMy0xLTEtMA_45fa6cfe-d32e-46b3-8dd2-cf23f215834a"
      unitRef="usdPerShare">-2.68</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtNS0xLTEtMA_fbdbcc70-790c-4eb4-baae-58ebc100e53f"
      unitRef="usdPerShare">-1.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzMtNy0xLTEtMA_6ea443b9-a28a-4731-9ee9-beb8b1814a03"
      unitRef="usdPerShare">-11.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtMS0xLTEtMA_c80ec630-c255-4fdd-ad89-129e0c36d573"
      unitRef="shares">8418038</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtMy0xLTEtMA_ff5d74a0-2004-4605-8585-d9646c0725cd"
      unitRef="shares">4281855</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtNS0xLTEtMA_60ed6bae-c335-4f33-a92e-00309011fef2"
      unitRef="shares">7174859</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yNS9mcmFnOjdiZjIxMTI3ZDVmYjQwMmE4MDZlYTUyY2JjYTdlZTIwL3RhYmxlOjQ1ZWJkYTVjN2FlYjRiODhiZGRhNzczMDYxMDc1MWUyL3RhYmxlcmFuZ2U6NDVlYmRhNWM3YWViNGI4OGJkZGE3NzMwNjEwNzUxZTJfMzQtNy0xLTEtMA_9d988c55-e211-4edd-aa05-5042ea981d51"
      unitRef="shares">1805773</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i88e0e8582c5944e28e652902589c2bc8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xLTEtMS0w_4d369c65-21e7-4847-8dfd-13995dccd1d4"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88e0e8582c5944e28e652902589c2bc8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0zLTEtMS0w_3db2bd2b-5b83-499c-a811-13e42b369090"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i1d8e37103bd64af1b9cc06f485522288_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy01LTEtMS0w_38d6295f-c4c3-43cd-9e53-bea2362c411b"
      unitRef="shares">6717900</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d8e37103bd64af1b9cc06f485522288_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy03LTEtMS0w_d2e0b653-129b-4f8a-ba8e-d226b5f3029e"
      unitRef="usd">7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1497135158547e98a1d099f75b92b6c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy05LTEtMS0w_3ab36bb5-6872-47a0-9a79-c8fe6b41ac22"
      unitRef="usd">113491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i017b702a13f64d4b98692ac37c6a1053_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xMS0xLTEtMA_ae92d7a2-5dd9-4e67-9185-edc782c0684a"
      unitRef="usd">-109715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia609730176c14fdab04d34b43a971355_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMy0xNS0xLTEtMA_b2457fbd-08d7-4253-9140-07aa73ab8b1d"
      unitRef="usd">3783000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gale:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC01LTEtMS0w_83834b70-f98c-442c-8908-30eb7b21cc86"
      unitRef="shares">2744078</gale:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="ie9971bd64ee244a9923e6376e30c4e54_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC03LTEtMS0w_2e2aa167-2541-42bf-8d2e-8ea11c9e8f88"
      unitRef="usd">3000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC05LTEtMS0w_1420bd87-09ae-4e1d-9998-4e1951073231"
      unitRef="usd">8489000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfNC0xNS0xLTEtMA_e2587cbd-35df-49fe-95ea-e65be427f5d7"
      unitRef="usd">8492000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc5f7643d04845a99ba73b35ae6c874f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfOS05LTEtMS0w_4b3c3ae4-3a15-4ff2-b063-4e9ee0b54794"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfOS0xNS0xLTEtMA_6bec51e2-b087-4be6-bad7-9242b585a66f"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i6c1db2db5213477e963d08ffc4069d65_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTAtMTEtMS0xLTA_35b8ee16-408a-4673-b3f8-9de7e611a165"
      unitRef="usd">-4473000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTAtMTUtMS0xLTA_dbde16d3-3fa5-45bd-825b-959dda62ec1b"
      unitRef="usd">-4473000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i17705d1efab94dde907052dd981f02a0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMS0xLTEtMA_b4b10813-8be1-4eeb-8f5b-c090ee0c2745"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17705d1efab94dde907052dd981f02a0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMy0xLTEtMA_a5210feb-5702-41c1-b3b1-8d67fb679122"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtNS0xLTEtMA_ac517912-dfc8-4e96-9265-29603a56c0e9"
      unitRef="shares">9461978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtNy0xLTEtMA_03f1a60a-b582-4d6d-81a0-1c2cbf8b9cf4"
      unitRef="usd">10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i448e315df994429faf64be5d9e92cab2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtOS0xLTEtMA_3df87d9a-a963-4e02-8522-3807efd4bf63"
      unitRef="usd">122126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic676874210a241b0962cf4ef4c61a42c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMTEtMS0xLTA_88209505-37bf-48de-b67e-ed0b5cc9438b"
      unitRef="usd">-114188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTEtMTUtMS0xLTA_957c333d-0f2e-40c5-bdf8-b898ffe954cc"
      unitRef="usd">7948000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifef9e512b2a5468ebe07f8b90a06af96_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMS0xLTEtMA_162c112d-ac34-40cf-9415-ac41a76787be"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifef9e512b2a5468ebe07f8b90a06af96_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMy0xLTEtMA_5bd24dd2-6492-423f-b363-973bcbe1e9b6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i81b1bd6d180f405fa9db296c77b6ed97_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtNS0xLTEtMA_a28956d7-41c7-4c1d-8f4e-348001bb399e"
      unitRef="shares">5080100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81b1bd6d180f405fa9db296c77b6ed97_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtNy0xLTEtMA_3ab8fb22-25b8-4a1f-bac0-bce8c3c4a1be"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if021b546b0cf4d20ba09dbffea09d212_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtOS0xLTEtMA_118eae40-bcb1-45ae-a915-68b1d75a3d48"
      unitRef="usd">107235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4efe31e6a2740e2a47f900a8411a6ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMTEtMS0xLTA_de4f1925-ebac-4f11-9602-d0e5f18de29e"
      unitRef="usd">-101147000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTYtMTUtMS0xLTA_6b0b6721-dd6a-4c14-9810-d0b754d12dbc"
      unitRef="usd">6093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gale:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctNS0xLTEtMA_6f80c985-e864-44bb-9960-6f7fc79814cf"
      unitRef="shares">3933078</gale:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctNy0xLTEtMA_651d1809-d350-4ac7-9fd5-6cecf771bd57"
      unitRef="usd">4000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctOS0xLTEtMA_228dacea-0d66-4ad9-86a5-0ad518cfc46b"
      unitRef="usd">14451000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMTctMTUtMS0xLTA_2daa0c22-eb1a-4267-ba61-8943c0658c8c"
      unitRef="usd">14455000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodSharesPrefundedWarrant
      contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtNS0xLTEtMA_e6304003-e9b4-462d-af40-3d264f8ae973"
      unitRef="shares">448800</gale:StockIssuedDuringPeriodSharesPrefundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="ibc0a1c1bb65f49a8955046b87e3565dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtNy0xLTEtMA_db124974-ca10-41e1-a754-3a272ed2643d"
      unitRef="usd">1000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtOS0xLTEtMA_4fbd67ae-a299-4aad-91fc-8c3a12f023e2"
      unitRef="usd">3000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzMtMTUtMS0xLTA_d02498cd-3d9f-4a94-89ca-23a8bb5de257"
      unitRef="usd">4000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81950c0ae1814f36a6d6d9500806ad53_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzYtOS0xLTEtMA_8b031597-ada2-4c22-88a9-fdf1fabfb2ab"
      unitRef="usd">437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzYtMTUtMS0xLTA_b1cb72b2-2fad-441a-80df-22ad8b3c36cf"
      unitRef="usd">437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzctMTUtMS0xLTI5NA_ac28e83e-43d1-44a2-9c82-71d9d6e42f7f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="ic656a9beca124dbd893b34aa5140bd0a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzgtMTEtMS0xLTA_61055b74-755c-4eb3-b847-2a6bfd728e24"
      unitRef="usd">-13041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzgtMTUtMS0xLTA_6cfa9cbc-7944-44ad-9768-5f71ed040cfb"
      unitRef="usd">-13041000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i17705d1efab94dde907052dd981f02a0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMS0xLTEtMA_559f0ee7-0a4d-412c-925f-e03391965202"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17705d1efab94dde907052dd981f02a0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMy0xLTEtMA_3e0703eb-bc13-444f-9ef7-1ddef76f48d3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktNS0xLTEtMA_b6f294b9-969f-434e-b275-ed554670b47c"
      unitRef="shares">9461978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i645c600a848a471a83b9b22bb3e706b1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktNy0xLTEtMA_253e70c1-6f7e-4f23-a7c1-849ae4381227"
      unitRef="usd">10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i448e315df994429faf64be5d9e92cab2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktOS0xLTEtMA_e90cb9ba-8bc3-4cb6-9659-f7b821bbefc6"
      unitRef="usd">122126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic676874210a241b0962cf4ef4c61a42c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMTEtMS0xLTA_8f77f039-9c8c-4232-8e2e-3d64ce670907"
      unitRef="usd">-114188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjE2ZDU4MTQ1NWU3MTQwOGQ5NWEzYTdlZGExM2E4MjU0L3RhYmxlcmFuZ2U6MTZkNTgxNDU1ZTcxNDA4ZDk1YTNhN2VkYTEzYTgyNTRfMzktMTUtMS0xLTA_302b58a6-94b4-4a5e-9e89-4e2b4b95a3fc"
      unitRef="usd">7948000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ic98a9c1849c14b238f015a559fd03855_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xLTEtMS0w_81bb5c0b-66c7-469a-99c1-85c59d105808"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic98a9c1849c14b238f015a559fd03855_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0zLTEtMS0w_819cbaa4-cdff-4434-a5bf-a15603f28402"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iae50a7116a1f45c48a4530ec81fdf221_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC01LTEtMS0w_86dc2414-4bc2-4c27-ab12-0f2257718cfe"
      unitRef="shares">2002702</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae50a7116a1f45c48a4530ec81fdf221_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC03LTEtMS0w_821efd05-7970-4ca4-ae3a-4696890ce8c4"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d096b69f27a4dc9b506bd230ab72aa2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC05LTEtMS0w_ed6bdbd1-4967-4522-9c3b-f8e8d1016a38"
      unitRef="usd">103862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd470f4d5da4812aa588bd34055fd56_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xMS0xLTEtMA_f974273a-95cb-48f3-9d0a-78ebc688b85a"
      unitRef="usd">-89526000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8251699c639640ee881bf02c2e33e139_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNC0xNS0xLTEtMA_10eb2def-ddea-45b1-a787-ad651b0e3b4d"
      unitRef="usd">14338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gale:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS01LTEtMS0w_100f71e1-7988-4cf1-9da4-f4f0df7b7c26"
      unitRef="shares">2032950</gale:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS03LTEtMS0w_24ba331e-dfff-4da3-8bfb-fe5d695efc2c"
      unitRef="usd">2000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS05LTEtMS0w_161584b4-330a-49f5-8db3-5a9c24622916"
      unitRef="usd">381000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNS0xNS0xLTEtMA_ff2f2b1c-7610-4f01-a90c-6e66218b0fb1"
      unitRef="usd">383000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodSharesPrefundedWarrant
      contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtNS0xLTEtMA_d46c2948-b70e-445e-993e-e2094bc62598"
      unitRef="shares">513326</gale:StockIssuedDuringPeriodSharesPrefundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtNy0xLTEtMA_5f48ca85-80af-4445-93bc-ebcf15b4a98e"
      unitRef="usd">1000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtOS0xLTEtMA_6e35418a-ea1c-4d27-8f17-be5c5e85a773"
      unitRef="usd">2000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTgtMTUtMS0xLTA_7f04c7b1-14fb-4e6b-8073-9151746b62a3"
      unitRef="usd">3000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ifa6b0c82be804b7a917e3e7ea0f7088e_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktNS0xLTEtNTc_37e67062-b642-4fef-b311-a1a3f612c225"
      unitRef="shares">230</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktMTUtMS0xLTU3_e37aea47-2bf9-412a-a160-9f93e49d5028"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i07a600cf08574dc0be53478d2cb53e0d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktOS0xLTEtMA_f2da9f93-0ca9-4b33-8d8b-0838fcc4786a"
      unitRef="usd">115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMTktMTUtMS0xLTA_c798e7a3-f462-4234-b44a-d4754c18a4a5"
      unitRef="usd">115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i333c91c266364b2eae464c53a8817f07_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjEtMTEtMS0xLTA_70d5288e-9aae-4eff-a736-861ef8a4dc72"
      unitRef="usd">-4202000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjEtMTUtMS0xLTA_66351b84-b0a6-4ca1-8364-f4e064654a6a"
      unitRef="usd">-4202000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMS0xLTEtMA_1cfb4bf0-d63e-47a3-be5b-520462711cb1"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMy0xLTEtMA_686ea433-5976-453f-bba2-6c99cd0cc60a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItNS0xLTEtMA_958975e1-fdad-4499-8225-539ed13e755b"
      unitRef="shares">4549208</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItNy0xLTEtMA_8117075f-1e0d-4714-a7a4-7f67824dbe0f"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7750e980bf85451d98229836daffbd55_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItOS0xLTEtMA_bd1d4778-3351-44e1-bc46-0f7793e4e22e"
      unitRef="usd">104360000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMTEtMS0xLTA_715e82b4-5558-4c8b-9496-d980543e1277"
      unitRef="usd">-93728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3865ec252344ced80fdda5644983129_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjItMTUtMS0xLTA_5fc98de2-b8eb-49db-9a0e-4a942a5fe35e"
      unitRef="usd">10637000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i12900c59fe2a4ff096fd101b525adf14_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMS0xLTEtMA_f4f477dd-0a5b-4cc8-8f2e-739b34afbd57"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12900c59fe2a4ff096fd101b525adf14_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMy0xLTEtMA_4a9c2429-1902-4a48-894c-ed1e7eb876eb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i86b2f91724d24900ac8e54e3b467f7f3_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctNS0xLTEtMA_395c139e-8c5b-4eb7-8a49-fca30d47e18c"
      unitRef="shares">440529</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86b2f91724d24900ac8e54e3b467f7f3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctNy0xLTEtMA_8d9f9653-c8af-495f-acc4-4e37c10756ec"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84f75e0d3fed4888b7432f8ab49025d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctOS0xLTEtMA_d9bc1b0c-eb57-471b-87f6-33709ab1ad5f"
      unitRef="usd">87099000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35b97499a01c4bbd86d34124af212071_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMTEtMS0xLTA_cd084bc1-be0c-464f-9fa8-b2e07f026846"
      unitRef="usd">-81855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8205cb47ed594c60af87958ca345c78a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjctMTUtMS0xLTA_e4dd9f6a-178d-4fec-a5b5-5255a1dc094f"
      unitRef="usd">5245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gale:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtNS0xLTEtMA_de99908c-44cb-4677-bf41-b481af9e383b"
      unitRef="shares">527344</gale:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtOS0xLTEtMA_17a32be4-da50-4e4e-800d-98c406668545"
      unitRef="usd">13416000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <gale:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfMjgtMTUtMS0xLTA_a772a156-84a1-4f74-b9ae-a2ab6c0543b7"
      unitRef="usd">13416000</gale:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtNS0xLTEtMA_1bb683da-40d2-44a3-8fef-f566200d6d65"
      unitRef="shares">2095949</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtNy0xLTEtMA_790a36b4-33fb-4143-a953-c4715b4b1249"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtOS0xLTEtMA_c0cf5e6d-5fb6-471c-80bc-9de087b2c59b"
      unitRef="usd">3656000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDEtMTUtMS0xLTA_3e637b15-2fb0-4321-916e-a52a073d2d16"
      unitRef="usd">3658000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <gale:StockIssuedDuringPeriodSharesPrefundedWarrant
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItNS0xLTEtMA_1fa4e4a7-3f17-4847-ac62-4b47fbc7e9fe"
      unitRef="shares">1485156</gale:StockIssuedDuringPeriodSharesPrefundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItNy0xLTEtMA_643d730c-c0bf-4022-b10d-76cdb8c310f1"
      unitRef="usd">2000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItOS0xLTEtMA_9fcc665a-f4af-4374-89e2-b24ff2906d81"
      unitRef="usd">6000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <gale:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDItMTUtMS0xLTA_794ec22d-83f1-40c5-9765-cf4ad8687c5e"
      unitRef="usd">8000</gale:StockIssuedDuringPeriodValuePreFundedWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i900639ff1cf64eea8ce2f19b215bdc56_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtNS0xLTEtNTA_693669a8-894f-439c-a4b9-3a80a2c5a9bd"
      unitRef="shares">230</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtMTUtMS0xLTUw_5deed578-5b20-4ce3-8713-1df91893a911"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtOS0xLTEtMA_e0847f01-62bb-4cd2-af2c-a565d28d2955"
      unitRef="usd">426000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDMtMTUtMS0xLTA_1e3a02cc-b150-439b-8cf9-2d72f6fe63d4"
      unitRef="usd">426000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <gale:DividendModificationOfWarrants
      contextRef="i32e0e5fddfaa4cd59299b6487a892b44_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDUtOS0xLTEtMA_16015042-90b5-4e1f-8d4f-5bf8c76167a3"
      unitRef="usd">243000</gale:DividendModificationOfWarrants>
    <gale:DividendModificationOfWarrants
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDUtMTUtMS0xLTA_2189a202-d0da-4b50-a595-40d094e30986"
      unitRef="usd">243000</gale:DividendModificationOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="ifad85cecbb6d478c84dd680e20b243d9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDYtMTEtMS0xLTA_9127ada0-9749-46c3-8c18-94704085f128"
      unitRef="usd">-11873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDYtMTUtMS0xLTA_080ded35-3e79-48c0-bc42-6da5ce6a5819"
      unitRef="usd">-11873000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMS0xLTEtMA_11e4a701-16de-4c39-9180-45ecb7a38b0b"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i789a0f37c09142ab985c13adff90f7a2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMy0xLTEtMA_90298eca-0845-4536-bfb5-d90d1f25aa0f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctNS0xLTEtMA_5a7a6a5b-8822-40fa-9fc3-600ed2aae8c8"
      unitRef="shares">4549208</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e733b367c614849b02a9fd90805dcb2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctNy0xLTEtMA_b76643e9-733c-4a41-affd-232cb842257b"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7750e980bf85451d98229836daffbd55_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctOS0xLTEtMA_54e914b2-90b5-4fcf-8357-210006b914d7"
      unitRef="usd">104360000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bfe31b82e994d5fb3fd1716c8bc1487_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMTEtMS0xLTA_a498e6d6-6016-4277-8f21-46dcbca0cc5d"
      unitRef="usd">-93728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3865ec252344ced80fdda5644983129_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18yOC9mcmFnOjhlNWYwMjBlNDc2NjQ5OWFiOGE0N2I5OTQwODU5MDUzL3RhYmxlOjM3MWU1MzJmZTk0YjRmNjk4ZmZlY2JiOTQzZjM5MjBjL3RhYmxlcmFuZ2U6MzcxZTUzMmZlOTRiNGY2OThmZmVjYmI5NDNmMzkyMGNfNDctMTUtMS0xLTA_b1642e4b-82d6-4e5d-a44e-fcf2516ce541"
      unitRef="usd">10637000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMy0xLTEtMS0w_301c9c12-9c0a-467e-83c7-9755c8073b69"
      unitRef="usd">-13041000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMy0zLTEtMS0w_691257aa-ad1d-41e8-95a0-bb4aea49b341"
      unitRef="usd">-11873000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTUtMS0xLTEtMA_2e379468-21de-49d2-8e91-a1f5c21b5a3a"
      unitRef="usd">437000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTUtMy0xLTEtMA_aadc0798-beb0-4168-a6d7-2cf8e6e2aa6f"
      unitRef="usd">426000</us-gaap:ShareBasedCompensation>
    <gale:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTYtMS0xLTEtMA_178bbf69-fd69-496a-b147-0da561f95576"
      unitRef="usd">98000</gale:ChangeInOperatingLeaseRightOfUseAssets>
    <gale:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMTYtMy0xLTEtMA_efec3e80-5ae7-4a57-bb57-5a2ee1a249ef"
      unitRef="usd">0</gale:ChangeInOperatingLeaseRightOfUseAssets>
    <gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjAtMS0xLTEtMA_fa1d1351-aba0-4652-882e-fb8df05c63b3"
      unitRef="usd">25000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
    <gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjAtMy0xLTEtMA_acae6ade-2ad3-47ca-b8ff-55a52771753f"
      unitRef="usd">1108000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
    <gale:ChangeInFairValueOfContingentPurchaseConsideration
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjItMS0xLTEtMA_13857269-1593-4082-a120-6606295115df"
      unitRef="usd">-268000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
    <gale:ChangeInFairValueOfContingentPurchaseConsideration
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjItMy0xLTEtMA_4a772e29-7ee9-44ce-b1ea-c4702a64a98e"
      unitRef="usd">-510000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjctMS0xLTEtMA_ff5d4ca2-0dc6-4842-921c-7f36aeb88d0c"
      unitRef="usd">588000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMjctMy0xLTEtMA_d43f83f8-9250-4b6c-b131-3267b8e38c00"
      unitRef="usd">480000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzAtMS0xLTEtMA_4eb19e78-11ad-4d70-ba2d-b280435425be"
      unitRef="usd">-2123000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzAtMy0xLTEtMA_a7ccc05a-7457-4076-af3f-f1117f62c73e"
      unitRef="usd">-227000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzEtMS0xLTEtMA_c12d7585-4bf7-4196-9b4c-32da5f336a3b"
      unitRef="usd">1133000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzEtMy0xLTEtMA_ad070146-a7fb-4788-bdd5-f39e7b13643b"
      unitRef="usd">-715000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzgtMS0xLTEtMA_ef499a90-e2a3-45b2-b478-3a0490456958"
      unitRef="usd">-13841000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfMzgtMy0xLTEtMA_9c911be2-ba00-4d5e-925e-e5065ec79ed8"
      unitRef="usd">-13467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTMtMS0xLTEtMA_098ac3c4-1ff5-4596-8dd2-fec2df56076e"
      unitRef="usd">14455000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTMtMy0xLTEtMA_211ae15e-788a-413b-aab6-b3219bb12e37"
      unitRef="usd">13652000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <gale:ProceedsFromStockSubscriptionReceivable
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTUtMS0xLTEtMA_414e58c0-8f03-41e3-abd3-3a38d6a11d1f"
      unitRef="usd">308000</gale:ProceedsFromStockSubscriptionReceivable>
    <gale:ProceedsFromStockSubscriptionReceivable
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTUtMy0xLTEtMA_455653ab-b768-414a-acba-3db89d76cd79"
      unitRef="usd">0</gale:ProceedsFromStockSubscriptionReceivable>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTYtMS0xLTEtMA_8ecc46f8-8e93-4b43-a6fa-1f4bd4ff9444"
      unitRef="usd">4000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNTYtMy0xLTEtMA_36e2ccaf-3978-4d2d-b616-91236a944a55"
      unitRef="usd">3598000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjQtMS0xLTEtMA_c3d79d11-6042-448d-8b7a-a3063ae6a9b9"
      unitRef="usd">14767000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjQtMy0xLTEtMA_8b7614e6-6329-4062-aed0-a9bd6584a33a"
      unitRef="usd">17250000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjUtMS0xLTEtMA_606262b5-5f2a-466b-a145-4e4c6cc3ed6e"
      unitRef="usd">926000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjUtMy0xLTEtMA_675dd142-d868-4b9c-a3ef-75ed866b2782"
      unitRef="usd">3783000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjYtMS0xLTEtMA_562961f0-6d43-48ac-aecf-985d39715019"
      unitRef="usd">7377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8205cb47ed594c60af87958ca345c78a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjYtMy0xLTEtMA_87dc18e6-6050-4a47-b428-4eb00f381523"
      unitRef="usd">5451000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjctMS0xLTEtMA_854f424b-b56e-4cde-afe1-d0ffe973f0f5"
      unitRef="usd">8303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if3865ec252344ced80fdda5644983129_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNjctMy0xLTEtMA_f36e6124-52c2-4aaa-817c-8be5e4c54018"
      unitRef="usd">9234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNzAtMS0xLTEtMA_19ffeebd-ccf3-4b87-8a53-52bddaaaea6e"
      unitRef="usd">25000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfNzAtMy0xLTEtMA_b6d7c3fa-2d9f-4221-b323-d0725be88e23"
      unitRef="usd">87000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODAtMS0xLTEtMA_8d2d570f-6895-4c3d-a64d-1c9395857535"
      unitRef="usd">976000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODAtMy0xLTEtMA_9a918fd9-b72d-4ced-9fb1-d4d2ce012731"
      unitRef="usd">550000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <gale:IncreaseDecreaseInFairValueOfWarrantLiability
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODEtMS0xLTEtMA_c8bd9de2-c6f7-435f-a1a1-5069f0930dec"
      unitRef="usd">0</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
    <gale:IncreaseDecreaseInFairValueOfWarrantLiability
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODEtMy0xLTEtMA_fff46728-ca20-45f6-a641-d281a63899f4"
      unitRef="usd">243000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
    <gale:NoncashOfferingExpense
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODItMS0xLTEtMA_0820db9d-1ace-45d0-93f1-4b3731786ce6"
      unitRef="usd">0</gale:NoncashOfferingExpense>
    <gale:NoncashOfferingExpense
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODItMy0xLTEtMA_01049cf9-fd11-494f-9f63-3510598cebd1"
      unitRef="usd">236000</gale:NoncashOfferingExpense>
    <gale:ReclassificationOfWarrantLiabilityUponExercise
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODQtMS0xLTEtMA_0443a0ad-dd23-44ae-b037-526ed79311af"
      unitRef="usd">0</gale:ReclassificationOfWarrantLiabilityUponExercise>
    <gale:ReclassificationOfWarrantLiabilityUponExercise
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zMS9mcmFnOjRiN2JhYzg5NzNmYzQ4NGU5N2QyOWI3MGRhMTkyNDQ4L3RhYmxlOjVkOGNlNzRhM2QyYjRlNDc5OWEyZmUyNTIyZmE3NTQ4L3RhYmxlcmFuZ2U6NWQ4Y2U3NGEzZDJiNGU0Nzk5YTJmZTI1MjJmYTc1NDhfODQtMy0xLTEtMA_7e19d762-39ad-474a-9f3c-89ddad732f37"
      unitRef="usd">68000</gale:ReclassificationOfWarrantLiabilityUponExercise>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY18zNy9mcmFnOjkxYTFkYzM3Mjc0YTQ5MzU4MDU0Nzk0MWEyMDNlMWVkL3RleHRyZWdpb246OTFhMWRjMzcyNzRhNDkzNTgwNTQ3OTQxYTIwM2UxZWRfMzExNQ_d5ee9561-0334-457e-bef8-ecbf084f1e91">Description of Business&lt;div&gt;&lt;span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#x2019; lead product candidate, galinpepimut-S ("GPS"), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. In January 2020, the Company commenced a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission. SELLAS&#x2019; second product candidate, nelipepimut-S ("NPS"), is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.&lt;/span&gt;&lt;/div&gt;On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus as a &#x201c;pandemic&#x201d;. First identified in late 2019 and known now as COVID-19, the coronavirus outbreak has impacted millions of individuals worldwide and continues to present substantial public health and economic challenges around the world. It is difficult to predict with any certainty the length of time and the full extent to which the pandemic will continue to impact, directly and indirectly, our business and operations. The duration and extent of the impact of the pandemic will depend on future developments, which are highly uncertain, subject to change and cannot be predicted with confidence, including the duration of the outbreak, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, the re-emergence of more severe outbreaks in the fall or winter, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on the Company's business and the Company's financial results. The Company continues to monitor the situation closely, especially the extent to which precautions taken by clinical sites are impacting the timelines for the Company's clinical trials, including the Company's Phase 3 GPS trial, but given the uncertainty, management cannot estimate the impact of the COVID-19 pandemic on the Company's financial statements or operations.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:LiquidationBasisOfAccountingTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNjA2NQ_8ca08561-fc60-46c0-bec4-4e00d6cf5e4b">Liquidity&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes. It is likely that additional financing, beyond the financings described below, will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#x2019;s research and development efforts will be successful. The Company cannot be certain at this time of the impact of the COVID-19 pandemic on its ability to raise additional capital as needed, or on acceptable terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;PIPE Purchase Agreement&#x201d;) with certain investors  (the &#x201c;PIPE Investors&#x201d;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), 2,744,078 shares of its common stock and accompanying warrants to purchase up to an aggregate of 2,744,078 shares of common stock at a combined purchase price of $3.335 per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $3.30 per share and will expire five years from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$8.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain investors (the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#x201c;January 2020 Registered Offering&#x201d;), (i) an aggregate of 1,189,000 shares of common stock at an offering price of $3.9825 per share and (ii) an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at an offering price of $3.9725 per Pre-Funded Warrant, for gross proceeds of approximately $6.5 million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share. Each warrant is immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$6.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#x2019;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#x2019;s control. The length of time and cost of developing and commercializing these product candidates and/or the failure of any of them at any stage of the drug approval process will materially affect the Company&#x2019;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had cash and cash equivalents of approximately $8.2 million, and restricted cash and cash equivalents of $0.1 million. The Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $114.2 million as of September&#160;30, 2020. In addition, the Company had current liabilities of $4.2 million as of September&#160;30, 2020. The Company expects its cash and cash equivalents as of September&#160;30, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements through the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfOTY3_273ce20b-2091-4d40-bd56-5a2ee4fb36b6"
      unitRef="shares">2744078</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTA1Nw_bf5832bd-ae29-4c31-baaf-2e93246317d4"
      unitRef="shares">2744078</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTExNQ_3feac986-05b8-493d-be55-f9da87241164"
      unitRef="usdPerShare">3.335</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTIxOQ_c1025834-beb9-4dac-b67d-e28cf6e48c2f"
      unitRef="usdPerShare">3.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gale:ClassofWarrantorRightTerm
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTI0OA_b7cb883a-9f5f-40ec-889b-23448855bd73">P5Y</gale:ClassofWarrantorRightTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTA5OTUxMTYzNDIyOQ_37041162-fe4f-4f7c-9147-f302f18ab02b"
      unitRef="usd">8500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharesIssued
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTgzMQ_cb5ee7cf-506d-4fdf-ba15-6e47246a980d"
      unitRef="shares">1189000</us-gaap:SharesIssued>
    <gale:OfferingPricePershare
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTg4MQ_09ead92f-3956-4ac4-9a59-8deb75fbe3f0"
      unitRef="usdPerShare">3.9825</gale:OfferingPricePershare>
    <gale:ClassOfWarrantOrRightOutstandingExercisable
      contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMTkxOQ_f29a4895-8b6d-46bf-b400-706f05f5f79d"
      unitRef="shares">448800</gale:ClassOfWarrantOrRightOutstandingExercisable>
    <gale:OfferingPricePershare
      contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjAzMw_559bd6f5-836f-43d0-9a21-82ad05bf3427"
      unitRef="usdPerShare">3.9725</gale:OfferingPricePershare>
    <gale:ProceedsFromWarrantExercisesGross
      contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjA5Ng_c71bc3aa-0f26-411f-9380-c9777cb3fae3"
      unitRef="usd">6500000</gale:ProceedsFromWarrantExercisesGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjM0MA_8c660561-0433-49ca-91b5-9d938d02efa1"
      unitRef="shares">818900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjM5MA_d9371f36-c33e-4661-96a5-a2639324f350"
      unitRef="usdPerShare">3.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfMjc0MA_bca39a6a-2dc7-4930-b577-35745fac5a20"
      unitRef="usd">6000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTU2OQ_2a93336a-b82e-47fd-b2ae-5525dd39e105"
      unitRef="usd">8200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTYxNw_1a3d0115-3a0f-48e8-9fda-a0e941d75ab9"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTczNw_bc46fb9b-a954-4157-abda-fe9cf1124c63"
      unitRef="usd">-114200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180MC9mcmFnOjQyZTZiNzNjOTEwODQzZjc4Njc5ZDdlMWQxMDZjY2M2L3RleHRyZWdpb246NDJlNmI3M2M5MTA4NDNmNzg2NzlkN2UxZDEwNmNjYzZfNTgwMg_029116f9-11a4-49bd-a29c-1c1e49e6b9ba"
      unitRef="usd">4200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzOQ_b8753c9c-0ca9-4a9c-9b0f-b386b25bfb16">Basis of Presentation and Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Summary of Significant Accounting Policies included in the Company's 2019 Annual Report have not materially changed, except as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Interim Results &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2019 Annual Report. The accompanying consolidated financial statements at&#160;September&#160;30, 2020&#160;and for the three and nine months ended September 30, 2020 and 2019, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2019 have been derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse Stock Split &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 6, 2019, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1 - for - 50 reverse stock split of the Company's outstanding shares of common stock, which became effective on November 7, 2019. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company&#x2019;s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans were proportionately adjusted for the reverse stock split.  The reverse stock split reduced the number of shares of the Company&#x2019;s common stock that were outstanding at November 8, 2019 from 227,800,147 to 4,549,208, after the cancellation of fractional shares. No fractional shares were issued in connection with the&#160;reverse&#160;stock&#160;split.&#160;Stockholders who otherwise held fractional shares of the Company&#x2019;s common stock as a result of the&#160;reverse&#160;stock&#160;split&#160;received a cash payment in lieu of such fractional shares. These consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units with Performance and Service Conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the nine months ended September 30, 2020, the Board of Directors granted restricted stock units ("RSUs") to certain employees that vest based on performance and service conditions. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense is recognized for the number of RSUs expected to be earned, provided the requisite service period has been rendered, after assessing the probability that certain performance criteria will be met. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or are not expected to be met, any compensation expense previously recognized to date associated with the RSUs will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, FASB issued No. ASU 2018-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU No. 2018-13")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820.&#160;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's disclosures. For the new disclosure regarding our Level 3 instruments, please read Note 4 to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the FASB issued ASU No. 2018-07,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Nonemployee Share-Based Accounting ("ASU No. 2018-07")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. ASU No. 2018-07 supersedes ASC 505-50 and expands the scope of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation (Topic 718) ("ASC 718")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's consolidated financial statements and related disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzU0MQ_72bfae86-63f9-4558-a4b5-9da1d2c94119">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzMw_db0be2e7-2325-42e3-9973-97670c89c950">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9d45ff94435e4d21ba5468a5bebac6bf_I20191107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfMjgwNA_751bb022-1b15-4131-b890-def380437187"
      unitRef="shares">227800147</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4f256c92ebda4e238a9aee699650ec0f_I20191108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfMjgxMA_816dc64f-f0a3-44b5-92e2-c20618a7b116"
      unitRef="shares">4549208</us-gaap:CommonStockSharesOutstanding>
    <gale:RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzU0Mw_922e5447-c5ab-4232-b71b-36b01ab76cfb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units with Performance and Service Conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the nine months ended September 30, 2020, the Board of Directors granted restricted stock units ("RSUs") to certain employees that vest based on performance and service conditions. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense is recognized for the number of RSUs expected to be earned, provided the requisite service period has been rendered, after assessing the probability that certain performance criteria will be met. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or are not expected to be met, any compensation expense previously recognized to date associated with the RSUs will be reversed.&lt;/span&gt;&lt;/div&gt;</gale:RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzNw_16f105f0-ca49-423b-8c01-21caa008ebbf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzNA_b3a46d71-c9dc-4ddd-b67c-bc604e84137b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib323751cda864ddea7a8246c632828fc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMi0xLTEtMS0w_d688da44-770e-4fcf-943c-0ca587174bcc"
      unitRef="shares">3864000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i57d28b5ddb4f4e639e1959c1669e686e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMi0zLTEtMS0w_7535d630-bcf1-469b-b8e4-50c75b6aa39b"
      unitRef="shares">302000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i236474c05e0144e19db3cd5297f11f83_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMy0xLTEtMS0w_0cf02f71-a1b2-4a36-b0fa-58ecbfd95b91"
      unitRef="shares">208000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7605f1eb40c54e9c842276a939abedd4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfMy0zLTEtMS0w_f5e8934e-d12a-4ccf-a3cf-c0fbfc7c2e7e"
      unitRef="shares">23000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i336f4731de7d4c87aac9eb314ce2c08f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNC0xLTEtMS0w_4889e936-4109-473f-b90e-0d2f38f1b5ab"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5a636ae8cbfc46d18fa54ecab7fe2024_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNC0zLTEtMS0w_4494bf70-8667-4055-96a1-68579179b70f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNS0xLTEtMS0w_b5be64ed-68de-4beb-a65b-2d9c887dfccc"
      unitRef="shares">4242000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RhYmxlOmQ3N2RmZGVhYWQ2NTQ0YzQ5NmY0ZDJjNzljZWY2NGYzL3RhYmxlcmFuZ2U6ZDc3ZGZkZWFhZDY1NDRjNDk2ZjRkMmM3OWNlZjY0ZjNfNS0zLTEtMS0w_34e471f5-5a0d-4c4e-b14b-0334587d89aa"
      unitRef="shares">325000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY180Ni9mcmFnOmE3M2IwMjBhZjM4ZTQ4MjRiNGVkZGVkMDk0OGE4ODM1L3RleHRyZWdpb246YTczYjAyMGFmMzhlNDgyNGI0ZWRkZWQwOTQ4YTg4MzVfNzUzOA_17124255-2cc7-4c1c-825a-a6993d333dd0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, FASB issued No. ASU 2018-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU No. 2018-13")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820.&#160;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's disclosures. For the new disclosure regarding our Level 3 instruments, please read Note 4 to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the FASB issued ASU No. 2018-07,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Nonemployee Share-Based Accounting ("ASU No. 2018-07")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. ASU No. 2018-07 supersedes ASC 505-50 and expands the scope of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation (Topic 718) ("ASC 718")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's consolidated financial statements and related disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYxMw_18c32f2a-e5f1-451a-b29f-ec207b07917b">Fair Value Measurements&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&#160;&#160;&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification during the three or nine months ended September&#160;30, 2020 or during the year ended December 31, 2019.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the nine months ended September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;br/&gt;Measurements&lt;br/&gt;Using&#160;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the estimated fair value of the contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to the Company&#x2019;s nelipepimut-S ("NPS") product candidate, of which $2.0 million has been paid to date. The remaining contingent consideration of up to $30.0 million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of September&#160;30, 2020, estimated future contingent milestone payments related to the Company's business range from zero, if no milestone events are achieved, to a maximum of $30.0 million if all development and commercial milestones are reached. As of September&#160;30, 2020, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 11.8% for development milestones and cost of debt of 5.4% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4MQ_25e0b964-a33f-48bd-9fac-2954e0ad7f70"&gt;five&lt;/span&gt; to eight years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYyNQ_2874a901-6c3a-458f-be28-72d61ef8840d">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&#160;&#160;&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi0xLTEtMS0w_9d9dd3db-f9ef-4326-8dee-53aed0380852"
      unitRef="usd">8002000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi0zLTEtMS0w_e332640d-8cdc-4b5f-aaa8-5f6b392b3701"
      unitRef="usd">8002000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi01LTEtMS0w_6d8dc1f3-196d-44ab-83d9-0ce32885949f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i31133d38f51742738c72afb224c21907_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfMi03LTEtMS0w_03a9cb3c-4229-4ddd-a0da-8e4538f68447"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC0xLTEtMS0w_4c55fbdd-4be1-4965-a929-77cc965c68f2"
      unitRef="usd">8002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC0zLTEtMS0w_628dcb8e-ff07-4f0a-892d-c85ccde1547e"
      unitRef="usd">8002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC01LTEtMS0w_b08b12b4-d921-4cbd-b778-a41888d1b89c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31133d38f51742738c72afb224c21907_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNC03LTEtMS0w_ccb31ccb-ce6a-4b49-8a1d-49acb33fa784"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi0xLTEtMS0w_4f2cfa87-7bd5-4bf7-85c7-81edcffc5100"
      unitRef="usd">27000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi0zLTEtMS0w_b21c6973-0415-498a-a735-a08cd592917b"
      unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi01LTEtMS0w_774b83af-d461-44b0-b3c2-5a91cdc47756"
      unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i31133d38f51742738c72afb224c21907_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNi03LTEtMS0w_4a4f6902-5a6b-4fa8-8414-24fe5ae6376e"
      unitRef="usd">27000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy0xLTEtMS0w_cf605c2d-ee28-4d5e-84f4-87d0451e6b10"
      unitRef="usd">5180000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy0zLTEtMS0w_72f7c693-8a4b-43c9-8471-d56fd98d2c7b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy01LTEtMS0w_926dbbc3-c504-4596-9a91-5e8f931a5a96"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i31133d38f51742738c72afb224c21907_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfNy03LTEtMS0w_540caa9b-3011-4c4e-88fd-b1bc030ecfc3"
      unitRef="usd">5180000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i111eee7793154c7cbef26ee3f9b7f76f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC0xLTEtMS0w_522f88ea-6fd4-43c4-a98b-83cb56815701"
      unitRef="usd">5207000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9e2ee8037fd448a0ba0b935eee1d6e15_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC0zLTEtMS0w_aa9ed1ef-ef5a-48c0-89ce-149b508949b7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i27de7fe30b534200ba87bbfcddc0e6df_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC01LTEtMS0w_8f38e309-5fe1-439f-b451-769686d9d0c0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i31133d38f51742738c72afb224c21907_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOmU1Nzc5ZDA1ODMxNjQ0YzU5NmZkODhmNmYzZGFkNzdjL3RhYmxlcmFuZ2U6ZTU3NzlkMDU4MzE2NDRjNTk2ZmQ4OGY2ZjNkYWQ3N2NfOC03LTEtMS0w_fb1e10ab-7c0f-48cc-b789-8a6e3d00aff6"
      unitRef="usd">5207000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi0xLTEtMS0w_770085c2-0071-49b3-b002-189ccddbd9e1"
      unitRef="usd">7027000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi0zLTEtMS0w_34f6a32f-2739-45fb-b7e2-ba2566d235a4"
      unitRef="usd">7027000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi01LTEtMS0w_8e5ca5e8-6b3a-45e8-b58d-9daaf8f0bac1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfMi03LTEtMS0w_d6d73805-2b05-47b2-bf66-5684b3f3c4a4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC0xLTEtMS0w_1a845617-dec8-4389-9aa0-f7d3578f5357"
      unitRef="usd">7027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC0zLTEtMS0w_4732f767-5f66-49f0-9406-db43374e5574"
      unitRef="usd">7027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC01LTEtMS0w_03b55816-8753-499f-a239-235c41c7b162"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNC03LTEtMS0w_c0642edd-eef3-4690-b1b5-e5c565e82ddc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi0xLTEtMS0w_025bbea1-5c45-44ca-b88e-193e3081beba"
      unitRef="usd">52000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi0zLTEtMS0w_fdf2fd02-5f6b-49c9-8644-98f6f14212d2"
      unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi01LTEtMS0w_118dfef7-1fbb-4e7f-8a91-7e53c71970d6"
      unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <gale:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNi03LTEtMS0w_aa49a7d5-7c11-4d8b-80d7-cbc8b2d89401"
      unitRef="usd">52000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy0xLTEtMS0w_b2c5a515-1237-4f1e-a6c3-199328f0a4b8"
      unitRef="usd">4912000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy0zLTEtMS0w_db1e69d5-3563-4783-80a2-bf50cc8e9da1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy01LTEtMS0w_12c3abba-074c-4907-943e-eedb98d2cf27"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfNy03LTEtMS0w_51a7de86-180a-4603-9e1c-7d2b9b76cb36"
      unitRef="usd">4912000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9a68dc9ea9524aaa8259232cb53ea81c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC0xLTEtMS0w_b4805498-35ff-49d9-9e18-d51dc10d4e74"
      unitRef="usd">4964000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i52f4af32287b4eebbb3e4bb756720009_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC0zLTEtMS0w_f0aab80d-eb36-4719-8b8e-d71fa7394530"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6c49530f9e1f4a7ab1e157266c80caeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC01LTEtMS0w_3cb856ca-51ae-4a5c-8ff9-401b95dea5ae"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i312df3f093ec493b8184ebf1b42c5b63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjI1ZTZiMDg5MmE4NzQ0MTRiMjNiYTU5NTk1MWRhYjY1L3RhYmxlcmFuZ2U6MjVlNmIwODkyYTg3NDQxNGIyM2JhNTk1OTUxZGFiNjVfOC03LTEtMS0w_d37e5279-b9d4-4add-8cab-8809577ad009"
      unitRef="usd">4964000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjYxMQ_af761fcc-5a01-4ba5-80a7-6caaa0bbe402">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;br/&gt;Measurements&lt;br/&gt;Using&#160;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the estimated fair value of the contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4007eb8b70cc49a894e1bdf6a68b797d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMS0xLTEtMS0w_126ea475-17e7-4984-bd2f-b6afc44ceda4"
      unitRef="usd">4912000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i7a08e3cbcb5346b484952fa5670010dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMi0xLTEtMS0w_52a87443-1490-4ac8-ae97-a561fac067b1"
      unitRef="usd">-268000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i484453f41b684c819bd4de89fe5e44d7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RhYmxlOjc4ODFlNzZjNzg5MDQ3ZTU4ZDhjMmJiZGMwMWE0YWI2L3RhYmxlcmFuZ2U6Nzg4MWU3NmM3ODkwNDdlNThkOGMyYmJkYzAxYTRhYjZfMy0xLTEtMS0w_034d10c2-bab3-4440-85c4-4e66d8327c7a"
      unitRef="usd">5180000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ib4b789d256a64b4c94443e234118e471_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfOTY3_1cad0acf-2287-4bb5-8dbd-82e2ceec2f05"
      unitRef="usd">32000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ic15be4f3595049579ffb1c76ee6bffb9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMTEyMA_7929d503-e7ac-4fa5-b142-414e5d2d764d"
      unitRef="usd">2000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMTE5NA_61433448-46fc-4b96-8276-35c03f6ef806"
      unitRef="usd">30000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow
      contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjE2Mg_d6670afa-b770-41ac-9ee0-4456da152fdf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjIxOQ_0bd30cac-939a-423f-b4ca-0f737ba92992"
      unitRef="usd">30000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2a3529684d284f57abc0008fc0964ea3_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjQwMw_4c30ddc5-16e6-4c74-b1dd-18450f1572d4"
      unitRef="number">0.118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic0ed1616c836452e8084ab91d06bef5c_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjQ1Mw_f6559bc9-7965-41e8-b5d3-e4a7a1888683"
      unitRef="number">0.054</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones
      contextRef="id8564c243eb44d16943c0ae16d68c94c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4Nw_251ba717-3482-453c-b726-3a04338ede60">P8Y</gale:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjE0_f4b2b04e-d3cd-4331-b54f-68ba176e7c00">Balance Sheet Accounts&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjE3_b533eddf-806c-4c6e-88d4-079f25c55c33">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMS0xLTEtMS0w_52a1dd57-fd76-4fc0-9acb-10b68473a980"
      unitRef="usd">693000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMS0zLTEtMS0w_d8236811-4cdc-4596-afd6-a7a8d18cd206"
      unitRef="usd">200000</us-gaap:PrepaidInsurance>
    <gale:PrepaidResearchAndDevelopment
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMi0xLTEtMS0w_1179146f-9618-4921-a40c-65c778c09da7"
      unitRef="usd">181000</gale:PrepaidResearchAndDevelopment>
    <gale:PrepaidResearchAndDevelopment
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMi0zLTEtMS0w_18d4382c-797c-4f26-8223-b2222a98cb05"
      unitRef="usd">224000</gale:PrepaidResearchAndDevelopment>
    <gale:PrepaidProfessionalServices
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMy0xLTEtMS0w_57a7a770-02e2-4cce-aa21-f79694a0b2f5"
      unitRef="usd">125000</gale:PrepaidProfessionalServices>
    <gale:PrepaidProfessionalServices
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfMy0zLTEtMS0w_f8e5fbc4-38a8-4c7a-bf8f-cffd83e38332"
      unitRef="usd">49000</gale:PrepaidProfessionalServices>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNC0xLTEtMS0w_95794dff-b220-4ab9-ade2-2d01ee98dd4c"
      unitRef="usd">31000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNC0zLTEtMS0w_f626f940-ad66-437b-845c-259fce9e36fa"
      unitRef="usd">84000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNS0xLTEtMS0w_9c18cdaf-31eb-49a6-b38e-5860d6255615"
      unitRef="usd">1030000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmODc3YTgzMTA4NTQ4OGNhMDgxMzgwZGIzNjRmYzQxL3RhYmxlcmFuZ2U6YmY4NzdhODMxMDg1NDg4Y2EwODEzODBkYjM2NGZjNDFfNS0zLTEtMS0w_a7716674-6bfe-4bd3-a536-4d5aa35ee5cd"
      unitRef="usd">557000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RleHRyZWdpb246YjE1NTE1YjZmZWYzNGQxNWE1ZjQzN2E3YjkxNDY1YTJfMjEy_1f3ee3ac-dfb2-45d2-b330-432e45b8b03e">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <gale:ContractResearchPayable
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMS0xLTEtMS0w_31d32eda-8105-4011-a608-bd0fa9368792"
      unitRef="usd">1202000</gale:ContractResearchPayable>
    <gale:ContractResearchPayable
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMS0zLTEtMS0w_3bff2631-9516-4c06-b714-df20fb7f6872"
      unitRef="usd">371000</gale:ContractResearchPayable>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMi0xLTEtMS0w_c6797f1c-1bf9-4597-a806-15709013e5d5"
      unitRef="usd">719000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMi0zLTEtMS0w_8c9b88c6-aeaf-4479-a9dd-eafa52cb8f9f"
      unitRef="usd">606000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMy0xLTEtMS0w_48273248-b7b5-438e-b2ef-241eadebf403"
      unitRef="usd">383000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMy0zLTEtMS0w_47f17989-9d89-4389-bd6e-5ca1509897fe"
      unitRef="usd">194000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMTUtMS0xLTEtMA_5fd4cd32-31e5-4d73-b6c5-ca0fcb9940f9"
      unitRef="usd">2304000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181NS9mcmFnOmIxNTUxNWI2ZmVmMzRkMTVhNWY0MzdhN2I5MTQ2NWEyL3RhYmxlOmJmOTFiOThlMzE3MDRjOTM5MDc2ZGUxZGQ3MDUzZWFlL3RhYmxlcmFuZ2U6YmY5MWI5OGUzMTcwNGM5MzkwNzZkZTFkZDcwNTNlYWVfMTUtMy0xLTEtMA_7ea842a6-b7f2-454f-b499-aced037d67e6"
      unitRef="usd">1171000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNjIyMw_6bf15a35-122c-4e03-964c-99630f607d15">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Office Space&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020, the Company entered into a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The Company recognized a current operating lease liability of $0.1&#160;million and a non-current operating lease liability of $0.9&#160;million with a corresponding right of use asset ("ROU") of $1.0&#160;million, which is based on the present value of the minimum rental payments of the lease. The discount rate of the Company's operating lease under ASC 842 is the Company's estimated incremental borrowing rate of 13%. As of September&#160;30, 2020, the lease has a remaining term of 4.25 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a non-cancelable operating lease for office space in New York, New York, which began on August 1, 2018 with a term through July 31, 2020. The Company adopted ASC 842 in the first quarter of 2019 and as a result of the adoption, the Company recognized a current operating lease liability of $0.4 million and a non-current operating lease liability of $0.2 million with a corresponding ROU of $0.6 million, which is based on the present value of the minimum lease payments of the lease. The discount rate used to account for the Company's operating lease under ASC 842 is the Company&#x2019;s estimated incremental borrowing rate of 13%. The lease expired on July 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense related to the Company's operating leases was approximately $0.1 million for each of the three months ended September&#160;30, 2020 and 2019. Rent expense related to the Company's operating leases was approximately $0.3&#160;million for each of the nine months ended September&#160;30, 2020 and 2019. Future minimum lease payments under the Company's non-cancelable operating leases are as follows as of September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current and non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease amortization of the ROU asset was $0.1 million for each of the three months ended September&#160;30, 2020 and 2019 and $0.3&#160;million for each of the nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#x2019;s consolidated results of operations, financial position or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#x2019;s promotional practices for Abstral&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#x2019;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss. On December 20, 2019, the lead plaintiffs filed a Second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#x2019;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#x2019;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#x2019;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#x2019;s behalf against the Company&#x2019;s former directors and, in certain of the complaints, certain of the Company&#x2019;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the two complaints filed in the U.S. District Court for the District of New Jersey.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNDAy_9192376d-658e-41f9-be58-f14dac98709c"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNDUy_f4129613-5bfd-490c-b39d-e06f7538465e"
      unitRef="usd">900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5d8d7a3b05b742f7a8ea647177b9d7a8_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNTA2_cb2b83c2-f4af-494d-83eb-05fb681e10aa"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8c8fdb34b2cc44a58467c8e3974f9096_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNzEz_29baf3e3-a4fe-4900-a910-ff66a0d1bc8c"
      unitRef="number">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <gale:OperatingLeaseRemainingLeaseTerm
      contextRef="i71b0db59425c4a98acfb161fe0504728_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNzcy_24dc0c36-5494-4077-a186-57bda2a1e8df">P4Y3M</gale:OperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTA4Mw_b282cd03-1f80-46c3-b16b-b23dc3d4d764"
      unitRef="usd">400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTEzMw_1d37e340-6746-4efa-ad1d-74c85452802a"
      unitRef="usd">200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i65906fccb4494d56a3acf5118e25adbf_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTE2NA_062fba28-5cce-40ef-b626-611b3ae57a22"
      unitRef="usd">600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i483df898bc3046c6803892473d43f9dc_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTM4Nw_2306bb07-5a9f-4128-a708-264c16851d7d"
      unitRef="number">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTU2Mg_3f89806c-c6d8-4a82-8933-84718fdd4230"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTU2Mg_f944eb72-bbdb-473e-8496-be0bb13db970"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTY5Nw_3bdc7054-8f8e-47ce-95ad-b70f96d6c09c"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTY5Nw_5bee32aa-1ac7-448f-8cb5-cd308e87e2b5"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfNjIyOA_56bb1feb-e7a2-4f7b-ae3f-6c695f27d462">Future minimum lease payments under the Company's non-cancelable operating leases are as follows as of September&#160;30, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current and non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMS0yLTEtMS0w_5aba471f-1aee-4b82-9c9e-5c85d77b4f5a"
      unitRef="usd">75000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMi0yLTEtMS0w_510255a4-6dc7-44dd-849b-22d8b15eb8fb"
      unitRef="usd">302000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfMy0yLTEtMS0w_b104f453-c9ad-48a4-8493-bded15cef97e"
      unitRef="usd">311000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNC0yLTEtMS0w_efe3fd31-fca0-410a-9798-c56981460876"
      unitRef="usd">321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNS0yLTEtMS0w_d8984249-26c3-4db1-b0a6-de45b1dfbfdb"
      unitRef="usd">330000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNi0yLTEtMS0w_a797a3bf-20ad-418a-9767-17527575fff9"
      unitRef="usd">1339000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfNy0yLTEtMS0w_47f3d850-8e43-44c0-a092-e45300d943a2"
      unitRef="usd">330000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RhYmxlOjkzZmQwNWQxYmQ2NDRlZDc5YWIxYmE3OTdhZTZmY2Q5L3RhYmxlcmFuZ2U6OTNmZDA1ZDFiZDY0NGVkNzlhYjFiYTc5N2FlNmZjZDlfOC0yLTEtMS0w_e11afd95-e8de-419b-bcda-e0783bbac920"
      unitRef="usd">1009000</us-gaap:OperatingLeaseLiability>
    <gale:OperatingLeaseRightOfUseAssetAmortization
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTkyNA_37cda2d0-39de-4b43-b573-f7ec87752b54"
      unitRef="usd">100000</gale:OperatingLeaseRightOfUseAssetAmortization>
    <gale:OperatingLeaseRightOfUseAssetAmortization
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTkyNA_d009ccb2-45d6-4249-9c16-09e99f1c7f59"
      unitRef="usd">100000</gale:OperatingLeaseRightOfUseAssetAmortization>
    <gale:OperatingLeaseRightOfUseAssetAmortization
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTk3OA_69718df3-3e59-4563-b1e1-20ddd5e7077f"
      unitRef="usd">300000</gale:OperatingLeaseRightOfUseAssetAmortization>
    <gale:OperatingLeaseRightOfUseAssetAmortization
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181OC9mcmFnOmQzOWQyYjhmNDgzYjRiMTI5Njg4ZmYwOWQ4MzgxOTA3L3RleHRyZWdpb246ZDM5ZDJiOGY0ODNiNGIxMjk2ODhmZjA5ZDgzODE5MDdfMTk3OA_ee13efc3-f2cc-4be7-8de7-c14f2b4850ef"
      unitRef="usd">300000</gale:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk4Mw_b196713d-10ce-499e-aa84-ac51c320e2ae">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized up to 5,000,000&#160;shares of preferred stock, $0.0001&#160;par value per share, for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized up to 350,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 29, 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Maxim Group LLC (the "Agent"), pursuant to which the Company was permitted to offer and sell shares of common stock through the Agent having an aggregate offering price up to $5.0 million in gross proceeds. In connection with such sales, the Agent collected fees equal to 3% of the gross sales price of all shares of common stock sold. Sales of the shares under the Distribution Agreement were made in transactions deemed to be "at the market offering" as defined in Rule 415 under the Securities Act of 1933. Shares sold under the Distribution Agreement were offered and sold pursuant to the Company's effective registration statement on Form S-3. During the year ended December 31, 2019, the Company sold&#160;524,097&#160;shares of common stock pursuant to the Distribution Agreement for net proceeds of&#160;$2.7 million. The Distribution Agreement was terminated on January 9, 2020. There were no shares of common stock sold pursuant to the Distribution Agreement in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain investors (the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#x201c;January 2020 Registered Offering&#x201d;), (i) an aggregate of 1,189,000 shares of common stock, par value $0.0001 per share, of the Company, at an offering price of $3.9825 per share and (ii) an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock  at an offering price of $3.9725 per pre-funded warrant, for gross proceeds of approximately $6.5 million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share. Each warrant was immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, was approximately&#160;$6.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;PIPE Purchase Agreement&#x201d;) with certain investors  (the &#x201c;PIPE Investors&#x201d;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), 2,744,078 shares of its common stock and accompanying warrants to purchase up to an aggregate of 2,744,078 shares of common stock at a combined purchase price of $3.335 per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $3.30 per share and will expire five years from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$8.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;The shares of common stock (and shares of common stock underlying the warrants) issued in the July 2020 PIPE Offering were registered under the Securities Act of 1933, as amended, pursuant to a Registration Statement on Form S-3 (333-246333) filed with the Securities and Exchange Commission ("SEC") and declared effective on August 24, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company has shares of common stock reserved for future issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Company&#x2019;s 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Subscription Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to December 31, 2019, the Company sold 75,000 shares of common stock for gross proceeds of $0.3 million. As the gross cash proceeds of $0.3 million were not received until January 2, 2020, the Company recorded a stock subscription receivable of $0.3 million as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfODI_06c887ec-c727-4b12-b15d-559506b94e79"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTEy_fef4cffd-3d13-4ebf-ad3e-14fb5c53cd39"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjAw_645a5e73-e79e-4478-9cf7-baf73689ae32"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjI3_6f200fe8-3675-4d2f-9c32-070bb0181d46"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <gale:SaleOfStockAuthorizedAmount
      contextRef="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfNTU3_64a690af-07ae-4564-b533-69b00f154ab0"
      unitRef="usd">5000000.0</gale:SaleOfStockAuthorizedAmount>
    <gale:SaleOfStockAgentFeePercentageOfGrossProceeds
      contextRef="i5478e2945c984f3da259e91ac87de63d_D20191029-20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfNjQ0_a47be586-67a4-449d-866e-d92a60634861"
      unitRef="number">0.03</gale:SaleOfStockAgentFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTA3OQ_fc9d228e-4299-4328-babf-4eed11e54a91"
      unitRef="shares">524097</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTE2NA_778e79d7-e01b-45c9-8fac-c2cd2bf8ae4c"
      unitRef="usd">2700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTI0MQ_dbdcdca4-aea1-4b0b-89a8-e9f2a2635e4c"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssued
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY1OA_4d53dcb3-7f94-4157-8df5-c7662dd5687f"
      unitRef="shares">1189000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY5NQ_44af0718-b79a-459d-9863-200c0d7ec4d8"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <gale:OfferingPricePershare
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTc0OQ_d0b40b1e-6c66-40e6-a41e-28fe4275e0ca"
      unitRef="usdPerShare">3.9825</gale:OfferingPricePershare>
    <gale:ClassOfWarrantOrRightOutstandingExercisable
      contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTc4Nw_07dd8c68-e8ee-4763-91b9-6c779c897bbf"
      unitRef="shares">448800</gale:ClassOfWarrantOrRightOutstandingExercisable>
    <gale:OfferingPricePershare
      contextRef="iea994a777cf84044889ade0f0cfca5c7_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTg3NA_31f356d7-7160-4657-adb1-6c079bf13c2b"
      unitRef="usdPerShare">3.9725</gale:OfferingPricePershare>
    <gale:ProceedsFromWarrantExercisesGross
      contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTkzNw_caf04f2d-9d6c-4053-a3bd-a16894ea900b"
      unitRef="usd">6500000</gale:ProceedsFromWarrantExercisesGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i2c335a4c261f473ab001ddbbb9edd2e9_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjE4MQ_edb94e84-eacf-42ff-a79f-53f46e35e828"
      unitRef="shares">818900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i354bd279ed2542818d5f6d96946a39b1_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjIzMQ_99dead69-bbe7-40e4-81b1-98ada447dab9"
      unitRef="usdPerShare">3.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icff2cabbd96a4395ad1f5fa4af3b03ce_D20200109-20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjU2NQ_92300213-37c2-463f-a05e-926f56cad628"
      unitRef="usd">6000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NDk3Mw_c06d4056-a06b-4040-a118-84626b90671c"
      unitRef="shares">2744078</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTA2NA_92b0525f-cbc2-43a1-9ab3-4a11b115dda5"
      unitRef="shares">2744078</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTEyMw_4dddbba8-bf34-4c59-b966-3197f35a6b96"
      unitRef="usdPerShare">3.335</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9fe21654d5bd481094895b468bb60e02_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTIyOA_84b38e90-670a-48ef-bb3a-7355b523b120"
      unitRef="usdPerShare">3.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gale:ClassofWarrantorRightTerm
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTY0OTI2NzQ0NTI1OA_549cbfc7-e189-495c-a5bf-26f3160d2e49">P5Y</gale:ClassofWarrantorRightTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i70f3f5e1afe24f20a19c775c5d4859b4_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMTA5OTUxMTYzMjY3NA_8341c26f-312c-497e-baf5-7daf39b26f8e"
      unitRef="usd">8500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <gale:CommonStockAreReservedForFutureIssuanceTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk3Nw_52ddd188-4ab0-41d0-b6ee-51910381a40a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company has shares of common stock reserved for future issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Company&#x2019;s 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMC0xLTEtMS0w_f1cf5ea9-0f7f-40a3-802b-1d9d2052930b"
      unitRef="shares">3864000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMi0xLTEtMS0w_214c2fe6-da70-4084-b9ec-e6166551f0e5"
      unitRef="shares">208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfMy0xLTEtMS0w_03a0d344-6df5-4277-ac87-bc650a2ec9ee"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNC0xLTEtMS0w_575faaf1-5b72-4fa5-b953-43f2fdc31bae"
      unitRef="shares">101000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
    <gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNS0xLTEtMS0w_b00e2950-f8c1-41f3-9937-3e8790876413"
      unitRef="shares">8000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RhYmxlOjYxMmQzMjk0OGM0MzQwODJiYWIwOGJiNDk2MWY0YjY2L3RhYmxlcmFuZ2U6NjEyZDMyOTQ4YzQzNDA4MmJhYjA4YmI0OTYxZjRiNjZfNy0xLTEtMS0w_29465096-a566-49a4-80d8-3798c1cf981d"
      unitRef="shares">4351000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjc2Nw_f5c9adff-dfd8-4ac2-9382-7ab826600753"
      unitRef="shares">75000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i17bc536b0ceb4c6da91b85b0b6b06ccd_D20190101-20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjgxNQ_adb27684-976d-43e5-b14d-eeacdd4b0ffd"
      unitRef="usd">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id35672082f7945928e2de21782c5ccf4_D20200102-20200102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjg0OQ_cd02740f-5a61-4c46-8f8b-30e25e7e4fb4"
      unitRef="usd">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <gale:StockSubscriptionReceivableCurrent
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182MS9mcmFnOjEzZjczMTIxMGI2MjQ0ZDZhNmUzNTYzNTM2NjE3NjA4L3RleHRyZWdpb246MTNmNzMxMjEwYjYyNDRkNmE2ZTM1NjM1MzY2MTc2MDhfMjk0OQ_9c674b04-1130-459c-ad37-3f092330478e"
      unitRef="usd">300000</gale:StockSubscriptionReceivableCurrent>
    <us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwOA_87ae06f2-e199-49d9-a027-0f0755ed0ccb">Warrants to Acquire Shares of Common Stock&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the nine months ended September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2020 PIPE Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-funded January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2019 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019 Exercise Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2017 Equilibria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants Classified as Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for Series A Convertible Preferred Stock, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined not to be indexed to the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,901.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,494.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of the warrant liability for the nine months ended September 30, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjustment to exercise price of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants Classified as Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the January 2020 Offering and concurrent private placement and the warrants to acquire shares of common stock issued during the July 2020 PIPE Offering were recorded as equity upon issuance. During its evaluation of equity classification of these pre-funded warrants and common stock purchase warrants, the Company considered the conditions as prescribed within ASC 815-40,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&#160;Contracts in an Entity&#x2019;s own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 815-40&#x201d;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#x2019;s own stock and would be classified in permanent equity if freestanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 6, 2019, the Company entered into a Warrant Exercise Agreement (the "March 2019 Exercise Agreement") with one of the holders of the Company's warrants issued in July 2018. Pursuant to the March 2019 Exercise Agreement, new warrants to purchase up to an aggregate of approximately 76,000 shares of common stock at an exercise price of $70.00 per share ("March 2019 Exercise Agreement Warrants") were issued on a share-for-share basis in an amount equal to the number of the warrants issued in 2018 that were cash exercised by the warrant holder prior to May 31, 2019. On January 2, 2020, the Company amended the March 2019 Exercise Agreement Warrants to provide for an exercise price of $7.50 per share (subject to adjustment for stock splits and the like). The reduced exercise price of the 63,000 March 2019 Exercise Agreement Warrants increased the fair value of these warrants by approximately $0.1 million during the nine months ended September 30, 2020, which is recorded as a deemed dividend increasing the net loss attributable to common stockholders and additional paid-in-capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
    <gale:ScheduleOfWarrantActivityTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwMw_17cc0cc5-4bb6-41ef-b945-09c545e168af">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the nine months ended September&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2020 PIPE Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-funded January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2019 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019 Exercise Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2017 Equilibria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if77a8a8ce50a4065b099f3a4946f25d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0xLTEtMS0zOTE_655daf60-7c2a-4a91-a0bc-2fb8db1d65ce"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0zLTEtMS0zOTE_3b487bf0-2ff8-4dab-a13f-86111fb1bbb6"
      unitRef="shares">2744000</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS01LTEtMS0zOTE_0a358893-9e18-4ab9-a0fd-857c43f5e11b"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="i1a06969186f544b098f9823b6f201beb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS03LTEtMS0zODc_d2533d3c-08bd-44ba-ab30-eb00395d5ffd"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="idd662d374f5e4b9b9f63ff15501e6a9b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS05LTEtMS0zODc_52ec9297-9090-46dd-bb22-acab8936b4db"
      unitRef="shares">2744000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2003e91715cd42cd807932a074fadd24_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0xLTEtMS0w_4d2061d8-d77b-4c36-82ae-d7ce0c96d293"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS0zLTEtMS0w_2df7c229-449d-48fc-9517-d95bd41e54e0"
      unitRef="shares">819000</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS01LTEtMS0w_72354da6-d1bc-4204-96ae-25575c8d49a4"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="id011ae33db9a49bfa4332611238d7399_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS03LTEtMS0w_239a206a-b599-4814-b385-541f8b6fa048"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i64f67ec1048a462997aa215f62c15d3a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMS05LTEtMS0w_4cafecdb-99fc-4ac0-b154-434f5615051c"
      unitRef="shares">819000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie4dd7532088040d9b73af1f7afd90860_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi0xLTEtMS0w_e1bfb9dc-10d7-44a6-a791-53d0d90b49a1"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi0zLTEtMS0w_f99a5628-7000-485e-add3-8ec012d736f9"
      unitRef="shares">449000</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi01LTEtMS0w_bf36876b-b0c4-4a30-9c2e-94b97a61607b"
      unitRef="shares">449000</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="ifbcafd2c082c419685428d7d49e052b7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi03LTEtMS0w_c9a96e81-175e-4f3a-a1e2-e2d83468dc9f"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i27ccbdec896542ac98d4fd115dff1bcf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMi05LTEtMS0w_3c41c1b5-28ec-4c5d-8943-42cd26d82495"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i39ef75fb2fbe4b15858d159ac382757d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy0xLTEtMS0w_ff19021a-1383-41ec-b081-dcc3d7a05bae"
      unitRef="shares">2000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy0zLTEtMS0w_6174697b-94ed-4034-94b7-987c934c3bd8"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy01LTEtMS0w_14c07857-30d7-4360-870b-23273fb97e9c"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="i6b6f070934f04a76863f29cb7ab31eae_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy03LTEtMS0w_f3a54e88-2655-461b-8ca0-1ac38d39e2e5"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i11d32eceb309447d9a734885748db45e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMy05LTEtMS0w_a0683777-fcec-4828-b94f-f80b7ff0a3d1"
      unitRef="shares">2000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i22fb77bdd14a4391afb857bad525ac58_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS0xLTEtMS0w_548ed0f8-3731-4214-85ec-da15c2de95a1"
      unitRef="shares">63000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS0zLTEtMS0w_c8c7d74b-945e-4e12-94f9-485a188aa26b"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS01LTEtMS0w_948db8bb-cd2c-4c42-878e-39812aba4a79"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="ie140598d76684f2c8ed2f22bd020d701_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS03LTEtMS0w_9f9ae6dd-ef10-4f9d-b436-c129b320eccd"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if92d800c33d7429d83e6b450093d5217_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNS05LTEtMS0w_cf1dd969-adf1-47a7-ad48-8ef85b3f886e"
      unitRef="shares">63000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9e8dbce17eee4277b5a56ab7ba7dee3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi0xLTEtMS0w_16153057-ac90-4af1-b0c2-e8d53b47aa0e"
      unitRef="shares">208000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi0zLTEtMS0w_32bc5186-0fa2-47b4-88a0-8d95339407e0"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi01LTEtMS0w_a81f8c94-0654-47b6-a0fb-0c875f4ac864"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="i7a746aca7f0347f395488a22f7504e9e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi03LTEtMS0w_62e79588-0a58-4e25-8f8e-fd47eb39efc6"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5f18bc2fcbb74091bfc8098930a1503d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfNi05LTEtMS0w_956f83de-a907-4c6b-a1f8-9440602777ca"
      unitRef="shares">208000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC0xLTEtMS0w_2201e20d-901e-461c-8a77-62d496f765be"
      unitRef="shares">19000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC0zLTEtMS0w_cbf30478-1458-49b1-bd3b-67fe084e3818"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC01LTEtMS0w_4bd56774-0d8a-4c3d-a1e0-1a7160f5be97"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC03LTEtMS0w_550f3a70-3d4d-44df-9dc1-2929401ce91f"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOC05LTEtMS0w_0e73b9f4-330a-4c59-bfc6-b215c959d5da"
      unitRef="shares">19000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i953ec750bdd64786866ccfc3f7f8baa2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS0xLTEtMS0w_8bf3475c-b926-4b50-a813-224cc2a594f6"
      unitRef="shares">6000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS0zLTEtMS0w_6f2e6b2c-6914-4f57-ab85-b2acc270cc2c"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS01LTEtMS0w_05d4bce9-614c-4c0f-a5c1-ed4330f05017"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="ic10bad83b5a14889af864944ec54dffb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS03LTEtMS0w_51e23c5f-7b8d-478c-aade-91d71a3804c8"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic9c5ca7b25c443cab31a8bdd3b02bad6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfOS05LTEtMS0w_254dc1e7-1929-4c57-9080-330baa82e51a"
      unitRef="shares">6000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtMS0xLTEtMA_8d75b708-cf0e-48c0-8b0b-5260ed8fff44"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtMy0xLTEtMA_c6a7dae9-f8bd-4922-882e-4fec4cd2fae6"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtNS0xLTEtMA_8bf47d22-ebeb-4154-8618-07837a9d79b8"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtNy0xLTEtMA_71e2ab39-3b64-412e-936c-b5b20a3f2fc0"
      unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTAtOS0xLTEtMA_c68d254f-0648-437c-bff8-3ee65069e5b0"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtMS0xLTEtMA_4eca72d3-9dee-4074-92ab-11b82b1bbb9e"
      unitRef="shares">3000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtMy0xLTEtMA_b063b639-74a1-49a0-89a3-61e8f45041b3"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtNS0xLTEtMA_e75d64fc-de54-4472-a19c-c3b510ddd170"
      unitRef="shares">0</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtNy0xLTEtMA_847565a1-d686-4935-a604-ad9148ab4f65"
      unitRef="shares">1000</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3b14755124449839e31591a62b76734_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTEtOS0xLTEtMA_14852efd-2312-4f7a-9148-5c76eb8e6a83"
      unitRef="shares">2000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtMS0xLTEtMA_3a0ed3d4-ff2f-4cbb-8d29-5293e81addb9"
      unitRef="shares">302000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtMy0xLTEtMA_8696a08c-ef8b-4116-bb16-0ad8f5795863"
      unitRef="shares">4012000</gale:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtNS0xLTEtMA_cc9bcce7-ea1b-4c70-91c9-44b00899043c"
      unitRef="shares">449000</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <gale:ClassofWarrantorRightCanceledOrExpired
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtNy0xLTEtMA_715ac4ad-47ee-4703-91ac-28cfc4206c07"
      unitRef="shares">1000</gale:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjIxY2VkMWY0MjAxMjQ3NmY5ZWIxMDRmYTM0MTk5ZjRiL3RhYmxlcmFuZ2U6MjFjZWQxZjQyMDEyNDc2ZjllYjEwNGZhMzQxOTlmNGJfMTgtOS0xLTEtMA_a7024a4f-c6a8-4ed2-b61c-4f73d202919d"
      unitRef="shares">3864000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDE5OQ_9dd3db0f-0e9e-4e3f-8c9a-15b8c6be8c2a">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,901.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,494.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy0xLTEtMS0w_4f1e9410-de3e-473b-9632-e76762d48283"
      unitRef="shares">19000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy0zLTEtMS0w_d90b19de-2e17-4ae7-bcf9-b183488868d5"
      unitRef="usdPerShare">7.50</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy01LTEtMS0w_80599139-94e4-4b4e-aabb-ec4ebf4eabc0">P3Y</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy03LTEtMS0w_6162b7ed-de00-466c-bb05-cd636d335626"
      unitRef="number">1.3154</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMy05LTEtMS0w_18253e9b-7561-4c84-a282-872b982b80ad"
      unitRef="number">0.0016</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC0xLTEtMS0w_b5a5b772-68bd-4567-ab2c-ee4998c7e9f8"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC0zLTEtMS0w_f5d015ec-3eb0-4da2-b663-f7f60a42d760"
      unitRef="usdPerShare">1650.00</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC01LTEtMS0w_7ee7d889-a925-46d4-8792-9994518006da">P1Y4M13D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC03LTEtMS0w_fb191b17-aa8d-4d8b-ba6a-bce43085115a"
      unitRef="number">1.3560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNC05LTEtMS0w_3c2fd750-35a2-4fcb-9d83-03bbb2953d60"
      unitRef="number">0.0013</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3b14755124449839e31591a62b76734_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS0xLTEtMS0w_b6a51555-a613-4786-93af-270b2b43a3e3"
      unitRef="shares">2000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="ic3b14755124449839e31591a62b76734_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS0zLTEtMS0w_75ba9fd9-277e-4b47-b826-bd8c30ecc85e"
      unitRef="usdPerShare">30901.09</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="i002c05b0c2c14d0abc2aafa0bb152faf_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS01LTEtMS0w_808d1b8d-04ec-4051-8ce4-2c1fca967111">P1Y3M14D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="ic3b14755124449839e31591a62b76734_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS03LTEtMS0w_eb772154-861e-449c-84e5-7babaef60f90"
      unitRef="number">1.3560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic3b14755124449839e31591a62b76734_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfNS05LTEtMS0w_95ecf282-11bc-47ed-b9c3-831ccc35ac8c"
      unitRef="number">0.0013</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItMS0xLTEtMA_d001f274-d701-4724-b497-5ada230c8260"
      unitRef="shares">19000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItMy0xLTEtMA_c1408998-d7ee-400d-8bf0-289a1ff89d77"
      unitRef="usdPerShare">7.50</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="ib03011f148cb4758a40c754e531e9467_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItNS0xLTEtMA_b64992f6-78ed-4b8f-8eda-439a20492567">P3Y9M</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItNy0xLTEtMA_819385e2-d52e-45aa-ab08-43bf19d8ef08"
      unitRef="number">1.1284</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTItOS0xLTEtMA_613e765c-aff7-4350-9ca1-9fbba8e1a1c1"
      unitRef="number">0.0164</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtMS0xLTEtMA_ebe86dd9-b9d0-4e02-8c1e-b90188ae59b6"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtMy0xLTEtMA_1cde35a4-e607-4565-98ab-9c87e078f6f0"
      unitRef="usdPerShare">1650.00</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="ibc95b8a4af8c45868a82d2bdc59aba55_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtNS0xLTEtMA_6a9f0842-01ed-4353-9dd4-75b131e7f5ca">P2Y1M13D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtNy0xLTEtMA_2c582184-59f5-4cdf-b8db-6dc1ce811c6f"
      unitRef="number">1.1491</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTMtOS0xLTEtMA_d482f123-2c4f-4dba-a90a-3d8329cdcb72"
      unitRef="number">0.0164</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtMS0xLTEtMA_093f81c9-14db-4934-be9d-30b7321a8a24"
      unitRef="shares">3000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gale:WarrantStrikePrice
      contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtMy0xLTEtMA_c22f3ca1-25a4-4155-b3c2-84a1a1626864"
      unitRef="usdPerShare">41494.00</gale:WarrantStrikePrice>
    <gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="i454630a01309432fa2cd4d7cff6dfe26_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtNS0xLTEtMA_ff2a9b2b-0e8c-4db2-ae92-a5febf67d2a4">P1Y5M4D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <gale:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtNy0xLTEtMA_5efdcc32-8070-4f23-a75a-aea1c86b5bcd"
      unitRef="number">1.1491</gale:WarrantsFairValueAssumptionsExpectedVolatility>
    <gale:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="icde95ad8907947079b64dbecdb9a5118_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOjY5ZWFjNzVhNjM2NDQ2NzZiNmU3MTYwZjE3OTNjZTdkL3RhYmxlcmFuZ2U6NjllYWM3NWE2MzY0NDY3NmI2ZTcxNjBmMTc5M2NlN2RfMTQtOS0xLTEtMA_858d64fe-ded7-4b40-a0b7-19ccaab22d67"
      unitRef="number">0.0164</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i057e07bc9bcb479399b79efcba85a739_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMTU5Ng_5e9a2e1a-5429-4f1b-b321-f72902094a42"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if56a535a800d461ab07716bd1239fb0f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMTY5Ng_0c5dd025-f791-4d40-bf8d-9ebbfc078687"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDIwNw_c67b8337-5892-4d53-9393-b7d1184fbbee">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of the warrant liability for the nine months ended September 30, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjustment to exercise price of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Galena February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="id9131a32521e475eab282e97afd922ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0xLTEtMS0w_acbc5c06-e5b5-4596-8441-fe436e699666"
      unitRef="usd">52000</gale:FairValueOfWarrantsLiabilities>
    <gale:FairValueofWarrantsGranted
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0zLTEtMS0w_684dac00-7c69-4e2c-86ec-65907c865485"
      unitRef="usd">0</gale:FairValueofWarrantsGranted>
    <gale:FairValueOfWarrantsCanceled
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS01LTEtMS0w_44e0217c-7047-476d-a08a-f45f4f822def"
      unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
    <gale:FairValueOfWarrantsExercisePriceAdjustment
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS03LTEtMS0w_00d141ff-6003-4d9a-8c1a-3c5a7f4e6c95"
      unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
    <gale:ChangeInFairValueOfWarrantLiabilities
      contextRef="icaa7ee072f68418c90eab9807ff88890_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS05LTEtMS0w_cb4b900c-ea20-4aa2-87c0-374abca13a2e"
      unitRef="usd">25000</gale:ChangeInFairValueOfWarrantLiabilities>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMS0xMS0xLTEtMA_7574f34f-81bf-43b0-9ca5-6f7728046a30"
      unitRef="usd">27000</gale:FairValueOfWarrantsLiabilities>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="id9a368a29d574fe8b2f0a5ba89d8b926_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0xLTEtMS0w_9afeeaa9-4121-45d0-a877-17447a605bce"
      unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
    <gale:FairValueofWarrantsGranted
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0zLTEtMS0w_1fed7196-6dae-43bf-8c8b-c7db5f65e5ee"
      unitRef="usd">0</gale:FairValueofWarrantsGranted>
    <gale:FairValueOfWarrantsCanceled
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi01LTEtMS0w_c6642ca2-638b-4656-bfc1-5bc27216f0fa"
      unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
    <gale:FairValueOfWarrantsExercisePriceAdjustment
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi03LTEtMS0w_36431bc0-5ac6-4f02-a333-62e30981a551"
      unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
    <gale:ChangeInFairValueOfWarrantLiabilities
      contextRef="i748eb79d990944f6a914e9133d97c2d5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi05LTEtMS0w_91160f3c-bbb2-41df-80b0-090deab19b72"
      unitRef="usd">0</gale:ChangeInFairValueOfWarrantLiabilities>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="i13c6c834d79b43b2b4810fe704177d48_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfMi0xMS0xLTEtMA_d9f1c8dd-c0e5-42b3-8ad3-6ae3848376f8"
      unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0xLTEtMS0w_c7d74f14-7734-4196-ac83-d714b78992c6"
      unitRef="usd">52000</gale:FairValueOfWarrantsLiabilities>
    <gale:FairValueofWarrantsGranted
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0zLTEtMS0w_c3985c3e-fcd0-40e4-8aea-3d72d401d85e"
      unitRef="usd">0</gale:FairValueofWarrantsGranted>
    <gale:FairValueOfWarrantsCanceled
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC01LTEtMS0w_40c3d25d-d70e-4e53-b926-32312d1f6ac8"
      unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
    <gale:FairValueOfWarrantsExercisePriceAdjustment
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC03LTEtMS0w_bac70c40-fc23-4223-944d-250216b112fc"
      unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
    <gale:ChangeInFairValueOfWarrantLiabilities
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC05LTEtMS0w_29465c34-3d22-4621-8593-efabcc62de2d"
      unitRef="usd">25000</gale:ChangeInFairValueOfWarrantLiabilities>
    <gale:FairValueOfWarrantsLiabilities
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RhYmxlOmM4YmIxMTY5MTI4MDQ5ZGNiMWI0ZWExMGMyNjcxMTg0L3RhYmxlcmFuZ2U6YzhiYjExNjkxMjgwNDlkY2IxYjRlYTEwYzI2NzExODRfOC0xMS0xLTEtMA_22138af6-e7fa-49bd-8a37-1d1e42eae6d0"
      unitRef="usd">27000</gale:FairValueOfWarrantsLiabilities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzQwNg_64c4c0e4-bf5e-4121-89c1-9711231b1a8b"
      unitRef="shares">76000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ieffe68af4fe345c0bb928ab15ae7ea85_I20190306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzQ1Ng_50c475fe-750f-49e6-8ee5-4c170fa64e93"
      unitRef="usdPerShare">70.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idcee970816de4898aab068f1436dc88c_I20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzgwNA_98abfc38-7fc5-4b66-a72d-b7f8dc959772"
      unitRef="usdPerShare">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gale:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="ie359a0832f7942bdbf02a2c59e430ed4_D20200102-20200102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfMzkwNg_75e54866-f11e-4337-a527-074fd69190bc"
      unitRef="shares">63000</gale:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="ic21ba327b68645e39db322f2b5490a05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY182Ny9mcmFnOjA3YmY1MjVhOGEwZDRjMjU4MDVmMDA4OGMwYzI2MzI5L3RleHRyZWdpb246MDdiZjUyNWE4YTBkNGMyNTgwNWYwMDg4YzBjMjYzMjlfNDAwOA_62a5c9f7-0171-4bad-93b4-c637b3b86782"
      unitRef="usd">100000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwNA_749b7aef-1347-4360-9a7e-0a7cc8f61887">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of 24,204 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to (i) 454,005 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) 2,684 shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than four years, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of September&#160;30, 2020, 100,689 shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options to Purchase Shares of Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the nine months ended September 30, 2020 and 2019, respectively, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no options granted during the three months ended September 30, 2020 and 2019. The weighted-average grant date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $1.53 and $54.00, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#x2019;s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, there was $0.8 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#x2019;s operating expenses over a weighted-average period of 2.12 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity of the Company for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Number of&lt;br/&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of outstanding and exercisable stock options at September&#160;30, 2020 were calculated based on the closing price of the Company&#x2019;s common stock as reported on the Nasdaq Capital Market on September&#160;30, 2020 of $2.65 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#x2019;s common stock and the exercise price of the underlying stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RSUs with Performance and Service Conditions &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted RSUs subject to both performance-based and service-based vesting conditions to certain of its employees&#160;pursuant to the Company's 2019 Equity Incentive Plan that will settle in shares of common stock. These RSUs vest based on&#160;the achievement of certain clinical and regulatory milestones and the respective employee's continued employment with the Company. As of September&#160;30, 2020, there was $0.3 million of unrecognized compensation cost related to outstanding RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity of the Company for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic7c4d8cbc2a54d81bb75603f21e71592_I20171229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjIw_2029afab-6732-4c37-a932-2b2e3659486a"
      unitRef="shares">24204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5e452b96408744e7b8df56fd8bb09e82_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNzQ4_37bab700-8edc-4136-9d71-ddf17e92f5f3"
      unitRef="shares">454005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2016b111d5d5438a9afb8026836b746a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfOTc3_3468f82b-2ed9-4d26-bcc4-7775deaf7932"
      unitRef="shares">2684</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTMxOQ_153322b4-4cb7-41e3-8397-16c0de4f0acc">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i0abf8b20b41b4bffba686b04966786a8_D20190910-20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTQ0MA_31503786-dad9-470e-831c-200302e6dbc0"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie0346c87fde44172b58c4033836ca055_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMTYyOQ_ce57177d-07d8-4900-8f84-f8958e0e104c"
      unitRef="shares">100689</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYxNA_f2adcf1e-03f2-4303-be9d-e29ef359b61b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0326b4a15fb4f79b56050d8f382451e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi0xLTEtMS0w_3fbd4604-4b01-46b9-bf4e-843b4af8f370"
      unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i02e7017a8cdc4a0282dd6943f37e6465_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi0zLTEtMS0w_6cf343e1-29a2-4f79-8d3d-26c226c760a6"
      unitRef="usd">-1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7978d211d17840e58f2b8d3d7d3796a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi01LTEtMS0w_372e5faf-aae5-44bd-b6f6-9a9ffa6b80b8"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fa5608939c04c9f8ee26f0aac67c972_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMi03LTEtMS0w_381c358d-73a6-43da-b0a8-81d14ee72169"
      unitRef="usd">-4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37be4be95af44ceaaaa2b49b0947ba57_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy0xLTEtMS0w_492f50f1-7eb4-4d1f-a3c2-62df4178786d"
      unitRef="usd">141000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c151f4f312b4f67ae012e478ef3df7e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy0zLTEtMS0w_fde215b3-2bae-4e8c-9204-7caae42976f3"
      unitRef="usd">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcce4f272d22498990237677ea1747bc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy01LTEtMS0w_20381012-ff73-4938-9c26-84f695c6b43c"
      unitRef="usd">427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if26e5d011619471ead5000df2785d4af_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfMy03LTEtMS0w_e80dee2e-54ad-45ec-a985-7e3a876775f9"
      unitRef="usd">430000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC0xLTEtMS0w_a44474d4-7504-4a50-ba67-2440e6058a9f"
      unitRef="usd">146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC0zLTEtMS0w_fb4d921b-620c-43fd-93ce-6f87eb12a5fb"
      unitRef="usd">115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC01LTEtMS0w_9b1ecc61-6e64-42df-8fdb-3cb8e330440b"
      unitRef="usd">437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjJlOWFjNDI0NzIwNjQ0OTZiYjAxZmQ0Y2MwNjAwZGRlL3RhYmxlcmFuZ2U6MmU5YWM0MjQ3MjA2NDQ5NmJiMDFmZDRjYzA2MDBkZGVfNC03LTEtMS0w_30561a30-6aa4-4c0b-b41b-d8dd06151f91"
      unitRef="usd">426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwMQ_282c087a-2f32-4304-a64f-6f1d7a11f9cd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the nine months ended September 30, 2020 and 2019, respectively, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMi01LTEtMS0w_ba478698-3bf2-4162-bd35-dbb1f5a9f44e"
      unitRef="number">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMi03LTEtMS0w_c345abbb-fff1-4857-86af-adb0d3371357"
      unitRef="number">0.0249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMy01LTEtMS0w_c39d0032-1dee-4e72-a9d2-49b0c65b64a0"
      unitRef="number">1.0624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfMy03LTEtMS0w_25d6f210-ede6-4cc9-9dd5-be2ff4a3d810"
      unitRef="number">0.9657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNC01LTEtMS0w_b2201cc0-2ece-4250-9b77-9f5c199779a6">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNC03LTEtMS0w_0dd3e9b7-d762-4ce1-a967-ca7c77c60644">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNS01LTEtMS0w_bb18f877-37d4-4ae7-85ad-428b78987b78"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmYwMjhkMGU2Y2FlNjRjZDViZTE4NzJkMzE2ZTZmMDg0L3RhYmxlcmFuZ2U6ZjAyOGQwZTZjYWU2NGNkNWJlMTg3MmQzMTZlNmYwODRfNS03LTEtMS0w_5452d3a4-81d5-434b-abfb-d109cd1d01f7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i25819b81a08a4c37884c9892590906c8_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjI3NQ_6633efc3-ca54-4646-b699-5b6cd699276d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5157db189dde4c2695638890e78b8126_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjI3NQ_b5947c7f-20a7-427f-aa24-ff014fb7f911"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjQ1NA_b23acd7a-c86a-4031-9833-46dba7be2b3c"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic25846bafe5d48b2be3621585891630c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjQ2MQ_7cbce498-8c2c-4cb2-ab0f-f1ca0800c449"
      unitRef="usdPerShare">54.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjgyOQ_00712fa4-56b2-40f1-9120-857d8dd8933c">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i670c721655b24536abbe20f1d9e66a1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjg2NQ_1bb0d081-d9c1-414a-9e19-63470cd041d1">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i046188f82f2c42d1b09d3e35bf7d8bf5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMjkwMA_816109d8-2187-4a8c-9143-b71f00bf2f93">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzAzNw_751577b7-f344-4167-8c03-a3b003f1ae1f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzMxMA_c6fda687-732e-457e-8ebe-79db897f5be7"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzUwMw_177a8d53-24ec-4713-9d36-e2cda69219e6">P2Y1M13D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYyMw_a1469ae2-e007-4df1-8536-b4be62ec426f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity of the Company for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Number of&lt;br/&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS0xLTEtMS0w_b394b987-e797-44ed-8bdb-3d20cc82c850"
      unitRef="shares">21520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS0zLTEtMS0w_9853d785-e80b-4b52-bedb-0a6aa874cd14"
      unitRef="usdPerShare">112.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1d368953b9684c55abfc6c7bcd6ce9cd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS01LTEtMS0w_dbc808f0-48e7-4957-8cb4-361ff8ca5164">P8Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i526ba136e5e243d480e699d976eac2a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMS03LTEtMS0w_8b6212cb-9edf-436a-b17b-24bde9bd8165"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi0xLTEtMS0w_c9f80769-7050-4363-9e23-1d12a441f068"
      unitRef="shares">186000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi0zLTEtMS0w_8d090d0a-4249-43a1-b1f4-107da3e4c4a2"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfMi03LTEtMS0w_f7685d52-4af4-4260-8308-61e09c3795dd"
      unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS0xLTEtMS0w_fe550d3d-86df-4a15-8d40-69c2229d812c"
      unitRef="shares">207520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS0zLTEtMS0w_69ef6613-790f-465b-b336-6756045edf55"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS01LTEtMS0w_8a126f26-24b2-4711-b638-ec245a28fd16">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNS03LTEtMS0w_714c81f0-7c5f-4a5a-99e5-ab39d4b24623"
      unitRef="usd">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi0xLTEtMS0w_8473241d-b8ab-48b2-b794-1ed1b7f36b5e"
      unitRef="shares">10892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi0zLTEtMS0w_1a6b0e37-bb5b-4a8e-95c5-1675e20c99dc"
      unitRef="usdPerShare">129.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi01LTEtMS0w_ad6bf8fd-14a9-46cb-ae42-d42122cf0be5">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOjczMzBkN2YzY2I4YzQ2MWJiNTgzZjA5NDdkMjNiNzdlL3RhYmxlcmFuZ2U6NzMzMGQ3ZjNjYjhjNDYxYmI1ODNmMDk0N2QyM2I3N2VfNi03LTEtMS0w_9ff34411-1524-4d54-b270-2b7d0f4d2801"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <gale:ClosingPriceOfCommonStock
      contextRef="id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfMzgwNA_367bb35d-ca85-4fc6-8927-a2ed0bdd14d2"
      unitRef="usdPerShare">2.65</gale:ClosingPriceOfCommonStock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDQ1OQ_66d895ae-9b2a-404d-8410-e9a65a0915da"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RleHRyZWdpb246Yjk3NzYwM2YyZWU1NDc0ZDgwY2Q4YWYyY2I4MTAxNDJfNDYwMg_6e7cef16-7c17-4ddd-9a43-358ab8a26878">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity of the Company for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i97541f70c99c4d0d99f8987a97e11b2d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMS0xLTEtMS0w_fca10be4-eb16-42f2-8cf1-aea1f33d7249"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i97541f70c99c4d0d99f8987a97e11b2d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMS0zLTEtMS0w_45bf4c16-60a7-47cd-bbdb-0f7f47502a48"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMi0xLTEtMS0w_24245ae4-10e1-41bc-8cc3-aa8d122b7bdf"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMi0zLTEtMS0w_c9cdf42d-54c4-4885-87ae-b854dd8d4d82"
      unitRef="usdPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMy0xLTEtMS0w_f8906885-c42e-4bdf-a9ea-a8a773f90a89"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfMy0zLTEtMS0w_2b067a75-b037-4a93-8b4a-3c6b70fb89a8"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfNC0xLTEtMS0w_6e6e490e-0512-433c-84ba-d141a1abf156"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9abfdffef06e4cf2b6fa0c02344c71a0_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183MC9mcmFnOmI5Nzc2MDNmMmVlNTQ3NGQ4MGNkOGFmMmNiODEwMTQyL3RhYmxlOmQwOWEyOGM1OTg3NzQzMGRiZTVkZjcwMjRiOGI1YmZhL3RhYmxlcmFuZ2U6ZDA5YTI4YzU5ODc3NDMwZGJlNWRmNzAyNGI4YjViZmFfNC0zLTEtMS0w_f52e7a85-22bb-4664-93fe-a5ab667987fd"
      unitRef="usdPerShare">1.89</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY183My9mcmFnOjJmMWU0YWYyNWY0NjRkNDU5M2VjZTJmOGNkYjkwZDFlL3RleHRyZWdpb246MmYxZTRhZjI1ZjQ2NGQ0NTkzZWNlMmY4Y2RiOTBkMWVfMTc4Mw_5f9327e1-d3b3-4ce4-8c5e-ac8494af73f7">Subsequent EventsThe Company evaluated all events or transactions that occurred after September&#160;30, 2020 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372743096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square, Suite 2503,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">438-4353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,461,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345370503080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="nump">$ 7,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockSubscriptionReceivableCurrent', window );">Stock subscription receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,333<span></span>
</td>
<td class="nump">8,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,509<span></span>
</td>
<td class="nump">16,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">3,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,219<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,561<span></span>
</td>
<td class="nump">10,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 9,461,978 and 5,080,100&#160;shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively.</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">122,126<span></span>
</td>
<td class="nump">107,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(114,188)<span></span>
</td>
<td class="num">(101,147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">6,093<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 18,509<span></span>
</td>
<td class="nump">$ 16,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockSubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockSubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373720600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">9,461,978<span></span>
</td>
<td class="nump">5,080,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">9,461,978<span></span>
</td>
<td class="nump">5,080,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373672184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="nump">$ 6,511<span></span>
</td>
<td class="nump">$ 5,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">6,312<span></span>
</td>
<td class="nump">7,523<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses and operating loss</a></td>
<td class="num">(4,492)<span></span>
</td>
<td class="num">(4,184)<span></span>
</td>
<td class="num">(12,823)<span></span>
</td>
<td class="num">(12,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,473)<span></span>
</td>
<td class="num">(4,202)<span></span>
</td>
<td class="num">(13,041)<span></span>
</td>
<td class="num">(11,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendArisingFromWarrantModifications', window );">Deemed dividend arising from warrant modifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,268)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(8,659)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (4,473)<span></span>
</td>
<td class="num">$ (11,470)<span></span>
</td>
<td class="num">$ (13,119)<span></span>
</td>
<td class="num">$ (20,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (11.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">8,418,038<span></span>
</td>
<td class="nump">4,281,855<span></span>
</td>
<td class="nump">7,174,859<span></span>
</td>
<td class="nump">1,805,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendArisingFromWarrantModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Arising From Warrant Modifications</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendArisingFromWarrantModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345394361256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">440,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 5,245<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 87,099<span></span>
</td>
<td class="num">$ (81,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">13,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for exercise of warrants, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,095,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for exercise of warrants, net of offering costs</a></td>
<td class="nump">3,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValuePreFundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendModificationOfWarrants', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,873)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,549,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">10,637<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">104,360<span></span>
</td>
<td class="num">(93,728)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,002,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">14,338<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">103,862<span></span>
</td>
<td class="num">(89,526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,032,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValuePreFundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,202)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,549,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">10,637<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">104,360<span></span>
</td>
<td class="num">(93,728)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,080,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">6,093<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">107,235<span></span>
</td>
<td class="num">(101,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">14,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">14,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValuePreFundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,041)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,461,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">122,126<span></span>
</td>
<td class="num">(114,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">113,491<span></span>
</td>
<td class="num">(109,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,744,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">8,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,473)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,461,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 7,948<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 122,126<span></span>
</td>
<td class="num">$ (114,188)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend, Modification Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesCommonStockandWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesCommonStockandWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodValueCommonStockandWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodValueCommonStockandWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodValuePreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value, Pre-Funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodValuePreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372871064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">$ (13,041)<span></span>
</td>
<td class="num">$ (11,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInOperatingLeaseRightOfUseAssets', window );">Change in operating lease right of use assets</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(588)<span></span>
</td>
<td class="num">(480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,123)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="num">(715)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,841)<span></span>
</td>
<td class="num">(13,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">14,455<span></span>
</td>
<td class="nump">13,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromStockSubscriptionReceivable', window );">Collection of stock subscription receivable</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,767<span></span>
</td>
<td class="nump">17,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">3,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="nump">5,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</a></td>
<td class="nump">8,303<span></span>
</td>
<td class="nump">9,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the period for interest</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right of use asset and current and non-current lease liability</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NoncashOfferingExpense', window );">Offering expenses in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification Of Warrant Liability Upon Exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Operating Lease Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NoncashOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Offering Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NoncashOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Subscription Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrant Liability Upon Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367862312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S ("GPS"), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. In January 2020, the Company commenced a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission. SELLAS&#8217; second product candidate, nelipepimut-S ("NPS"), is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.</span></div>On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus as a &#8220;pandemic&#8221;. First identified in late 2019 and known now as COVID-19, the coronavirus outbreak has impacted millions of individuals worldwide and continues to present substantial public health and economic challenges around the world. It is difficult to predict with any certainty the length of time and the full extent to which the pandemic will continue to impact, directly and indirectly, our business and operations. The duration and extent of the impact of the pandemic will depend on future developments, which are highly uncertain, subject to change and cannot be predicted with confidence, including the duration of the outbreak, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, the re-emergence of more severe outbreaks in the fall or winter, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on the Company's business and the Company's financial results. The Company continues to monitor the situation closely, especially the extent to which precautions taken by clinical sites are impacting the timelines for the Company's clinical trials, including the Company's Phase 3 GPS trial, but given the uncertainty, management cannot estimate the impact of the COVID-19 pandemic on the Company's financial statements or operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369254168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text">Liquidity<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes. It is likely that additional financing, beyond the financings described below, will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. The Company cannot be certain at this time of the impact of the COVID-19 pandemic on its ability to raise additional capital as needed, or on acceptable terms. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain investors  (the &#8220;PIPE Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), 2,744,078 shares of its common stock and accompanying warrants to purchase up to an aggregate of 2,744,078 shares of common stock at a combined purchase price of $3.335 per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $3.30 per share and will expire five years from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$8.5&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January 2020 Registered Offering&#8221;), (i) an aggregate of 1,189,000 shares of common stock at an offering price of $3.9825 per share and (ii) an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at an offering price of $3.9725 per Pre-Funded Warrant, for gross proceeds of approximately $6.5 million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share. Each warrant is immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$6.0 million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or the failure of any of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had cash and cash equivalents of approximately $8.2 million, and restricted cash and cash equivalents of $0.1 million. The Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $114.2 million as of September&#160;30, 2020. In addition, the Company had current liabilities of $4.2 million as of September&#160;30, 2020. The Company expects its cash and cash equivalents as of September&#160;30, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements through the second quarter of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367862312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Summary of Significant Accounting Policies included in the Company's 2019 Annual Report have not materially changed, except as set forth below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Interim Results </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2019 Annual Report. The accompanying consolidated financial statements at&#160;September&#160;30, 2020&#160;and for the three and nine months ended September 30, 2020 and 2019, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2019 have been derived from the audited financial statements as of that date.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2019, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1 - for - 50 reverse stock split of the Company's outstanding shares of common stock, which became effective on November 7, 2019. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company&#8217;s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans were proportionately adjusted for the reverse stock split.  The reverse stock split reduced the number of shares of the Company&#8217;s common stock that were outstanding at November 8, 2019 from 227,800,147 to 4,549,208, after the cancellation of fractional shares. No fractional shares were issued in connection with the&#160;reverse&#160;stock&#160;split.&#160;Stockholders who otherwise held fractional shares of the Company&#8217;s common stock as a result of the&#160;reverse&#160;stock&#160;split&#160;received a cash payment in lieu of such fractional shares. These consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units with Performance and Service Conditions</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the nine months ended September 30, 2020, the Board of Directors granted restricted stock units ("RSUs") to certain employees that vest based on performance and service conditions. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense is recognized for the number of RSUs expected to be earned, provided the requisite service period has been rendered, after assessing the probability that certain performance criteria will be met. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or are not expected to be met, any compensation expense previously recognized to date associated with the RSUs will be reversed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, FASB issued No. ASU 2018-13,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU No. 2018-13")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820.&#160;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's disclosures. For the new disclosure regarding our Level 3 instruments, please read Note 4 to these consolidated financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Nonemployee Share-Based Accounting ("ASU No. 2018-07")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. ASU No. 2018-07 supersedes ASC 505-50 and expands the scope of ASC 718, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation (Topic 718) ("ASC 718")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's consolidated financial statements and related disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369199992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any financial instruments into or out of Level 3 classification during the three or nine months ended September&#160;30, 2020 or during the year ended December 31, 2019.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the nine months ended September&#160;30, 2020. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September&#160;30, 2020 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s nelipepimut-S ("NPS") product candidate, of which $2.0 million has been paid to date. The remaining contingent consideration of up to $30.0 million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of September&#160;30, 2020, estimated future contingent milestone payments related to the Company's business range from zero, if no milestone events are achieved, to a maximum of $30.0 million if all development and commercial milestones are reached. As of September&#160;30, 2020, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 11.8% for development milestones and cost of debt of 5.4% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjkwOTFhYjE4MjQzY2Q4MGZjOGIwZmRiOWJhOGRjL3NlYzpiYWI5MDkxYWIxODI0M2NkODBmYzhiMGZkYjliYThkY181Mi9mcmFnOjkzNzkwZThiZjdkYTQyMTZhNzQ4Zjc2MWJjOTc1YjM0L3RleHRyZWdpb246OTM3OTBlOGJmN2RhNDIxNmE3NDhmNzYxYmM5NzViMzRfMjU4MQ_25e0b964-a33f-48bd-9fac-2954e0ad7f70">five</span> to eight years as of September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367862312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts</a></td>
<td class="text">Balance Sheet Accounts<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369281208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Space</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, the Company entered into a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The Company recognized a current operating lease liability of $0.1&#160;million and a non-current operating lease liability of $0.9&#160;million with a corresponding right of use asset ("ROU") of $1.0&#160;million, which is based on the present value of the minimum rental payments of the lease. The discount rate of the Company's operating lease under ASC 842 is the Company's estimated incremental borrowing rate of 13%. As of September&#160;30, 2020, the lease has a remaining term of 4.25 years.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a non-cancelable operating lease for office space in New York, New York, which began on August 1, 2018 with a term through July 31, 2020. The Company adopted ASC 842 in the first quarter of 2019 and as a result of the adoption, the Company recognized a current operating lease liability of $0.4 million and a non-current operating lease liability of $0.2 million with a corresponding ROU of $0.6 million, which is based on the present value of the minimum lease payments of the lease. The discount rate used to account for the Company's operating lease under ASC 842 is the Company&#8217;s estimated incremental borrowing rate of 13%. The lease expired on July 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to the Company's operating leases was approximately $0.1 million for each of the three months ended September&#160;30, 2020 and 2019. Rent expense related to the Company's operating leases was approximately $0.3&#160;million for each of the nine months ended September&#160;30, 2020 and 2019. Future minimum lease payments under the Company's non-cancelable operating leases are as follows as of September&#160;30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease amortization of the ROU asset was $0.1 million for each of the three months ended September&#160;30, 2020 and 2019 and $0.3&#160;million for each of the nine months ended September&#160;30, 2020 and 2019.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss. On December 20, 2019, the lead plaintiffs filed a Second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, certain of the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the two complaints filed in the U.S. District Court for the District of New Jersey.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367865112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to 5,000,000&#160;shares of preferred stock, $0.0001&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to 350,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Maxim Group LLC (the "Agent"), pursuant to which the Company was permitted to offer and sell shares of common stock through the Agent having an aggregate offering price up to $5.0 million in gross proceeds. In connection with such sales, the Agent collected fees equal to 3% of the gross sales price of all shares of common stock sold. Sales of the shares under the Distribution Agreement were made in transactions deemed to be "at the market offering" as defined in Rule 415 under the Securities Act of 1933. Shares sold under the Distribution Agreement were offered and sold pursuant to the Company's effective registration statement on Form S-3. During the year ended December 31, 2019, the Company sold&#160;524,097&#160;shares of common stock pursuant to the Distribution Agreement for net proceeds of&#160;$2.7 million. The Distribution Agreement was terminated on January 9, 2020. There were no shares of common stock sold pursuant to the Distribution Agreement in 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the &#8220;January 2020 Registered Offering&#8221;), (i) an aggregate of 1,189,000 shares of common stock, par value $0.0001 per share, of the Company, at an offering price of $3.9825 per share and (ii) an aggregate of 448,800 pre-funded warrants exercisable for shares of common stock  at an offering price of $3.9725 per pre-funded warrant, for gross proceeds of approximately $6.5 million before deducting the placement agent fee and related offering expenses. In a concurrent private placement, the Company issued to the Investors who participated in the January 2020 Registered Offering warrants exercisable for up to an aggregate of 818,900 shares of common stock at an exercise price of $3.93 per share. Each warrant was immediately exercisable upon issuance and will expire five and one-half years from the issuance date. The net proceeds to the Company from the January 2020 Registered Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, was approximately&#160;$6.0 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain investors  (the &#8220;PIPE Investors&#8221;), pursuant to which the Company agreed to issue and sell, in a private placement directly to the PIPE Investors (the "July 2020 PIPE Offering"), 2,744,078 shares of its common stock and accompanying warrants to purchase up to an aggregate of 2,744,078 shares of common stock at a combined purchase price of $3.335 per share and accompanying warrant. The warrants were immediately exercisable upon issuance at an exercise price of $3.30 per share and will expire five years from the date of issuance. The July 2020 PIPE Offering closed on August 4, 2020. The net proceeds to the Company from the July 2020 PIPE Offering, after deducting placement agent fees and related offering expenses, and excluding the exercise of any warrants, were approximately&#160;$8.5&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The shares of common stock (and shares of common stock underlying the warrants) issued in the July 2020 PIPE Offering were registered under the Securities Act of 1933, as amended, pursuant to a Registration Statement on Form S-3 (333-246333) filed with the Securities and Exchange Commission ("SEC") and declared effective on August 24, 2020. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Subscription Receivable</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December 31, 2019, the Company sold 75,000 shares of common stock for gross proceeds of $0.3 million. As the gross cash proceeds of $0.3 million were not received until January 2, 2020, the Company recorded a stock subscription receivable of $0.3 million as of December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369247432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants to Acquire Shares of Common Stock</a></td>
<td class="text">Warrants to Acquire Shares of Common Stock<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Outstanding</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the nine months ended September&#160;30, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-funded January 2020 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017 Equilibria</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Liabilities </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for Series A Convertible Preferred Stock, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined not to be indexed to the Company&#8217;s common stock. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,901.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,494.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the nine months ended September 30, 2020 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to exercise price of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Equity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the January 2020 Offering and concurrent private placement and the warrants to acquire shares of common stock issued during the July 2020 PIPE Offering were recorded as equity upon issuance. During its evaluation of equity classification of these pre-funded warrants and common stock purchase warrants, the Company considered the conditions as prescribed within ASC 815-40,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,&#160;Contracts in an Entity&#8217;s own Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Modification</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company entered into a Warrant Exercise Agreement (the "March 2019 Exercise Agreement") with one of the holders of the Company's warrants issued in July 2018. Pursuant to the March 2019 Exercise Agreement, new warrants to purchase up to an aggregate of approximately 76,000 shares of common stock at an exercise price of $70.00 per share ("March 2019 Exercise Agreement Warrants") were issued on a share-for-share basis in an amount equal to the number of the warrants issued in 2018 that were cash exercised by the warrant holder prior to May 31, 2019. On January 2, 2020, the Company amended the March 2019 Exercise Agreement Warrants to provide for an exercise price of $7.50 per share (subject to adjustment for stock splits and the like). The reduced exercise price of the 63,000 March 2019 Exercise Agreement Warrants increased the fair value of these warrants by approximately $0.1 million during the nine months ended September 30, 2020, which is recorded as a deemed dividend increasing the net loss attributable to common stockholders and additional paid-in-capital.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369460808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of 24,204 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to (i) 454,005 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) 2,684 shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than four years, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of September&#160;30, 2020, 100,689 shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to Purchase Shares of Common Stock </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the nine months ended September 30, 2020 and 2019, respectively, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the three months ended September 30, 2020 and 2019. The weighted-average grant date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $1.53 and $54.00, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was $0.8 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of 2.12 years.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of outstanding and exercisable stock options at September&#160;30, 2020 were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on September&#160;30, 2020 of $2.65 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs with Performance and Service Conditions </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted RSUs subject to both performance-based and service-based vesting conditions to certain of its employees&#160;pursuant to the Company's 2019 Equity Incentive Plan that will settle in shares of common stock. These RSUs vest based on&#160;the achievement of certain clinical and regulatory milestones and the respective employee's continued employment with the Company. As of September&#160;30, 2020, there was $0.3 million of unrecognized compensation cost related to outstanding RSUs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367857848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluated all events or transactions that occurred after September&#160;30, 2020 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345366184104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock', window );">Restricted Stock Units with Performance and Service Conditions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units with Performance and Service Conditions</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the nine months ended September 30, 2020, the Board of Directors granted restricted stock units ("RSUs") to certain employees that vest based on performance and service conditions. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense is recognized for the number of RSUs expected to be earned, provided the requisite service period has been rendered, after assessing the probability that certain performance criteria will be met. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or are not expected to be met, any compensation expense previously recognized to date associated with the RSUs will be reversed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted an Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, FASB issued No. ASU 2018-13,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU No. 2018-13")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820.&#160;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's disclosures. For the new disclosure regarding our Level 3 instruments, please read Note 4 to these consolidated financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Nonemployee Share-Based Accounting ("ASU No. 2018-07")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. ASU No. 2018-07 supersedes ASC 505-50 and expands the scope of ASC 718, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation (Topic 718) ("ASC 718")</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company's consolidated financial statements and related disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock Unit, Performance And Service Conditions [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367994312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367847640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September&#160;30, 2020 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369470904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345367999672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text">Future minimum lease payments under the Company's non-cancelable operating leases are as follows as of September&#160;30, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369413704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369256312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity Table</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the nine months ended September&#160;30, 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-funded January 2020 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017 Equilibria</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,901.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,494.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the nine months ended September 30, 2020 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to exercise price of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Preferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galena February 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345369320888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019, respectively (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the nine months ended September 30, 2020 and 2019, respectively, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345378846904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">524,097<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="nump">7,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,188<span></span>
</td>
<td class="nump">$ 101,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OfferingPricePershare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightOutstandingExercisable', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromWarrantExercisesGross', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember', window );">PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="nump">2,744,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="nump">2,744,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share (in dollars per share)</a></td>
<td class="nump">$ 3.335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OfferingPricePershare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightOutstandingExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightOutstandingExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OfferingPricePershare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Price Per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OfferingPricePershare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromWarrantExercisesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromWarrantExercisesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345365960760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 07, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">227,800,147<span></span>
</td>
<td class="nump">9,461,978<span></span>
</td>
<td class="nump">5,080,100<span></span>
</td>
<td class="nump">4,549,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373684504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,242<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">3,864<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373313816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">5,207<span></span>
</td>
<td class="nump">4,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Prices&#160;In Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable&#160; Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Unobservable&#160; Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 5,207<span></span>
</td>
<td class="nump">$ 4,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372779384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) - Unobservable&#160; Inputs (Level 3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, December 31, 2019</a></td>
<td class="nump">$ 4,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the estimated fair value of the contingent consideration</a></td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, September 30, 2020</a></td>
<td class="nump">$ 5,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372760488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - Apthera, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration payable, maximum amount</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="nump">$ 32,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration paid</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow', window );">Contingent consideration payable, minimum amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones', window );">Business combination, contingent consideration, timing of development milestones</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones', window );">Business combination, contingent consideration, timing of development milestones</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Weighted average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, measurement input (as a percent)</a></td>
<td class="nump">0.118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Cost of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, measurement input (as a percent)</a></td>
<td class="nump">0.054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=gale_MeasurementInputWeightedAverageCostOfCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=gale_MeasurementInputWeightedAverageCostOfCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=gale_MeasurementInputCostOfDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=gale_MeasurementInputCostOfDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373160280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 693<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PrepaidResearchAndDevelopment', window );">Clinical trial costs</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PrepaidProfessionalServices', window );">Professional fees</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PrepaidProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Professional Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PrepaidProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372903688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,304<span></span>
</td>
<td class="nump">$ 1,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373407496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeaseRightOfUseAssetAmortization', window );">Operating lease amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringDecember312024Member', window );">Office Space Lease Expiring December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringJuly312020Member', window );">Office Space Lease Expiring July 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, discount rate (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Office Space Lease Expiring December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Office Space Lease Expiring July 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringJuly312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gale_OfficeSpaceLeaseExpiringJuly312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345376854648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (remaining)</a></td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current and non-current operating lease liability</a></td>
<td class="nump">$ 1,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345378931560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">524,097<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockSubscriptionReceivableCurrent', window );">Stock subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OfferingPricePershare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightOutstandingExercisable', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromWarrantExercisesGross', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OfferingPricePershare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember', window );">PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="nump">2,744,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="nump">2,744,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share (in dollars per share)</a></td>
<td class="nump">$ 3.335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gale_DistributionAgreementMember', window );">Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SaleOfStockAuthorizedAmount', window );">Sale of shares, common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SaleOfStockAgentFeePercentageOfGrossProceeds', window );">Percentage gross proceeds from the sale of share (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightOutstandingExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightOutstandingExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OfferingPricePershare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Price Per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OfferingPricePershare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromWarrantExercisesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromWarrantExercisesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SaleOfStockAgentFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SaleOfStockAgentFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockSubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockSubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gale_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_PIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345378773240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">3,864,000<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">207,520<span></span>
</td>
<td class="nump">21,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan (in shares)</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance (in shares)</a></td>
<td class="nump">4,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding (in shares)</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345376993608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">4,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">3,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2020PIPEOfferingMember', window );">July 2020 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_January2020OfferingMember', window );">January 2020 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_PreFundedJune2019OfferingMember', window );">Pre-funded January 2020 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2019OfferingMember', window );">June 2019 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember', window );">March 2019 Exercise Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember', window );">July 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember', window );">2017 Equilibria</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Canceled Or Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2020PIPEOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2020PIPEOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_January2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_January2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_PreFundedJune2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_PreFundedJune2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372819640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">3,864<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">131.54%<span></span>
</td>
<td class="nump">112.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.16%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 1,650.00<span></span>
</td>
<td class="nump">$ 1,650.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 4 months 13 days<span></span>
</td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">135.60%<span></span>
</td>
<td class="nump">114.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 30,901.09<span></span>
</td>
<td class="nump">$ 41,494.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
<td class="text">1 year 5 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">135.60%<span></span>
</td>
<td class="nump">114.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373179592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2019Member', window );">Warrants 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2020Member', window );">Warrants 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Decrease (increase) in warrant fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_Warrants2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345373294184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, beginning balance</a></td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, ending balance</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, beginning balance</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, ending balance</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants, Exercise Price, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345377104968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 54.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">454,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Increase in number of shares available for future issuance under stock based awards (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345377164584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345365248184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">106.24%<span></span>
</td>
<td class="nump">96.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372742312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">21,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">207,520<span></span>
</td>
<td class="nump">21,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">10,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 112.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">13.38<span></span>
</td>
<td class="nump">$ 112.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 129.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140345372917608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 54.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M)X)M4;,Y7&E(!0  <A4  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R5
MF%UOXD84AJ^WOV*$>K$K0;#'$,(J02(DV4;-LB1.6Z55+P9[ "NVQSLSAO#O
M>\;&-HG,L7N3^.N\///UGC-SN1/R56TXU^0M"F-UU=EHG7SM]Y6WX1%39R+A
M,;Q9"1DQ#;=RW5>)Y,S/@J*P3RWKO!^Q(.Y,+K-G"SFY%*D.@Y@O)%%I%#&Y
MO^:AV%UU[$[QX"E8;[1YT)]<)FS-7:[_2!82[OJEBA]$/%:!B(GDJZO.U/XZ
M<Z@)R+[X,^ [=71-3%.60KR:FWO_JF,9(AYR3QL)!O^V?,;#T"@!Q\^#:*?\
M31-X?%VHWV6-A\8LF>(S$?X5^'ISU;GH$)^O6!KJ)['[C1\:-#1ZG@A5]I?L
M\F\'@P[Q4J5%= @&@BB(\__L[= 1QP'T1  ]!- / ?:I7W . 4[6T)PL:]8-
MTVQR*<6.2/,UJ)F+K&^R:&A-$)MA=+6$MP'$Z<E,;+DD/:(V3')UV=>@:=[T
MO4/\=1Y/3\2/R7<1ZXTBM['/_??Q?6 I@6@!=$U109<G9\2QNH1:U*KAF>'A
M<[$]([93%_X.QRG[Q\GT'+1__IDNE98PY?Y%) >EY""3')R0O!%>"@M!D^=]
MPNMZ' ^WK=XC0C$L*8;M*!Y3)C67X9X\\41(74>$2VF9<H3HO"0Z;T>TX#(0
MOIE1!.9T;1?A2L4<^N73IX9I,"K91BW'3#*PL,R!3G<7KK5BH<+ZZZ)DND!U
M;F,=Z#VY"T).YFFTY+*.!=>P++OG../A!<(S+GG&;7B>^#HPBP4Z:\ZBVM'#
M==S;AX>I2QZ"%2>N%_#8XXI\DR)-NN0^]LX05-NJ;,]J PMZ0L(P,C.B7>)J
MF&]$2#(3::SE'O[[M2UH4+^YQ2"/O-EN _G,WLB]#[,O6 5>1HJ,=X,DM7H7
MUG@\M"E&2"M"VH9PZON0/52WN(#!BSGY$=?W'2XY(L]0)RCB_@1CXC F:0!C
M0H>6T\60*T.WG?^%/#-W,.3/8A?7XN)R<ZA47J!20>&JU&#CYOX1KIR0"RFV
M :R$6D)<<_Z"H57YPL9=_B/:0BC-0O)WD)Q>);BB;5G..<9690X;-_QL#*=0
MQIY&P04^C^W1%PRE2A0V[NX/PH->66Q$C+ER@\C N>@-G*&#$55IPL8]_CG0
MD"'$BMCT\_(+<;F72NBO6BQ<:2:B",S'U<)[[9)?K3,+\@=)F"1;%J:<)% J
M984DQEVE$QO/ Y!J_2!>$W<?+458B]N02!Y<K""M<@7%W;SH,7+[YFU8O.8G
M$UN#T'SJWDRQXHU6J8&V2@VS5$I3EN2U2-9;X!AI;2'?H/CRL?Q_3U:E!-HJ
M)=S'4%3FFS13Q;$"M98,5VP@JYR?MG)^4S!!A@=C70M9NPP:=.8B[C'/@ZTH
MU W<SP4QPLK^:2O[=R,6AN0Z5?!:U8\EKM-0D=/*]&DKT[^-N%R;V05EV$YO
MP&6CA,7U?8<+-A6_M/)\BEMVT5<;#GV% >$RC4"5\U/<M(LE^<XDW6Q?37ZD
M&K)E;/RL=D^;*P\S97/RLIV,!^?V> 1U^;8.JC)_VFJ3,(.5)R$OW<,N_8W\
MSNM[JFFO8-G.V!J,L,T"K>R=XNY<6-==H$S&?.&01K M7X-<KV?3GF-C6_[*
M\)V&\KW8[1VSW<'#VK78(-9T$%%9OH,;]$>JPS;Y-!<N]XA5%TYE]PYNSE-
M\G.LD-5-[NL&@9,+L']TJF7\)SOL4\0S6[/\@*M\6AXH3K-CM'[U>7X:^9T9
M^U(DY"L(M<Y&L-)D?L"7WVB19&=D2Z&UB+++#6<^E^8#>+\20A<WY@?*8];)
M?U!+ P04    "  G@FU1Q= =#>T%  !L%P  &    'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;*V8;7.;.!#'OXK&[73:&2>6A#$X<3R3)KEK9GIMIDZOKV50
M8DT!44GDX3[]29@8C(2<WMR+-H!W5S\M8O]:+1ZY^"DWE"KPE&>%/!MME"I/
M)A.9;&A.Y#$O::%_N>,B)TK?BON)+ 4E:>V49Q,,X6R2$U:,EHOZV8U8+GBE
M,E;0&P%DE>=$/'^D&7\\&Z'1RX-O['ZCS(/)<E&2>[JBZGMY(_3=9!<E93DM
M).,%$/3N;'2.3BX":!QJB[\9?92=:V"FLN;\I[FY3L]&T!#1C";*A"#ZSP.]
MH%EF(FF.7TW0T6Y,X]B]?HG^1SUY/9DUD?2"9S]8JC9GHW@$4GI'JDQ]XX^?
M:#.AT,1+>";K_\%C8PM'(*FDXGGCK ER5FS_DJ<F$1T'-!UPP(T#?JU#T#@$
M]42W9/6T+HDBRX7@CT 8:QW-7-2YJ;WU;%AA7N-*"?TKTWYJ>?'UR^KKY^O+
M\]NK2_#Q_//YEXLKL/IT=76[ D?@^^H2O'_[ ;P%K "W&UY)4J1R,5%Z9.,_
M29I1/FY'P0.CK&AY# (X!AABZ'"_\+M?TD2[(^..YOON$SW?W:3Q;M*XCA<,
M3;H2@A8*$"FIDB>>B,$N8E!'G Y%)'(#=&Y 8B[HKXH]D$P/X<S5-M2L#F4^
MLX=EC&&PF#QT,V(;13B*=D9[E-,=Y=1+^8U*)5BB:,/Y6N!MU+##@B#L\?IM
M]G##'6[HQ5TIGOS4!68M$\%*M2T<"=6DZXRZ.$.+H4]I6P0P=E/.=I0S+^6-
MH"5A*:!/NK1**NNL<K6A0G^_W77F(IXYLA;TH6VC,!Q8"=$..O)"WW)%LE?P
M1=;0\R#H+U7;*,93[ :,=X"Q%_!K2051K+@'&=55&@A3CH_XW5&E;VI>%VYL
MXR+4H[5M,!K(YGP'._?"7A='I> )E5(O4$F)2+;?5DH?M$Z66O6<M'/[O4;6
M=W7 :(\7P;;J0R_QGYRGCRS+G*4<VHMRCJ8]KD-6^V =.4)>L$M:<LE4]RL:
M7IU-K"[#+.R_;X=1&,P&.%L%0?@5'Y '#=OIB4,X[\,YS&:SCMD^7BM'*'B5
MPF6,K%G&%*->F4.M@B"_A)PG":^T3("2/ ^58>30@BBRIFY;!7,X4#90JQG(
M+QH:4%346XX[27'BVR*! VBM?]L*H0@-X+=B@OQJTJ][+ZS/3E*'?'26=@-J
M&PT6/-3J!_H= 3F445LAIAA9"\*V"O%\J-2U0H)^3TEV&1V#@A='S12<V+94
MQ%%?_!Q&0\BMG""_GES2.ZJI4J#(TX$58,L#GN$^HM]H?PO=2@CV2\@/(@3I
MO'LG'[95 D<]/(=-.$37Z@CVZ\@%+\P[-XLSX;KI3.M%P LGI$,A4-P78H?5
M=(Z&0#NMR&N$Y, 'A!TR <-97^K<9FA ['"K)OA =\/SG"FSC=F6T^0EN8GF
M!>^_<$7![(,3W!O8G%&<R)(D]&Q4FIV3>*"C)7 UB/]#H/W)MXJ'IUXIK;N0
M#<_T"I+OWL2Z=I[6_9)Z]BDJ;@4+^P5+]P_-UR[-2&/P%AY#"-&[-V@&3TLB
M@.[,*GH*PK%^;/YM?Y$;(HR\56K#!?N'IJ=@185Y(>?F!3U0H9@6:%#VXZ-H
M'$((&O^42G9?$&7\"_[RE$EI1+36SDI)I2],!25*CU$JFJ^UG+[T\[65;M&;
MI\XVO5D-AQLTK\E^AEM-Q7Y--<M7]XX'TAN$\$""QV ^GL[0>![%]9SU"XGA
M&/7L_W/JME%>\C<VK41)ZU.N[/G8F4Y7]]C/IZ-Y',AGJ_W8K_WG:<I,+=5U
MRW2^1ZP "2F9KF-.2EO6$<8(]_<I+CL8X6 (M]T 8/\&0.\(J[S*S!(W!WPL
M84ZUQ[:0'R$T17'<!W490FTZL*G"K>YCO^YOM4 .%APGMBWNT7QJ,=M6NLL(
MW,!!NP<(_'L 2[SJ!?U[$VB&Z)YTN3HEEYFC4YITCD+-.?1?1-RS0NJ]WYWV
M@\>13H'8'NUN;Q0OZ]/1-5>*Y_7EAA*-;@ST[W=<JUMS8PY<=P?LRW\!4$L#
M!!0    ( ">";5&+['(DX0(  &@*   8    >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULM59=;]HP%/TK5K2'5NJ($PB!"I H,+52UZ*FVY[=Y$*L.G%F&VCW
MZV<G:1J@?'4:#\0?Y]Q[CG.3W-Z*BV<9 RCTDK!4]JU8J>S2MF480T)D@V>0
MZIT9%PE1>BKFMLP$D"@G)<QV,6[;":&I->CE:U,QZ/&%8C2%J4!RD21$O%X!
MXZN^Y5AO"P]T'BNS8 ]Z&9E# .I'-A5Z9E=1(II *BE/D8!9WQHZER,G)^2(
MGQ16LC9&QLH3Y\]F<A/U+6P4 8-0F1!$7Y8P L9,)*WC=QG4JG(:8GW\%OU;
M;EZ;>2(21IS]HI&*^U;'0A',R(*I![ZZAM*09^*%G,G\'ZT*K.=;*%Q(Q9.2
MK!4D-"VNY*4\B!K!:>T@N"7!/9;0+ G-W&BA++<U)HH,>H*OD#!H'<T,\K/)
MV=H-3<UM#)30NU3SU&!T?Q?<W]Z,AX^3,;H:W@[O1A,47$\FCP$ZFQ(!J8I!
MT9"P<_05?4$VDK%>E3U;Z>PFAAV6F:Z*3.Z.3 %D#=3$%\C%+OZ /MI/'T.H
MZ8ZA.]UUNJT]5\;=RKB;QVOMB#?5Y0)"0(3T&8?/%R@C BT)6P ZHRF*.&-$
M2)2!*!R??^2X2.'G*<P#LQS@!L;8Z=G+NK.#L#4'S<I!\S0'Q9U!9*%B+N@?
MO6&<%*L?RB_B>S5='LY_&_H/X]8,M"H#K4\9H%(N#HMO;8G:E+T/L2;8JP1[
MGQ*L7X]2D32BZ?R0:N^@ZGV(-=7M2G5[K^H13Q+]POR',F\?5^8'86OR_4J^
M?X+\DVO<WSK.9EF\FP=_#'+-0:=RT#G=P7%%WMG2U&VUG:[?V="^C?-P!SN[
ME'<KY=W3E9]0[=TCY6_C]LIW\/O7#>\U$("@6O(0O3^Z@3&SYP/BU#Z=SG]^
M 9<)ZL8=W]NJS(.PPH!=:P-,#_:=B#E-)6(PTSS<\'4 4;0UQ43Q+.\,GKC2
M?48^C'4K",( ]/Z,<_4V,<U&U5P._@)02P,$%     @ )X)M49>6':T,!0
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ME$ (5P#X?\6Y>ONH.FCOJ2;_ 5!+ P04    "  G@FU1R0VB<+L'  !'+
M&    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+V:^V_;-A#'_Q7!*+ 6J&N^
M]"J2 /4+S=8V69QN&(;]H,AR+%267$E.VO]^E*R8%H^D8B<-4#1^W!V//)*?
M+RF?W&?YMV(91:7U8Y6DQ6EO69;K]X-!$2ZC55"\R]91RK]99/DJ*/G;_'90
MK/,HF-=.JV1 $'(&JR!.>V<G]6>7^=E)MBF3.(TN<ZO8K%9!_G,8)=G]:0_W
M'CZXBF^79?7!X.QD'=Q&LZC\NK[,^;O!+LH\7D5I$6>IE4>+T]X'_'YJUPZU
MQ5]Q=%_LO;:JKMQDV;?JS?G\M(>JC*(D"LLJ1,#_W$6C*$FJ2#R/[TW0WJ[-
MRG'_]4/T:=UYWIF;H(A&6?)W/"^7ISVO9\VC1;!)RJOL_F/4=,BNXH594M3_
M6_>-+>I9X:8HLU7CS#-8Q>GV;_"C&8@]!TPU#J1Q(+*#HW&@C0-]; NL<6"2
M W$U#G;C8,L.NDX[C8-3C_UVL.J1'@=E<':29_=67EGS:-6+NERU-Q_@.*UF
MUJS,^;<Q]RO/1A=?9A>?SL<?KB=C:W;-_WR>?+F>61=3_NYB],?'BT_CR=7L
M-VORY]?SZW^LOO5U-K9>OWICO;+BU+I>9ILB2.?%R:#DV50Q!V'3\G#;,M&T
M?)V50:)P&YG=+OG,B_(\FENS,@N_*0*,S0%&V6K%I[3.>V+V_C"?Q]62"!+K
M,HCG_?/4&@7K6-V5:4>L,-RL-DE0\LZ,HT4<QF4[R( 7<U=1LJLHJ:,R3=1A
M=!NG:9S>\A67!&D86:]YH8IED$?%&RLH>5/A.XOBMQ9!V%,58!O?KN-7.]/=
M&3H9W.V/,+1@#-G$WYFU,J>[S.F!F3\BV^$VIK.7BTV8W4YX!(WD+D$+W+:8
M0 O/1;[?MII"J[Z'/=M6#PW;#0VK_:AF:,[3D'.CX+7DXU&_>E,MOWH2+[-D
M'N4%7Z+?-W'YT_KW*DL2B^^[]T$^_\\PH^Q=X[:Q+N=%L:G+D2VL<+MZBJIA
MBR_\]@>\Q3Q(R^*ME7(H<O/XP37,BK+8GXFJA6N#:643ES*F'CMGE[[S,NFK
M9I\#4L:484>:.EU6K7ZYNWZYQ_6+ZPTK^A'E85S47X)N90N^A5;K[%%5<4'R
M!/FVSS2KW=NE[[U(^JJJ>"!EZMB>M.(]L%*)5#9E&$W5_%VW_>.ZO5GSE_O]
MYDJQO]BD<TZ'AR'H*I4/YQGS;*S+&2.A$M"ORUJI#1!(5:Y/8V(JD"**KJM[
M@@@_H:MW45%64X]_R8M0YG%8T;LQ2./N$C6MMY8319JD!?.Q&?I/3%I9(9,,
M:*<I (_-A*]YU:]. O7.RX]'15"I*67[%(H,(F^L'4;M- 5L,3./YFK-3SS5
M</'I&_?G<;*ICT'K/"N;$Q'_E\3!39QPXO;#)"B*>!%WS7D&DNT31N4N=5BU
M^R08CLT0_\+WSB0KU(E!\/8Q]EPIM6FW73LY06AL1O0DG1L$ZRQ:<PF(:@GH
M*T\,D*^RO%.8,)OY!'F:W 6%L1G#4NZ/R'>((5(Q<J@KB=;&S*1:%2:V/)]4
MC3'J(+FXT*[O4Y?H!DAP'IM!WWD@^7V3=M07@A@,!#0A"!$7$4WZ@M?8#&SE
MJ:0KY2%6H9A23RZQWUUB: (PJ&@,4<\A<HFA7=_S;=V&280\(.CECR=$()L<
MB>SG/J 0!;P1);ZM(2/9.[0?"?#G.*00B'+J29O[N#$RS3-E'*SINA %Q"P*
M?JDB)E @V)A2[907&H%T:(3G5L0$<A^4B'5>4BBB:'9 (J0#.?+\_SR*F$!5
MH57$1$@*<N2I_WA%3$PRHYVF4 _$K!X.4<1$07(LX[[#J)VF8#@Q,]RD'@E$
M;Y\1),.GTZR=FN S,?/YB=J10":"VTYH8M2.5'"3FH_51VA'"H^\*NU(X>$9
MW'A"$WDR*1M3:$>%G4D[4D%V:B;[09?9ROI2B&PP$-#$1A["2+.ZJ: Z/?0N
M_A$I#RG$K(-\*E<8\AIT#)J "L.V,'()M>4*0[L^1A@S5S-&>Y?^].6U(Q4<
MIT=R_+FU(U7PW:<4N;I%(OA,7^A^7CD9(9TQ8[8M3S4;3#4F3S5U)(U^I(+T
M]"FD?Z)^I(I[ ^9YVJU!@)\>>7M_K'ZD$/Q,+A*\+0 /N6 4S>T.%>*!FL7#
M(1J'0I7 9+A-.HS::0HA03N$Q-Z8;TN1K:LTU:-MD@WM1WQ"#3"S&C")+*8@
M+*:(2?6;=MNUDQ,D9F82/UIF$:3",.O&L,+$9P[V=1LD$QAF9@P;998RWR&#
MO'-])E_?L&X&*TRP9#-1-(8)P?)M]U1AU^<(QIYNA 2$V:&/WO5W=)H"PX,V
M& IHXKC8]76;*=M[.FZ&>-<=G:;&"B*[\KW(B,%#-^@8-)&W+$5;&%/F@_6K
MN/W'R'=U1S@F5 *S7UYG,4%I]D)/X;N(S2"QB<N85F<Q@6QV)+*?0V<Q"%Z/
MGS'EF08)+C\_4@;R- _KF8 X>SZ(,\AGS.1'=QU&[30%Q)D9XD:&*JZ_&0-/
MN3K-VC^B$7BW#SKL'TI0&Y)=WH<4)D:"VH+^]D'T?PQ!FXB.F: **] K: ((
MJK)1$51AIR;H8.\GE=5/;#\'.4=,8271@GNB=RX?Y'S[J]7MFS);U[^RO,G*
M,EO5+Y=1P'?5RH!_O\BR\N%-]</-W6^'S_X'4$L#!!0    ( ">";5$"$HM2
M @8  .06   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK5C;;MLX$/T5
MPNC#+A#7(B7?@B1 XJ38 FT3U.GVF9;HF%M)5$G*2?Y^AY0L.2*EI+M]L769
M(<\<#N>,>/8HY ^U8TRCIRS-U?EHIW5Q.IFH>,<RJMZ+@N7P9BMD1C7<RH>)
M*B2CB77*T@D)@MDDHSP?79S99W?RXDR4.N4YNY-(E5E&Y?,52\7C^0B/#@^^
M\H>=-@\F%V<%?6!KIK\5=Q+N)LTH"<]8KKC(D63;\]$E/EV1I7&P%G]S]JB.
MKI$)92/$#W/S,3D?!0812UFLS1 4_O9LQ=+4C 0X?M:#CIHYC>/Q]6'T#S9X
M"&9#%5N)]#M/].Y\M!BAA&UIF>JOXO$O5@<T->/%(E7V%SW6ML$(Q:72(JN=
M 4'&\^J?/M5$'#G .'X'4CN0KD/4XQ#6#J$-M$)FP[JFFEZ<2?&(I+&&T<R%
MY<9Z0S0\-\NXUA+><O#3%ZO;+^O;3Q^O+^]OKM'Z'OX^WWRY7Z/;#VAUN?X+
M??AT^WV-QNC;^AK]\>Y/] [Q'-WO1*EHGJBSB08,9J1)7,]W5<U'>N9;HL\B
MUSN%;O*$)2_])X"]"8 < K@B@P.N6?$>A<$)(@$)/'A6;W;'RP$X8<-G:,<+
M^_BD:H>VL#D4VDJ1(=AODFJ>/U0)RS5GZG1@GJB9)[+S1#WS?($=G@KE78'*
M<V8]S3;>7XQQ&$3X;+(_)L9GAA?SL#%[ 6S: )L.$G"9_ -9"QM=(RU@H\<B
MCWG*4%X#-D_-=6R(*A5+3$+]*DNS!LQLF"61C^U$L(_B'V.SWQ,4BPR*H**F
MC/CHJX:<'O$2A?,.=QX;,O,3-V^PS@>QKG8T?V OV4@9($;2E"(DMH8N1)5B
MVKOL<P?3<M&![9H$?M"+!O3BC:"WE$NTIVG)#%+@.(,B;6E'CU1*FOM!+QQ$
M8S+MH/;88!PL_,B7#?+E?T2>&^I-_L*EXHE="W^F+!U@9-:EW+69XA[2<= 6
M[6"XRECPJK-U;&8@J,LHY73#TU>W$3Y2"3S(UIUD!>4)8D]FZ[!J%J%W3 XD
M9#WFBX6;+KH$^:RB11]%I$5,!A%?QK$H(>E009_I)F5>@,23?9B$780^,S+O
M0=@J!0Y?0RA+YN4T+J4T&7BTCE[\H0,,X]"![UJ-YWC: [\5(/RZ KU:Q+VH
M(\]^#A>./OGMHED?\:U"X6&)ZFKTEN<41.K-ZH-;^<'#^G,G1<Q84L_#E2IA
M(J= GEA!A(=BNV72X(B%ZME2KO#@*)IV*Z;/+)Q-20]SK43A5S1*I(?^&^!6
MU5V5&Q5+7NBJL8\9W_?N-U=_PL"I!V\6*=RJ%!Z6*9.KQ8NU8$],QES9M1C2
M)^R*3]0%[)J$TV6//.%6G_"P0#7["X#O0882M'GVIJH7MBL[.)K/NFV,SVQ.
MICU\DU:?2/ J=I['TK8O4!I,'"=5-.QG"0F20G53)Y N2DL>:].561-3 CL/
MCSU\H=907O0]1[U8_1'@&H7S14^K2UI9),.RN/I-<2$*W?*.H0U[X'ENEA?2
M$LHI%XDW9%<RY^&\N[@>JVDTQ3TQM\)*AH7U=\?,C.H-1NO*[R(,NBKGL5J2
M,.J)MA5I,OP]MRZ+(F7F<X:F*.$JAF^84E8E_" CD.'5>0I4P"'=(*VVDF%M
MM0I5U5)@+BFM*!BR*I803 >3:F;H]5+F2J?357ML%CW22EII)</2.D!7?O@6
MX_D>8-L:!DO_J^)+6O$EP^)[V_0C[@>4G?K099EKB^[0==FR=>B]GKT$NP*[
MG#M%QS6:]M;65H/)L 9_S I@RD0#FL7'"4]+*[T@$_J@S7F+?ARG$#'?<DBD
M(:$C0[);Q^.:D*BOAK;:3(:U^?;0]#1],#>G>R^[=[M&]'\WS,25:B=(UX2$
M/9_VI!5S,BSF7]EA&6);)M#M%GVO5@-].BP5^E; FYNZ,_'B7SIG-@Y^UV36
M[44F1^>%&9,/]AA5(4MY=?+6/&V.:B_M 67G^14^754'KNTPU?GO9RI!RA3L
MI2T,&;R? Z&R.E*M;K0H[*GD1F@M,GNY8Q2^MHT!O-\*2.?ZQDS0'&Q?_ M0
M2P,$%     @ )X)M47/X%M(M!0  9@L  !@   !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6RE5MMRVS80_94==J9-)[)N=IHTM3UCV;FU=J-82?/0Z0-$KD2,
M08 !0"OJU_<L2,IVQG$Z[8M$@GLY>_9@@<.-\U>A9([TN3(V'&5EC/7ST2CD
M)5<J#%W-%E]6SE<JXM6O1Z'VK(KD5)G1=#S^:50I;;/CP[0V]\>'KHE&6YY[
M"DU5*;^=L7&;HVR2]0N7>EU&61@=']9JS0N.'^JYQ]MH%Z70%=N@G27/JZ/L
M9/)\=B#VR> /S9MPZYFDDJ5S5_+RICC*Q@*(#>=1(BC\7?,I&R.! .-3%S/;
MI13'V\]]])>I=M2R5(%/G?FHBU@>9<\R*GBE&A,OW>8U=_4\D7BY,R']TJ:S
M'6>4-R&ZJG,&@DK;]E]][GCX-P[3SF&:<+>)$LHS%=7QH7<;\F*-:/*02DW>
M *>M-&41/;YJ^,7C,PZYUW5BR*UHU@08A' XB@@N)J.\"S1K TV_$NAGNG V
MEH%>V(*+N_XC@-HAF_;(9M,' RZX'M+^>$#3\73\0+S]7:7[*=[^5^*]]6ME
M]=]*2AW0J;/!&5VH5ANVH+GGP#:JGHJ7VBJ;:V5H@46&$&.@/T^6(7I(Z:\'
M$!WL$!TD1 ?_G_O_%(C>7K._EIVQ>'%^?K*@<[UB6N2:;<Z!7GG7U -Z8_,A
M/8HE4W;JJEK9;4;.4];Z9#^2#J3(@(*]$+%/*4=ZG8.7I79UJ; U<FYB6LG;
M +1RD"X7!#S673,^@$KVI*NJL0ZYO*J33X"I1_BE=ZH@KRSBHX+>W!8(*V6%
M85?#]]\]FTZ>_D(& XAJ[XHFCV)>2"MY0&L%=#77NFKBWH(>9:_FJ&$@11B=
M8Y@ U<J[BBZX<CYUUSAEZ3>.D;VV:SIM<Y^BW_@3943EUXSF"T<?M:D"O6_@
M3!.$__A^ HH )+*&K#:ESDM)5K=J0@D(0<I[M97"8G*,VYI1$:!1J6 +9QL%
MBQ*J*]=3M)5&( )H74*-J;_1D2H*+^WM:0LU1IQO*DD@,SLZX]8ZQY@P>IU$
MC&Y+(4GQ'88[W+ZQ]*NR#:9RVFV#5&JG!LE>B6(*))P#+],^Q42=]$Z*N(T8
M<&N$3;MEHV.)N=M$IFJ+^8_DAILKKK0:2&DG%^<#<9!L<H" !B&? IHAK5"K
MU(*\U'R=-F"BL&2-4X5SAXI$<(81WR-HD)/B2Z%TAO=(Q;+1MY7R^TXIBEZ_
MN)SN%=J#6-1]CWJW;7$WK1,NI(Z(HS'V6.\RP<J;+;6;: FS$/O(Z3/.1^FN
MT. K+C1 )AS$GT5-(<VME'ZCT80KZS96%)-L)H^%T.GCG01M;IH"?4>GP!"*
M72LY_[Y(W ,< +\! &$= &VA?-%N1,]#.@F4MG-J%?AY!Z4 )(JYY-KY*/M<
MSDB:C/?>M>+!65RT.Z:?*H,L:;"?*W*B P *_N9P$C<-$O/=S :6T"R#!DE>
MQ'T#7C)VHNBFH:PL^XEX>R<ETE\I ]'1K!]E;<H!)'#&1FU0/GP\BFQ],$^2
M@PA%8#V$_3P6*5#M]34@@ZV234$S=+<I%+K*59W4U>VS1]F\M:1^]*;-<<8Y
M5TM0-1U/G@[IO33@WGJPGCCUB"E3HJ7_@C&\_) ^U,[>PTS[^<Z&_R&0517J
M+F4<=^,RNY^H3#)EW^I@V_F[*5:[XS7<'*]+SB5S+%U(Y\!=0H;WG;FC6W>?
M2HJ1&YX0T]C87H-VJ[M+Y$E[=[HQ;V^@%YCSVN*@X!5<Q\.G3Z#2]E;7OD17
MIYO4TD7<R])CB7.(O1C@^\IA''0ODF!WM3[^!U!+ P04    "  G@FU1M[3D
M]84*   P'0  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;,U9VW+<N!']
M%=3$E;*KQG/3V);6LJID[3I1*ANKK,3[D,H#A@0YB$B !D"-M%^?TPV0<Y>U
MR3[D19HA@;Z>/NC&G*^LN_-+I8)XJ"OC/PR6(30_C,<^6ZI:^I%ME,&;PKI:
M!GQUY=@W3LF<-]75>#:9O!W74IO!Q3D_NW$7Y[8-E3;JQ@G?UK5TCQ]595<?
M!M-!]^"++I>!'HPOSAM9JEL5_M'<.'P;]U)R72OCM37"J>+#X'+ZP\<YK><%
M7[5:^8W/@CQ96'M'7Z[S#X,)&:0JE062(/'O7EVIJB)!,.-;DCGH5=+&S<^=
M]$_L.WQ92*^N;/6+SL/RP^!T(')5R+8*7^SJSRKY\X;D9;;R_%>LTMK)0&2M
M#[9.FV%!K4W\+Q]2')ZS898VS-CNJ(BM_%$&>7'N[$HX6@UI](%=Y=TP3AM*
MRFUP>*NQ+US\57]K=:[#X_DX0!P]'&=IZ\>X=79DZYGXV9JP].(GDZM\>_\8
M9O2VS#I;/LZ>%'BKFI$XF0S%;#*;/"'OI/?MA.6=')'WV972Z%\EI7\HKJSQ
MMM*YC&@PN;AQRBL3X@-;B$_:2)-I68E;/%2 7O#BGY<+'QS \Z\G+)KW%LW9
MHOE_$^UG;A5_7RHX4S?2/(JE],+8($IEE(/-N:"G3MTKTRH_%-ID59MK4XK"
MV5HTSN9M%H27%;VE()"$HJ4,"E2ZXV!X+-2H45T]QGT!*K$W4RKW%"G>3Q\T
M(J1@&,S2)B@$% ](;&;-O7)!+RI%!BH_$M=!:"\J?:<@-BQE$#*'0]"'B!<Q
M]J8<BH5ZM)! .ONG'I7F,Z<7,'-!3#)$G505/L-9Z'?T_)'W=*$)EHP(&H&@
MS^0CFTM)ERY;LIDY(E79AE(="0+VD*U_LT)ZWSIH5R*3AA25H ^3#(=\WT)&
M;V!OCKR7NI+D]FJ)Y08AH]"ZN''#P#_^X70V???^"8-4 =*%Q9UH:,R4]T5;
MC;9  /L( UB1(>0@8L&:$.P _J0TD5J-Q4A]^G;U^>OUCZ^G9P(2<E7K3* &
M*#QRH2M*)T+FI/9J,TF9;'3 ?P(=^S4DQYA;,]4$]AH@J!' ST;\I46>3Z:Q
MG(=;N5&,E9PP@T"+6Y6UCB,O;EI$ BPK+DNGN 3%2]I)T9I-WM]<W_QT8 V_
MG;Y_A5"%91\%#0B"0)W?%W'=O>IV#D73.M]*Z(-)JZ5&/C8MEJ0JIW<:N%"<
M*YPM%948/$"]W*/\1%/)+%J= Y-9J#B0)&A;;;1HP"&B\,37GXM".8!I '-F
MPW?S^7#R[E3XI73K:LML72/BD)+=L16(?;2142@=,(MET-IT86H;^@H0RQ)>
ME&0GA!U2L"T<.*<G"S!1OI8&5S,6\.)D='+R1H THH2CUD2T]J:MD'J@L5:Y
MABD(@'I0+M.>X=,VA$-/F8 6+K7N_8[JR8YFKA+UT"#N*,M[)1Y157[-7WGR
MNQ,>K3J2 9%5UE/=&G'9ECB&Q3SB..XRZ)9Z/DP)[I#2*SPB&K1; /VH=*)B
MTK4&#=H@_"V4BB3J5,6<;CNKX![ZH8ZZU4-'[J2NCQ)\)#NZ> ]CP&4#@Q_
MZASR%Z>C-V@GJ@J%'8M5FA9-F3C[?<OU?ZK4W[M(@7WMHR>Q.M>!W3D[=HOW
M^J!]7<PXQU_6PKM,K\U^J5_MU=]T.#T]&TXFDZ?JSZQ-W 3_V>ELM_!>Z@,Z
MYO/3X2DTH%]_G0[YO@PWJP[GS#$KMM(),9^BF%^2F#Z?3UG[+EF[OW_(JDMG
MO=]J,';0^G:-5AQSV*(VRH>;D_T2>KJ"T(X8IC<#+#O:LD?AVS7 B,KW ;%:
M@FDE.IU,-ZQ*FUC]WP''\40<INO3Z>GP['M@.<B49R=KJ(S$3Q)%DW13/_9,
M(CY$L/30&O5Z*:MBEVW[G42[OX4TOQ.V_P_V?#N:K-ESLQ5#OMI*.HYE4UG*
ME*Q@KY$T?(I:2<.Y6_>-=*9O--Z1LM1=;,JC=<ZVY5+<HQ^WK1?>@E2W>_NF
M753HX&AOAV*_YNC.?VS!M(C>U+IH#;M8ICF'^1A-H\LCG%,0+8(#[ 0:+DK2
M :<IK_'MHO5H#E"[>&^\Y$';[S2GL;P0D=RJ.*PL)8/GD1&L0]0/0-A%;%XW
MI@+$(&JJY2,UN*V)36:_V+=%@=+CQ*> I0(LVM B<P>Z4X2NX(*IT$A?%UM
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MXSCJ#MW'/ ^%(_$UD1U??-%I%;N*](62Q?TA@4'B"(9Y73%P-[54YJ#Z?5^
MU8R.$&Y"[FEZ<6T9,[:T*V2D-%S-AOW1#ISG[I#9.!RDVZ-A.H:*%!AZA0@0
M$^ZP;F\)>>]LNFRJ0+,X=&@I72K%.S[/]TDI+TSH_'A-IJF]\NJ06_@T[K"
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MFA8IP^F(-64H4)7U@9.G(TP8FUP3SI8BS^D.2CH !Y.D*C+P )\;%"$GR=(
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MTHEJ>/TYJ/[#4'WZ#7D7K=%I7Y7ARR!"J=?F%WT-B65DN?DC>2]%XW(W!%*
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MW:#J!LE'<B>SW03M@L31X./N@#S'E15&[9;UI7%E)3&I:+9,E/1D6VO;_42
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M[N]:^T_D._BRY$9<J_1/&=OD8C ?L%BL>)G:>[7Y153^3%%?I%)#_[.-VQN
MQ:@T5F65,#QG,G=_^6,5AX[ W.\1""J!@' [0X3R';?\\ERK#=.X&[3A#W*5
MI &<S#$I"ZMA58*<O5Q8%7U*5!H+;7YD-Y]+:9_.1Q8TX_HHJK2\=5J"'BUG
M[+W*;6+831Z+>%M^!(@:6$$-ZVUP5.%"%$,6^AX+_, _HB]LW Q)7]BCSSG&
M_KI:&JNA$OX^HG/2Z)R0SLE_#-WSM?SPW3P8S]Y4NM@=%*C06L2,-K'?$\&N
M55;P_(DEW#!>VD1I^0]L* MF%9MZON_C/V82KH5A:L6*1HE!)1Y[X0]AQY@5
M7+,'GI:"%4([ 8]!ES-I3,GS2 S16 :=\TSKX=0_8#]R.K[>^(><?8BL6L)Z
M<(:%,(;_;0>$R*U OV0.QGE>1^V=A!3+94E-?[760@"'6':"HH/#BX-3Z#J;
ML/?\46;L9ZW H=]^NZYDKM:TQ6-%J1&<16<WB8R2+3@;B DXDTEK 11L42L(
M/ "#R /I](0$5("YM5-%EB"X#S)?HT=\#0C7W JG"]\66D:B"OB+Z= '3DA3
M=$;F;*V5 0Q:14+$9LAN<S"5YQ7_D8>F!-2&I\)X'8M (LB2 'LE *+X7/*4
M,OH]PL5]3C4)5A!@@?=[9:"@AVQ!^RL5U<X2&$+3BYY$;2"IP'"Q0)>@67/#
MR0$#9 L[*+1+2 NWI 6.DD]P=M4!&C".&U?095@9[+Y,!9N,IQV["Q&56EH)
M8*XBE&3CLS $M X@0G\F2C(*=BC'*-:MD$YM_ @QA:UT ,%)MD:5G!0:"]DE
MA?" QPQ;O 0H[TI*-JIX$M J FF5O1.1R+ ?PO&A?B $TV#B^6>SOKSL NSQ
M#CLQAZC6M81Z7@3#65UM0V*#OM! !BPV0LZQI&#M5YZ7<.*S,\?G) WAHQCF
MZE@-/1<P9-II_K!G[1AI=&OAKM01\)K8Y0PDY<!_L[],"^,W%7=$0EN8@4#Q
M@P#\VFQ)W]9O:Z$OL0E'*U3KR(BBH1$/7>55$9$GL=0B:AN +9^V%+GE]*D.
MX.U!?'7,,&#LOE7^H=+:PCZ1I[O4Q,;>>'YVE/=;OF].@);W*X*H$'L,.ALL
M[% >5F X/)L'TU:4HG(B#R":3.;>'/# Z?=R55+W;+@&,K'0BH]"1]+P)3 #
M%GI/^1U#,:M0[*MWI]@V$Q-7%O $IPO@@UR\>#6<-LR]%" B@+3B$ABB:OLB
MY9$K0DX4#<1,WFJ1NJZJ<8E'F,^-<'3/D?"AHC6* .('#$>C:KL3J*[B_;+8
M) K3964D"S*%- P[OE0B_0%VI]5NBN;CN7?66S)5^"M58CO\85L"0W;#H74J
MV\0],H-30KI =Z&4!1Z3U7Q!P=Q !C" T")LA=R,+U4N7B8\71'S&K;2*B/_
M&\D85#L"W*+(;<IOY;X4-ZCW%;SIY/] [LWQY'NT+!ZCM(SK"FI"A]5'\XE+
MCT=!VJM'O^5VY- 2WKICYMLQZ.W=S8$]7T.CI.);<^E>G^QQYK;9:BRD$%%2
M:;E.)PZ*@3>;P#$\FW>*6T)C;!<XH.!1Y#!N]0]8+>HP'>Z=0P;VN@??+&D.
M:K1UNR@,=YGT$!I7Z TT.K*?V6#]#1SZ.Y;W&G&G]^+*[_9V@*AZ,L"B5!DW
M>%R5:[A"LTEG[GAFTQY6_3_T*@9\IUGG[>'A7.HI@A,J],-K-."F3S6 VN!I
M?2S4I-\38H+5&4*^-%U[.);SC.;8[7;E%2=6 _'BT$#,3L(P?!E,7L&?4RB0
M%,];9(L=@^COS2.4>KZFG&;@#"H]&2QNK@>GM!Z+*.4(N9W(VT()FDJYHI M
M1&&KD=L_Q(5X#^X),+P3^@&O5' "KDI;ZLX1 F(KN'.I#9 )15J5!L"9T]?L
MS[K55&GA=I!3C83>_-6DNH>KPMV&NNN!/V?WBX_;+\<SO[[3' 73YJYRJ_H,
M8>B.45^K;V%K3N&Z2Z&OQS#"?9WRFZQ(U1.,,<Z-YB @=7/VN[)PZ7Q^""=>
M.!U7NA;ETD1:4F"@G"(!A(Z$=*<E2$*1/>?F-)L>F6![ICH89L.V%:%FVKMR
MQ$W2N[>^^ECP$=%2!UF9ML/"H6J#O4KCK,GK&U+7;]WZO6N-$X"]( P/?00;
M=;XE9D*OZ8LI'ET T'U6;-XV'V6OW+?(=KO[HON>Z[6$2DW%"D3]X6PZ8-I]
M)74/5A7T97*IK%49_4P$W/PU;H#UE5*V?D #S:?JRW\!4$L#!!0    ( ">"
M;5%,PH:EK0D  +X<   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;-59
MVW+CQA']E2E&3J0J"B3 BZ1=K:JT6JV]6]ZLRG*\#ZD\#($A.1: @6<&HNBO
MS^D9W"A>)*<25^5%(H#I>_?I;N!RI?2#60IAV5.6YN9=;VEM\68P,/%29-P$
MJA YGLR5SKC%I5X,3*$%3QQ1E@ZBX7 ZR+C,>U>7[MZ=OKI4I4UE+NXT,V66
M<;U^+U*U>M<+>_6-G^1B:>G&X.JRX MQ+^P_BCN-JT'#)9&9R(U4.=-B_JYW
M';YY/Z;S[L O4JQ,YS<C2V9*/=#%I^1=;T@*B53$ECAP_'L4-R)-B1'4^*WB
MV6M$$F'W=\W]H[,=MLRX$3<J_283NWS7.^^Q1,QYF=J?U.H'4=DS(7ZQ2HW[
MRU;^[/BLQ^+26)55Q- @D[G_SY\J/W0(SH=["***(')Z>T%.RP_<\JM+K59,
MTVEPHQ_.5$<-Y61.0;FW&D\EZ.S5-ZXUSZUA5K'K^+=2:L'NEUP+P]2<W:@L
M@^ONK8H?+@<6\HAJ$%>\WWO>T1[>%^R+RNW2L-L\$<DF_0!Z-LI&M;+OHX,,
M[T41L-&PSZ)A-#S ;]08/W+\1B\9S_.$N7PT[._*"O9!FCA5IH0S_GD],U8C
M>?YU0."X$3AV L?_$V__MWBSYNC7TAH+XV6^8#\O!9NK%%5*5Q).J2N5Z"V>
MN@J2MKD&SX+GZ[\9MNK(YI5LT\B.O6SC9 -'''$.]5GF\T-0?C!$UXIL)G03
M8G8L<QQ6I8&.YN1-K3C[9$S)\UAT#>BS#R*NZ$.B#R_8]W0:K&^?A(ZEP:\;
M(DM%,KA]*J!ELLEAAPKN''<(\KE,U_[FW:>[6_9U/A>:?/77OYQ'8?261?VS
M\;BYVKQ[72Y0S$0]89]Y7I);':LM+N?0^SD/NE=+G[ [+4[GI?/985;C\04[
MQI^3+88ML\\EXN"<U9!'6\<;6^KCT9A]X3I>>LK:O>QZH84 9%LV'>UE@D<U
M+=A4FH3G'?G#\_T:X%FM_ CQTA(Y=HU4S!^%MG*6"G(/&%%L=WBR_H]';; =
M+^APQFZ1NZF<:<G9=+\!;::!,F+?\U3DG'T4,UT% YS"_:*[)UORKZ@*Y-W6
M\>/PA/S>!CI"<D9LW!^&415=.C+JGT_'[-OK"S%6Z*Q(2=QORW?)+;K+FLU
M)JQ%H3"48,S-LL]62XF@@1=+)9_!379]&J?<&#F7.%<SZ3LT%9"]^WG0*GG3
M/N6&_5AQI8C^>$C";M5;@S?,E("*R@J5Y]4LL))VR3#$/$I@2Z4KF\L<X( $
M- ZD7L@MAZ3]*GB P,WH-[R\-QZY=I*4BW$5\&VQSOTK 1-@<YE!RFS=15J&
MQW1)]A,T.ULJ,/XB]$+H@& <A=BX97<PG5).4"*LT)@K\"Q7EKR(TQ+8\H0[
MN.I(=PEY]M9L^-<)9,)8"75 ,N=2P]RT%*28ZO271B4>QZITL$QN1N#33N#1
M=SHJP5[!D70SGCJX]W-J DD!NX8_$A%C$H6]8"3SZK?K&?MUHF>5+FTB,R.)
M/SW+%#)+H\#Q?%LN*8B'2B?>FW4X5"H3)PSV6@^!9'\A?.\P9&>\Y/G"Z;>I
MT98VWJE[U79>:LTK#;F7L_<ICQ].[^.E2N'(0DM**IB3B-0GO-WL\'F!Z+QA
MUPX:=G2^0\WV66=&-6CY()Q0P8YAM4>=$VJ?J#G*)<24':\%USC^BTKA%N?X
M[S!XF8?3.1H'T^3@[UZ!ZD?L+)@,V2@8#EDX"H/)&&3#()SBWQXT/F)A?SH9
M.HI@A#NC23 =>K)12^91.,)Q^.%B& ;#"YR/+K;.>[=MCQS_#UX[F[ PC()S
M\EH83,>O\EH4H-^$X3BX"+?(ZMYUQ,9A?WPQ]EX>C[;..["HC7ML[7%X5U25
M EBB12MA*G\V9\JL2.4FI0/V; 80;9&=B+:.2M\#C<QDRC4KREDJ8PP2&.ZI
MEE&Q[DRPJ6,JYZ*C'57>AFY:T.9+L04*N#VAY*D+FWE>M9ZSWHS;<WZ_"ZW
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MN 4""4CQ4*-HJ-D1&UX82!,!*!4/F4#P6]9M*H?G[N@<SI'4]H3T3-COI.S
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M.='/S':L?D8&Y I$EC9#7)VUAH\+/C%Q%T11/AO\UH%L,DF/51'Z\L;3!@@
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M3GF?\8EF]QF,$XFPL3MDVC;4T DTNDY>DUYC90+VIR,WNP<($$H-3KO@98@
M1[IU8C;3TMJI'QTW2EU44!1NLH)U8Z]]?'5#&/S_#8'\_R;_8M%WHMWZ=/."
M;IG^Q#LJJ9^I'CYS(7PJ*#.$IEV,VK#2#A(][3&)OB$:/1.?@Y"7Z]OR=['A
MMIA=;[E/6K\DY,K.^?<22C/:?OA187UW_9/,=?@E8K,\_)X#)IJ#2D2F9MC:
MBTY'G?"VK/GB3<F_2Z#BO,GY<J$D"IT6X/G,&-]\(07K'ZJN_@M02P,$%
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MU."P'JR8SX"!ND=U>65@ @3YG7884ZP#F0*R9(/;F./9G(K-.>I\G=YY\!/
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M=6<'&;O9,#$52W$65*Y3]!,&\[L"(5>"'K8C5^T(R;9"S*L0M2.D8&1;(TK
M/4F6$--]65DGJ]G*8ITLT\K:@3T!9AS$"XV"6F24@#K9\D\]FR,NR:YJ0_[F
M> (_2.5>,U+A*XOE&G7?3_0SN'2U+HD/O<?T$1JF-0$;&)Z,ST?D&4/B#:IR
MK V%C"$>PFUR;V!P$<''#^-X$'^&T4D\BF$8G\%;313N/.,2]<8/*P.^%]L7
MW9_V\W#1CH%7]W:8WC"]X41$8$ZAT>G%60"Z'5#MQJK*#X6ULC1B_+*@F8[:
M.9 ]5W2;W<8EZ/\EYO\ 4$L#!!0    ( ">";5'#0,H?N ,  * *   9
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MR#6XN!IZH)IYU&R,K-P,6$M#$\4M<QKAJ*P!W6=2FOW&!NC^%.*_4$L#!!0
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MTZDS<D@":UIF^EYLOT&=4-_PQ2)3]I=LZUC/(7&IM,AK,"K(&:^>]*4N1 N
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M/;)J9*J)%H7M!1Z%QL["#E-L_D": -Q?"Z%W$_."IIV<_0=02P,$%     @
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M&9P E_ U5Z5A,C/]T%(.CB1,:]Y1Q1L?X+V$>R5M;N"SS#![;1]2[HT \5:
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ME2 TDX(HR,?>;7@S36R\"_C.8*L[8V(K64KY;">?L[$76"#@D!J;@>+?!J;
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MI[>#7ZF8L41J35,=RCT--%^17KBE \47]OKFD2O%8_LX!SH!80ST[U/.U>O
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M;J8:YY6!N@@C=*'1#>2PW+@K$(P_X-ZOM,8/PT_EYE*=_ 902P,$%     @
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MZ$JY+#\ESV\$W65GKDLJ!(VRRRV0%;!T@7R_IE0<;M)CW.*WBMF_4$L#!!0
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M"&V ZPO.U7:@[\WJ.VGX!U!+ P04    "  G@FU1?YWAKS8&  !4*0  &0
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MT%ID]C(%FH L LS[E1#Z^:88H#Y8F_\/4$L#!!0    ( ">";5$CIK'WX@,
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MR132$=; 0Y)FYH88T*_P12'EGQBD*AMX9@;;:*@$,!A=F/%*T8(/29H&EFQ
MV1@4.#/:T)PGNQN(:ZESFSI$,DOM.?Y=MD4)QA]6B4JS@G;1.L/__5M*MP':
M9TM^X!LD]/]!?UAI4NA?EOZP$JLP^)_I+P*VT>_5#O3VOD8'QAU/- C<DHW?
M'9&QRJ] ^<3(U)WQU]+0C<$-]W1M1&47T/NME.8TL=>&\B(Z_Q=02P,$%
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M(<F'Q3UZ_>I-0+97KV3/R_;.R,XYU?IX,:1"?I-?'2_6'T^2<V0WU)ZJ[,]
MVILZ[8U/>Q/^@(@?EOX*+6'-A&!B;?<KIR*%MD4O50=>U1W=W;1/QO&NQ4F_
M=M(/.O%5[@Y;8G_86&MW^>>'*SV4>OTC#TF[A4%M87")!7@!E3+=;F+0U<2P
M-C$,FIAE?]ES:\EEW*$ZY$8;Q=*O;+69&78U<UN;N0V:*8^L.X*KUK5I,W%[
M8N(MZ;?;&-4V1O]UEX+(_F6+CDY\D&&[#9PTN$N"1A:@F"78S*)-[$ 9MN2
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MKY_MA  AC:I-E?H"L7/.^:ZQO]Z6\2<1 TCTG"94]*U8RNS6MD480XK%-<N
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M:&[._FZSO+Q"?6<"$T*2##9HZ@W&J(<H;R7E1/&].=BON<)K@AGN\"8'0B_
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M@0K"*.*PGE@S]WKI]C3 6#P2V(O*,]*A/#/VHA>_HHGE:(\@@5!J"JP^=K"
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M*INC/^O^I<T_ 5!+ 0(4 Q0    ( ">";5$'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ )X)M4<AI
M,POM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ )X)M49E<G",0!@  G"<  !,              ( !RP$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  G@FU1LSE<:4@%  !R
M%0  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ )X)M4<70'0WM!0  ;!<  !@              ("!B@T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ">";5&+['(D
MX0(  &@*   8              " @:T3  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  G@FU1EY8=K0P%  "S$@  &
M@('$%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ )X)M
M4<D-HG"[!P  1RP  !@              ("!!AP  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( ">";5$"$HM2 @8  .06   8
M      " @?<C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  G@FU1<_@6TBT%  !F"P  &               @($O*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ )X)M4;>TY/6%"@  ,!T  !@
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M970Q,BYX;6Q02P$"% ,4    "  G@FU1#XM':88'  "V%@  &0
M    @(&67   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M ">";5%,PH:EK0D  +X<   9              " @5-D  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ )X)M4474W7V:"0  M!H  !D
M             ("!-VX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  G@FU1SG+$?7("  !Z!0  &0              @($(>   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ">";5'C5H#"SPH
M 'D=   9              " @;%Z  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ )X)M41AI^QCC @  ,08  !D              ("!
MMX4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  G@FU1
MPT#*'[@#  "@"@  &0              @('1B   >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ">";5%(VXQ.%@,  *@'   9
M      " @<",  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ )X)M496SJ;&W @  \ 4  !D              ("!#9   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  G@FU1MCS.CKD"   @!@
M&0              @('[D@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( ">";5%@"\VP+@4  -(.   9              " @>N5  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ )X)M4<0?:43.
M!   I0P  !D              ("!4)L  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  G@FU15.J)4>@$   S%0  &0
M@(%5H   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ">"
M;5'@6\AT?@(  &@&   9              " @72E  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ )X)M4>:$M$?Y @  6@H  !D
M         ("!*:@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  G@FU1'>9E(IL$  #1%@  &0              @(%9JP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ">";5&A%GC7O0(  %,&
M   9              " @2NP  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ )X)M42OA*(&( P  \ T  !D              ("!'[,
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  G@FU1=.!\
MF\0"   U!P  &0              @('>M@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( ">";5&8]4P"O0(  ,P&   9
M  " @=FY  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M)X)M46^\^=6,!    A4  !D              ("!S;P  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  G@FU1'G<;5[4"  !@!P  &0
M            @(&0P0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( ">";5%ENK6U;04  +<8   9              " @7S$  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ )X)M48EWFM0) P
M,PD  !D              ("!(,H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  G@FU1?YWAKS8&  !4*0  &0              @(%@
MS0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ">";5&.
M;S3A=P0  &03   9              " @<W3  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ )X)M42.FL??B P  E X  !D
M     ("!>]@  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ">";5&K,GSB[@,  "<.   9              "
M@3+L  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ )X)M
M4<.6U=,_ P  '@P  !D              ("!5_   'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  G@FU17?8P-U\"  !D#0  #0
M        @ '-\P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ">";5&7BKL<
MP    !,"   +              "  5?V  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ">";5'EV\!*Z ,  &,>   /              "  4#W  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  G@FU1N#;$W*D!   N&P  &@
M    @ %5^P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  G@FU14]DK*;(!  !3&P  $P              @ $V_0  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     -0 U &H.   9_P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Balance Sheet Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BalanceSheetAccounts</Role>
      <ShortName>Balance Sheet Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Warrants to Acquire Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Balance Sheet Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BalanceSheetAccountsTables</Role>
      <ShortName>Balance Sheet Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BalanceSheetAccounts</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Liquidity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details</Role>
      <ShortName>Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gale-20200930.htm">gale-20200930.htm</File>
    <File>gale-20200930.xsd</File>
    <File>gale-20200930_cal.xml</File>
    <File>gale-20200930_def.xml</File>
    <File>gale-20200930_lab.xml</File>
    <File>gale-20200930_pre.xml</File>
    <File>sls20200930ex103.htm</File>
    <File>sls20200930ex311.htm</File>
    <File>sls20200930ex312.htm</File>
    <File>sls20200930ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gale-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gale-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 149,
   "dts": {
    "calculationLink": {
     "local": [
      "gale-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gale-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "gale-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gale-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gale-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gale-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 361,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://www.galenabiopharma.com/20200930": 3,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 9
   },
   "keyCustom": 52,
   "keyStandard": 245,
   "memberCustom": 22,
   "memberStandard": 20,
   "nsprefix": "gale",
   "nsuri": "http://www.galenabiopharma.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.galenabiopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Fair Value Measurements",
     "role": "http://www.galenabiopharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Balance Sheet Accounts",
     "role": "http://www.galenabiopharma.com/role/BalanceSheetAccounts",
     "shortName": "Balance Sheet Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.galenabiopharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Stockholders' Equity",
     "role": "http://www.galenabiopharma.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Warrants to Acquire Shares of Common Stock",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock",
     "shortName": "Warrants to Acquire Shares of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Subsequent Events",
     "role": "http://www.galenabiopharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.galenabiopharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Balance Sheet Accounts (Tables)",
     "role": "http://www.galenabiopharma.com/role/BalanceSheetAccountsTables",
     "shortName": "Balance Sheet Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gale:CommonStockAreReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.galenabiopharma.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gale:CommonStockAreReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gale:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables",
     "shortName": "Warrants to Acquire Shares of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gale:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Liquidity (Details)",
     "role": "http://www.galenabiopharma.com/role/LiquidityDetails",
     "shortName": "Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i9d45ff94435e4d21ba5468a5bebac6bf_I20191107",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i9d45ff94435e4d21ba5468a5bebac6bf_I20191107",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)",
     "role": "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gale:FairValueOfWarrantsPotentiallySettleableInCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)",
     "role": "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i111eee7793154c7cbef26ee3f9b7f76f_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i4007eb8b70cc49a894e1bdf6a68b797d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)",
     "role": "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i4007eb8b70cc49a894e1bdf6a68b797d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i0b0a4c1020ef4e46ab1bc5dafb6ce8c5_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gale:ContractResearchPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gale:ContractResearchPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)",
     "role": "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details",
     "shortName": "Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i354bd279ed2542818d5f6d96946a39b1_I20200109",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)",
     "role": "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i526ba136e5e243d480e699d976eac2a2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "gale:ClassOfWarrantOrRightNumberOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "ia56bf35b15d3478f9d8fe55b6d0fb495_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gale:WarrantStrikePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i2c335a4c261f473ab001ddbbb9edd2e9_I20200109",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "ieffe68af4fe345c0bb928ab15ae7ea85_I20190306",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i526ba136e5e243d480e699d976eac2a2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gale:FairValueOfWarrantsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)",
     "role": "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i526ba136e5e243d480e699d976eac2a2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gale:FairValueOfWarrantsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gale:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "id230efc5b5ca4548a0cdf9a3b3605cfa_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails",
     "shortName": "Stock-Based Compensation - Allocated Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails",
     "shortName": "Stock-Based Compensation - Assumptions for Option Grants Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i526ba136e5e243d480e699d976eac2a2_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i25819b81a08a4c37884c9892590906c8_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "role": "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i51b322ac35ef4442a1bd0062c10dca84_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i12900c59fe2a4ff096fd101b525adf14_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "i12900c59fe2a4ff096fd101b525adf14_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.galenabiopharma.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Liquidity",
     "role": "http://www.galenabiopharma.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gale-20200930.htm",
      "contextRef": "idb8e0b67b2924497b4a8b36361c1fe1d_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gale_AptheraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Apthera, Inc. [Member]",
        "label": "Apthera, Inc. [Member]",
        "terseLabel": "Apthera, Inc."
       }
      }
     },
     "localname": "AptheraInc.Member",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Timing Of Milestones",
        "label": "Business Combination, Contingent Consideration Arrangements, Timing Of Milestones",
        "terseLabel": "Business combination, contingent consideration, timing of development milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in fair value of common stock warrants issued in connection with various equity financings.",
        "label": "Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings",
        "negatedTerseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ChangeInFairValueOfContingentPurchaseConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in fair value of contingent purchase consideration.",
        "label": "Change In Fair Value Of Contingent Purchase Consideration",
        "negatedTerseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentPurchaseConsideration",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ChangeInFairValueOfContingentPurchasePriceConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in the fair value of contingent purchase price consideration.",
        "label": "Change In Fair Value Of Contingent Purchase Price Consideration",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentPurchasePriceConsideration",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ChangeInFairValueOfWarrantLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Fair Value Of Warrant Liabilities",
        "label": "Change In Fair Value Of Warrant Liabilities",
        "negatedTerseLabel": "Change in fair value of warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Operating Lease Right of Use Assets",
        "label": "Change In Operating Lease Right Of Use Assets",
        "terseLabel": "Change in operating lease right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Changes In Fair Value Of Warrant Liability",
        "label": "Changes In Fair Value Of Warrant Liability [Table Text Block]",
        "terseLabel": "Changes in Fair Value of Warrant Liability"
       }
      }
     },
     "localname": "ChangesInFairValueOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gale_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Issued",
        "label": "Class Of Warrant Or Right, Number Of Warrants Issued",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_ClassOfWarrantOrRightOutstandingExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right Outstanding, Exercisable",
        "label": "Class Of Warrant Or Right Outstanding, Exercisable",
        "terseLabel": "Warrants exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingExercisable",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_ClassofWarrantorRightCanceledOrExpired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Canceled Or Expired",
        "label": "Class of Warrant or Right, Canceled Or Expired",
        "negatedTerseLabel": "Canceled/Expired (in shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightCanceledOrExpired",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_ClassofWarrantorRightFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Fair Value [Roll Forward]",
        "label": "Class of Warrant or Right, Fair Value [Roll Forward]",
        "terseLabel": "Class of Warrant or Right, Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ClassofWarrantorRightFairValueRollForward",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gale_ClassofWarrantorRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Outstanding [Roll Forward]",
        "label": "Class of Warrant or Right, Outstanding [Roll Forward]",
        "terseLabel": "Class of Warrant or Right, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ClassofWarrantorRightOutstandingRollForward",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gale_ClassofWarrantorRightTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Term",
        "label": "Class of Warrant or Right, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "ClassofWarrantorRightTerm",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gale_ClosingPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Closing price of common stock.",
        "label": "Closing Price Of Common Stock",
        "terseLabel": "Closing price of the Company's common stock (in dollars per share)"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gale_CommonStockAreReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock are reserved for future issuance.",
        "label": "Common Stock Are Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockAreReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan",
        "terseLabel": "Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent purchase price consideration, net of current portion.",
        "label": "Contingent Purchase Price Consideration Net Of Current Portion",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentPurchasePriceConsiderationNetOfCurrentPortion",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ContractResearchPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Research Payable",
        "label": "Contract Research Payable",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "ContractResearchPayable",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_DistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distribution Agreement [Member]",
        "label": "Distribution Agreement [Member]",
        "verboseLabel": "Distribution Agreement"
       }
      }
     },
     "localname": "DistributionAgreementMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_DividendArisingFromWarrantModifications": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dividend Arising From Warrant Modifications",
        "label": "Dividend Arising From Warrant Modifications",
        "negatedLabel": "Deemed dividend arising from warrant modifications"
       }
      }
     },
     "localname": "DividendArisingFromWarrantModifications",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_DividendModificationOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dividend, Modification Of Warrants",
        "label": "Dividend, Modification Of Warrants",
        "negatedTerseLabel": "Impact of anti-dilution protection on liability-classified warrants"
       }
      }
     },
     "localname": "DividendModificationOfWarrants",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition",
        "label": "Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition",
        "terseLabel": "Operating expenses weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gale_EqcWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eqc Warrants [Member]",
        "label": "Eqc Warrants [Member]",
        "terseLabel": "2017 Equilibria"
       }
      }
     },
     "localname": "EqcWarrantsMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value of Warrant Liability Assumptions Expected Term",
        "label": "Fair Value Of Warrant Liability Assumptions Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilityAssumptionsExpectedTerm",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gale_FairValueOfWarrantsCanceled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Of Warrants Canceled",
        "label": "Fair Value Of Warrants Canceled",
        "negatedTerseLabel": "Fair value of warrants exercised"
       }
      }
     },
     "localname": "FairValueOfWarrantsCanceled",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_FairValueOfWarrantsExercisePriceAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Of Warrants, Exercise Price, Adjustment",
        "label": "Fair Value Of Warrants, Exercise Price, Adjustment",
        "terseLabel": "Adjustment to exercise price of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrantsExercisePriceAdjustment",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_FairValueOfWarrantsLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of warrant liabilities as of the balance sheet date.",
        "label": "Fair Value Of Warrants Liabilities",
        "periodEndLabel": "Warrant liability, ending balance",
        "periodStartLabel": "Warrant liability, beginning balance"
       }
      }
     },
     "localname": "FairValueOfWarrantsLiabilities",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_FairValueOfWarrantsPotentiallySettleableInCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of warrants potentially settleable in cash.",
        "label": "Fair Value Of Warrants Potentially Settleable In Cash",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "FairValueOfWarrantsPotentiallySettleableInCash",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_FairValueofWarrantsGranted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value of Warrants Granted",
        "label": "Fair Value of Warrants Granted",
        "terseLabel": "Fair value of warrants granted"
       }
      }
     },
     "localname": "FairValueofWarrantsGranted",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_February2017WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "February 2017 Warrants [Member]",
        "label": "February 2017 Warrants [Member]",
        "terseLabel": "Galena February 2017"
       }
      }
     },
     "localname": "February2017WarrantsMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_InProcessResearchDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-process research and development.",
        "label": "In Process Research Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchDevelopment",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_IncreaseDecreaseInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Fair Value Of Warrant Liability",
        "label": "Increase (Decrease) In Fair Value Of Warrant Liability",
        "terseLabel": "Impact of anti-dilution protection on liability-classified warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfWarrantLiability",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_January2020OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "January 2020 Offering [Member]",
        "label": "January 2020 Offering [Member]",
        "terseLabel": "January 2020 Offering"
       }
      }
     },
     "localname": "January2020OfferingMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_July2018OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "July 2018 Offering [Member]",
        "label": "July 2018 Offering [Member]",
        "verboseLabel": "July 2018 Offering"
       }
      }
     },
     "localname": "July2018OfferingMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_July2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "July 2019 Offering [Member]",
        "label": "July 2019 Offering [Member]",
        "terseLabel": "June 2019 Offering"
       }
      }
     },
     "localname": "July2019OfferingMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_July2020PIPEOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "July 2020 PIPE Offering [Member]",
        "label": "July 2020 PIPE Offering [Member]",
        "terseLabel": "July 2020 PIPE Offering"
       }
      }
     },
     "localname": "July2020PIPEOfferingMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_MeasurementInputCostOfDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Cost Of Debt [Member]",
        "label": "Measurement Input, Cost Of Debt [Member]",
        "terseLabel": "Cost of debt"
       }
      }
     },
     "localname": "MeasurementInputCostOfDebtMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_MeasurementInputWeightedAverageCostOfCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Weighted Average Cost Of Capital [Member]",
        "label": "Measurement Input, Weighted Average Cost Of Capital [Member]",
        "terseLabel": "Weighted average cost of capital"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageCostOfCapitalMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_NoncashOfferingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Offering Expense",
        "label": "Noncash Offering Expense",
        "terseLabel": "Offering expenses in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "NoncashOfferingExpense",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_OfferingPricePershare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Offering Price Per share",
        "label": "Offering Price Per share",
        "terseLabel": "Offering price (in dollars per share)"
       }
      }
     },
     "localname": "OfferingPricePershare",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gale_OfficeSpaceLeaseExpiringDecember312024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office Space Lease Expiring December 31, 2024",
        "label": "Office Space Lease Expiring December 31, 2024 [Member]",
        "terseLabel": "Office Space Lease Expiring December 31, 2024"
       }
      }
     },
     "localname": "OfficeSpaceLeaseExpiringDecember312024Member",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_OfficeSpaceLeaseExpiringJuly312020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office Space Lease Expiring July 31, 2020",
        "label": "Office Space Lease Expiring July 31, 2020 [Member]",
        "terseLabel": "Office Space Lease Expiring July 31, 2020"
       }
      }
     },
     "localname": "OfficeSpaceLeaseExpiringJuly312020Member",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Remaining Lease Term",
        "label": "Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gale_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Amortization",
        "label": "Operating Lease, Right-Of-Use Asset, Amortization",
        "terseLabel": "Operating lease amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Options reserved for future issuance under the Company's 2007 Incentive Plan.",
        "label": "Options Reserved For Future Issuance Under Companies Incentive Plan",
        "terseLabel": "Shares reserved for future issuance under the Company\u2019s 2019 Equity Incentive Plan (in shares)"
       }
      }
     },
     "localname": "OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_OtherWarrantIssuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Warrant Issues [Member]",
        "label": "Other Warrant Issues [Member]",
        "terseLabel": "Galena Other"
       }
      }
     },
     "localname": "OtherWarrantIssuesMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_PIPEInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PIPE Investors Member",
        "label": "PIPE Investors [Member]",
        "terseLabel": "PIPE Investors"
       }
      }
     },
     "localname": "PIPEInvestorsMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_PreFundedJune2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Funded June 2019 Offering [Member]",
        "label": "Pre-Funded June 2019 Offering [Member]",
        "terseLabel": "Pre-funded January 2020 Offering"
       }
      }
     },
     "localname": "PreFundedJune2019OfferingMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_PrepaidProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Professional Services",
        "label": "Prepaid Professional Services",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "PrepaidProfessionalServices",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_PrepaidResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Research And Development",
        "label": "Prepaid Research And Development",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopment",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ProceedsFromStockSubscriptionReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Stock Subscription Receivable",
        "label": "Proceeds From Stock Subscription Receivable",
        "terseLabel": "Collection of stock subscription receivable"
       }
      }
     },
     "localname": "ProceedsFromStockSubscriptionReceivable",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ProceedsFromWarrantExercisesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Warrant Exercises, Gross",
        "label": "Proceeds From Warrant Exercises, Gross",
        "terseLabel": "Gross proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercisesGross",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ReclassificationOfWarrantLiabilityUponExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Of Warrant Liability Upon Exercise",
        "label": "Reclassification Of Warrant Liability Upon Exercise",
        "terseLabel": "Reclassification Of Warrant Liability Upon Exercise"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityUponExercise",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted Stock Unit, Performance And Service Conditions [Policy Text Block]",
        "label": "Restricted Stock Unit, Performance And Service Conditions [Policy Text Block]",
        "terseLabel": "Restricted Stock Units with Performance and Service Conditions"
       }
      }
     },
     "localname": "RestrictedStockUnitPerformanceAndServiceConditionsPolicyTextBlock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gale_SaleOfStockAgentFeePercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds",
        "label": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds",
        "terseLabel": "Percentage gross proceeds from the sale of share (as a percent)"
       }
      }
     },
     "localname": "SaleOfStockAgentFeePercentageOfGrossProceeds",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gale_SaleOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount",
        "label": "Sale Of Stock, Authorized Amount",
        "terseLabel": "Sale of shares, common stock gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmount",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Warrant Activity",
        "label": "Schedule Of Warrant Activity [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity Table"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Warrant Valuation Assumptions",
        "label": "Schedule Of Warrant Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfWarrantValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gale_SeriesAConvertiblePreferredWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A Convertible Preferred Warrants [Member]",
        "label": "Series A Convertible Preferred Warrants [Member]",
        "terseLabel": "Series A Convertible Preferred"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredWarrantsMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gale_StockIssuedDuringPeriodSharesCommonStockandWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Common Stock and Warrants",
        "label": "Stock Issued During Period, Shares, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockandWarrants",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_StockIssuedDuringPeriodSharesPrefundedWarrant": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Pre-funded Warrant",
        "label": "Stock Issued During Period, Shares, Pre-funded Warrant",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPrefundedWarrant",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "gale_StockIssuedDuringPeriodValueCommonStockandWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Common Stock and Warrants",
        "label": "Stock Issued During Period, Value, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockandWarrants",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_StockIssuedDuringPeriodValuePreFundedWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Value, Pre-Funded Warrant",
        "label": "Stock Issued During Period Value, Pre-Funded Warrant",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreFundedWarrant",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_StockSubscriptionReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Subscription Receivable, Current",
        "label": "Stock Subscription Receivable, Current",
        "terseLabel": "Stock subscription receivable"
       }
      }
     },
     "localname": "StockSubscriptionReceivableCurrent",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gale_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_TwoThousandAndSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "label": "Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Plan"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_WarrantExerciseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Exercise Agreement",
        "label": "Warrant Exercise Agreement [Member]",
        "verboseLabel": "March 2019 Exercise Agreement"
       }
      }
     },
     "localname": "WarrantExerciseAgreementMember",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_WarrantStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Strike Price",
        "label": "Warrant Strike Price",
        "terseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "WarrantStrikePrice",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gale_Warrants2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants 2019 [Member]",
        "label": "Warrants 2019 [Member]",
        "terseLabel": "Warrants 2019"
       }
      }
     },
     "localname": "Warrants2019Member",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_Warrants2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants 2020 [Member]",
        "label": "Warrants 2020 [Member]",
        "terseLabel": "Warrants 2020"
       }
      }
     },
     "localname": "Warrants2020Member",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gale_WarrantsFairValueAssumptionsExpectedVolatility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Fair Value Assumptions Expected Volatility",
        "label": "Warrants Fair Value Assumptions Expected Volatility",
        "terseLabel": "Volatility %"
       }
      }
     },
     "localname": "WarrantsFairValueAssumptionsExpectedVolatility",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gale_WarrantsFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Fair Value Assumptions Risk Free Interest Rate",
        "label": "Warrants Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free rate %"
       }
      }
     },
     "localname": "WarrantsFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://www.galenabiopharma.com/20200930",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r142",
      "r144",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r142",
      "r144",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r131",
      "r142",
      "r144",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r131",
      "r142",
      "r144",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r26"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r61",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r256",
      "r257",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r145",
      "r147",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r147",
      "r171",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r52",
      "r89",
      "r91",
      "r95",
      "r98",
      "r204",
      "r207",
      "r223",
      "r272",
      "r278"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r32",
      "r52",
      "r98",
      "r204",
      "r207",
      "r223"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured and recorded at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r148",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r141",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r141",
      "r143",
      "r194",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration payable, maximum amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low",
        "terseLabel": "Contingent consideration payable, minimum amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, measurement input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r22",
      "r47"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r47",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r224"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r50",
      "r52",
      "r73",
      "r74",
      "r75",
      "r78",
      "r80",
      "r85",
      "r86",
      "r87",
      "r98",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r129",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Common stock to be called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)",
        "terseLabel": "Warrants outstanding (in shares)",
        "verboseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r129",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r113",
      "r275",
      "r281"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)",
        "totalLabel": "Total common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001\u00a0par value; 350,000,000\u00a0shares authorized, 9,461,978 and 5,080,100\u00a0shares issued and outstanding at September 30, 2020 and December\u00a031, 2019, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTotalLabel": "Total operating expenses and operating loss"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r81",
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r59",
      "r67",
      "r69",
      "r84",
      "r102",
      "r119",
      "r127",
      "r178",
      "r179",
      "r180",
      "r192",
      "r193",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r45",
      "r115"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r213",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r216",
      "r217",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r138",
      "r140",
      "r213",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices\u00a0In Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r138",
      "r140",
      "r213",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0Other Observable\u00a0 Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r213",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Unobservable\u00a0 Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedLabel": "Change in the estimated fair value of the contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Contingent consideration, September 30, 2020",
        "periodStartLabel": "Contingent consideration, December 31, 2019"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r107",
      "r108",
      "r271"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r58",
      "r89",
      "r90",
      "r93",
      "r94",
      "r96",
      "r98",
      "r203",
      "r223"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r52",
      "r92",
      "r98",
      "r205",
      "r207",
      "r208",
      "r223"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r52",
      "r98",
      "r223",
      "r273",
      "r280"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r52",
      "r98",
      "r205",
      "r207",
      "r208",
      "r223"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities measured and recorded at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the liquidation basis of accounting.",
        "label": "Liquidation Basis of Accounting [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Measurement Input, Expected Dividend Rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r34",
      "r35",
      "r36",
      "r46",
      "r52",
      "r58",
      "r63",
      "r64",
      "r65",
      "r66",
      "r68",
      "r69",
      "r76",
      "r89",
      "r90",
      "r93",
      "r94",
      "r96",
      "r98",
      "r223",
      "r276",
      "r283"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r66",
      "r70",
      "r71",
      "r77",
      "r80",
      "r89",
      "r90",
      "r93",
      "r94",
      "r96"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r65",
      "r83",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r256",
      "r257",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Adopted an Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Current and non-current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.",
        "label": "Option Indexed to Issuer's Equity, Description [Text Block]",
        "terseLabel": "Warrants to Acquire Shares of Common Stock"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityDescriptionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r53",
      "r88",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r106"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "terseLabel": "Contingent consideration paid"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r148",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001\u00a0par value; 5,000,000\u00a0shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r105",
      "r106"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash received during the period for interest"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r139",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r139",
      "r240",
      "r242",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r187",
      "r298"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r11",
      "r47",
      "r48"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r127",
      "r181",
      "r279",
      "r292",
      "r297"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r59",
      "r67",
      "r69",
      "r102",
      "r178",
      "r179",
      "r180",
      "r192",
      "r193",
      "r288",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r236",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right of use asset and current and non-current lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Net proceeds of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccountsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r147",
      "r170",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r147",
      "r170",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r148",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r152",
      "r159",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions for Option Grants Issued"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r29",
      "r50",
      "r85",
      "r86",
      "r116",
      "r117",
      "r118",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r154",
      "r173"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Total Number of Shares",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Increase in number of shares available for future issuance under stock based awards (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options expire from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r165",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected lives (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Average vesting term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Averages contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Aggregate common stock (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r50",
      "r52",
      "r73",
      "r74",
      "r75",
      "r78",
      "r80",
      "r85",
      "r86",
      "r87",
      "r98",
      "r119",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r54",
      "r55",
      "r56",
      "r59",
      "r67",
      "r69",
      "r84",
      "r102",
      "r119",
      "r127",
      "r178",
      "r179",
      "r180",
      "r192",
      "r193",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.galenabiopharma.com/role/LiquidityDetails",
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r84",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r119",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for exercise of warrants, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r13",
      "r14",
      "r119",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r119",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for exercise of warrants, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r119",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r119",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r52",
      "r97",
      "r98",
      "r223"
     ],
     "calculation": {
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r56",
      "r59",
      "r67",
      "r98",
      "r102",
      "r127",
      "r178",
      "r179",
      "r180",
      "r192",
      "r193",
      "r201",
      "r202",
      "r209",
      "r223",
      "r225",
      "r226",
      "r230",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r51",
      "r127",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Accounts"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BalanceSheetAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r61",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r256",
      "r257",
      "r258",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": {
     "auth_ref": [
      "r72",
      "r80",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.",
        "label": "Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount",
        "terseLabel": "Decrease (increase) in warrant fair value"
       }
      }
     },
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input coupon rate"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.galenabiopharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=35686142"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=SL109261905-112644"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229355"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r299": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r301": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r302": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r303": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r304": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL109261756-109256"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001390478-20-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-20-000037-xbrl.zip
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M5.9'VW^>'#;V$,P'YK1["M?#_0ZORF]W\&'MS]-R'>98V^F6#]#EN]KF9P%
MZB,Q&?P;,V:<S&Q +E/(:$$LIU3;E0T$1* :,:E^?W.'GN,G;Q_JX->7W74/
MRJ4!(YYX<Q6:HZ3?ZK7;0/?=O.-,_3"8]D[3;\/52^K_B/IXE/K,4NFB#)FU
MP (,6999Y$G&8Z0^&$5P$"L;V\&%A@WM$L6O3OY;$@^-C%L:[\(GG26%?T1A
M/DIAR:@Q7HA,,@GRK;#/P*2"5UI3JZ716J&5C;3^4R/M>QB_Y9?$?11Q+\M;
MB; %@2\^!ZRBBL1E)OW#J."9Q4#B2,#8Y1XC$4 Q?Z 316W;:M6#:4933U;G
M+=4W@>2^('O='"\I_6-*'XQ0FE/O&!$J0\XIH+2)F:7$9U( A OP:S2)*QN[
MF^\.=IY";**<1-1&"Q#!,)9:FV@<E5:(&+FF-\36V?#%'6(GWVG=]]I7 ,]#
M6B<;<GVK;CJ=5OQDVN"_=%OM_>3_U4*[,67"EZ]TPS5VF]5&F0$Q2.5ZDQ[5
M_CH]//V #T^/\@K9X>7K^BG\O3Z\_NOTZ/2,OZ/[]?"O_:NC3_[<$B8.KX_1
MT3;,>MO7RXU*7MG^.Z\T]NAA[>RZ^JD,?RNG\'FC6JO'<FWGXK.PS($G2S.D
ME4D>KLZ,<BX+2FDMD/,N\I4-OL:_0;K=MG')^ROUFGF?<,U>4L@K=XD9A$4&
MZ1@=DN!%&^W X;56J:@5088G8F*-,9+9\,5*R0>7-T!4_UC9J^P.23CPTM8/
MNBUW=M*J@TW?V0%WHGM5:75#\>G!>3WO@F\Q"!+L)_<4W*@$Z#  FC*9JP<#
M,I^"G-:.BL\KY".M;N\W#AM KNN_3LIO=QM'-1CO^NCDZ-/A%9 99/*R7CW=
M0>7K8PZRW:C4-BFP!JV\A>]J?Y\=U?9HN>9PY>U' O^_'OX&[M4[(A]%N?;A
MNKI=A\\.,; 'L(9#1V]W 0_VZ^53=UFY_HB.:H?P_TJ\(]]$1R\"4ED$PSMC
MW(!-QB3//)-&8<:10P[L\#5$ACPR9(KORK=4#(8Q!E'DF<;1$D\)6'W1@1&@
MB?F.HB[$^,]>!SS.3F>KU;!YLPA!)'\R;QX#CL.K3@ZL47R\F03]."1\[]3R
M!EQ1C>6\'CI=< ZGK-AQ.1^RP]EUY?KLX@A@]^C4GQW6/B3H/ZE<?V!'IXZ4
M/_T%[.( "<KHOM17:V5:K?U9K[X%MB#[)Y7MO<M*8X=6MD\:E>O#R\-&F5>N
M_\[+U_NQ?/J1E3]\)APTJ18L,Y0FX\OZ3 .\9D1S%I#Q,DHPOM[SPR5D?YMX
MI+(U)!Y ;:,,<.TNRZ>'%Q602Y E(!Q =6V'5[;WST#NKH].]Z[N$Z],]LCA
MM:]7KG>N*J>;I +073D]:91KE1/0]PCD&Q@"1C_]*T'VU0L@^\W=V$<[Q "N
MJ@N=!T(V*3RTWBE":$#<4A$N6N]>G0-).GGCO)[B:<5G)^U$^SO1F;7+CH<A
MWMP=HW__VYL.YM!I]=K%NR+\MSY@J %=GV'P#0<*10AF^ [  -[''%S%8D+A
MP;#JUMZ_[T84[O]X8_C1W='/"S]A^*[3->UN<ODWAE$\A(>_N_WN9II^Y%*=
MI=C6W6^&[X<W>7-GH8;C)/U;+%KGQ,"BWBQ#(YA.KQTV!K<OOAP.,?QN^#Z-
M\2 =,,;4>AZQ#8Y13TR4(.&4 FV<]<%^WDO33U?-P/+W [[=_HIBG&%Z,]#@
MFR>N:*_@YKM+-HBUKG\\V'[R:GI"48B.6^X,XTP9D-FH#07.1MQ%TU_-&6'F
M.ZMYAS^?MIIW5H 380VF(O! @)^80D%H[;44P3AB2%H!L ()Q3.U EAGF&04
MOYR?WH?V01+%F\?S^1>8UNBE!6H;4';/9+VO?I\^W [-5B-92U\/^UB N#/$
MF[NS_Q'G.T0(5QQQ9 (3F"B =JT=6 S,*Z;MY.@^>-IPG*S"_EL/-[L$U\'E
MW7(_J.AS^+:_SWCK=J3 ;[(PDTE2C87#L7F9 ^#>7 )<$#J;[PM-UPZ^N*0_
MXN]O'KS1S<+=S&>";'F'0(0;0B.."H.^509;$$Q#N1:!:@+2.3EH6B0"C1$Y
M07RPM@H;I R8@5(IYK32A&NDD7!J8!')V;:(Y"0LHKL:!W/I+58:K%_FB-!<
M4+"749 *5I.(?@!BL&[P8O;6+>TR/W+=TJ5C6C<'#,= 6<? 04U;8@,5! .&
M*XT%16ZP;GBVU^V1%O@8UTV!XQ)@E8CCFK% 5!"<: 2KJ1VQ(*=](!5S *3]
MZ-I6JW'>:J80RETPG2R*BO&@*/8J4(D1.#6"&7!KM'-(1*8X)X2HQ:$.?-YH
M->>)-!:#GX\I3QC#9-!@A'BD=93<:@+NYL*09M/[/$4G3?V]R?U><\N<YUU3
MGQ,R(2RM1 2<N"B89U8KH4F*]3EA,.)T8<BT'[HF;P:_8]K-O'G<F1/Z&(&T
MI$ EX3"+WEC$/&6645-(%Y\<?::U D'#DR9\#P%\&:,UH4%0\&' :F&!LRE8
MRO,,]M,WX;WC40I&/6**<2"H-9):RDT OT>RN'@$G9B*F#YQ ::\)=YR@BF3
MH/<%T%G%Z!@2V@N^>,1]?<4R?:IB*1'W.$1C-0//.SG8G'BO%8Y@/* Y"B?-
MDA<TIEB28-P)A(QBRC")C:)66T*LI4$B8?'"4&>"7M"82,,8.*B8^Z@U8T1'
M U:V#=SKH(DSEBP,::;D!8V)3$Y( :8'P<@0ABW2@KC(0F1.8,.(6Q@R3=H+
M&A-]8H@Z<$PL,9P)%6Q ,BJKD4'"1"WF:+]I5O3/&#>;%+;)0?-8H<@0CT:#
M":B%D]**X+5<&.I,2/^,D31@G6$+(F,1X)DGR!H$Q(DQI+\$3W"#?O'TSQC)
MY$#7@)T0A"&2H4# C(NZL.@P-L*XA2'3)/7/&.EC'3+886L%CTP;I3E'(%1*
M!LH%]VX*^6OS#'532:R[I[)TRG<V 2O,(A5&@/Z"CY "@\)SNG@$G5H,:O+$
M=8(+HVUP!A/FK5>:6LJ,X9@AZ]&#&>GS3=S)QZ"F0%6MC'98,?B'64)51)@;
MSG7TB*K^3@C6"[!3-5$?8&S[5($C(S$6!D?&78I$<8J"4SCZ2 A>&.I,S@<8
M%VF41UI8H2.1AGFG+4?"IMQE8R4QPR3=!2#-='R L4F0]4R" ^VY-TQAH Q7
MRGH*'C6/GHN%(=.$?8"QB1'A6&CM!-4"?+2@%+;@7CL2* VPFI.CS[16()H4
M1U#$!H68E49C\'^"# 9%B90*4\B]G&>PGWY2*))&(.0B4ER"9D V< H+[8FS
MG ;D%X^@4_&"ID-<2JG3V!$AJ ![.:23&LQQ:@"X9$1R\8@[62]H.E252@/<
M4NF0QHP8JQ5WF!H?HP84OC'FYI^8D_6"QK43'R1-Q_^D$YBE@U"(&/!/-5*(
M>V<7ASH3](+&1!HI.0I:(1L59QQ[K0C1B@IO8K3^)GPP_Z29DA<T)C*!31TH
MMHH$K<$5BI9&CR463ED'(B47ADR3]H+&M1-/E>#!$4XH8RZDVJ?>&RX8 V'"
M1$^./E/C4*+!9N8ZIFVZ&)$6P*$(6TXXJ&',BA50"[!7-T$-K,:7BR LB>"8
M$N8)2UNH3@7. K5,R"@C71CJ3$H#CY$T+$H.7B6-P3.EE)6,DJB,9>D\G5\<
MP9F&!AX?F2BW6C(-;@9VS%JOA*<,$V8BP01)O#!DFJ@&'J,8$<2=93)XKID3
MR$0E-5?.4,:=5&9R])G6"NATWDG'B%U,IX*,<H%$K"W!W'K'Q13.,L\SV$__
MD#4E 04.AF0TACG@:Z*U%6#M&Z6)96SQ"#JU..3DB1N-5]P%9ZWPL-A.,>^%
M0H$@FVH&Z<4C[N3CD).GJD211AZP 3>(18(,UDY*[E)U":[MS:E,.LBQD;-K
M+NR'>NHP\AZ6[:J66F'TBUYV_KP:_:9/XJ**X?N]]SM[S2^I[F1[(L>]Z&-3
M;48O?0%QDV^+!6<>]"E3&&FF- </2H$,HX"&IU:6-'WFJ0@Y+DN=64^D#IYP
M1A16GD?AM=!,&*IOSGVEZIP+0*;A;X94>FTB :;J,1 I&*V9D5*ZJ!ABX/AJ
MXP.*R$5GP&"??2+]0.OUQ:<==GM-'_R@M.NKB]"8J.-B3.?P+$B-851SXW'D
MT8"S2RVB+CQ4Z79)IJ=HKU%"_4![C5[Z NU%'*7<I.)@.#))C87E]MY:"T#I
M2="3D[AI<?5SZC?/*%?/EH:8/G-KSWB,FC'* _,$V^) I.$V6..$C8.30JGN
M_BPQ=SJ+ RL@Q\#<X&UPX30)UAL6"%5&FY#*S@J.@D.W*Z!F<074&%; 4D(E
MQ\X;)5(U!B.-(DPX08DB*L[3::1-&,'G]5XW_Q(.@NNU\VX>.CN7KMX#+;7;
M;C62'NMUB_K_U3CTJ(=E=_^\>GB NW@P4':+>"B"2T^4Y:#>6&1!4!VPYMIA
M(7002H0Y"JXL#BM,)R)#J&"2.<13GU(&?. M=9X3+2/&4<W3D;:)L,).X[S>
MN@K]5C/5\S34(B*$%(A''"Q#CK.@G6*$2&$TU<:"/3Q/L?7%9(LI;;E0D9PC
M[(/TS"EIC-/!4LQ<( ZIN$2+^S']3K>=N^X@&^9C,^]V]@\^+B)B<".H,$$Y
M&QU+53TB^!C!&2MC@!LM$6,66&-BJ''3[6+0#V[X^=UV$^?P<CC H_NG/*>9
MW/1=NGM4N./6?I\*=RY]234^C$,(4FJ*.7/2V1")"(%&#2(J19S]:E6[)F__
M;>H]D+!RGUO2 +OM\$\O--V]<,[-Q2.7=O:3,+9!6.>D@I4.) 2%J(P^->1(
MA7BLIASHB+T(F,\5S6Y>_@M&-&UW<O4N? GU;Y!MKPD(VRFNP#^@UI*!ONW>
M23#58J#(<LJ 4ZQ1TH*&]MZA(/Q\"?VS&8@L&>C9N\484^JIBAQ+1B153A(3
M+2',D70.<*X8Z)5I-E&>IG/"0-H43:"#T9PP8XPB7!/:/RML%)Z#(F5S(O1C
M+%S&24Q[V82 LF AV%03F%DKN9 @ZTC/%<V69L?D&4@XICE%40<,G"2-Q6"L
M2B*$4\B9, >=_I9FQU09B&+B(XU@5P1@)6H55BS8B"TCCEM!YXJ!EF;'Y!F(
M(22#558BYXK:FRQ@ZZ, :\1*+?U<,=#"4TL:I )U-EF%3-A4! %L$ /V1MI,
MF*M*J3-*MNEO$ !1&:>182L4<ZF/J6<^*!T##XSY^?(D9XFTK^*V66:ETIYP
M0$QFF=.,,1H(91BKP ;G.?$LX^>?O4[>#)W.IONGEW>*<U,C.:V;Y]T3H-Q>
MTZV]*D;B\57[QMP&%BG7' $\2AVCQ4Z*$(2%EWJ.,'**I)D^#B*+#',8A@R1
M!2; .;*.>Q.M<$&Y.8CISX1DC3-(;B@G&K22)XI%#NZJ@X53T2$M6##TYZ'(
MHV\XXJ<4RJUV=1Y&[GC_ZT\A/S[I!K_Y!>9Q'+9:G6XUSEFS'Q0\%JFD$!6,
MDZ"08L9J[)&P(?(Y:/8SZTS2YXKM8%\AT?)56$(JL(RD,8@BSS2.EGA*F*71
MZ1 UF:>*\1/CC4Z[N[YOFL<#1DAORWDS;_0:BZCKO>*".0*6LP47!PO-:-$^
M0GBAP*2>)[]VJAQB+A>50[A77AIJ$;>2D2B-"N!P22REU?#%'/2B?P<P#AJ]
MV6T;U^V9>BVT&R.<48TQ=^'@W+A07+ES>9ZGH.9V<,60%*?LP'&IG$U_VNMT
MB_#I;JM="1>;SK5Z\(S-X_?M5A->NGYP]5YAC9NK#D 9>-/VG8_G'D@*'IQ
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M [/:ZBAHC)ASE%J%:SO[:G<V*/DZ>\T(4? ').;.,^*\0E)38M)15N,]80L
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MCABE"T%+I+#P@2FM# B74&"?4N&=4L/2+A,X3+Z@M+I_DOTE<D7!A$2*%A4
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M:K<P?G-F1.C74]OF!HQXXLW553#MT'Q(ZM\7\]GIN^-S*?//MGLNJ[6]SR&
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M?=[3++"$WA? FKG<&^3]]=/1Y]B#FK3H[=V(GG+(4L1])DTD8(!JDAGPB+.
M#*R[)H8'O[)!4*;@'<?DN\(WTYKE&690P<B_%.">+*!\%/)_7<+.C\CW:L_S
M5 KNK>VO':R5=AKG]=95:)?NXD:ITEK[]0GQP^E'"U\=6S>];X=.9_#G'4P
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M>J3!LXC 0D'%#'2GR((+5 ='.34:K#2-Y:_W66A@G+X>:=)9YOK[DU;S9]V
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M(&PE#4*:$"&7[:Q3S<ZBHG4*SBDJ^B J.N,ZLB%9G<8!$@PKQ ,89(56:=L
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M@#B0@(PQ.G]G!,&*44:J1EYZZ;881:F+(71/^3Q$;NF&R7P!(%^R,V,!\OH
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MC2^4IU">>V):R8"I"]A-R0VS3D='*:+":<0M2>3&>HR<!^V93[_(UITH(%=
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M[/+1QP^0'KMCSP?PR^2;7R> W>Y6FEF]Z?NIIK_RZY=V&)[^8LP+(4E6VHN
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M?3T@\SK=NQ]>+I0:?]KKI.4<[/]WU!Y^332O,\H+^+K7SW/;&0[[;3<:VB2
MDUZKU\VSZ_<ZZ:$^'J1YYHIIA1 NBK'36LP&4Z/!6X0U%PE9F40N.H&"P8%$
M*FR2?L'8%40C%$)V,R&3H!AS3"HO"=?<.$RMB6G[:2R"=_,2LA^W8RJL;$G$
MF.F[(*RRR4YT2&M*$<?1(A,]0Q)C"-1:T%YO;?.FX*9)\:JZ+VT,9A1>5GC9
M"GC9_6#SEI[!A8$].IY.&9A34G(&!B6!>L0M)\C&&!!EU#O-*14J6;FBX&C!
MT8*CJ[=OE<!@-'91"RY(,(G4&,UD2#KH@A#SV;=W-P,M$/O8$#L3*R\X&,+=
M)%8^^H@T$PK1M%VP=.FUH+:V">9-)E=5'K< ;0':C0?:12Z.B8O B-,4C.%!
M1,=B((I(KYU/%%;=CK2+WQ<7R'T:O^),X(GE1H,,$DE,).)4*:0C)8C+9)YX
MB[T786O;L*:BUWT$"\?";PS:/D382D'P@N KH,J1:2G 4T$9YQZ"QC$$*R1/
MFLX(-84JKR]N3P.$')&< G=(TP3>'$1 EG- B313D4YK$)QDKMR43&T,5:YB
MC'ZN-E7Z-[0_;_\K?9E,?.:S/.0]MCHE)?@N+:55F62 AO6Y0++M?DT/V^CV
MAC!H#'N-X2D,(&FM34HRK(HH=ZOEL?F'V.[:KF_;3III^D55B^O%I72^?\R+
MO\A%FM)Y;U!5VOJE#QT[;'^&7[^TP_!T AHS[[J0&IZ^Q;HT@]'P]K<LL9XG
M[;/TW"WXTGC3.[/=Y5957%V*V:]YMA5T..L2I!'KB*:<^0QZB; FY'/&61W\
MGXQL3=YTVI\\P;G]",CUP?Z%;$P/^(OM?+%?!UL_7UF'LW9W,B%%TXR_7Z];
M5R7&!]AE8Y5)P-SK5PFAO^2V?/T\*LW&UF 6C=-^/H?^<;=,"-[:/LG*G*L3
M[>8SK"HV9+=OW?MS;TENU+*/K6Y6\?U7KW:.&Z\.7NXWCG</]EN[^\>-W]X<
MO7W=;!RT=F]7VZ>?^NY1Z_CHU<'>SLG^7N/X)/USN-\Z.6X<O6SL[AS_7^/E
MJZ-WQS6>_S]WSM*I-!PTVMV$I[U1^JPP^*G.$WX[P?O%9[G]+]?_>?LFY)M%
M)MO_F,#I MOS@7#QFWP$BZOT_O+3J^-S>BQ41W9:BXX]'\ ODV]^G=@H[6[U
M7-6;OC^<TU^9@N$+/ ;$BQ#@B\^_>/E%]=)W1&/\FE0OE#"WOHQ?D%M?^]''
M$OZ"8'ZOC_WQ:X+=_D>7FJR:ZV/O"+.^TUXU6]^)_F+SW$G8KN^E>EA&+WO]
MS*X:W?1*XRP-/QTT('>JO1JI?87L+KN([/M%G(ORUG4%*:;XUACV!1_UV2S9
M=V'_&YW]L&L'IXW8Z7T9-&*_=];HG4-F?<F^R?;DYV1.P."7>7;0'9;E\EMK
M!6Z\%4[R>57M:"R3=;0Q'LF;GJVF/L5%;H6"TX"=5(X:RA-A=MQJQR23Q),(
M).1T0HHOT@G3-RNY'IKF$KY,L),-Q'9WE%;U:(P_O>Y@G=V.WPZ/)V['-^T6
M37_KVT?1^M9*8W_GK=_>BA;]_>O1NP-V^-N;T\.3O[ZV]G[G4[?C'W\=_=;J
MM+ZEU]*X]Y_>9)>E.'JW__7#V=NOK9.#].\^:YU,WS-Q.[;>_<[?T[>L]=O^
MMP][_VFGOX5;W_X2[T^R"_. ''[ZS]G[$T]:>Z?Q,@3]&'_YDV'BC2<4&8\M
MXE(!TLPK9)007F/%G,Q)B:R).:E'4N**DI0+DFT.DCU)8G1!LCH@V;=+)).&
M4*&L13:0@#@!C8RP&+ETKH'EQK'J]F3STJMKSB6GS4CRI4D?TJ;W[4XR[B<<
M,_TV?^^S13+*W2C;W=6;(W6Q..YC5*Q=FX4RX3+A,N$RX3+A,N$E^_/\@&XQ
M55?*DZ@]JNC,X)GWV'Y<;]0-F<?__K[!7;&O%K&O+H/3JEP."DP9+C6B)!>%
M,8$B#88@2Z+PE#AAF=W:YLL'I]7/6U04=/5=*HN"KD9!I_FLU@:/E='(@<.(
MDZ2J5@:%J(\:)%!K95RSUI(+.4'JRPAV3VWW(USU;'0@[?U&M40Y6&Z4?K"#
M 3R?WGQ/P0ZJ)AQC:1QTCR:R>)5%\29/[2B^'<!.)8:"1 LAT?LK]>.4=BY*
M@V)(7[B1%CG"%<(Y:X%$(X226]MF525*ZIA%]'R5=05,X4<5S(H*/Z *3\D$
M1/ ,-$;"@D+<"H6<2U^$I0#$4FY@Y>7)GF6OZC+AXG5:+<>,MMUO?+:=496%
MX7MG9[WNV!>U7/_G-31P'SD@ZH83ZF42QA]9%D=QMY)$E6DYZ?AV,!B,(!QT
M=WO=[KAU][OV\/0/VV_W1A=YF"_'J63=C^4X6^@X^[0SRTBC)8$P09!U-MG&
M4M!<10]0=#I$++QD+C?MO%[L:9V#G(I6KYR-WA@35!2^+@H_XPSS%J0-@*@-
M#''EDPFJ8T1"6$&5(DJPQ%])D]Q0*+..X4 ;0*O6W'7W/:W*$7\?<UQ3SOQN
MAXNPO^*]>]!(\[L =R*4UZ.^/[4#V)V53<'3A?#TX(I+CVFAJ#2(")/P%&N*
M+*$828DE-8(0$1*>4EE\>INHPJL,L2XJ_*@J/*5$W"I%@1JD  S*E820(V"1
MYPI3*[DU.AWN@JRJ$&-A11ON;!I\%ZM=.=T;MAL:G;9U[<X2<=N+]QA\_,_8
MM+VY=A->"'DD>:%$7?7I=1_.;3LTX.\<"0-C)>H-3Z'_S(("GL1A.Y/3U<_W
MB'LP_O>@>R&7/8C0[T/8'XMGIQN.LFS*+>,]*,F51G,Q)C[I+44X>(FXYA09
M2CQ2D4D+3NN ?:(D>@6%2HM!42OE77D\85'>QU'>J3T1.(LZ_9=45F#$G?3)
MGF $,9HP60/3'N.M;:ZOVQ-/HKR;QG[6;L(+V3ZUIFL[WH_KUIW;KSF=NURG
MUZ>^R'>'P$14K\>2*GB_"-Y_NW*'SL$1 THC0FQ /"B,G*4!.:HQ9X)3X1(4
MT":A-<FP+]?H=:)KWSF B\H^F,K.W((K[ST6%BDN%.)8260CBR@20E24U"N6
M599>S]FJXQWXYOA[TA;OC^!&?X\?)6.E.YQUH3X7Y\_CLHOE2$46WZNIB I(
M+012^[.\PA,:5#I*D@D9$T@1(Y%QW"<[,E@1&9.6N2I4AUWG%>5RN::Z7&-R
M451W2=6=X1<!*TQX8A4J.L25ULB%(%!DR5!PA$F>55>19>)JBPNH3+A,N$RX
M+A/>D!".UCQ%]Y9Q;"[7NVY-J<R3>#V3*'-!]]?]WN=V@/#OKV\'.<?@,CEV
MYU*>A>LLQ'4^SIHI$+DQUF $U#+$A:/()<:#F,7<8"ZD$;JJE:Q742NY-FTS
M5^@<?9:(\"35B0LB/!PB3*T?XPTA#A(.6(P1#P+R53@@$#CWZU0&PA@1N%R!
M@_5Q>C%N$%$K$RX3+A,N$RX3+A,N$Z[5A#>K>UJ<9.R7[FG+=$_;@%V\EI[
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M;LFNM)W"B\9XE.N  .O.3$M;S96O*?]<?6\='!PF>;O9UW69 R;LOAI6Z9&
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MST[..SM?4AY)&<8QB63$"8NP[GN6AZ"?69J%C*91EFZ]BN,4"XJU(I9>#=(
MY+O;GC,;\T3EL9%:,!/33.3"F"3/$QX:%<[W/&OV?-U[_AT+V$2)5@FSQ(:"
M$N;.U&(3$Q6'292)5$91LO6*M3C+6W%XM=9_5=K#.0X1D'N]F7EMRXO03G7K
M[GK[7/FT+/KN2S-Y9\K +/I2O(E<(IK_P^%1^:M#O=*9@1^?#GL IKZLT]R+
MZ7IU7WW[;6#/Y6"40>S^^EN,J+K$5_! 10,CCT;BPBD7V%6Y:Z:S+.H5BW5;
M-Q4V1X+13<9#X=6 4OFH4JE720+GVNKU:M4A:[4B2S?%W!,Q$SOH8AHCW_16
M!.H_]IF1J]8VCRAV6X_'A'^;L<,&H,:=@3XPXV\@=5]7"1?%BS]5"MOG7_(X
M-IRQE"@N)&$QC8E,(TEH(D.PM=-$6;F9ITKS#2^M%-SRLMY#;>=]")'?^V"^
M^8_A7O_A\#TJ7/VYL0/;G8XK^^ V;E^O^_IS:71RN@+6F(U6*;JUS(7*",']
M^VWKX\&G8NMWE_M65N.NU/0REPBK]052E&7]1TM[791[/<NL*I.HG.<7$W3G
M6(]O<E[=OA'%=.R?5V\QX,;J,7)LYJ]<M)&PPX"ST;P-X8NT#3SD^@):>*T9
M%%X@EJ&A>'*$&58G ]B;N1X_U\;=X'SDJB^=(@'0Q7B GG/,/.OJ4H%WH:38
MLWHV=>_+=K'Y#K;'N$EC=_KEA#0F=!7%K-SB>"AG"8>XOM6RUU=6C;LNI&O6
M"*]OP,!X[:/F76&?6KJ9&)MY]IC!FF55.*N/J^A5>7%5,VN]F EFZJ\F52FP
M^88&&/_0F^]4W4$_R_O5)35,)CWGS+>KYU,Y]6$^KO!,^>?2PL.WK:H.S]6M
M'(%DQ3S,WD5]2S$)&4>';4!4UTUA=B;D-G?>/=')97WSR>&OBL:H\B2JVH(O
M7G1BBD24V"CD-B1*L!Q%IR29PD6,E!!AF!DIKT2Y;H;H[ "MO\>*O+"?@=O0
M)^K;ZY3)XS6EM>M4]M%TXKN1PFB[SC=1Y9G7X[[*0E"5>E^9"V7O!?]FQ!%,
ME3VYA6NJ[@O17EPZ]/-XO U"L.?&M3QD?P;J(PF\SN[K;F%9IWGOUUF1JGFY
MPW'9X[6HZC#-*K"URNI)1:T88CG(FAMOZBK?KA+&WL'CSK=+>Z<\=)XYW+ \
MUT#Y%(8%*ZJ^),[!Y_>C$C<@1<NZ<;I<CL&576S=<@/@[2"HBK(^0=^[!.40
M&WF(GIKVRB"-,I/?9WD[T2,F/OM=S%]NOG<+7"4W*I1HY3LJB;!\^EY[ R[S
M9-[>M8N+.^F2ZDD/$A'RP-D0ZM3H*=:BW(&95!.9UP'>^^X7 VMCOW;;ZQ9B
MWRY+BA<M(W:^2"I8HM.(J%PKPK36V-),$:F2D)F,131=:5YM#,(ZS7G8ZPW/
M781NA4%8'F/&)[6RCS4 K(6<E<0RQS(U)QE7O:$$@BL,7X'*_+&MDM<N2G#"
M;L]U7@M^<^P)RAA<7_S^Q[6RJR_&)]T!*>,3,*BA_&0R'+D_5QU(^LJ(L] &
MK#5#7"&]46'^J'[YM^X6HYZX^*,[<.OI;OJWZ\0-F%$^$MY21@'D^78:IA@(
M,!G#?[IZ?!DCL.UB!/XUT5>_2Y+M-,NN_3K<CJ[][D>/C=AV&,8_]=@??\<I
M7?]@^7:4IK=Z[+_<^OHUAKU"NOC_MNC6/))#(X']$0:1X[/J>;-+\RN7QJ/O
M>/%54EG>;4]EZV/>_";>=9$E'333V]Y,W[MJIL]88QV+<_72#5\<E'P+*_!R
M)A[E=]EZ+-)Z,L:,!U*.32D#6NJ_?S#?GK&3AY[MS0+,3?=U74&O=.%K-SZ^
M>=HE[*.8@%D'SB<?5#.HKTD8K%B9,0YM0Y;F;B=TDL8TY9'2(DM D3$B%1DH
M12JA<19G5JW4*FMI]?0N:?7W4SIWW,'%[$B//DW=\_2H_[VWW_] ._''/GQ_
M>O3Y0]PY_! >77[@G?Y1>+S[UUGGLG=V_/DH[KP]NJSN@7=-C^-/R?&NHL<P
MEN//;TZ/=X^BSN['L\[NU_CX[./7=K]-]S]W>L=G\)RSCFUWP^_O#_<F[8/P
M_(M.LDP+QDB:AH8PJRS)&77IOSQ+HY1)I;9>T180PC4-*)<9;&U,A=\ZYKH]
M4_T LF_$MFMAOP&*:X&"ISK.)-=:,LM,@K6,<IZK*$ERDV2)ZY<0Y250P"\K
M@*)!@U^.!I<S-$@YY3K!Y@K*1H0EN20R,XSP4*5<)@+;QP :A%=K=6PH%MQ9
MX;'N?T]$X3FH>_E^2M%9,=UG!E$Q35C*5,A-&#$&^*0E59K'N:O]D-%;Z#(-
M1/UBB+JH*2RALF%LTXB(2,:$"9H0&5I!>&:4M#KG,H_0\KD:MW1'B%J-! ^J
MD2R]\J<TDN?/T6D2<AL9R4+%F<E5QN(X341.<R&-UJQ1.IX"1\^5#LM-EE-F
MB(YB09@"$T10^*%"*ZU*56Q2 QQ]M5W:KV/HY^U'P8B%^[A-GC'V4)I@7\Y(
MFU0SE:5"J-Q(&C%E8A5FMM$F-AY[.J]KV@3VE#8YQ9:V84Y@9RV1>6A(J&-+
M,QM)+L#@B=*K?>5^SN!YHOZ-9\S17"0TP40^D#4LT5%F!6@52LC4&F#AVV@3
M=5_GI1D/M2A.&S[? #Z?ZQB,Y4S:-"19DJ2$A9QC4]:()!E/\RC-91I:C(?-
MXBC^]P;Q^GW]%_<Q(4KG3'EL3F$&V,NB9V8.FI?J]?RIH)OF>.2IX,9!33^0
M7)J$&0U H0UATD@B$BY)K,'NS%)M%1Z/L%;,[NT273O7/2%O10,UUT"-BGG&
M$BFLX9IE,I:&)G'$,Y[E44)#U?@ZG@*>S/40R@Q+(\L)%Z$F3#%#9,0D"2EE
M'/ DRX78>D5C_FS0Q&DP_W*!<==%Q=Z]4%%3Q6A5 &<4KBIFTI0Q:LH8-66,
MFC)&91FC6Y0E>MA\ V"_6KWS\7 PQ%9P+INPJ7Y>]F'8^1*E$=@4G)-8J104
MA4B1+.8"K(\\IYI2JO6&E@#^:) ;%CH,+&QRL*.'6.7[B>:AO1L$.].3:3'!
MFC=9*\ "W%4EB\YP.]@Y^.2^(1%M+>ILOWICWF!6M.NQ%K1]$K2K2O';X7 $
M;)[%X>_!;K? %&?L6@.*9]^<#\=?R6O7UF%6[K=VS<=Z9QO,Q[KN%5NX*K@Z
MY<IL_?Y@B_+#)?#;4QM(T'?5VS&)#G3=HBSXU1]B5=$J-[H8@3UE88GT?.8+
M/7T 6N<9YU6">546.I@M;UFNQ)5MK0J.N2N6Q^3J1\T*?+D"HZXAT<1GWN '
MMHL6F*LX6I3%E,L*IE5Q4\P_]ODQA5FZ7)J3[F#@JCBY'/&J*FD0\7H!L=H@
ML7AT205=-%E]^V"@^!.7DX?O]PWE?#;?&"_UQ<.6TWPPH:]6TWHZ&$I,97=*
M4'< AF<13(LRH]HW>@W>X[\!O6Z-6_,2NACR[=9, S".NZ,JZ:AV>;WO:*VJ
MK\L4A=>.QD/<;GQ([Z)L_=SS.:)][#\[]N!6+39NC2_*6^;ASTK*SG(HP;S'
M1,[:#KB*<]I';>%*8YOJLKK_U?)N5;& JH(=3.@O 6\<7P11K>BN!JL-,Q==
M)I:8-66ITA2O%#*8DW*Q';RI"A* 8KQ XR=B[,O!3<>S78#]!FE3KORH9["&
MFJN)W!E.3,!*E+A-$9MUM7U=3RGMM5IB-U7\>'21]==T8$J!Y5I,U(36 OJ$
MZ88)K7=]UX6Z;)XVA)$.9I7\G$>*_.E*==34C25I$Z:_2MI4-1L+X,*>DS*^
MI/-\J,C=SN]'?,&1LE+4O'+*!)L]#^9%4?"&D^&PE%1E$9!B>WD3@V(Z<G4F
MX):=@]<!#SGA8=DR?(3IDCZ/6@U'#I+QFA2)8U.V?:&,"BFK_BQ\6*HM,.K?
M?=<5_/77[?2\9ON\QM;BI@8N(>G$U-IT^PWV-.$+NY0"Z^H6^X1:E^^^0!#U
MTI9(!_.J92TOL<HJ*_.^-X-JMZ]4*YF7R%Q!DJUR?DBVU8.[;B(U3:@VJZ5&
MX3C.FAANE1*W6*+P&Q?N*JG/^P>50W%=:IVVY%HV@CJ!$M'K>=H73:MDO.^<
M439EQT;;0IVVRF9%@9I5O"%5:==9X1M?W<9WEG6E>M!)/JO';FHJ5OE!3?ZW
M9BK=;]'OLZ:G%Z1:,2R34%L1<>[:_KA"!K.N:R[9NBQX4WMMI5:4U6A@S7^+
M?R^KHM[P?!R3ARNQH"^Y)V%YH=EKL1ZN['6+4ZRU\VO4E]NU5:BH<:[3/+G^
M<S<9TT_7B)X9'?,JS==H)3F)XLV13%CV&4C\4'S'+EZE$&+A[W\$!U[,STHK
M[RS*^?J-V[]&3'ENG8F"&@0O&)BN"%JW7WB0P_+!LTH./?,=817A1GRO:S+%
MK#\9@ C8<F9PBDP)WXQ=NQ)7)Z=N="P.!7Y?!(VZQ7J3P5J"R+(%['JI=,'$
MVA-C5T>YQ,:NJS[3[TZJHLJ^'U/-C*NCX?7][F: 6)+L#\=0[U&,=8M\;V@<
MUD#T+BXKFJD SRXS0(6!/XM\R];6K<[@7NY)6G3]2=KM&RGS>*LY?FN.WYKC
MMY=Y_'8]FS[8B-C#-T^?=2=]-W<$SH\$-N34+FI7IW9G7R\[EU_/CT'=.#[3
M7X\./URT#X]/.Y<?V/&9BMN?_SK;/U31T5D[7#ZUVS]LT_W#/WO[;__J=^*/
MIYW==]\[_3W:V3WM=RZ/OA_UV[QS^4^W??G1ML^.OK?/OT29HK&-!3$<\Z=Y
M) @LM25&Q6$J0PPUELM]8B*CHS2-\R13@L6:RA3;?V89%48G84J73_E6G[&L
MO3?ZS<-:G ;/8VMB&@IF8\:3,,OC-+2AI'DL*,6<S$>K8X<KY!9HIP 3N=@9
MZ/>ED0W:;;EF>G_PL>HPY[I .T'P@LGWHO/A2YRE3.2PQHFB L@WLT2:."-I
MK)/(V"QCH7Y")>Q<T-FLS1_HYC[JVCE[Y' Z66[9Z*C%'V;-Z65>,%I,ZD=0
M^)!:DT+I.HEW5RCILMX/L+BQ:-WCE8BJG53\=.F\C2N4Q^+MB//UUYZ+MSE-
MGDJAO&:P#SG8VY5AO&65O5^4"9S=I$Z&/[;W=N<'['>HK/?+RN4M3_>:<BI7
M.AL\LZJ!MUN&#],AR"TO&/YVW<O\[^\&3G?<\4ZZMAA_!7GF/OK-!P=$O[_(
M]3J8Q[/XA=I'KY];F/U9<$LI9_'#=S[,I5RT^&4NVJ=:X,^5M:D3%5U<GT>J
MO-#O:MTSCYX<Y V6/VY!$?<KJ74+.OKY?/)FD!L]R$<JB?:+..@U-ES# V^P
MTLR*\J_WKINT075:_O->DWMR"9+30B]E1T919(Q)TYQ&G*E426/CQ!AJ<YG:
M-'&=).^9?XWTM#/0^,_>G*IF'J:YYW-3<B)_UG=4YD1^BCJ7BA_O[D3[N^WO
MG3/,B?S$._UC>-]IOP-O/'[[YFOG4I]=R8D\_$0[E[VO[=U/K'VY%[N<R,.O
M\7'_ ]M_>Q0?GW6^'GW&G,NE$K2YSK6F6A*;&TL8C1.2:6,(1U=C2+,PPX.T
MK!7>O^SDYM5T:_#H&>%1;F)CLI"F5C.6B5#"_W/* :,BG9B(-WBTN7@TS]$V
M%""(A9ID"ANY2&Z)$"(CW"9XFB%I&D8-'C5XM/EX%*?:I-;04'+* 'BDR%(I
MK=):A2;1M]2/KBMIU4#1 T%1-(.B1&=:19:2*$\T84Q(DE&=DU 9&F<9SUF^
MOK)5#1@U8/2 8$2CB%)-,\NCE,4IS50:"ROCF*DXRL.T :.-!",ZK[Q-1:XD
M!94HCG/?X$Z$6I#,, [;FF2,I9L(1C<XO*J3:<R)^#%^-5<N7KDF7[P'[GQC
M78J'0VQZ6D:'S*-!7)AUV?AZ(31D;4TPGJE\N]NTGX'D>P0WI3\X:L3=_<3=
M8FEHQ;F5(.28-!%A><*)R$'PI:E2\(=*,KLNM^2=..(7EXUNT.R%H]DC.#D;
M-%L3FLV=FDF<:24S0ZP-4\)L"'I['@,59UPI#=O&L,E&@V8-FKTL-'M8%VD#
M9&L"LKE+5(:9C&+)B,YC4,N4U$2F:48$B[(LTY',<K7N2OX-E#50MOE0]K .
MU@;*U@1E<X>J4I)&\(,HDP@P,UE.,A&!P9D+^(9:D6;L:4'9\XXMK&41_ER(
M[F)1=MR#%179[Q45>MN>#,TH-WV4SSO0_;.KZ3695[^Z3W.E9Z>S/#?-Y.<=
MX%X'.0']XH^9ZK%O2^HI_AYBR8XN%G\[<+70,)ODW>"U4U\:K>3V6DD]')?9
M6%FP@DDJ-2?8-8UD7,&/R&AEK>*P_5NOXG2#NJ0]D@758,ZOGM6CNZF7K:$&
MB1X<B>8^:QE'*LE32D(6 1+EF2 BI9R(,%.:Y[&KIK*!31L;.&K@Z''\S T<
M/3@<S3W/:<ID1H4EFB4184R&1%(5$R[R2&G%TI0G#1PU</04X.CG?<4-\#P2
M\,S]Q$PPF^0A(DTB"0/CC&0L8B1FUG!A$IHF9L,LLN?M"/;%*4^PJ!B6^NIJ
MXROD7.L4OD4+W.?1Q/:7!#_^.2U@A$7Q>MB7W8';B?D.O:YO4.7!OVC Z"Y@
M=%%S#RF;A%S%FABL#,@T-P!&EI$LU2'CD4DDEM7EK2@+-R@'X!?TM'ZN#/TP
MCI6&EQ^-E^<.EC2VJ4IR2C+!0+&@*@=>3B.B>6)UGNE8K='!TG#S)G+SP\:_
M-=S\X-P\]T_D<:*E5)0H'C+">)Z07.01X2:SH'T)+O+U^2<:;MY$;EY/"%BC
M;/]:EIY;_IR%2HA<$AI&&.S*0-G.K"8RDBJDH5%6T<U3ME]47NCJ4N'K3@XM
M"W"O"!ZZ50' 9^F37>/2/ /H?P0_2RW^L8D#OA_*[]<S37D<VRPS@H#5Q= ,
M8T3D&99Z49(G6<1=P2G>BL-UN7C7QSH;?BC5P&<#GQO@U6J0<YW(.7=@@6YL
M=&0L,98+PC(5DBQ7AD0LESS,<OAG?25I&NQLL+/!SD?W(3;8N4[LG+L+,TLS
MV+.<<(OU36ANB60\(FF2)UFB<QVJL,'.!CL;['SB'ML&0-<)H'/GK)61B4(A
M2:I"B\JG(C+-,(<W,52'H; V>6YFNW/M_LMU[WO5= N\]KLGU].N&6S3+;#I
M%GBG#F:[1I7- B-L%ACE+[*/V_7- OV_M=YN3>/ IG%@TSBP:1S8].1[FH-\
MYCD=3>/ E].+(A=)IE5N1,YCALV=8I['-%:24R.R2*'7)<JCF$9-HZ[;.6#.
MWD7'A\?=]NX);_?W&%P;M@\_=MMG'7C^)]XY_!JU/\.U9T?1L@.F??9/K]-_
M=[Z_^_7BZ/"$=G8_?.^\?7?1CO\ZQ?OV#S]]/W[[IMLY^V>Q<6 *=DC&54S"
M,,4*W9(2&88QB;)<*:VESDVT]2IMA?=/C=N\<-<&CYX1'O'8,F%I'&>I9,9(
M*:EA4J8\26,87M[@T>;BT3P:@3*;"!I;$J<T)XQ;261J8B)%S)-$QY0+UN!1
M@T>;CT>)8CFGH04!"L"4"CSIX&F<)"H+E3#R=GC4].IZ9"BJ'>X;K@0W&4DD
M%0!%\)ODF2:Y%L)F-@1*CIYQ+E #1L\(C&@4:TMMF%,#L$1E%F7,2!M)%BLN
M$]J T4:"T?R@7"<ZI5G(22SA!TLEJ$0V20A/,B:II8J)]=6Y?KP\ILUKR/=4
MKGQ1"6*_H''@2XDA>QDA8H_@K'SFS1T>2>@MM ^,1,9X$J48$I$11K.<Y$*$
MQ*::\C2S''ZNR1EP5Z9X&K&S#:P];UA[!)]G VMK@K6YCY.E-+9IDA*.&CS+
M;4AR%B9$2T9IR@SGZ;I\G VL-;"V(5/>&-=I@VAK0K2YJS2DDO,L2DB6<@J(
MEELB8IJ3F'+%(I7**(D?K0M7@VD-IFT>ICVL![;!M#5A6JVS8)BPV&@LTFH!
MTY(\Q))1G!BN>,)-%FO]>$U2UX5ISSO^L&DNV(SRT4;YO(/AF^:"MY[<,U!.
M?MX]_L);63R68E(/V0UC+J41$0';BA/&E" RRPR)0+6D819)(\76*QYO4"N+
MIGU.@SD/X[MNNGD].A+-'=E6V]AJ;*ICL:E.CK7O$\9(GMG$1@P,([UVMT\#
M1PT</1V?<P-'#PY'<R]T%&7:&IN2R$J (Y-:DF'Q_M1PJM(H3T/=-!=LX.A)
MP-'/NXL;X'DDX*&U$JHL%ZGF)%788D!CW>E0IT1)E<E89SESQ:<WR2)[WH[@
MIKG@1H5&OMA^)X\%1O7F@A($A. 1)[!E*6$V,D0DBI(HSVF<V5 PF6V]8BW8
MT@W*$V@:&&VX8Z7AY4?CY;F#18,5FN2@6%">4,+2C()B(3#UAX=*92;7XCFG
M(#;<_-"Q< TW/S@WU_P3L:)"2D'"E"G"\C E.:.&&*.EZQ1JX_5U6FBX>1.Y
M>3U18(VR_6M9NM9<, *[WV0)B4 N$Y:$E !0*Y+J6.8R392DR>8IVR\J=[1I
M+MAT*=@$Z'\$/\M+Z%+P2"B_T%Q0LBSD+,_ #+,6%#>=(\IG1/-(JRC4S&#"
M%J!\PIY-EX*FR4L#GYL$GP_KU6J0<YW(68L0"H606:B) 468L#3*228S0W0:
M69'2G'':-,AJL+/!SB?L0VRP<YW8.7<74B4SGBA!>"0,88(KDEF;$Q9&,N?:
M""Y,@YT-=C;8^<0]M@V KA- :S43:6IXG.9$YIH!@&I-,B4DR;(PYVDJ-)@-
MS\UL7]%<L)Q:9]H'9E$+S0;=L[L#;0; *?FV;R_HIXQ=@&;37VY26+^/)K.[
M'H6!8^?:/37!ZV$?WGD1:%C"P7 23,;P0&O& 7YHNP,Q4%W1"[J#8C*&N0\F
M!?P^&0;#<3"<3H*A#<HF1X'JB:)P7:0<&NCI&+8AF, [)J=C8_". 0PAZ,.X
M3HO #-!K?&!&$]>\S),*#;&#61SBQ;4'7!@Q+F^XTNQL.X"'F* SG)@@:P55
MB&8 8]Q1_SOMCDUP<"K&IL"QPFSA]<'!9*B^MA!; N$\V##)7M>/&Z["5ZI3
M,3@Q.%GWY]RU75UPOIS;Z1Z'W]QZEMO!(FT@C2EWRC1U8[D-M?P<C=UP5TDE
M#!MGCH9%U[71&YN>P+YI9:_+4@;4[BH9-IS?(B3PYG1R_2U76GO=G@<.NWW8
MGHXY#SX.^V)P/T[ @Z6%G:C]/!U7HQF)$T/DV(BO1%@8[!^B=RXNBJU_+?8>
M[0ZJAZ<QO'UY[M?.T-JUS/!*3\3XQST1_U^Q,6,) "A 7?B/KA0R#_,(;*PL
M9E3I++0JDZ'5,I<BT^I+% )\N0ZNCJL'$]\I2=S ";<A-9:G]IYPNVK:6Z\.
M]MZ_WSD(WK][LQ<<O'ZWUWF]=Q"\_;C_Z>]6\*[S>GN#A][9/X2Q'NX'K_<[
M!_OOW^WN'.[M!F_>=78ZK]_MO \.#N&#]E[G\" @@3\HGQJ]P1/Z[=- 3'5W
M8O3OJSA_"8B]RLCSV)J8AH+9F/$DS/(X#6TH:1X+2O-HIA&72L*B"JQE9D*9
MI#+.8P;SDDQDDB8TB51D3:2_[+K^VE$8D7FC[445=Z;7UG3==GD8NS_X:-1T
MC"+S3U%TBWIW0M>2\.."F#N$<?W9 RGX--7AGOF?CQ?'G_5(QBS9/VS3_<,_
M>_MO_^IWXH^GG=UWWSO]/5!Q3_N=RZ/O1_TV[US^TVU??K3MLZ/O[0]?A$V3
MR"I%N(#U9E)P# E,2:*$$*&4AH7Q5F# 9A@AN8ZG9H7<^I6JV\X/U9;KM19U
M34S_?=28H%L$HH#[>KWA>1'\YEX^G,+T=/'['U= 8&U+E=]JI99LD,WI%)YQ
M^C.=PC.VG3'V$"VB<WZ[?M9/JT7T:M_%:LOT;K/9I&:T*!H")QN<9E]*!6>O
MN0\^%3 )/^E:LU__54U2-!ULKT][:EVU/9LZ^4V5PA7>3GA :F0FTU IEHLL
M9R:2VB8B@<_R5*_!VSE3!6N<_KD[.;VB]A6+>E^QJ"7.@E?=LYZ)DU2Q_=TW
MO<[E\5GG\@3>^8$>'WYBQ[NG9^W^7]WCM^WS]N>]$,81+SM)X7K6_OR)=OJ@
M4>Y^/>_LZEX'QK3_MGUQU/_KZ]'ESO>C0W2P'MOV0;W&?IP8P5).HM2DA.49
M(U+'ELA$6,68,EJP-46P-D4.UP+R"WJR*2; 9& ,WD%C;K)@KP)?*L+,4"4Q
M'),EDF4LY[$5/$G1L-5JI8V[B( %S!1^6Q?>70-W;T5W\'Y8%.\&JC<%T^;=
M8!_V>HS.\+$Y-;#-W^!Q:MAO,/%.F%BOL,9CD:6,41*Q/"1,J(P(DZ<$R"&R
M0H5)*J.M5W&2/;^8_DT%O6LUVYEE'U1&?1/!WX0"/(QRG#'&J6613#*FLBB7
MFFF3Y=9PPYA.43E>+1H:Y?CI"()Z+860,AV%"MM/2TH88R')N&*$F231&8U3
ME6*IS5:4A2\L@N#IA G<P9/<K6>(3;Q^/=!XFQ'J-!B;T7",=P8C&,Y0!YAI
M>3*+(N@ZOD3%7 2C\5"6+%B.T.A6H+N%@CU';5V)XI0,IQ/;&YX'_:$VO>W@
M\$=C<V?8Q@4'O,7^JN*_BT!@E( _L,9![HQ0$Q2M /2_;1P'V.J12W5S'O7I
M!"96?\%(7/BP"+AW.L(G_^<=T% RF6:YCGDB$B:9RH$]J(DIBZ+,L#1RKH)H
MV57PKO/F07)9=S"DX<2[#3_B;_MV?SI!-;AP&/@_L <S'$R>)@[^]-'1_N$1
M_1(IH4.A+,$4"L*DY"334I,L-C%@CXIMR+=>T7C[*I0%P)0]) <I"J#=H3<]
M@26Z0/JXY$A!"D %;!/8:V"'X<A]C+0'>P"PX4)QX#%@KPYA1STYNR"9H7M8
M&<SCHEG3?Q?!P/2Z(S/J]J<3<A#\MM7Y^V#K=V0K/57 &O#@K@9^:.&;ST^[
MP)UWH5T5<6F8I3SG(1AZ:6ZMC%2:&)-(^#6_R=KC=Z#AOSV7O1F.;TK#?N-C
ME@8G.S"!;^Z,],62;/MP[Z*]\R7-XUSSD!*3"D48&.1$1BPF+&*&ZUBG"=-@
MB?V(9D]%$4AC!@!W("F!W)!N/-B"?@44BU1X+>S^%#2&,A1,14 YQC+#$B$C
MJ;@65B;*9(I?HRC>A:KND^7_ FF)=W:^)!&CE+&,L,0"+<D\ >Q+$T*Y"JE-
MC,W"!  P_!$Q@88 4M.=JE8*0L^H^C%V%94(2&BZ*(^=J,>HP&(6RZ=\+%_A
M8_D U+YU\9!Z<EH^LWI&7URXR,9N48#V@I^4SX"'%["YA16S=^.WUU+Q= #
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M2I(QKDC,<ZM,;FABQ=:K[!D:\I[!XNV8;ZRLOW6@7%,0K2F(MF%*U>VKIRP
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M&UI/%Z8^&N1EH5^PR:ORM-(,C.TV240/&7FTUQ_UAA?&?/1K7O-X/3OW[F/
M4#V72"5IGMI(D4C:'-,74R(RP**(IV$>1M1PS;=>I=&]XQB;"*1-Y-!U'<$T
M'+IF#ITK"IG*99:IA @C+&$LS8G(M2;PE^"QDIG-[=:K)$PVB$.?MS>I22EZ
M1-E?'HC4U_R-:6#EIV"EGEC$LCBE,<O ZI"<,(Q]D;&Q)&:1$=I(RT(*]D>V
MKD(K&^07:=AS?8*_8<]ULN=<ZC-0RM,\RTFNX0>P9TZD3@P!-(UX"%^DUFR]
MBO)[QQ\_7GY1=1X,@S4_YNC'NK(9<#/@9L#-@)L!-P-^T0.^DS-@LU.#[A9
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M>V4&"Z3DBOF"\ERX2FQN<8+>L"B0QF"EI5L;5S9R@#XE+-*FX%>)E5]$,1S
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MBHVZE6Y_A5!G4'G6!5NQ-Q(9\)SRL;?1'NY)7[=J!3I!7CG[JA$&R>*?@76
M^<+N5/IZ;2K%SOX6K6\<*A#'R@2%(B8.9;&,=+(>>>H#=4G;R/W*.EV[2EM#
MI:+,])@%D8#$O:S3MHH$N/8XY6B0YU9\&V"TP-);^AWN5W7@,F:!F>$S89WE
M<RFQ58'6G8@*QO/I,+C@ ]C^R$9+$'?8(6VL1M$D:JEDHB"J5OLJ35VC2LR+
M5R#P"\)Z:3F0NU=XYSIK=E+#^=CO^.-<,NB2,9O#AQ3_<?5R<8'\,3!JA]EH
MC=8_L5NDL$U^>WOXZ?!+-YFY-K^ET."RAR&.[-LB*<X.5*-B)F7.W-AT'61Q
MCT]IY<O-\R$];$\=WSC%D>+:Y_'#=P=/'0_[3>.WRS;S+1&)">X"528&*CC5
M1 >19##2<&F9<63@^"+XJDTSOW2; )U7C#,'9'?CD ?!@G<,J63 I"$BE\!(
M GDE)0U!2)VKG)!5HLU4U^<,N $*'CG%[N+_O <95/[/6Y" J'\ZY-PFK AH
MQ<I8T%_ JC5:,I#XV..@HN=!S_2 3KH\+^;:KM;R8<O69;<9W/0D!%%6QAF,
MY6,>"KRI^\KWWV.PCP)V'#L2<[MRB3B.$ED.?U*=(J=*1.SMRCI;,YI>;;<Y
MWO]""KUIW%L"1&L,MTHIGS3'G&O0>T+$"?ODK?#J/A*@((+B",EN^FH[^0C+
M;J<LD-3OY0SOG".]]3-V?*.;$QM?,VGP^MDA5B%H+T'MU+D+JP)4,,09H!2E
MC-=@,#B0#K!'JWJ:;#CM1)3ZA=/EK%SM;BV.5[>PBV>HJPL%CWN05 4>,RGD
MB.42BR0Q(<'X541BQ"7H#S9W0)$>*^,289ZZ CS4+/"X2B1E\.RBE[UPE)["
M7S^+$@2@LM[&=^)3HMXZ!P+#<F:$#22)9$'P,8>9CR,[UZ!IE#!_Y&7H*,^U
M208 ,X"3V"T\Z:_86?+C%R"*!UV#)PHJ1I >A(U@R#(7D"52&PZ,BC'0BUR;
M0BS#"(R+L!?Y8$SH^][0OWO:M+ZTRVP1:DFQ%$C#NB C((D_3V,+=J,(VQ3'
M4H<EQD^+@S83C[I<3R;;"U<MI;/C=E9VP3IMG-K>^)3*35;3;$@L(XOWDZ+4
M,R9LKE%*$E?,.B#J$)QSH$$%&LTB[*BI@G3DV1D9S^_R\:CPY_G@ON[@QN[K
MA<X\AT^',>3,0\U1M#XA3E-"5IF$!$M<1B:BIJ!W@ZJ[:N8WO 9R<T!2\8F5
M[FLI90B,A3P=71R1!WG%]+']"^C#F!!MD :Y7)@2]'*.- '1:K0-EG,5K#.%
M:+T:<!QKY6NUK7P<<X U91V3DY,8&J40G82>_FD.;P]25@KP+&K- & VBLH7
M_Y0?MK-7+1_9S"&U;BT55;B.X_B;^:!VZ=&^$/.X&,L;?^\FG 0[,I_SFL#[
M*5C?O1[LRW.O\>>XC%<<LTB[*,TS@N.RV,L%7>/VP9K'4#BJ8,WMF.H+K0-3
M488Q)0PQY2GHJPQ %XN(#)5)2 _\ED%77I,!\B*]XOG,;AD.7YQ/?/OCUI1[
M;G*,7WW&HMWC5_2\*V[PBZ\=I* -2A  2!67A_"4D])NIYHIG%@2D=@4*:C"
MV!(#YK3PN2JT,(X/^P2P0=!-58D"#^\(Q;O[V[3^ZQ.N;_Y@.V"G8!G .I&
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M[IE$FMH(?_J(O9&!&K8P)6Z!Y2[NB#=WTM->/O<&3(B-H,T[8[EQR7+&J"3
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MHQ?#;],X_Q+>EGH:3]ICB3W\=-Q1;(3'FB1I&&.*D%"JFL7,-[*B2+4QGM#
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MQ_5>3?C1@TG$ZP TBJ- G#J&M T@?6UDFFNF9-++R+=5-;)7?F=% *_\SHH
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M@Q=_W/ZX-7Y[T?"RDW$TE#L<BQVN%>V(&X-V9VNUS?))C;Q:HR[$^;6#V_V
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M>3?02TZV1?V7ISN;]9.=D[^;]?U/K/XAOP>^^^$]?%9O[&YNG>WL?SJ_K)?
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M?46^7/G@\B&CR>-$9?_O><\3E<>3S@9;AVRY=^5S:[GC^*6S3M>\^)IS3*6
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M=?7;\!SL#1S'7X<?!]/%0J?#/W_\=771_^O;L?[7M]\-L$^TLZOO/__Z>C:
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MRD?NQ"F+)Q+WYY83D!&">J') ;,G>*5K!"%2DQ$Z1.BIY2)UC 1)RWA\>=7
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M_W$,#F;W&7E/.B(*GX?8Z02(2==+8/?*UR@>>$!&;  [=AY?LS#X*3;7X^Z
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M28K*'[.(Y"JF8=86A<GCAW$PY+(_$!K .$S!42(3% 0R95-D>R8V*CN; '\
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M%_4=LKA%)O0L]Z;FV=\\:&$3(X.9A(6XTC<:1%Z[D,R0^P@7B"ZAGD,HGSX
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M#/I@C?:DM/YX,NC^^Y?!_6UO-.[]Y^EN\M\#*2\!L5R)6J-QGEV)4?0_ )_
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MAG[>,N]I(-OH$,S+TGWB+ +F'QQ#W#L@(JG43F>&WT,"!IJ^G0"R'"A^1.[
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MIPY+I.03+(^.K4,Z#^TX^'76U+ZG-2\]TA'7/%%]CA;PTX?_ U!+ P04
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M-IFE%&M'>I]9R)86Y:1EY!SI;TWB5/?#>I3DZ5$3/=X2T><.OTA^<34K+/#
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MFOMZ)<9J(]]^:' ;QN%MC7T5,^Y-JGT7SK]Y^>;Y%9SIU0VL: D-X3&$@&G
MQ$*,F9FH;/#<&1YRMT#[W8=_L[KK15HM_,.:XU_-TT4MY+/QQ:?QZ+H-64XF
MH@J&Y1@UT]D:!DF3KB(::60T6;=)C;P/U6.S^OI308\%%U?@5C MWX NH%K:
M>FM1'>F J3_MC5N)OL&ZL1Z<2+88S379+)JLEZPM\RK-;]7QR=!F!*Y)1/.
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MP?FB8G?C1%Z7Y^3+C;\@+E*N+R?I(\ES/A&CZ84H*K&,DB8BM&9!AMI'.OM
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MVX(L>AE8DHB^: VEH^^T_=B/AP:-Y=[WD?;5#GP->PW(OXW/83:?P<"7B#F
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M2F?G<YHNYW(G*;_W;C4=QVO=PV:7::]TMI&VU$YH0JK@M' Z!HOHO8HI%)?
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M24*V)CD5M37*>AVX)+5)'B2ZF'P,6@S6 5T*M7ZI'NA__-O_#U!+ P04
M"  G@FU1"[ Z*)9O  #_=P  %    &=A;&4M,C R,# Y,S!?9S$N:G!GS+P'
M5!/MOB\<!45J5$":$I6F5$40D!(;(B(B*%V(@G0Q(M(D9%2D"$*D"PAY!06E
M1:1)C70!$>E20U$ZDE#"0)+)'?8Y>Y_]O?M=Y]OGKKO6O2-#PLH\_?__E6<F
MLG^PQQ"[+UTPO(#8MFT;PA_^AV"/(ZST_=V<$0AC8X0\ H'8A>#<=ARQ'7ZW
M!S[U3'<CML&OV[9^F>Y!<&Z]1VR]W_M?[[>.,[>Q#DX'#3UON3B9.=VZ'0#7
M/(0XA]B^;=O6SW\>'#LXMHZ=G)P<.[AV<G%MG;NX>;EW[>+9Q<7%P\_#P\L'
M'US< DA^/H&M]UN5;!7?*@7_\.WBVL7W/S[8GQ%[=B'RMG-S;#N,V+YG&\>>
M;>P&! KN_8YM?SO^/HAMVSDX=^R$N\3#"U]0LAON/@?'=KBS.SCAP6X+@C]'
M<.[9L??0\3,[!4UO<1WV$E)]'/-ZE]39PEIALTZJ] F'^T^X>?:)B(J)R\C*
M'3DJKZ9^4D-3Z]2Y\_H7#"X:7KIVW=S"TLK:QO&VD[.+JYN[]P,?7S__@(?!
M3T-"P\*?1<3&Q2<D)KU,3LG(?/,V*_O=^YR/1<4EI66?RBOJZAL:FYJ_M+1V
M=??T]O7_&!@<GYC\^6MJ>F9VCK:\LKI&7P<W-K?&M0W!L>WOQU^.:P\\KNWP
M&G!R;8UKVW:_K0OV<.XX='SGWC.F7+>\! ^K/MXE=#;F=6$MM]0),ZJPP_U.
MGGW2:N,RM*VA_6UD_][ GOQOC>P? _NO<0TB^#BVP8O'L0>!1FS60SS3;,2.
M_CZ];;A+/9 (\P#481>H[XC-!R,FA,MM)0@39:51'Z,./_![<8R_W/?G7K2F
MN@HH3UX\D$,Q]%)I,CF@&)OV]5 /WW%"AJPP_M$V^^,TV7F+&C"2U$[:( X5
MN5LBWVT0@459"]5I"GZASSDYNR77W8+^8>.LQWL+:=76P@MBX1S>Y3R9<HD.
MB/VQ.X#+3ON/)]W\T)GUONG*8,N;H2 [RI4VQXTXS8GGS1+/$@S,3"V[CA;'
MSN15K <6#;,1XS.48DO6/FPX&M2(8[JR$6&9^$[,JG7-039B;-2$5E"!!@]C
M%_45W=NHQ*M.MUY<R,]^80!Q7B./MZ!+4*R]GD9LQ,X*@(V0-EV+1D'N:!S7
M&OX09$-Y\ T-248Q](%.9S"8C0@.0#<1P(<:B\)LA'[J!!+B_\E&B"^@_[4:
M-D+ D/6.C9B)<\> ZMULQ,9A0MX]-F+%E#&&LIQ _<I?OSSY;_2\'MH?QX!K
MZY3M(5,]LMF(97T4]2=QD  ]._D6[I =FHV(/;+9C&0CU%$UV_ZSUQWV;,23
MBW@*6;SF&%!['B\.8AM1@DPGDNNIM[V#=C_LYU041;;=N7O@W%%-3:=K:]O)
M 0I4-@+BMF8C./- %@,-4<@"5;<FD6&6@RJAJ[:IV=7506>_F3^V_^;?DQ#M
M[)CDLY^CCWQ/85EEMUQPHE[JYT^?EA66;?JGDCQ5/% D_R"^._<$K7[)*/O=
M#1P=+ES*+^-A;L"=Z@%J[=71/SR+*0BFKI&8WD$/"R*VG%P>;K(O[,[7-C&K
MCM85;87=*/F<<OFA)-0?O<QQ-J+V7LE0E!_$$TDS+I!V9BC23Q9N]S]OQ'L3
ML?H;_Z9O/U?\U>:I&Y\2VD7U6T<D*B[!4_#3L[F\$4=6FJK7L[YR26,N(=5W
MI8MR@M!''LL!BIW)[PQ]T$TFD@;2>5;YI6_Z.I]O2@=>1]Y$Y #4%=*@!!1I
MT(!E2IJP$8V6B4P9T+P YP4F98#GZD]ZO/,/;K T=+IUIUOZL)MMB-WOLP5!
M5H\Q9D!],-D=NRGG"X"FLT1F#*;$(3-V7#STD%GP#%&^>PHO%Y+H$WG%W\_"
M[>[DM[65PE_D/[<%+S3R%.LU>:88=P$>-AQ<3/.'24Q-;7H6&Y'AY\)&A$@F
MLQ$M0G]NZP;9?IPRG;G^>6Z3L >0P5:X)+(1]=_(KMA-)=0>,C4 #A-A Z;.
M/#T4KJB3)L%&<,6Q$33S.0QU;&DP%7HV0H2$'KK\9^@*L-Z39](&X/@TR +@
MB/O/RO4R&S MMK^3_P]VW*#_D]_&#(N*?$<36;9@9 'G>TSU 75B-U<+F6IK
M$BDI"\K!,4FCN817217,I4OT>ZH\^ D/PN23J_)AR\IG-[CL+UQ_$72&5$\$
M _H7^>'$S)S0@)!PJ8E<>BHDP,E&Q&/ ;JA.' ,EG<-T*.$IX]]XD;8*\3G=
MSXG:O6\V#<I![#/1!?W]7<??FIG>B#P_.*_<O'H ;G8'2)E$$BB% F\+_(<:
M4CHB2L*9E@&N22EIW3<N?\BOSI7?Z7#ENUTX:E&<\9"L"^?L(&'#H"F?C7!,
M6X?BK/MG]/%VC4*3?$-[=BG(R&7\8)F$Y%P*N"+I[7=7P?*3J;[P6#IHJB^$
MV#HM)U68(M/T-K"0RD4?[7Z YF2>H_F%/ C0.>KB2W_H_%:F2DGAAIV"EOG!
MNX>$!*$OI($<ICB, 0ELQ*^#FR:L9XGHS6L!&*_Q17$?[[N7"LUN?.S,+4CK
M"*4)5%^R/I=V5+/&=2Z-:-_\;5".*=1/?TJT+C( VVEB"=/Z-WW*J6=N0;V
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MA2M@%6\0>>>_*0@*EVU)7<D2'05OCJ:ATB]OKXB^KUV5BED37EF W09RH"G
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MYG(@JP5,&29+B[A.,%YVR?9/*H5QI<O*%V.O,.D\@_'^&0T;;QB&S]D :QU
M)[ +;[$B.L_FF]K)/;,-<7+&BY\1QQ[CH]E=S9#65]#A4REM(VFB;.QI=JE"
M*LZ8#T3-8L]Z2]_UL"^5A^?4?&JX.SW*K5,4M*A-Q3]0=6;Z[;ZZ+H63V4[_
M$&_:KX8/K!/4$2'8"V!A7/,>_3"UXV>PV*A*ZF$-JA:T\!RY'7G8QTBRAQ_:
M^H*Y<+]!I%NJ\C0(Q $8UJGN28,7.^+PY,\>YV*Y^38^C1QL)>Z)ZTEVFIL3
MQ\V8DAO1/);@[WW[B@?+-&7X0"^PWI[Q6@#.S/3).A0$YX/KU.F5[C0#^%1Z
MR1%@5>TUN "]ZV),=P+N_<UAOD%\6$0MLMH&-0'?Q<2$,Z>1VTBNZ61F#VV+
M<:74_E_(_^\8_PJMG8O9!B?NB!@PR2FL7V-IGEQ]<*J$))VG;E%A0YV 2&L&
M=9MY6(XIH(=%7.><Q#%YJK_")V;9)%2OPKH*4*-<4S0*C>I+"YF&X(#G0TR)
M5B!.G8OS>7EL4)VZFV_Z$#<YI[?G2^Y'X?I!I-O LZMZHCF45YD/1G?7#T2I
MR<]*<6K]TI8[)(X328P+(S!%5J[R% A%>I2\_NIY^9><,WE,^]9/I<A#7$%/
MUDVP<P6ON1MN=K\I1Z$+6#<8C6UK;S?ZV*E"GK<NEK32&YS;CP"K]RB@?T"/
M "V8?.\5!%T(47ZG@#F,9=ORYZMJ0R*NYEN=OF>+^8@ ZKN]9C'>F9@A\*X:
M9)YJ,7L$(/-VL.#;ZU,+NT#5JRS(:K^*?WEV 5'W QP%[ZPB#3,X<KF8'/_M
M:_?Y>)\G*$5A<E$:8O6[UA)3T[;%#R;Q:H5/K_!ARVU2GI7$^#2!C2!.E@T$
M2RH_&<5B\GKO3BAW[QQO4^Y.%_/:\]^.9G*<'-]?O&>3^J:T75(5DG4>63*S
MJA8X@^_@1+?>8>.Y=_%"U+%O915_9#2:&LP<P:9KQ-$M4\9WFH"?'YM-6.A$
M%>_A-"2@[3U3_M>9)+ITN2]4)7N]S,G4S\NB[4(Z^Z;(DB9J$#G%0?G*DA!-
M9S_@<987/;<6PSOF[-C8/J+C[?UX7\NN/ -ZLNZJG-' 6:]S WRRA3S]##5J
M%=E:GRI*6K<G>R>IGAIM!7WZYH^JQDN+7R:_/ :MJ5!<TSH.X>IJ[GL.>C+_
M0B"F3+@:L11PG-H\XO\PC?G=+"",__M!85;X0_V32BPO]-0@2M-?T;++/%LB
M,XL-'5KO9T*IKYS8F$O5+NH9^NJ/D?CHHFK+3C+O7_O@B@J?U7:5M[:+IJC&
M7 D?9M6$]YD%U;15N#0<[EJ#NWC"#^^2?K_AQ3'VJNO>@??3T6GV8@^#W8Q9
MML^$\465:UJ4PD/>2E7QU?D8R>&PH=($^,N1]][JU-O0H1CW-]XO/7I@R:3,
MQ2H$G7N)R9&Y.)\ 9-]2@#*!=&O2GT-,TV+7T[$97VLQ];24O->R">B4,H]&
MN:$F_(#L.A=55G)CI2QF?/XKL)N+_=]3W<E6^4?CN_\N>&U*H-]+;K\-\[VL
M;@"<"W2%3U.?J'DEK.2H"GS(:+&#5=OYF;I6CF%2_=(LB.?,)>6Z:1K;DR7#
M@@:SP5*S&FWJS7Z')44W00MOX#7YJ339F.],X0D!O#92*/RPDS.JVZF^*WJB
MNX%=PH'C ^9[5N>2AD(;BWG*UY>WJ&+VQ/@"YB2X)B?^%/KWG1X1SK&J784+
MOAM3C>C\L]VFL@JN&>4!UF/B.>4W@0]P[_-U[O1-'DX<''S<HCH/S#Q#5Q6L
M>L+M':.!Y<Z964YSN?,_:7MM6V5(EIU@7\WG3EM5:=,;-C==?Z_@?QG/^_IQ
MOKF;'3O@1K=G@U6$#NX;".--+^FB/#H"U,2PLJ_!&N\A1PE$+;(/K]<? @VA
M..;.P24>,.]7I'Z? LF>2XG]_B,F.N;_8:2"KK#PW-89F@SV\(Y&>,8@EVE.
M (1E94R-6/RES6I,1=!",9(-[H[E@86,,*]#!-+>1U>';V]NC\C73U?']E;_
M,U8L._%7F#.FVWZ%BWXAL5/+XM4RHU!L7*5-BWF/>7U61O5'K8D-C'[\&P'S
M??FV9HP\X=$R</9?K@4AV@F>/IS?VUHG)-!E; ANG?B"ZVR6P"K_PTX'LQ(X
MR9[20RT#QL+84'ZY"6WBE0W)YP[O4_J7^U)7HDJ%/ /MX0N5R.W4K10PY88%
M?;)MT)ADF/S)E5'89S2Z47W3?NCEJ,;\F=*!YY"N__N;C4^#NP:5/Y%J A$J
M*IE687]=K1!_(OD:'WEDVSN429MF1_9H5 2UIP[N@'2. -Z(:1Q!<D.8ID17
M890PS\K_;2M>:Q=N0!+48\6R\G4-3\VVKUWK/S!T>,-Q-^B;"O0ZUSA\6IE2
M2PH@%I \S,G8ER%<Z%4<LJ4)D\D1\N5_[W/4WC J?7A'6N9;/A>334L=WJ$>
M<S[VNYY0HBC9[Z"(4L/(@GD= 4[V4/M+F;_FZ^;R<?E<K7H!"/J)RW9XGV-R
M^W;_/FUP9 >\Y683?ZYXQ6!?<<_W;V-YHQ/1L-5+G$V7)\/_5^;6J-*!7@HI
MZ#!$J5)<SO;D\FW+Y ]VU?+%$3VAZU)TG(T/_?H1(.M-C#1\6C/V"* _NKXV
M/[-%26ADO,5Z!+QR ]7:0$V[#JT%.=>;+J_9.5Q]+#QN*G-)^[D!3)IVG#FJ
MQ\^H.@(L-.NID%DVV%\B[RZN7>#NO[J^Y1\!U^&/Q=Y\;_LH[&C.=H;_Y$LV
M&H+)+DX#N<6,(VL4NN''5\N!MI/UV5 ]I=#7U9^>-;Y@(S;?2P^>"84(X5-\
M_VJ8./1X%A@;Z[UVSCT"O&ZW= I1VO!R$6P)KB3@[+8& [Z14=3KB1O)); K
MC+>[B%>YY7 _NB$5_:1==#*D!34W:\K9OU/PZEX,M)A?S#]H5)O[@Q3P,:X/
M1+J+Q>.,J4< &G]X6*?R?3DZE(3Y">)<=[K/DK&FAK3?$7;;&QK0*@&9S#1A
MX:A@BFKX[SLL0U9?$>U-^ L/,XUPFMRNV2!M31P!ZGP8SHO+8+CSP=S^3A.R
M@&I_GS1T&-?LC_3VD$ ]"T#ESO&FS/[FN:O4_V)'\]Z(J<@]_55P'I#D#$S"
M*WP;IDIQ;10O<5VTD*^.7VRAM=!6/5X7AQ.,B1P7DC/ZA!-5#\'NE8YKF;-&
MD)" 0/&X>>^F>\7G)[<W[*<6@%D8+;7SYX4M;LON8)GL6*_SQ2Q*-F2D03>O
M)1'8T!7Q&9H7E#34+W^X$'Z])=S*E&:X=P,G;KK?4)?C&ODD,/ 1?!I3['FP
M.H-F?([TQ07_ A&N;K$((N%'U!& C89E7F_O)8&3*V'P!:*DVYB8;_VL_T]!
MFI&GU#!/J=AMFVTV.R$1 Y8%C7=>1!Y>40'2K_0< ;HG_UP0KV03\JGI$XB_
M:QG_0 -P_IM]5EK9BPRP38E4>^NH%:V*;X:L^X13YYG@X>R]_F?+R8CY"!.6
MY3U T@SFP^N8;-&LE=PE)Q+/E(>KVY%+.L&O<VU8JE?F:QF!BQ'T-/6"+BR<
MFGWRV5\FI1H0W1]+:=A8HKG 1!D8E3Q7R+=VT5\PR\#/R/JSPL?]M$R5WLK]
M^GZRYA)_9@S@H<-Q_:J ER"T?=<\/L"!')JY,!LI'+G>H3X_[?0'^#B;VU=S
M3NVBS(W%MR&_FZPL$\PY8V+@'1#X8^099K>6?1S6QR*NQIFN24UW)SC(T:O$
M#=J^U(JE.0KI-B^JQVQLX@'I_%T)WT7_^73F>]OEG^'EM^Z6*C5T%3"=M4Z>
M\/4:RL?7PXB^-H/2-GWN7@*-89*:1N50VL]+3KK^!T[S=X?'<V6J$Z/4B@JG
M?[O<FFRX<D$LXW9D=X^^+%4$Q(X&"^S^HJEL5L-8_O/4+*,P9.LEJ,;))X8W
M%P*^0#>;?$BJ5^ZFB27P6QF]JPB]47I]^(&$V,,41#CC-=8#RQ'3#034PT]2
M'_^<]6R(!]J.7[Y9Y[<?;_1>)W5\N:X>V-AB\_2_01T%Y+?H  )N0R__.NFW
ME5DE77&RBO[@DOBLJ'-OAI'B"<:+ZP/PZ?B*?]BI&4H5:86(I.E2X7WY@LTO
M[^W)ACC3[D:/^N:\,/H(O;K&ST=&MA8[>-Z47*T1&A0MWH@1B0B>.:AL4EB&
MS/Q<&7(_<(NRGZ&[I%/"F,[M41%SN.V:M?L%XQ7GRA9BYUKK%K@VG$DX"IC<
MD-*JOQ# Z?1/(#&M.F/=9IL_3O/6TW2CCS5&31\II2>>I4Y)@;48]:"%MV .
MK/_6ZTAXLDY (.%[B)G"?3.)B\5KIE"NC(Q!J8%W,_+-WBNZBJO@2_".&__=
MS#A)A3,Y1)<2J$8A%>M SO8K_X(<!RM<9Y,;-U79LJYY.O+:.EQ6/W:/[_KL
M*[$+QL\'_TUTV)697I1J[,H-7-YWS:UW:4*WH.L/3KN_LRM.*S*O%E&R0LJ)
M#T?(ED1(;:]Z1='F=2U:L0OE1X#M-(L4)$7.%7[-39%%\U1&:\PYYC"2='\^
M 4[*@9F0_'/"BJC1,1-?/EKQHWD?_@SEL/%0!M&N*?^( M%YP4S+?G(FLR<9
M]4=VNU9AJL6(\9ZUA(#G(+1$WD*T0E\^-\+\A=ZU<(@EQOF[EWWZ+[?"_JR3
M?Z29O.F/Q'A]92>_/]5X\MAQ0U');R]ZQGDN1R*]903L29O:5J:'2I[)C?;@
MY"&:SK4QIG;69>5=&R#HX7KLPKS%V34.$IB 2,76^JLHL--OD8M_%B\.\GML
M3T -#7<M>X?2^413OD4=<P*37(\ R?G7DQ?MNY"Q>CRM4'4'*IEPCZXK/Y !
M&CG1F6'4>U[$]-6)X($ ZRX!FN!"8C>"@^Y&-5B<OT2]\??G>F=S3TKP*L+O
MI<:DT,.K^OOL#PON'R\V>7.V!^;, OX:-0SEPSQ&M28W=&&L_.R1)W1L+]<%
M/VDB3"^_&$H$=M;.W*KJX[@F^1R2<RS%H?U::N3(LK]Y_VY&\@-S1D0&]CWN
MW<,Y[D2OVW%-&4FM.0Y-DFI58UD#<T93P#KPQM(B>/K.PF3R OR,[XCOH1[B
M[.V.6]G;+IS[W#=IVTW\CT'ZSP'"/WI:P[*W[ZCXREF5&1FY#JR%7XT=!YK\
MT0/ (DE]1%52\EUR0^R>5(@NEVN#XV*(*$R>'G@/E'#W287TGPN0VL=GB]\M
M&HGE3VR_RW&<S$3%1+7,1^UA/PY7=);+I-AR!#DZS3@7MU;&^-%52)_A)#,X
M53X:^0(FAW6GNM-N^2J!OZ3SST"+URY6#ND4,X5TY#Z= ^2X!\:Y1(_1G.#]
MY726HM58VQP!1C4ABP&<X<U<5*D2^A6@$5DR[K, H@L[O664C5^W3_R+:<>^
M,2_P".PZ(=;JD>!LS'>)WYBV1$DF$8>362YH6)@5E.IQN26):(Y[HI;9$6*8
M=)YC:\:\NTU+$.[X+#@AZ ZR;9,(US-W_GWP(4UZL<:R@*X7L>T,<03G#")S
M)_7 1X#8F"/ \A4FQW\C>&5'@.(Q^R_P#D?0LN \'W;#!7E0%<%%%^PA).N&
M,=G*"J9G?@CE"(B@RQQG"S%._ +!&N>TO23N[*JN@DF.7)>GJ=I,MB+R(TC_
M4IR;KZS[V>!8N3HS(9]R[0^8\ VV?YQV2I>. ([%@A BED+JL$$<UO&#_]N(
MA1% DHRQ!X;['?.T*U>94+ 2R^LZZIB6A(.8[%FTZVNY[05>Q:O96O%#./6P
MS,H+SI_RS]6U7"@O&G\CNP:GBL\G;K;^U[8DJJ9O!/>=P"/ 6?2'93[W+$\+
MQ2#0;"!8'-[Q*$;H'_(*=J$87IN8H&-<TE/^3VMY=J)X[T/*0,Y%%9*_E4WL
M< WOR%L-'4I=3A=M?:9!CJ*YXZ7ZQM*2B@W&QOCX0^ =_G!_KCCX)= C!F01
ME0"S7-QZI:=)SB*F8A!?_EVQ7,N8&<@)O.?IP?8P%>W(&]PV]!R@_TCO#BM]
M:L=,8G<OM;!65O[?JQ4.%TFLJ[5.LJ#XDP76]=BID,54;@?$=5FROW=SK.B9
MP6RKG^^%A#][VM=:=9)=@M8X.+)ODUN@X\:8V>S7/AFF+8V/&LT=L\*2AE9\
M'0UDH)\S6B;0H3/168AN$%5F?@.(BADZ @BC43P.OOM7W(Z3;7=S)L.^]CK)
MLGUYM 6YH;=XWGR(U)]RZ<ZQ"7B'D9P759@FR1P^ ARO*H(3DZ-UJ)F.=?KO
M3RWWNPLLE;F+-4#6G\M2E)B=G%8_3:-*W1L;WD$SI!]H:>Q>)4&>D^$;F:3Y
M/E90E=>!5H6#C,?IMAYB2C-KZF>'Y<S83E\_'4K_?%QC8<>->:;[O6I\FKO9
MX)3K+"C)I?4K5+<RKV5R\V=?[U^]2X8*_'+5Y8F3$=96%K\1()UQI[:#W"3C
M8J]G,R 9[$(5[@$=2/+N"'BIEB&QE<@4,&VSN1MCW];(SH>$]8DR)/?+0!#>
M(T!"P!'@I3U=\+^!%9'#%<26&#FMBF^Q-8,MWB5T8!"P\F$&>=]^=;\[8 J\
M".P9YIL+C^V>._%KKPWRP!.2//C9._M1>7F3=O,IVP=:#X^-HNA6#$0['_T)
M6;BZBC!\RB?FZK@<='1TSOE[2OY]*5,YOR8\SV6/YXK]>U5/6^$O2XS8#(LU
MT2;FGRG[7S;'G(@_)/8VVAT\=&X.R>#Z'DG;QKGZ&&:!DG]_:;*V,#NX6O0E
M=W#EP(OFA:(KLU*Y[ *B<VM/ )>\G-GKU.VQ_+22+=X3:#P2N XE&L5E_K<-
M]VP/@=,$O!L=O)3XRJKWU^Z;*>>&H7O,U6W_TY&/0O9.8ZW:99E]0 ZF)C5#
MUZ.'R3$"TR^[XX])'PY-(?+(&#O@/LB\''JJ,<@]ET<^0U&F@LGV7?G $;K^
M0INHU2A,UA_Z+%G]_!M?\IM/E3Z5@.\&)Y<D?8I-N\\!)U8M*\S!/2%^J@$1
M.YIBZ&G3+ CTNM8<GP<3[7SQ=N6535L!XYVHBBS]_M46A/8H<[<!),^4+Z$K
M&]$O=GUC7@GX[[3UFIG76EXQ5FJ3/0RCG]YVO"FL%VQ$YY$&+>:#W,'/D:>Q
MXVMU>%#RWG<MG6 S["#7>D+N(HCX"C4^_ I;L]^ED!R)28XB6)S^=]@])]R0
M-G:?NXBOLO!.UMV4"R_T^_C^ ,[?.EY.=V*\8O+00\EQ^5?)B2]WV^ .&6+/
M9UU54CI5^&P!-P'GPP%!QFMF?. +-P.K3(HC@T++K"JKH-YB2R?1>,7HR.)/
M'JTWA\1OHX54'6[XV91VM$.O72ZV;)%?48V2EYLKV1GD@:HDO:K\V2U3GI)A
MX0Y&P4EWAZ>L71A('=E*F#XY/@7OUD88]*P;VST8\Z2$ZL>EC)8M.]G;:'/)
MB/(O?]4KIH)IE^F25(5*H[)PC\7]^/J/)MSO4)=Z1/Z*,KL1.>!O2;MK^3?)
MTG_?V;_H&'L:URZ!;S%U%JLWH:UM8>*? N,@$KV5@T!;FS+![=*2@3R[E@"[
MC5T[NWE7N?\>QVA,<R>!^X:IXMA>X(68V7PMZ@2I8<DPC[2YTYL=F@M+%Q8D
M!LM=P..[O_?T6PF8VL+B3SY5QNDQ:!?I7-0>DE-7MR7=A5K%U<./9I.?N9^A
M*R\'K\LZF>]S<&NVM39DM6ZN#9^T5\,_)]%V*K%B8-1$>MLH=P2=H]K4'*:3
MHF:<T$40D<A1@C:I#M]P'MB'-2RO3QV@EA(WQ$O_F[1_^0HF39WA>O5D8Y?%
MDTXA/2EXYQEELTA/YZQSM2?B^_(UKC+&UL$FE@:!!,4LB.&%TLU/3?89+? \
M;W_@&9.X$BV_GP'O#UK$#\1@TRP5V&#$H;FFDIF7O2F)K^3VMJ@6K68WL%S3
MQ%Q@K>C*/K3Q8[=W:4^TI %/S;N!QO*?;=X1VN O [,Z;QZ2GGVMMV67&7$.
MF9U'Y?VGD"^_,+_E#M-YN!;!\<^$N7HNZW&WDWZVYH[.NN!5!VH</%.D;$7?
MN A]2),=@"_&PY]L'6I#0'3Q3T<  F3+3W:DRWNJG$<T,2DY)<#?Q]"N_;!?
MO6R%4"LD'[G=;=QO8H>56Q:<@936UVN IRLZ1&Y2 TE&=T9@T83/9&QRI95E
M*03BA^FDUH]J >5O<6#4[BY5#^U7KR7)]E=8CN>5$D-G1APAT_*7MO_;G>3W
M@5=CKE^\ KHZV^:\$UFGWAMS?I1YC7K'YE=(A52(/-"I/KOW<-3]W>;#='8M
M]1HKHR4P@.K-9 ND&<5\'_43X-K88]F80U#7S/K[&]!Z.+?OZS")MRY_7GTL
M>&\AEF'K<<[<)','.,(NVW(BS[[3\$&)-[\3^:U-(7YZ^DMURP<->@E7\EL_
MF^:W ;Z&YDK&F]6YH=$8/6M&+&CAO2]-'G87QY0(7^G52NS>2IZ32>F"H^:,
MEOL@;#/O/MTVYI]*<DC?+BPOOZ%_6)LDBQ1,JTJN(%:TM+6(9?>+%YH6&E+E
M.(7$%3P2[9SWH TMT+69M6ER %&;5?7P,;HO.7>)@.Q "D/ )YGB;LJF42'%
MUZ)!MJ':'P8!7GB7Y^"312).:H^,_[!4X1%B)I;@&NNC)\4H:57_3(U9B+"_
MDGL^+MW/_.-Y 8VK7D_@H;:'N'^G>%?'"'*>[GP6V;!F22E#LTBUO+%BBL[
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M.&"DLR.!(["ZO_AK(!AZ/V2GO?6W?$[5[8=;ME]N*?D?OBR__J!OT?J&Q/P
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MDZ9SP'%-$QO=CTP,JYO<3VH^2;XN] /#B'W.5]7^45$5)0PBE0F(.(\A96$
M)9)$)5F2\A#;GM8</GQJS% )9;R.8?0=^QZTXMH?W1RA=_GXYAI,!O[L7>%P
M.LLYI_<5YSE'CQSM3.><,KOG.F>OZ7&V\U#(=VM3WZ3U037Q 3)#,N19!EEU
MM*JHA-0L[BF1 4=$A5ELM:YW#3*UCU:+"6LY-VY3!T_U.20M_/\>\!GX SX!
MS>7H"GN,'-SV'K :R3_?"S,W)_P%,#J][>?N'<^M?D'Z/?_YI6M[4-]/^==<
MR(7XRU+D*F_=)NWS9RRC"(G(%%E""41$[W$($1*R,!6:$\.$1<GLJ"Y9]\O;
M/60?!\<(M'CWI/^P,JNW%C*'(I^OJ[2AYV*YDE5<(-#_F^>4Y7.]*D%NCCJT
M>J;THSN-7I@5"S;U /(XI-H*>@-V1=T]M?.'FP/#^L-O)**] D<WNK5#II-U
M+SQB//*UTV6/@RUOZ>=FVN8]W*M=EW83<%PYM2JG-]M)#]MFKQ.%4\D2"3G2
M^TI$9019*C(8I4C/@ J8MF!=_%#7B3,UR_;"D57O@@)73IJ=;VN\J7C=@\-!
MJA/X <^GO^Q*B49UJ/E![]#CYNFI;CQ;%JO97_)%_K1^:C==:10ADA*8Q%(;
MN")3D(0A@FD<T%!13"BQ\L<=/7EJ[-<(9T=MQSAUL]15V@],.(U<'G>=9[7M
M8 A]SPX[Z/\Z9(;CAX[RD9_5I?U>SU]P99FCN\7S>E6^EU_E/&Y>,D)E'"=8
M0LQ8"E&<ZMTF#C(8AE&8X"P4E":]JAP=CS6US_/GQ9*5LOAJ0A/^\?=A&OP)
MU$*#[RJQ0>Q80*0+9SN3PQ-Z W_>VR)'-PUB-Z!!;(#4)PM,!BES=&*XUZER
M=%[OLT6..F[IX;#:/':[Z7K?>%UR6<XPBAD7$8%8! HBCLU/A$ 4$D'CC,01
M3>UKIEJ,Z/(IC%?UM(V&WCBD;@#K5PC5!G0>4"'3)()1&"-M1(42TCC.8)8D
M1"6)"%A";$N9#@+Y\,5(3P N>]0GM4';POOG#[_1V'LO3G]'6'^X.7C__.$W
MDO>OPO%KA>,VRV?S,IK$8%J:OZP>9?M"@O)1RA40>K?U!T^N03O8.EV#%QXQ
MGFO03I<]UZ#E+?WLYOLVB/*]U!OB]KDO;]9%H5^O64;#("%8&\Q)$FH*IA'$
M(=6+'PF8(C0TY]@NIG/W<%.SGN^W$:9&W"T+N]G,%S"V,YO](3<P]VY!JR2]
MV;"N7KL::?T9SG:H^+2=+XPXJOELI_VA!6UY5P\C^M_H8DV+%X/<O5+:1%I\
M:;:&2<)CA6@ 64(3O04/N::0+(/:>(Z3.(J9Y%;^L.YAIL8?C:!U\[U65 ?+
MXSR>%L::%Y0&YHJ3 /4)?CF/E(-YY@6QD2RSGLBY&5X7 >FTN<[?/9ZY=5&#
M/4OK\M7]C"RK_*(/R\576:ZDJ.IREE7JR^[?S='%A^7JW^5JFWVT?5)]TV%'
MFEF<RI@&.("IR"*((I)"JD0"5<))K%*4,N1T=/MJFDR-VG]>%!O9 =^M^,NU
M=F[VX>N]'G:FYV]BTE_W?/D&;/3?M#[[QN?KRE53:Z.M7PV!OFX%7O0&>8M"
MF[KJSRI^]0GS:7"_GC*CVO*O/F>'VX37%ZC?8OM0++F4HGRG(6[\)6WMAW+&
M@I )A4+]LE5U%M(8D@C%D(<HYC)C/"1.9::[!IO:DO5!L\YS(V_=+;RMUK-;
MPL=MZ>H$VVYU\07AP O PQYRK5]^(ZD_\K;!PR>_=HXW*@7::'[(4E;WN$?S
M?#0+^R9=)]':I"D,DB2&""O3)"GB,,M"FJ*,1TQ9%6X^>.[4Z,'D*N;E*N=T
M#OXBJ0FAJB/G?EH^T7QAN1L_!*^; ZZ 9&A[KR\:3N$^)W2_-MAG]Y&CA?J<
MT&,WT.?4G_LM[CL''[>+NNSIXW*N[R_K#-M-^*O,>$PS1J&@!$&4BA1B&C$8
M!R230J1A3)V:"]D./+6O^OW=[8]W[^\^W[W]!&X__ 0^?;Y_\S__]?[]3V\_
M?OK'W^,HS/X$WOZOG^\^_[O;PF\]$79&P!#P#LP0[W=/04W9C3K]?HA 8U=T
M?)H'UF./:BJX(G)H-CC?/W+;M/?Y0MZMY%,Y"_2TI$)PF"@<021C#IE* H@)
MEE&@D H#MR(@5XLT-8J[NO<6^,7H!BKE7.N+7#_!=@0Y[K2-Z$P;<,;&:XQV
M!/(D^J!MI?IMM#T[0M%;E[/C)_=,I&OJ[=\M^/))?J;?=M:1#W(URQB7/(XI
M)"+D$+&$F^,6O56,.4\9"E+,N5.F7/=X4V/B5ERPHM_Z!LM<@MB.+CT"-S 7
M;C"K105:UMTXQ1N@Q?68LF:'B]><M M#CIMT9J?_45:9Y6W7EA0^S5Z5>=HX
MQTT@8,UZ9;E^JG]7%9[<MO C<1 EG'$HPY1J$HICB#$/]3^0-B&E-AA3)Q^W
M7_&FQED[@@*U+)K#NK8)ZYW^JVU-]8&FT](^?+5)&MI6;!0S9Q0=W7/KID2;
M'KH;%<'N_-:U@<$@K1V'F8!AZ@-[D?"5"@/[1/=\16"OH_0]QSS16BR.TX3R
M@$#%@P B&6)(TRR#/)4R"QGC-',\OYQ^P[:K^K1=T:!MXIW9AF_(-E8GMM=O
MP>;2>\UWT[4Z[/I=7G(Z_W=)B[<+\1-=R9EB"B4T1# 4)(1(!7I7F84!S (>
MI6F<\#A5U@W8S@PRM4^]D1/4@@(C*="B B.K0VNV<Y!V?_>^@!KXN^^%D5L#
MMPL@7-/,[=RCQVOL=D&YO29OEZ[MM[+K'>,;6CX^%$M3\TG\^/)S:;:6F[R,
M6[[*O]9G$^TI&@IHA+"0,.9<0D2R%)(PT.M^$N*$XB 4@5,>EKL(DZ,*+3Y0
M\^6O343.MAL W<C^1S=;H<>\V%D2PZ(],-^8L+$*[%9\XYG_SF@ \L7W8)ON
MM=5BD$/0_B#ZM%5Z2#&J)=,?I4,[YXHG]76N/R_+?%7J#95<E1^TODV"I$QP
MR)7IN,A,M5!)!&0J4GKG0U(2($KUCLC-JWYZH*E17"MGW>W$1,D"6HGLZE$_
M@ZNM*_UZM ;WH3= U3)6P?C<=ZKI)1S\^LS/C#6RL[Q;XV,O^87K^S9).8S.
M^+!<R6VAMZVK5"@LD4P9E%$40415#!G-(DB2B*$P2 5C;IYOVY&GQAR[@O]3
M$YGDVCC%%G1+__004 [M>CZ!HLG?D6 K-_AE&&^R*UQ^NZ[8#CYR!Q9'3(Z[
ML;@^P-]YWF[ PJX;N;&B7@X.?01"&0L2! .:9-KN"3"D"4M@C'D4QXI' ;7*
ME_<GTN0H;OWT9!*@S;'0SME/NPMQI;OKIZS_.=UP$S$T05Y*BFPS'UM-1C^!
MZP?MT*=NCE*]^DE;/Q1M3M=Z/KE';9)MT=\SL6/LY:@N<'7HUTATOUZ5*UK5
M7KO]\J6H6D3<+59%OBAS7I5G^KB<S]\M"W//C$@6!C)((<9"\[="FK^)3& :
MJ! %D:(1M=JRCB_ZU'A^(S'8B%Q7=G.H#C+NW'<O!-.>T1$7C%Z!OS?;$(\=
M#/0"<^XM ;\8)$ #A4M)F7%?&H<R-9-]>48J?3/^2^2IG,ZK3%QGB9YQ)1JO
M[,^K(+U72NAU)' //WB[6)ET)R'T%UH^+/68\_\O?WZS%')&J\)L+(4A0Q%$
M69I )N(,AE2E,@XE0LSJS+%[F*G9&[6DH!'U!M3" BTM,.+:1R%T('LY#L$/
M7@.OYGVA<@I&N(S$%>$('0\?+2#ALH*[(0D65U^=6=T6)DTX2TF<"L@I2B&B
M.(4L2!D,2(A#(B1% 9FM3,D7.R?4\1!.'_]FH.'>Z*I^#6B.+7;K'/=.CG8K
M\GH=0@-_[GM9*=XKN9Y7?:!LYE>IV'I>RXX,90^56=O"T88#FR#8(),LXSB"
M(I$"(D$X)"Q$4(8QI3CB-$GMNQ ?/W]JZ_JF"+P1T6$;> (YBPW^=7@,_"'O
M0=&GVNH)3!SVK]=A,](FTQ$CMXW@>00Z=VLG;AMO2W5>YKU]3\=E?9RV&Y=Q
M\UR+?*D()ZG>GZ10QD$"$2,9I &BVHB1D2E8'U+FX'IU%V!JQ+?3"V.YTPLC
M+\';<I4_F:YXX.?2!/#].*?\[U"KK$4KV_.TAR+GYH]_T2;FW,5]UF/J;#RG
MPT[(T/[/-IEMVY7D^E0U/]B[.""'G8.QW(BV<^'+^]<?M6X?7H_GCNB)ZZ_U
MOC_MBN?TVQ#K/79NGDKG#S07=XLW]#FOJYL^-6>5,X1%D J$( U5!%&HM\HX
MQ0RBF. P4G$LI%-CP<M#3FUQV4H,GK7(,%\ 7@OMMF.V -MN!^T7PH&7@QWT
MC+1 H]?(:XI%&XDOI#PZ[[+MX?&YZ[88==1=N#T*A[MRASM[F+M5)>2&WZK*
M V6SN^)48)YH8 -LTG^4MFDQ,W4-0RFH2E6&(ON]^KE1IL8M?];"+BBHQ'4P
M?LZ":&%=^H!F8,ZH1-P8++60??;P9V%R, 1]P#62M=</-C<+[Q(<G6;<V9O'
ML]4NR;]GD%V\N)_5]69.RW)CY-T7'_,OCZNZYNZ,(:PR;6I!H1*L=_8X@"R@
M"F+.*0DB&<?2J11BQUA3X\)*U)W]N\845.(ZEF>V@=G.T/($WL!L>05NSK:5
M!2(^C:JNX4:UIBST/C2C;&[IFRQ$5U5\Q;WJ*$H<QIAD9N,6A8'>N*&4&WN*
M0)20.$EBO75C3G7ZK$:=&J=LA-[$T!_FNEBD\5XQ"78\XQW:H5U\/E#MD2_D
M@)+?7"&;@4?.$W+ XCA'R.5F'SUW_R8-^4EQ^U7_]DN5CF2Z07W4<CQ(_5(N
M5C-&LB0)$8>AY"%$&$60T4# + VY0CQ,$^'D9W(58&K,=="7]P:(1F90F.C-
M[V@)*'BN9?_^FEZ]%G-CQV)#(C[TAO.PGV\K/6C$!ZW\P"AP QH5AFKR:P_>
M<&U_+61XQ4; ]@AUMP9V>$Y/%WN5*+[I;[[-Q-S8""H+LD@%*>2A,GF0)(0T
MDIH#0Q[*3*F4,Z<MW\41IT9UM<".A6PNXVKI3/>)UM"^]*;TP\YQ]VZ6]@ V
MES4Z7EWI%P<=UY-NB\&1(]WZQM[5,\V!U-MO)O9>WBY$Y:^J1VUC,G&J!%4J
M@CA+]2Y012'$08P@BT7(4R5)FCB1B\684Z.71F0@:YEW2\VT4;!]2LY8H9^8
M .((PR@5)OY0O^Y4I@BJ4!*!XS!,,'>)+O:-_@CAQJ^(OMT"X!G3@9> %LY&
MW K-VN_?+@[>HY8= /)<,?7BL&,74+7%X40]5>M;>YJ9G!=K*1Z*I9)E69W>
MOI/;T/R,1XFB,H(1T?2#(LD@P4D,A41AE,@DH+%5H56[X::W FS%!$JZICI<
MP-;2SO2&V-!&9BTHV /-B#H M=B!XM6V[!YQ7,/22OLCJ]+NKIY'D\NGIWQE
M?(.F9]R;Y<)LE.6"YZ:O="Q$J.(("L*U*<EC#(F(8H@3E*!0I2(4S.EH\OQ8
M4R.0'5&K%9?O"@N^J^IEI8Y>N"ZH+8\G_0 X]/'D 79[<GH\F;P,AM>3R8[A
MQCV9O*SWT<FDQ2U7E#&L^\G\M"[T4Q]DD2]%G<LM]:8WYZNFJ'R5"/Y!KN[5
MNV6A9+[2^^)RE@8X("S$>H<4<6VGI)I>LB2 (C 5X4.41DGH7-WP"H&F1D1&
M%:K?"W/PQNOHR;*J#+9^UC]^U1H9)[;^8[%1KKU@D;ONL:Z>3=O3S_'F:/"#
M40-UK0NHE0&U-G6['GD#MAHU-=V:<AVF!+6>MQV]/%=:]("P]P*,U\@T?EU&
M#PB>+-?HX[D](G$WCLE-D$KYQG#+7(I9@M,@0%D*)9>F!X\DD+)$0!E1D8HH
MS2CBLT55L4-\MHS)[1C/ZA,F]2=\-.IPGW/E9__:II7]VJ:5R6^RX'EIVS/M
M(MC=-.D%NW'H;^=<XGXG#:^5U!-<#L&[GF ;*7ZW+WQN$;P6F'0&\7;=/UX<
MKX46>Z&\-M=?<\"[[6)"@HA+RB#G.(0H51021&,893P+(R&Y$+'[:>YDCVX_
M?7K[^5.?D]M>Q[23/9,=\/!U^)/6USQ6M3M#]71@>LNKX YC9BWG.=]M<I,R
MH6C& YCBD$*413&D41Q!R0)!34Q^'!)'!_F9H2;W"6\D!:VHO8-B.P"V]I)[
M@&UX#WD?Q/IXQR^ X=DS?FZTL;WB%[0^X1&_=$=/=];)&LX[!0Y_?#G=1/6X
MP.%!G-G;9@MA*D]450Y54R,U"L(PS%@($YXJO?%**<0,93!F5 J9IEA$3F&P
MXZLP-7X["N5L!:_*?E@6.WS%-X*0 "4QX3!*F'XC:(8A28E>HP*FM^291%2Q
MF7X&6_[?\4[LJC+B6U$U0Z\:3.Z$UTW^Y;#TL$YZPH?VR0Y52OD"L0R3 _-J
M,^G5]SN^%N-ZBU]MEH[\RZ\G2=\ZS9\>Y=P4FWBFBY=91CE'@E/(HXA!1"B!
ME., QI%"4N@-&L^L>@2=?OS43)6FV' E(FAD="W&O =?]_)P/2@#4[<3'CTJ
M+I]2^^I*RWL/';G"\BF%CBLKG[QJY!U2G6QXM] K9.5:+ZN(R,^/=-$PSU]E
MN3*]6.L#L5G 29*FIDE\QF*(8D$AX5$&M05,94RT,:R)P/Y :FSY)WK 50L)
MOLL7H#1JEHXQ3*--_\!V[A"S^9NQ;IN4[1WMFXCRE=9_:_LV[XI^56H0)F#4
M]IRV29BRKK+_-@S8GC/BS6SM.[['0C[O\X6\6\FGTI1.)*FI:"9,.V\4"05Q
M&*10ICB02F%"D+BZEL]FN*D9LQUE:8S,H!+:1TF?+>!VJX0_& ?F]BL1]%/<
MYPB8P>O[;$=\_1(_1]I;5?DYOLM],_QFJ??9VZ@"+A3%"D.9F,QPCAFD81C#
M!)- 1ID*:)S:[H/WGCPYUC#".9\_'@-V>>?;&X:AOWI;!)PVO">UO6*ON_^\
MT;:Y)]78W>&>ON"J<(%2&QBFZ'*;[T459DE(E%[1PP0B_3%"$NI-J91IPN,P
M5'%B]2UV#S.U#[.5$CS78O8*##B$TBDHX J Q@D(*$$CX3"9<AT8#! '<#C2
M:\0 G-'VS/G_N:O=U]Z?FGC/S_K6F6!*B013*(B)#$*9MN(%C6'(><0BK(D@
MLG9![SYX:A]X*QLPPMDONWM875YU^R(P\!=LI[S3BGM*TRL6W+W'C;;>GE)B
M=[D]^?<^37!HU3.]RG/XHI_W3K;EE^@7_8<_%\NR?"B67$I1SD*:1MSX@N,L
M0Q"E7$*JN/XL4Q1PC'&$ JL06^>1I_;);@4%7XR<X+D1%)A9!*M'"4JMGME"
M5N[=7E7CW.>GFP4&17UH;RNM>ZE4@IMFRH8RM.R;@G!F*O3?*_E!J\!0.+NT
MLQD([['ZV/C%W;&I30_LNKO9N#QPQ#8V/?3<[U_3YP']MF8?92GU38^W"_&3
M_"KGRV?S%C;U59HB_SB)5"QB!3,6F\"YF$.B@@3&08@QBD,5!$[[-(LQI[9
MM")7B?=B*[3;YLT&;+N=G&<(!V;[/?1VY-T47_+76Z$'0#[W?#;#CKH!=,#A
M<#?H<NLU6;/+32)9%3IJ$A.9RI2,"%0\3B!2DD,L-?4P%4><L8A2;-5,_L(X
M4R.9,UFR7VII^R1]'D-K85+Z 6Q@2CG3J/+//K'JDQ][%6;CI\>Z8-<S._8L
M(G;)L<>WOT)N[%D=3J?&GK^\KY&VHOE"BK>T6.2++^4MU^_)>FZ"FWZ2*N?Y
M:D:D2A0/$\@S3B 2(8&8)Q2J,".ARF(:4J<C\LM#3HT]=R34%EHEHJMU=A%E
M3'F"0@,PY12B4$G(<$0A8SR.&0JXRM(>P7.>P!X_[&T,S&T-8I_OZ^#V<"TL
M:*4%W^TBV0A\WJW4PQJV1<>O,7QQU)%M85L4CDUAZSO[,?S=PI2<6A;-)I"R
M!%$6,BB9,E5C> )I*!D,5<0BQ;$(0Z>60_N/GQISM]*Y4<<!9'8TT1^(@2FA
M%6R K?!IG7U^Z <CC/I1G];N\ ,^<Y6/ECQ5H-*]^KF458F%62IXIC_3 )(T
M22&*600)RR+(.441"EF(8J=OMW.TJ7W*!\UV0&'$A4L%UZ;$MI'XF@X[AU#;
M??/> !R8 HYZYWQLP=/"UE7)AVJ3<P:4X7KB' [XB@UPSNC>W>WFW$W]".6]
MU ^1^R.\SRG+Y_GJI8G*+G]:RUD42Y:F80I%9GK(9UA!'&4"JCA0BC%!(K<V
M"+8#.]',"+T0/ILQ@%J;TGW@*5_D3^NGAG&>&ZG=>,9Z!NPH9PA<!V:?6F23
MHGW 0ANY;\!J"9BLNL_[(R)7J'QRDO78H]*3*R*'3.5\_["D]4%^6WW^5<Z_
MRK\L%ZO'<B;#D"!JZG"D%$'$];Z&A28#D63&@Q5F 8I<#*2^@DS-=M(O:3@,
M:QU-@5\6NP;82;':#?AW20MPO_ 0N>8+Q-?@NR-9)LE_YQ#KRX=GG]<SZ%W\
MQ[JLB\._6Q8?Y*\[U;6*Y4+_R&5=.OY;7LXX87'(3&D&;GH7B@Q!1ED&!2$J
MBD0:)L)IU^@T^M28<$=XH)8%T.*#W5IQ>PJ 7XP*KO7UG";'CBX'@WQ@CMQ!
M]I,I44(+48*?GX6IX'0!6_?H^SX8>0W*=Q)@W%C]/M@<A?#W>LBK5_7[L*Z<
MN%&0HB!"(:1!G$*$!(4L)0HRT_LOB"(54OEJ)=IJ&5T^W'$JL-7=#Y:UO&"Y
M%?@5RE&<G5G$(Z&PB3(G"3$=>26D.!20R(P+02B*<3Q[KG+)-0D5J]_ [!Y*
M.Z1G\&AN;[3-^B5?F-,HP.B\:F4RH>E.XD303&20JB#0<YYR/=U4FS-QS$."
M&0LBV4SWVX7XS4QV*^O(4RWKSWF"\VQG&;WJS UL/0U6%;'6= +%82Y-PB2J
MP)P5\K=1[N42Q@.6(SP8:%AGH/&OO-/?WHR%$8\#',$D2P1$*8L@"Q,,&4M5
M0O5?J-LIJ:L 4]ORZN\!#>/\VT#NU^G7!\@I.ON,#N-[^P[1>PTOWT:&27KW
M#A'JZ]4[>D[/O2Y_E&)MTK(V4;Y-1PUM$C;#YK+\BQ9C74AQO_@H35=V+9FF
MX+S\;/+I/\MOJQ\U%G^?12E/2<(P3 ,4:_-8,D@YRV 6*!IGC"68.?6V\2K=
MU*BQ:0QC<H=V= &M,H"N^A<:]SJKEL;P:\W5T(9PHU?5?'$S'S?@TO1I4WFC
M(:A4!+]42@*C):C4]%GX>PCXO9K 7@4<U_P= MLCTW>007JN"FM6YB*GQ<MN
MRJXY,A!4(BJ$:39!$XA$DD(6A!',$)4T%6F$B%O_W7,C38VM/S5U$FJO9)^S
MF?.@6A*L#ZB&)DL7E-PY[A("7OGJ[&#C<L\EG8]XY.(-U_9&VYRFU8=I41"F
M0=2$J^OM;\IX@&%(8PQ19+H;)DD,59)@I$08".34GLAJU*EQQ>VGGX&1#P91
MW_9H71A;'MOZ1NX5CVL;, =((G!":9AN:ET#OU)C-0LLSO=8L[FY'P5U'/O>
M%V\>C8_P;K%[1;[@^?-<[Y_; L JCFF$"8=4"081#F-(0\RAXB(D,B6")]2%
MGJZ6:&K4U1V2LBQ K92I\KYW6:/7%:6;KY]<.UX<=<H&YLQ19LN94[TA[)-O
MKQ=J5"[VAN$A3_M[<(_:*&^6BZKN;EN"I2G(.4O"F,1<T[(*0P51$,<0RT#!
M4*8XDI10I*Q.3;H&F1K3OM'/S3F=@U61ZW_R96F;W-$)93<)^@)H8%YK)02;
M"DL/+D6%.P%RJ'[B :B12I^X ^96]>0"$ITE3\[=.UZ]DPO2[Q4[N71M/\OU
MH#=>?3:M]^;F+'OGS-IX\KBI2Y7/UZ923Q(QDB"F-](RBS4O8@PQHQ@2GK&(
MI!$)A=-NNI\84V/.5@M(F[Z:?/GTM&QCAPZBR8PJ=76[6IG^448]Y]#.*AU^
M9@:F[*-FI[4*E3.PGI>]** ?-_/2J.+/_+P.2I\V9T])1C4TKT/KT+J\\FD]
M3,J'0KY;+X04_[9>&%\#N5=*FE.1QEFF" \C%&'(9&R.I&D*<<QB2'"B>)0I
M&BII;5I>&&QJ1*G%A:J2%_P;7:QI\0+,FPI:J1VLJ4LP6YB='L$;F,L,;N\:
MW+2LQOU(-J!==D*ZH^=@DWI$<23;]$HTW0Q52W@Z#=9+SQC/<+749L^ M;WG
MBMR8W3#+62A92L,00R$0A4BP!!*I)"0JY3B@*,YBVC,#8G<<EQ=[O R&'STG
M*^PCRW :AQF#)DL2(LP9I#1.8("(7K<RE2)">B4;7(?K\,D";WWF!>Q!:GG2
M?@U(0Y^P5[+MQ=1[CJ4_I;CW6/B]0<:/93^EX\E8]),7]BRO93J-:G9^IKEH
MJDVW;:[BU/0D403*--&;_3A,( M3!&.,B!)(DI X5:(_/]343-1*4L?:6>=Q
MM/N\_: S\'=>=UANI&P+R@_0-^PR&%ZK99T?;=Q261>U/JJ3=?F.?K2@GZGM
MLT***E"GBON;*1K$&4'F (0KS0?&Y1<DB>8#%DHJ,Q*G3GZ_$V-,C0@V(H*R
M[N'RWX(_!$$0_N/OPS3XTS-M*LC_"20W^M?F_^N_-$X_NEX]+HO\OZ3X$_BD
MS13]JUN@7X:OLECE)NCV^?#Y87:3!$'K-!2RS+\L3.'3/X'%LOUM7I9K$XF]
M$'OYQW2EQWA>5?8TB(.;>E==-X'@S6_#FVJCXT9MI]X%.TZ[<H:'WU WX#<-
M>IH8ZKL*7W]DUH&"3Q8[-<RH]-6AYR%O=5W:C[#^O%R*7_/Y?)9$*!))I+D)
M2<U2,HD@2:(,\BC!<891@*13,$W[X*E14RN7V[>\@<GN ^ZC_,!?[46]G;_/
M0R5]?I2;9X_Z)1YJ=/CY'?V]9]2$7G:TJ?&@I_:1EO*AR+G4ORYS4>6)+1<?
MY.I>-0;)P[*H_(A$1#B.1 RSF!"( DH@S4SQ;6'.#66B0F05JW^-$%/[EK=J
M&.M@*[IC8$&?Z;!PD8\ \L"<L8-OJP*H= ![2@"MA>G'U^@!&D5&F 7'\(^!
M9V/$\)!F5I[;67FN9F7O([@!"STM2P5X,RW/M49_\!A%<@6@%Z-,^CQ[W"B4
M*[0_BE*YYED]5J&[1=6:L2S;R)B=YFDSGL42,X5@$F0<HBQ.(>,)AQC%,64)
MXUD66"\U72--;3VY6\#G6EA07-5+\3+&%NN'+^0&7B3N%J"1<QNO]I-_P!RH
MWA=P(_&YQ5OGB[-MD.DDYLX'C,>^-GKL4:S5#6X\NML0_7^M::$):O[R49I5
M=B80)XF2 D95"ZY ;W!HJ'^*611G(HQ#1:P8M&.,J7%G*R;8R EJ0>T(H O-
M;J[TA-' +.D.C_67;0' =FM>MGOS4O(_?%E^_4'?_8/Q;9H?H/EA9S?>]>11
M/G8+U=K/W.;2UZD@^O:;+'A>FL#CIB =#G$6A-JLXJFIK,($AT3& M*(QSC-
M0I+%S"GOWK>$4R.7'0%?K[#@\3S:.0-?=78&IC6?A05W])Q>8<&SDS"EPH+'
M0OZF"@N>Q=AW8<'S _5;(=Y4*0O5F<P#+>Z+3RMS]E@=SSS(HA)EEA*L=]))
M"%-*"40RX/ISP!+**(EBJ4(:1\2%\RW&G!J+OVDR.^I3P\TI<,7H8CF?TZ($
MS[*HV=V1W&VFP(ZN/0,[N(NVPK0YB=4"FT3A6N2F>[86NJ9??V3J )%/>K09
M=E3"<\#AD,)<;NWAW_LH^9R69:YR7G'C?=OL>U-]\.?GY:+A03F+L4(XS A,
MF Q-X7,%304HR ,9A8FB/,!6Y-1C[*F1U*'TYF"CD7];HA,8#5J#Q26/U7%>
M++R$PZ$],'--"F@'[^)P@(_D;_0)O)O[L1]TG0Y)QT>.YZ+LI^N>T[+G(_K9
ML&^?GN?+%RD_R>)KSN49$WM>S7 EBY9N^65A@O0>JDR"-Z;FP?M-_1:6<!*F
M*H 1X@BB"">0)1F#4O^H",H0YMC%WO4LW]26G58]T.@'SNVL;\!627.ZNU43
MU'J"2M$K:O?X?A/LS.Y7G-\1?20;W\=VKWK3QH/7H:EOZ'.^HG.CEY[J)U.Y
M9:#*/@,A[M/B]RWBJ+N#@? ]W$D,-4Q/5XA9L38+U7U1]Z#>2=I*N,(X5@2J
M-"(0L8!!HK\@&(64QEP2&F78K7O6I2%=J&"<9EB-J)[Z8%V&/$%2,KV=2Q@5
M>G>7&-=3&$ 5AZ%0G"9A$KDG=?J$?<0N5:>[4^F%M)9AP&E0H5(T#A2,!<T@
MHCC3;S[2!A(C*4\%B>,,N6: ^I^$$;I''72-&@7\-$Z#V'A>TQ@IB!(90HQH
M O7O&))A$DOJU,K%)_"CE-D9EW(L7:T>01S:SVI$-6]JNU->%J 2=Z#D75MH
MO/I7+XTYKG/5$H$CSZKM?3V+?]7/;6I]L$!)J4() R+T+C>C <1*@QM')K=/
M$SUF;C6]=I\^-0[9/;\!OS:$XEAV:P\].Y;HC<G E- R@?\ZUB<U]EK+:F^
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M519L:4T7-N.Z? *[HP_X)9C^AR8OHVJ$*+>2.Q*&%>J*!B*6)((I-E5J>1I
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MR2Y?W+,#C'Z.E/M-9MJ0P9?&T5+^M);_+FGQ^=?E_^GN6WODQK$LO^^O$##
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MFRD7;W (A'GS#W;0A*%(9,(3(@#'N "0J%F=<H8!0@4O(4LP-8NW/?WXJ;'
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MG,31D:,*/\8!TG7V\7:,=*48-]EL_>7E] /J>J1IKATKG "$J010E!"4.$E
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M2G;+T;O.<KQN4OR*/,TW9*'UNFL=YY%ZZ0:R0)C6N[Z%O5&GWD"8GV_L&VI
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M>K[7<3TK6?^-=?/K1O^X*V!@1]>W>XW,B'_:K\8X4\@NINLNZI___*%PB/I
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M!AMOD>D;G[T5I_>'NRT_W<3XJ']ZD _/&UUYM:J=@E]7?\RRHL04<0@2R$H
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M@P9'5Y9O\/4RF/'@+4T<F#]O9%WWX@^>31"D!H0O&6]3"L(SPF<K0O@>Q^&
ML:V>_VFSGO^WJ%L6S3@7DB$, :$(*6<3,D (RD!.I8@ETBFBYD>%Q\^?&KLW
MHD5/6K:K(E7.X6EP(G<=2H$)LA4N:H&JQ;L.$8N#KNN0&>G(R@HANU.G\_H/
MGA^=N&V\DZ#S,N^=Z0Q<YK@/M]S,^7SQK&,-/VD6K9GUO3+<ZY6N!3X3:4HR
MF D@<$P!+$4.*,,<L**@BNOBI,16^>V7!IP:U?7EC78"JX6BNBGZT@AMZ9!>
M!-UP<\XCE*'WYZY#T7Z+SA :K[MTE\8<=Z/.$(&CO3K3^]SXYM6"5-6#K).
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M".U=?45"T"^7>[S]<MCC;9N<=%]5SX]MP]-Y]=]OUT)TA7YU=,PLSAG+)))
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MN;NM]8(6+ D$N]=UL&<1QUTTA\'W:(4=:!BW6>"#>O][+6IE)G,&%6L71!(
MTXP#(HL2(!B70C"!:&[5%WC_\5/C8"W=-1U_#\ S8T]W2 *3GP4:UMQU6FF?
MU',PPJC,<5J[PP__S%6^<IMZQP,?^QUOL(12&1RH16$.H(C5%XW20KEE&)&<
M$TRS]+ILI],#3^U;'TA6Z2G@N0?1&9L8;, %0CKT"G)"(%^;='4]V+=/PW(
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M@?UQC3$V/NGF\J"C,HXQ!H>D8WZC&^^HM>CZ6? >M[UJ7_R$,^7XY"G@4F8
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M?1#K+O5KSK;?0QFG/$U3 M)"<  +F ',8@E2E$+(&"EE9D5(@Z--C8D^=)4
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M@>/VROTPT7"^\DAA-@$%)/RBE(DLXM\_?$:YK<XOU^5M28G!)R(&+E7*Q.2
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M%-[X8^7N2?8BWWZSZ+_3G.(N9_W>,Q^RS)!/GH]F<Z!7T?>7N9F\&8208,H
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MR,M3/" V,TYL,H%Q'1QU5=ZF54SA73_V/<//3]/99<G*WSS4>O5'&=0*J12
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MWZ.L$2_R]*C9+24>5(4-8/+A\5P/,#@Q/$J9RVQ7AF&@9"!)*!W$998LVU(
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MP>C@!UHU!;4%OA>+^6J:NH>(B_E[B##]"NG\#G,I61]IF6<-Q4);] ZM")Q
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MPPMT=%SX^:5?=ISL<)%"]M:4,F;C&)%:9.(H'NTQ&..1#:EUORO[1Y=H8D[
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MHK0&8HH65(BBKM-5X$) )W(V/K:[W^N"!8,4V/ZE%+A[)/:BP_L([L[AV.G
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M6O,"_R8\XDLZ$(\6E_M1$,5'OVC\OV-VI3;TQGXP/?K/)QK<TM3O>_]1$MB
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MERO\H1Y0&]QWOX!W-9&J-'FPYXKP_?!3!Z/TJX)O/ EHNI)N=PUW#G/O :>
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M9Q8G R( A-Y$#+^63*V9K"U)$)Z\2WEFYTRABF'/:ZQ)@3=)Z%'QX7C@)Y/
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M5 I!=<[;V'!G2YAAPQULN%-!X&+#G:>;7NUS5=<,=)MBXYB7:QSCFH9BU#&
M5!Y@FY/8#XBN/3$5 6W\GW+*/UOZ#ET_$+"E-E%!<&[69,701),5P['=%V[#
MC^PX9\</GU.TXI<J%I"_I=Y0+9A(X> YBFG@,>=-[E31->XQ6'@NWS%M_HC7
M P!GZ>HC#[K EO[VHL$4_C=*Q\')_P-02P,$%     @ )X)M45&2:7X%"
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MZ5%1Y!"GFN=E(B%D,0IL3)U1/Q-X4N#Z) E@<NU')%E03.C+)9-2NX7_6C+
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M;&4M,C R,# Y,S N>'-D4$L! A0#%     @ )X)M47M8#[[G%P  >>P  !4
M             ( !(I@! &=A;&4M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( ">";5'!MP"KW40  *;M @ 5              "  3RP 0!G86QE+3(P
M,C P.3,P7V1E9BYX;6Q02P$"% ,4    "  G@FU1"[ Z*)9O  #_=P  %
M            @ %,]0$ 9V%L92TR,#(P,#DS,%]G,2YJ<&=02P$"% ,4
M"  G@FU1Q&)J=V*N  "390< %0              @ $490( 9V%L92TR,#(P
M,#DS,%]L86(N>&UL4$L! A0#%     @ )X)M45MJ+346:@  BN($ !4
M         ( !J1,# &=A;&4M,C R,# Y,S!?<')E+GAM;%!+ 0(4 Q0    (
M ">";5&X57D<:!@  #S3 0 4              "  ?)] P!S;',R,#(P,#DS
M,&5X,3 S+FAT;5!+ 0(4 Q0    ( ">";5%1DFE^!0@  .@?   4
M      "  8R6 P!S;',R,#(P,#DS,&5X,S$Q+FAT;5!+ 0(4 Q0    ( ">"
M;5'&:[[@! @  .P?   4              "  <.> P!S;',R,#(P,#DS,&5X
M,S$R+FAT;5!+ 0(4 Q0    ( ">";5%E]WAD:08  +D9   4
M  "  ?FF P!S;',R,#(P,#DS,&5X,S(Q+FAT;5!+!08     "P + -0"  "4
%K0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
